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Abstract
Infection due to cytomegalovirus (CMV) can cause morbidity and mortality in the post HSCT 
setting in those who acquire or reactivate CMV. Approximately 60-70% of patients 
undergoing HSCT will reactivate CMV and without prompt antiviral therapy 20-30% will go 
on to develop CMV end organ disease. The cell mediated immune response notably that 
mediated through cytotoxic T lymphocytes (CTL) is essential in the maintenance of viral 
latency and the resolution of primary infections.
Peptide mixes were utilised that cover the CMV antigens pp65 and IE1 to study the 
functionality of CD4+ and CD8+ T cells in patients post HSCT. CMV lysate was also used as 
it contains all potential antigens that could stimulate a T cell response. There was no 
detectable CD4+ T cell response to CMV lysate in patients that had detectable CMV 
replication, additionally the CD8+ T cell responses against pp65 and IE1 was not adequate to 
prevent CMV replication in the absence of a CD4+ T cell response. The data presented here 
demonstrates the importance of a CD4+ T cell response to CMV in the HSCT setting and also 
highlights the benefit of both a CD8+ T cell responses to both IE1 and pp65.
By using overlapping 15mer peptides both the IE1 and pp65 antigens were mapped and new 
epitopes are described that could be used in the construction of peptide vaccines. New 
peptides were identified from both pp65 and IE1 that are presented in association with HLA- 
B*2705 and B*5801.
We also examined the CMV specific T cell responses in individuals with Common Variable 
immunodeficiency syndrome (CVID). Three CVID patients developed CMV disease and 
were then treated with antiviral therapy. The data presented here shows that these patients 
have a high number of T cells that respond to the CMV antigens IE1 and pp65, indicating that 
these patients do experience CMV reactivations resulting in persistent antigenic stimulation.
We also investigated the influence of different HLA alleles on peptide presentation. Our 
studies revealed that a HLA allele hierarchy exists which is dependent on the alleles present 
in an individual, notably those who are HLA-B*0702 presented CMV peptides in association 
with B*0702 regardless of other HLA molecules that are present. This is relevant when 
considering what peptides should be included in a vaccine.
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Chapter 1
Chapter 1 
Introduction
1.1 CMV disease
The human cytomegalovirus (CMV) is a P Herpes virus that currently infects 50-85% of the 
general population (Alford et al. 1990). Infection is highest in communities where people live 
in crowded, unhygienic conditions, and hence is more common in developing countries. 
Primary infection with CMV is usually asymptomatic but can present as mononucleosis, 
persistent fever, myalgia, headache, lymphadenopathy and splenomegaly. Following primary 
infection the virus establishes life long persistence that is characterised by periodic 
reactivations resulting in the production of new infectious virions. The principal site of 
latency is in the peripheral circulation; the cells that harbour latent virus are unknown, 
although macrophages and monocytes are thought to be the most likely candidates. Following 
infection the virus is excreted in body fluids (urine, saliva, tears, semen, milk, and cervical 
secretions) for months to years after, resulting in the spread of the virus to other people. In 
healthy immunocompetent individuals CMV does not cause disease and primary infection is 
often subclinical, however, virus clearance is rarely achieved and life long latency is 
established.
CMV is a significant opportunistic pathogen in immunocompromised patients. Primary 
infection or the reactivation of latent virus results in uncontrolled CMV replication, resulting 
in organ involvement leading to death. CMV disease most commonly occurs in 
immunocompromised people, notably in AIDS (Acquired Immune Deficiency Syndrome) 
patients, solid organ transplant recipients, stem cell transplant recipients and neonates. The 
occurrence and severity of the disease is dependent on the length and level of immune 
suppression. These patients develop pyrexia that can be accompanied by viraemia; an 
ongoing increasing viral load increases the chance that the virus may penetrate tissues. CMV 
infection can also induce an immunosuppressive syndrome that leaves the patient unable to 
deal with super infecting bacteria or fungi. The organs affected by the virus varies according 
to the type of immunocompromised patient, however, the main complication involves the 
gastrointestinal tract and affects all patient groups.
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1.1.1 CMV disease in AIDS patients
The human immunodeficiency virus (HIV) currently infects approximately 30 million people 
worldwide, causing an acquired immunodeficiency syndrome (AIDS) in the majority of HIV 
positive individuals. The HIV virus infects CD4+ T cells that gradually with time decrease in 
number, as a result these people have marked deficiencies in cellular immune responses and 
are susceptible to opportunistic infections caused by bacteria and viruses. CMV could also 
interact with HIV leading to increased viral replication accelerating the disease progression. 
Many mechanisms have been suggested by which herpesviruses may interact with HIV 
(Griffiths et al. 1998), some studies have shown in vitro that CMV can transactivate HIV 
(Ghazel 1993).
Approximately 45% of AIDS patients will develop CMV disease, this number has increased 
due to the improved treatment of other opportunistic infections (Hoover et al. 1993). AIDS 
patients most commonly develop CMV retinitis, which in severe cases can lead to blindness. 
Other CNS involvement can develop such as encephalopathy, progressive dementia and 
weakness of the lower limbs. The chances of developing invasive CMV disease increases as 
the CD4+ T cell count drops (Gallant et al. 1992; Leach et al. 1993; Webster et al. 1992). 
Treatment involves the use of ganciclovir or foscarnet to reduce the CMV viral load and 
prevent the development of life-threatening complications.
1.1.2 Congenital CMV
CMV can be transmitted vertically from the mother to the foetus during pregnancy, a 
transmission rate of 12.7% occurs in mothers who are CMV seronegative before pregnancy 
but acquire the virus and only 1% occurs in immune mothers (Fowler et al. 1992). The risk to 
the foetus is due to primary CMV infection in the mother rather than the reactivation of latent 
virus. After birth 90-95% of infants infected with CMV will be asymptomatic, of these 
approximately 15% will develop hearing problems or have impaired intellectual performance. 
Unfortunately, 5-10% of infected newborns display cytomegalic inclusion disease; these 
infants have a poor prognosis often having permanent neurological damage, in cases where 
severe CNS damage has occurred death usually occurs during infancy.
Currently there is no strategy employed to monitor pregnant CMV seronegative women as 
this would not be practical, however, the vaccination of women before childbearing age 
would reduce the incidence of congenital CMV. The development of a CMV vaccine to 
reduce the incidence of congenital CMV is currently in progress. A live attenuated Towne 
strain, recombinants of the Towne strain, canarypox virus containing gB are all underway and 
being tested in the clinical setting (Gonczol and Plotkin 2001; Pass and Burke 2002).
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1.1.3 CMV disease in solid organ transplant recipients
CMV disease is one of the most challenging infectious complications after haematopoietic 
stem cell transplantation (HSCT); although its impact in the solid organ transplantation 
setting (SOT) is less serious it can still cause disease and graft loss. In the SOT setting a 
CMV seronegative recipient receiving an organ from a CMV seropositive donor is considered 
at highest risk of developing CMV disease. Approximately 27% of CMV seronegative 
recipients receiving an organ from a CMV seropositive donor will develop CMV disease 
within 3-6 months after transplant (Razonable et al. 2001). The incidence of CMV disease 
also varies according to the organ transplanted, lung-heart transplant recipients are at the 
greatest risk, liver or heart recipients are at intermediate risk while the kidney recipients are 
the least likely to develop CMV disease. CMV disease is mainly associated with the 
transplanted organ, in the case of liver transplantation patients with CMV disease present with 
hepatitis, in solid organ transplants the infection can become more wide spread causing 
pneumonitis, enteritis and hepatitis. The role CMV plays in graft rejection is unclear with 
many studies producing conflicting results (Evans et al. 2000; van den Berg et al. 1996).
A major problem in SOT that is not often seen in the HSCT setting, is the emergence of drug 
resistant strains of CMV which are resistant to ganciclovir (GCV). The highest incidence of 
drug resistant CMV is seen in the lung and kidney-pancreas transplant recipients (Limaye et 
al. 2002). The emergence of drug resistant CMV strains is thought to be due to the prolonged 
use of GCV and suboptimal plasma concentrations allowing for viral replication to continue. 
The vaccination of solid organ transplant recipients would reduce the risk of CMV disease in 
these high-risk patients leading to higher chance of graft survival and consequently better 
patient survival.
1.1.4 CMV disease in HSCT recipients
In the HSCT setting CMV disease is a major infectious complication occurring after HSCT. 
Following HSCT patients are immunocompromised for an extensive period of time, during 
which they are at an increased risk of developing life-threatening infections from bacteria, 
fungi and viruses. The gradual reduction in immunosuppressive therapy allows for the slow 
process of immune reconstitution to take place. Among HSCT recipients the reactivation of 
CMV will occur in 60-70% of those at high risk (CMV seropositive) during the first 100 days 
post transplant. The organs targeted by the virus are normally the lungs and digestive tract 
this, is in contrast to newborns and AIDS patients where CMV targets the CNS. The main 
pathology observed in HSCT patients is life-threatening hypoxia with radiological 
abnormalities seen that are suggestive of interstitial pneumonitis. The diagnosis of CMV 
pneumonitis is made by performing a bronchoalveolar lavage where CMV inclusion bodies
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can often be seen (Springmeyer et al. 1986; Stover et al. 1984). Unfortunately, at this stage 
patients are often in intensive care and may be too ill to have a BAL performed, however, 
they are usually treated with GCV and CMV specific hyperimmunoglobulin. Apart from the 
lungs CMV infections can occur in the digestive system resulting in extensive ulcerations. 
Because CMV infection in the digestive system often presents with symptoms similar to 
GVHD, diagnosis is usually made from biopsy material where CMV inclusion bodies can 
often be seen.
CMV infection is better prevented than treated; once CMV disease has developed the 
prognosis is very poor with only a 50% survival rate. Ganciclovir and CMV immunoglobulin 
are usually given but are relatively ineffective at treating established disease. Modern 
strategies for preventing CMV infections involve the pre-emptive use of ganciclovir based on 
the early detection of CMV replication by PCR (Einsele et al. 1991) or antigenemia assays 
(Boeckh et al. 1996; Osarogiagbon et al. 2000). The pre-emptive treatment of CMV 
reactivations has increased the time of onset of CMV disease with the development of late 
CMV disease (+100 days) being the main problem.
1.1.5 CMV antiviral therapy
Ganciclovir is currently the first line drug used for the treatment of CMV infection. GCV is a 
competitive inhibitor of the viral DNA polymerase, its activation requires 
monophosphorylation by the phosphotransferase encoded by the CMV UL97 gene (Littler et 
al. 1992), followed by diphosphorylation by cellular kinases. Although GCV has been used 
successfully to reduce viral loads, it does have some drawbacks, namely poor bioavailability, 
low potency and myelosuppressive effects. Its myelosuppressive effects can further hinder the 
recovery of the HSCT recipient immune system, therefore delaying the reconstitution of the 
patients T cell population. Ganciclovir is administered intravenously following the detection 
of CMV replication by PCR or by an antigenemia assay. The pre-emptive use of GCV 
requires the monitoring of patients CMV viral load once or twice weekly during high-risk 
periods, in the HSCT setting this is conducted until at least +100 days post transplant. 
Monitoring is extended in patients with GVHD and in those who received a graft from a 
matched unrelated donor. If GCV is given prophylactically it causes marrow toxicity, and 
drug related neutropenia (Goodrich et al. 1993; Goodrich et al. 1991; Salzberger et al. 1997).
Valganciclovir is also available which overcomes the poor bioavailability associated with 
GCV and can produce similar blood levels seen with intravenous GCV. Valganciclovir is 
taken orally and can be prescribed on an out patient basis, a second drug foscamet (FOS) is 
also available for the treatment of CMV infection. Foscamet can be used in combination with
22
Chapter 1
GCV or in cases where GCV causes marrow toxicity. The emergence of GCV resistant strains 
of CMV means that foscamet is prescribed to those patients who do not respond to GCV. 
Initial experience with FOS indicated that nephrotoxicity, hypocalcaemia, hypophosphatemia 
were the main problems associated with its use, however, with sufficient hydration and 
electrolyte balance these side effects can be overcome; however, this does mean that it can 
only be prescribed on an inpatient basis.
1.1.6 Adoptive transfer of CMV specific T cells
The adoptive transfer of CMV specific CD8+ T cells is an alternative treatment for patients at 
high risk of developing CMV disease or for those who are not responding to antiviral therapy 
(Einsele et al. 2002). The first trial demonstrating the effectiveness of adoptively transferred 
CMV specific CD8 T cells was carried out by Riddell and co-workers (Riddell et al. 1992), 
who showed that adoptive immunotherapy with CMV specific T cell clones could rapidly 
restore CMV immunity safely. The original strategy employed involved the generation of 
CMV specific CTL clones which were subsequently expanded using donor derived CMV 
infected fibroblasts and IL-2. (Riddell et al. 1994; Riddell et al. 1992; Walter et al. 1995). 
More recently HLA tetramers have been used to isolate CMV specific T cells in the donor 
which have then been transferred to the recipient to provide protection against the 
development of CMV disease (Cobbold et al. 2005). During this study a low number of 
tetramer positive T cells were transferred (total dose 1.2xl04 to lxlO6) and consequently 
GVHD only occurred in two patients out of nine, the severity of GVHD was grade II.
Despite recent advances and the potential of the adoptive transfer of CMV specific T cells, 
this type of procedure has not gained as widespread popularity as one might hope. This is due 
in part to the fact that the production of CMV specific CTL lines is laborious and it can take 
several weeks to produce sufficient cells to transfer even in modest sized adults. Furthermore 
at least 1 x 109 cells/m2 of body area are required per transfer and at least 2-3 transfers are 
required to provide sufficient protection. However, with each transfer one is running the risk 
of transferring alloreactive T cells from the donor and triggering a potentially dangerous 
GVHD episode. The other potential disadvantage of adoptive transfer is that the T cells that 
are being provided to the recipient are generated against one strain of CMV, therefore the 
recipient may not be protected against other strains of CMV (Walter et al. 1995). In transplant 
combinations where the recipient is CMV seropositive and the donor is CMV seronegative, 
no CMV specific T cells can be generated from the donor unless a vaccine is designed and the 
donor vaccinated prior to harvest. The limitations of adoptive therapy have caused an increase 
in the search for an alternative preventative treatment for HSCT patients who are at high risk 
of reactivating CMV.
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1.1.7 Rationale for CMV vaccination
Currently there is no CMV vaccine licensed for the prevention of CMV disease in high-risk 
groups. Despite many attempts to develop an effective CMV vaccine over the last 25 years, 
for the prevention of maternal and congenital CMV no vaccine is licensed or near licensing. 
An effective CMV vaccine would have to stimulate neutralising antibody production as well 
as stimulating effective T helper and cytotoxic T cell responses. A problem encountered with 
the design of a vaccine is the presence of different strains of CMV, a vaccine would have to 
protect against all strains. Currently five different types of CMV vaccines are in clinical trials, 
progress is slow and these are only in either phase I or phase II trials. The first type of vaccine 
investigated is a live attenuated vaccine; these types of vaccine have historically provided the 
best protection. The Towne strain of CMV has been attenuated through 125 passages, this 
was then used to immunise transplant recipients, children and women (Mitchell et al. 2002; 
Plotkin 1999; Plotkin et al. 1991). The results from the attenuated Towne vaccine were 
disappointing, the attenuated strain produced a different type of infection than the wild type 
and unlike the wild type it did not induce any long-term immunity. Subsequent sequencing of 
the attenuated Towne strain revealed that a large segment of DNA was lost during passage, 
this resulted in a different type of infection. From the work conducted on the attenuated 
vaccine, a chimera between the attenuated vaccine and a wild-type virus has been produced 
(Kemble et al. 1996; Schleiss and Jensen 2003) in order to overcome the failures of the 
attenuated virus. The chimera vaccine is currently still in clinical trials and has so far only 
been used to immunise healthy CMV seropositive individuals, as a prerequisite before 
vaccinating CMV seronegative individuals. The third type of vaccine currently in clinical 
trials is a recombinant canarypox vector containing either the coat protein gB or the tegument 
protein pp65. The canarypox vector is a non-replicating vector that can direct the synthesis of 
the CMV protein, thus inducing CTLs (Gonczol 2001). The fourth vaccine currently in 
clinical trials is a recombinant envelope glycoprotein, which is safe and able to stimulate 
neutralising antibodies (Frey et al. 1999; Marshall et al. 2000; Pass et al. 1999). The last type 
of vaccine in clinical trials is a peptide vaccine that incorporates CD8+ T cell epitopes that 
could stimulate a cell mediated immune response (Diamond et al. 1997). The success of a 
vaccine requires sufficient knowledge about the target CMV antigens and the type of immune 
response that would provide the greatest protection from CMV disease.
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1.2 Antigen processing and Presentation
Cells infected with CMV are recognised by T cells, this recognition of virally infected cells 
requires that antigenic peptides are displayed on the cell surface in association with 
membrane bound MHC antigens. These MHC peptide complexes are formed by two different 
pathways the cytosolic and exogenous pathways (Germain 1994; Lehner and Cresswell 
1996), the pathway used is determined by the source of antigen. Viral proteins that are 
synthesised in the cytoplasm of the infected cell are processed and presented by the cytosolic 
pathway. The exogenous pathway processes extracellular antigens such as extracellular 
bacteria or antigens taken up by endocytosis, these antigens are broken down into peptides 
within lysosomes before being presented on the cell surface. Peptides produced by the 
cytosolic pathway are presented to CD8+ T cells in associated with MHC class I. Peptides 
produced by the exogenous pathway are presented to CD4+ T cells in association with MHC 
class II. Each pathway is shown in figure 1.1 and described below in more detail.
1.2.1 Endogenous antigens: The Cytosolic Pathway
The cytosolic pathway produces peptides derived from viral antigens produced within the 
cytoplasm. In the case of CMV the cytosolic pathway is known to produce peptides derived 
from the coat protein pp65 and the immediate early antigen IE1. The pp65 protein is part of 
the tegument and is present in the cell before viral gene expression has commenced, allowing 
pp65 peptides to be generated from the endocytic pathway as well. Peptides derived from 
pp65 and IE1 are readily detected on the surface of infected cells and a number of CD8+ T 
cells specific for these antigens can be detected in the peripheral blood of healthy CMV 
seropositive individuals (Gyulai et al. 2000). All cells except red blood cells express MHC 
class I molecules and are therefore capable of presenting peptides derived from intracellular 
antigens.
Antigenic proteins produced within the cytoplasm are targeted for proteolysis by the 
attachment of a protein called ubiquitin to them. The addition of ubiquitin targets the protein 
to the proteasome, which then cleaves the antigen in an ATP dependent manner. The 
proteasome is capable of cleaving peptide bonds between two or three different amino acids. 
The proteasome is a large mulitcatalytic protease complex consisting of 28 subunits arranged 
in stacks of four to form a hollow core, proteins are degraded in the hollow core by a series of 
proteolytic subunits. Two subunits of the proteasome, LMP2 and LMP7 are encoded within 
the MHC complex. The release of interferons as a result of viral infections increases the 
expression of MHC, LMP2, LMP7 and TAP, which in turn generates a different spectrum of 
peptides. Peptides generated by the proteasome for presentation with MHC class I molecules
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Figure 1.1 Endogenous and Exogenous antigen processing pathways
The processing and presentation o f endogenous antigens in association with MHC class I 
molecules and exogenous antigens presented by MHC class II molecules are represented. TAP: 
Transporters associated with antigen processing.
Modified from: Roy, C. R.: Immunology: professional secrets. Nature 425: 351-2, 2003
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are typically 8-10 amino acids long, almost always terminating with a hydrophobic or basic 
residue.
Following the generation of peptides by the proteasome, these are then transported into the 
rough endoplasmic reticulum (ER) by proteins present in the ER membrane called 
transporters associated with antigen processing (Deverson et al. 1990; Kelly et al. 1992; 
Kleijmeer et al. 1992; Powis et al. 1991). Transporters associated with antigen processing 
(TAP) transports peptides across the ER membrane in a process requiring ATP. TAP is 
optimised for the transport of MHC class I peptides, favouring peptides containing 8-10 
amino acids with a hydrophobic or basic residue at the carboxyl terminal end (Neefjes et al. 
1993; Shepherd et al. 1993). The majority of peptides require TAP to be transported into the 
ER, however, a few peptides have been described that are TAP-independent. TAP 
independent peptides can be generated by two pathways, firstly peptides can be generated 
within the ER by the action of proteases located within the ER (Hammond et al. 1995), in the 
second pathway peptides are generated in the trans-golgi compartment by a protease called 
furin (Gil-Torregrosa et al. 1998).
Once transported into the ER lumen peptides are then able to associate with MHC class I 
molecules (Allen and Unanue 1987; Braciale and Braciale 1991). The MHC class I molecules 
are made up of an a  chain and a p2 microglobulin chain (B2M), these are synthesised on 
polysomes along the ER. The MHC class I molecules in the absence of a peptide are unstable 
and are rapidly degraded. The assembly of a stable MHC class Iipeptide complex requires the 
participation of molecular chaperones that facilitate the folding of the a  chain and B2M chain. 
The first molecular chaperone involved is calnexin, which associates with free a  chain and 
promotes its folding, the B2M chain then binds to the a  chain, calnexin is then released and 
the a  chain:B2M complex then associates with the chaperones calreticulin and tapasin. 
Tapasin (TAP-associated protein) brings the a  chain:B2M complex into close proximity to 
TAP where it can acquire peptides that have been generated by the proteasome (Grandea and 
Van Kaer 2001). A third chaperone called ERp57 is also reported to be involved in this 
process, this chaperone is a disulphide isomerase which is required for the breaking and 
formation of disulphide bonds within the MHC molecule. If TAP has no peptides associated 
with it the a  chain:B2M complex is then rapidly degraded, the binding of a peptide to the a  
chain:B2M complex stabilises the complex and as a result it can dissociate from calreticulin 
and tapasin. From the ER the MHC:peptide complex then proceeds to the cell surface via the 
golgi apparatus.
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1.2.2 Exogenous antigens: The Endocytic Pathway
The exogenous pathway produces peptides derived from extracellular antigens which are 
internalised through endocytosis or phagocytosis. The exogenous pathway produces antigenic 
peptides derived from extracellular bacteria, any extracellular antigen can be processed and 
presented along this pathway. Peptides derived from the CMV antigens gB, gH, pp65 can be 
processed and presented by the exogenous pathway. These peptides are typically 15-18 amino 
acids long and are presented in association with MHC class II molecules. Only a limited 
number of cells express MHC class II molecules, these are cells of the immune system that 
includes dendritic cells, macrophages, B cells and activated T cells.
Following the engulfment of the extracellular antigen, antigenic peptides can be detected on 
the cell surface within 1-3 hours. The processing of extracellular antigens involves three 
compartments of increasing acidity, each compartment contains hydrolytic enzymes which 
work optimally under acidic conditions, these include the cysteine proteases chathepsins 
B,D,S and L. The first compartment of this process is the early endosomes (pH 6-6.5), the 
second compartment is the late endosomes (pH 5-6), the last compartment is the lysosomes 
(pH 4.5-5) which contain over 40 hydrolytic enzymes. Antigen is progressively degraded in 
these three compartments resulting in peptides of about 13-18 amino acids, which can 
subsequently bind to MHC class II molecules.
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1.3 MHC molecules
The ability of a T cells to recognise an infected cell relies on the presentation of antigenic 
peptides in association with MHC molecules on the cell surface. The interaction of the T cell 
receptor and a MHC-peptide complex can have a number of different outcomes; one of these 
being that the infected cell will be killed.
1.3.1 MHC genes
The MHC complex is a collection of genes arranged within a long continuous stretch of DNA 
located on chromosome 6 in humans and chromosome 17 in mice. This gene arrangement is 
called the human leukocyte antigen (HLA), the HLA locus is designated by a capital letter, 
followed by a number denoting the allele. The HLA genes are the most polymorphic genes 
known, with more than 200 alleles identified for some class I and class II genes. Any 
individual person will only express a limited number of these molecules with up to six 
different MHC class I molecules and up to twelve different MHC class II molecules. For the 
HLA class I genes each person inherits one set of A, B and C genes from each parent, for 
HLA class II six parental class II products (DP, DQ, and DR) are expressed, these six 
molecules contain a  and (3 chain combinations from either parent. Therefore a total of 12 
gene products will be expressed and will segregate to provide the 6 HLA class II antigens, 
this relatively small number of MHC molecules are able to present an enormous array of 
different antigenic peptides, this enables the immune system to deal with a vast range of 
antigens.
1.3.2 MHC class I structure
The MHC class I a  chain is a 45kDa transmembrane glycoprotein encoded by polymorphic 
genes, these are located within the human leukocyte antigen complex (HLA), the p2M chain is 
encoded by a highly conserved gene located on chromosome 15, this does not contain a 
transmembrane region and is non-covalently bound to the MHC class I molecule. The heavy 
chain is anchored to the cell membrane by its hydrophobic segment and has a hydrophilic tail 
that extends into the cell. Structural analysis has revealed that the heavy chain is organised 
into three external domains (a l, a2  and a3), the a3 domain and the (32M chain are organised 
into two anti-parallel p pleated sheets. This a3 domain is highly conserved amongst MHC 
class I molecules and contains a sequence that interacts with the CD8 molecule on the surface 
of T cells. The assembly of MHC class I-peptide molecules is thought to start with the initial 
interaction of the f32M chain with the folding class I heavy chain. This empty complex is then 
stabilised by the binding of a peptide, the resulting complex is then transported to the cell 
surface for presentation to CD8+ T cells.
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1.3.3 MHC class n  structure
The MHC class II molecule contains two different polypeptide chains, a 33kDa a  chain and a 
28kDa {3 chain; these two chains are non-covalently associated. The two chains consist of two 
domains a a l  and a2 domain in the a  chain and pi and (32 domains in the (3 chain. Like the 
MHC class I molecules the class II molecule also contains external domains, transmembrane 
segment and a cytoplasmic segment. Unlike the closed binding cleft observed with the MHC 
class I molecules, the MHC class II molecules have an open cleft capable of binding peptides 
of 13-18 amino acids. Two sites within the a2  and (32 domains are thought to be where the 
CD4 molecule on the T cell binds to the MHC class II antigen analogous to the binding of 
CD8 to MHC class I.
MHC class II molecules are synthesised and assembled in the ER, where they associate with a 
protein called the invariant chain. The invariant chain stabilises the MHC complex and 
prevents any ER peptides from binding to the MHC binding cleft. The invariant chain is 
involved in the folding of the MHC class II molecules and subsequent routing from the ER to 
the golgi, then onto the endocytic pathway where it acquires peptides. As the MHC class II 
molecule moves through the endocytic pathway the invariant chain is gradually degraded 
leaving a small fragment termed CLIP (class II associated invariant chain peptide). CLIP 
occupies the binding cleft preventing any peptides from binding; the non-classical HLA-DM 
molecule is then required to exchange CLIP with a peptide. HLA-DM is non polymorphic 
and is predominantly found in the endosomal compartment, this mechanism ensures that only 
peptides generated in the endosomal compartment can bind to MHC class II molecules.
1.3.4 MHC-peptide binding
The structure of MHC class I molecules has been resolved by crystallography (Fremont et al. 
1996; Fremont et al. 1992) and demonstrated that the peptide binding groove contains clefts 
and ridges that bind the peptide through hydrogen bonds. The binding cleft of the MHC class 
I molecule is blocked at both ends, therefore, it can only bind short peptides of 8-10 amino 
acids in length (Falk et al. 1991; Guo et al. 1992; Jardetzky et al. 1991). The binding cleft of 
MHC class II molecule is open and can therefore accommodate longer peptides of 13-18 
amino acids. Peptides that bind to MHC class I molecules contain specific amino acids 
(anchor residues) near the N and C termini that hold the peptide in the cleft. Peptides that bind 
to MHC class II molecules do not contain specific anchor residues; peptide binding studies 
indicate that a central core of 13 amino acids determined the ability of a peptide to bind. The 
binding cleft of the MHC class II molecule is slightly elevated, allowing the peptide to make 
efficient contact with the T cell receptor. The MHC-peptide association is very stable (Kj 
approx. 10'6) under physiological conditions and as a consequence, the majority of MHC
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molecules expressed on the cell surface are associated with peptide of either self or non-self 
origin.
The interaction of a peptide with an MHC class I molecule is different from interaction of a 
peptide with MHC class II molecules. Each type of HLA molecule (A, B and C) binds a 
unique set of peptides, in addition each different allele binds a distinct set of peptides. All 
nucleated cells express MHC class I molecules, with approximately 105 copies of each MHC 
class I molecule present on the surface. It is estimated that 100-4000 peptides can be 
presented by each cell and evidence suggests that only 100 peptides are sufficient to target a 
cell for recognition by T cells. Peptides that bind MHC class I molecules contain two anchor 
residues which are generally hydrophobic, one located at position two towards the amino 
terminal end and the second anchor residue is located at position nine on the carboxyl 
terminal end. The anchor residues at both ends hold the peptide firmly in place allowing the 
peptide to arch away from the floor of the binding cleft. The arching of the peptide brings it 
into close proximity with the T cell receptor allowing for slighter longer peptides to be 
accommodated. The discovery of conserved anchor residues in peptides that bind to the 
various MHC molecules has permitted the identification of specific binding motifs enabling 
the putative identification of antigenic peptides.
1.3.5 CMV Immune evasion
Despite the efficient antigen presentation pathways and the subsequent presentation of 
antigenic peptides in association with MHC molecules some viruses have developed 
strategies to avoid immune surveillance. Cytomegalovirus makes use of several gene products 
of the unique short (US) and unique long (UL) region, to escape detection. CMV escapes 
from T cells by using several mechanisms that either block the expression of MHC:peptide 
complexes or causes MHC molecules to be degraded thus avoiding the presentation of viral 
peptides. The US3 gene is expressed in the immediate early (IE) phase of virus replication 
and encodes for a protein that is capable of retaining MHC molecules in the ER, thus 
preventing the transport of MHC:peptide complexes to the cell surface (Jones et al. 1996). 
The US2 and US 11 genes are expressed in the early (E) phase of viral replication and encode 
for proteins that cause MHC molecules to accumulate in the cytosol where they are degraded 
by the proteasome (Jones and Sun 1997; Wiertz et al. 1996). A cell devoid of MHC molecules 
on the cell surface can be targeted by Natural Killer (NK) cells, however, the virus encodes 
for several proteins (UL16, UL18, UL40) that can protect the cell from NK mediated lysis. 
These proteins block NK mediated killing by either blocking the expression of ligands that 
activate NK cells or allow the expression of inhibitory receptors that prevent NK cell killing 
(Orange et al. 2002). Lastly the product of the US6 gene that is expressed during the late (L)
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phase of virus replication is capable of blocking the transport of peptides into the ER by 
blocking TAP (Lehner et al. 1997), resulting in fewer viral peptides being presented on the 
surface of infected cells. These immune evasion strategies lead to a reduction in the number 
of MHC molecules on the cell surface and prevent the transport of MHCipeptide complexes; 
thus escaping immune surveillance. The efficiency of these individual gene products to 
prevent the presentation of viral peptides can vary, for example several B alleles including 
HLA-B7, B8, B40, B41, B42 and B48 are resistant to the effects of the US2 protein, the 
presence of these alleles would provide an advantage to the host (Barel et al. 2003). In 
contrast the HLA-A2 and B27 alleles are very sensitive to the effects of US 2, meaning that 
viral peptides would be presented in the context of resistant alleles such as HLA-B*0702. 
Therefore when these alleles are present together with a more resistant allele the possibility 
exists for the more resistant allele to predominate in the presentation of viral peptides 
therefore altering the focus of the immune response slightly.
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1.4 Antigen presenting cells
The activation and generation of the adaptive immune response requires the T cell antigen 
receptor (TCR) to recognise fragments of antigen bound to MHC molecules on the surface of 
antigen presenting cells (APCs). APCs are highly specialised cells that are capable of 
capturing and processing antigens which are then presented to T cells in association with 
either MHC class I or class II molecules. The most potent APCs are dendritic cells (DCs) 
which are capable of activating naive T cells and are thought to initiate most if not all T cell 
responses in vivo. Currently, four types of dendritic cells (DCs) have been identified, these 
include monocytes derived dendritic cells, dermal DCs, Langerhans cells, and plasmacytoid 
DCs, these different subsets differ in their location and maturation. Other cells capable of 
acting as APCs include B cells and macrophages, these cells differ in the type of antigens 
they engulf and process.
B cells are particularly efficient at taking up soluble antigens such as bacterial toxins that bind 
specifically to immunoglobulin receptors expressed on the cell surface. These 
antigemreceptor complexes are internalised by endocytosis, the antigen is rapidly degraded 
and antigenic peptides are presented on the cell surface in association with MHC class II 
molecules. Like dendritic cells, B cells express high levels of MHC class II, however, they do 
not constitutively express the co-stimulatory molecules B7.1 and B7.2 and these are only up- 
regulated upon activation, in the absence of an infection B cells cannot be activated, it is for 
this reason that an adjuvant is included in all vaccines to induce a humoral immune response.
The third type of cells that are capable of acting as APC are macrophages. Macrophages are 
know as scavenger cells due to their ability to engulf a variety of different antigens. These 
cells have a variety of receptors that recognise different microbial cell surface components 
including a mannose receptor, a scavenger receptor, complement receptor and several Toll 
like receptors. These APCs do not express any MHC class II molecules or B7 molecules, 
however, they are rapidly induced following the engulfment of antigen. Macrophages cannot 
take up soluble antigen as efficiently as DCs and B cells, but are important APCs being 
especially efficient at processing antigen from ingested pathogens.
Dendritic cells are derived from a small CD34+ subset of haematopoietic progenitors that are 
present in the bone marrow. Dendritic cells are produced in an immature form, which then 
migrate in the blood to peripheral tissues. Immature DCs can be found under most epithelia 
and in most solid organs where they survey their environment for any invading pathogens. As 
immature cells they have very low levels of MHC molecules on their cell surface and do not 
express any co-stimulatory molecules that are required for efficient interaction with a T cell.
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At the site of an infection immature dendritic cells take up antigen and travel to local 
lymphoid tissue where they mature into cells expressing high levels of the co-stimulatory 
molecules and MHC molecules and here they can encounter circulating naive T cells that are 
continually recirculating through the tissues. Once T cells have been activated they then 
expand and differentiate into armed effector cells. Dendritic cells can also produce the 
cytokine IL-12 that further enhances the adaptive immune response and the innate immune 
response, notably the natural killer cells (NK).
Dendritic cells are important in stimulating T cell responses to viruses which fail to induce 
the up regulation of co-stimulatory molecules in other APCs. Viral infection also induces the 
production of the cytokine IFNa that can also activate dendritic cells. Some viruses can infect 
DCs, although the use of the cells own protein synthesis machinery to produce new viral 
proteins results in the presentation of antigenic peptides in association with MHC class I 
molecules. In cases where the virus does not infect DCs viral peptides can be generated as a 
result of viral particle uptake by phagocytic receptors eg. mannose receptors that recognise a 
wide range of viruses. Viral peptides generated from the degradation of extracellular viral 
proteins are usually presented by MHC class II molecules, these peptides can also be 
presented by MHC class I molecules in a process known as cross presentation. In this process 
exogenous antigens are engulfed by phagocytosis, the ingested material is contained within a 
phagosome inside the cell. During cross presentation the phagosome fuses with the ER 
allowing proteins to escape (Gagnon et al. 2002; Garin et al. 2001). Protein translocation 
occurs due to a channel formed in the phagosome membrane by an ER protein called Sec61. 
Sec61 exports proteins from the phagosome allowing them to be degraded by the cells 
proteasome (Koopmann et al. 2000; Romisch 1999). The peptides degraded by the 
proteasome are shuttled back into the phagosome by TAP, where they are loaded onto MHC 
class I molecules present within the phagosome. The phagosome is fully competent at antigen 
processing and presentation meaning that in the case of viruses, a CTL response can be 
generated from exogenous antigens. The mechanisms that govern whether an exogenous 
antigen is presented in this way are currently not understood.
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1.5 Adaptive Immune response: T lymphocytes
During the 1980's it was recognised that T cells were important in the control of CMV 
replication and hence protection against the disease. In the HSCT setting Meyers et al. 
(Meyers et al. 1980) demonstrated that the cellular immune response was suppressed in 
patients with CMV infections. In addition it was shown that CD4+ T helper cells were vital in 
the expansion of the CD8+ CTLs. The suppression of the cell-mediated immune response in 
HSCT, SOT and HIV positive individuals, allows the virus to replicate uncontrollably leading 
to the development of CMV disease. In these immunosuppressed individuals the fine balance 
between the virus and the immune system swings in favour of the virus that can then replicate 
with few obstacles.
T cells recognise antigenic peptides presented in association with MHC molecules on the 
surface of an infected cell or presented on an APC. Antigen receptors on T cells recognise 
these antigen derived peptides, leading to T cell activation and the destruction of the infected 
cells. In the context of viral infections, CD8+ T cells recognise viral peptides derived from 
intracellular proteins and are presented in association with MHC class I molecules. CD4+ T 
cells recognise viral peptides derived from extracellular proteins such as viral coat proteins 
that are processed and presented in association with MHC class II molecules. The cross 
presentation of peptides can occur, as previously described, whereby extracellular proteins are 
processed and presented in association with MHC class I molecules. Although T cells are 
important in combating viruses, they also have important roles in the recognition of altered 
cells.
The T cell receptor (TCR) on the majority of T cells consists of a heterodimer of two 
polypeptide chains, a  and p, that are covalently linked by disulphide bonds (Davis and 
Bjorkman 1988). A small percentage (1-10%) of T cells have a TCR made up of y and 6 
chains (Haas et al. 1993) these cells are non MHC restricted and recognise phospholipids 
antigens. The a  chain is a 40-50kDa acidic glycoprotein; the p chain is a 40-45kDa 
uncharged or basic glycoprotein. The TCR chains contain variable (V) and constant (C) 
regions, these two regions are connected by a joining (J) region. In addition the p chain 
contains one or two diversity segments, the variable region contains three hypervariable 
domains. Following the connecting portion of the TCR a transmembrane region of 21-22 
amino acids spans the membrane anchoring each chain into the membrane. The 
transmembrane domains are made up of positively charged amino acids that enable the chains 
to interact with the negatively charged acidic residues of the CD3 complex. At the carboxyl 
end each TCR chain contains a short cytoplasmic tail of 5-12 amino acids, although the TCR 
is antigen specific it relies on the CD3 complex and associated proteins for efficient signal
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transduction (Weiss et al. 1986). The CD3 complex consists of five separate integral 
membrane proteins (y, 6, e, t,, r|) that are all non-covalently attached to each other and with 
the a|3 TCR. The cytoplasmic tails of the CD3 chains contain a motif called the 
immunoreceptor tyrosine-based activation motifs (ITAM), which interacts with tyrosine 
kinases and plays an important role in signal transduction. In total the TCR complex is 
equipped with ten ITAMs, the £ (zeta) chain of the TCR has a short cytoplasmic domain 
containing three ITAMs. The phosphorylation of the ITAM serves as the first signalling 
sequence step leading to T cell activation.
1.5.1 TCR signalling
The engagement of MHC.peptide by the TCR, leads to the clustering of the co-receptors CD4 
or CD8 with the TCR, this clustering of the co-receptors helps activate the T cell by 
triggering various cell signalling pathways as shown in figure 1.2. The clustering brings the 
Lck tyrosine kinases associated with the cytoplasmic domains of the co-receptors together 
with the ITAM. Lck is constitutively associated with the co-receptor, after TCR engagement 
it associates with the cytoplasmic tails of the TCR complex. Another tyrosine kinase, called 
Fyn, associates with the cytoplasmic domains of £ and CD3e, upon receptor clustering Fyn 
and Lck phosphorylate ITAM. The activation of a T cell is tightly controlled with both 
inhibitory and activating signals, capable of promoting or preventing non-specific T cell 
activation. Lck and Fyn are members of the Src family kinases, which even after activation by 
phosphorylation their activity can be inhibited by a protein tyrosine kinase called Csk (C- 
terminal Src kinase). Csk phosphorylates the inhibitory tyrosines of Lck or Fyn resulting in 
the inactivation of these kinases, being constitutively expressed in resting cells therefore 
preventing the non-specific activation of the T cell. While Csk can inhibit the activation of a 
T cell, the transmembrane tyrosine phosphatase CD45 is required for efficient T cell 
signalling and can counteract the effects of Csk. The balance between Csk and CD45 
determines the activation of the Src family kinases in response to TCR engagement. The 
addition of ubiquitin is another mechanism involved in the regulating the Src family kinases 
and the subsequent targeting of the kinases for degradation by the proteasome.
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Figure 1.2 T cell receptor signaling pathways
The cell signaling pathways activated following TCR:MHC peptide engagement. The clustering 
of the co-receptors brings the protein kinase Lck into close proximity with the tyrosine based 
activation motifs (ITAM) resulting in the phosphorylation o f the ITAMs. The phosphoryation of 
ITAMs activates another protein kinase called ZAP-70, once activated ZAP-70 phosphorylates 
LAT and SLP-76 thus activating the MAP kinase pathways. The main cell signaling pathways 
are represented, the product o f these pathways activate transcription factors and subsequently 
regulate gene expression.
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The phosphorylation of the ITAMs on the zeta chain of the TCR creates a docking site for 
another kinase called £, chain associated protein (ZAP-70) which is important in propagating 
the signal. ZAP-70 is recruited to the fully phosphorylated ITAM where it catalyses the 
phosphorylation of a number of membrane associated adaptor molecules, which initiates 
numerous cell-signalling pathways such as the Ras/MAP kinase pathways. ZAP-70 is 
activated by Lck and once activated it phosphorylates the substrate LAT (linker of activation 
in T cells) and a second linker called SLP-76. Once activated ZAP-70, LAT and SLP-76 
propagate the signal from the cell membrane to the nucleus, several classes of proteins and 
enzymes participate in this signalling pathway. One of these is the enzyme phospholipase Cy 
that hydrolyses a phospholipid in the membrane to produce inositol 1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG). IP3 causes a rapid release of Ca2+ from the ER and opens Ca2+ 
channels in the cell membrane, these calcium ions are required in many T cell effector 
responses. DAG activates protein kinase C that causes the release of the inhibitory molecule 
IkB from the transcription factor NFkB resulting in its activation. NFkB promotes the 
expression of a number of genes involved in T cell activation and T cell responses such as 
inflammatory cytokines (IL-1 (3 and IL-6).
The activation of a T cell requires the induction of new gene expression that is achieved 
through the activation of transcription factors, which bind to specific DNA sequences 
initiating transcription. Transcription factors such as c-Fos, c-myc, c-Jun, NFAT and NFkB 
can be detected half an hour following TCR engagement. Several transcription factors are 
involved in the activation process these transcription factors are activated by phosphorylation 
of the MAP kinases (mitogen-activated protein kinases). In their inactivated non- 
phosphorylated form transcription factors are found in the cytoplasm, following 
phosphorylation they are translocated into the nucleus where they are able to initiate 
transcription.
An additional transcription factor called NFAT (nuclear factor of activated T cells) is 
activated through a different pathway. The activation of NFAT is determined by its 
intracellular location as it contains amino acid sequence motifs, one is a nuclear localisation 
signal, the second is a nuclear export signal. The activation of NFAT depends on the enzyme 
calcineurin which is activated by an increase in intracellular Ca2+ that is produced during T 
cell activation. In resting cells, NFAT is found in the cytosol due to the phosphorylation of 
the nuclear localisation signal thus preventing its entry into the nucleus. Once calcineurin has 
dephosphorylated NFAT it can then move into the nucleus where it associates with the 
Fos:Jun heterodimers that have been activated by MAP kinases initiating transcription. The 
immunosuppressive drugs Cyclosporin A and tacrolimus are used in transplantation protocols
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to prevent GVHD by inhibiting calcineurin, thus preventing the formation of NFAT, therefore 
inhibiting T cell activation. The activation of T cells is tightly regulated and can be inhibited 
at various stages. The co-stimulatory signals required for T cell activation provides another 
regulatory step whereby an inhibitory signal can be utilised to prevent T cell activation.
1.5.2 Co-stimulatory signals required for T cell activation
Due to the relatively low affinity of TCR (Beeson et al. 1996; Davis and Chien 1993) for 
MHCipeptide two additional signals are required for the full activation of naive T cells, firstly 
the interaction of the TCR with the MHCipeptide complex, secondly interaction is required 
between the CD28 molecule on the T cell and members of the B7 family present on the APC 
or infected cell. The B7.1 and B7.2 molecules are constitutively expressed on DC's and also 
on macrophages and B cells following activation. The ligands for the B7 molecules are CD28 
and CTLA-4, these are expressed on the surface of T cell membrane as disulphide linked 
homodimers. The CD28 and CTLA-4 molecules play an immunoregulatory role with the 
binding of CD28 delivering a positive co-stimulatory signal activating the cell, whereas, 
CTLA-4 provides an inhibitory signal and down regulating T cell activation. CD28 is 
expressed on all resting and activated T cells, whereas CTLA-4 is undetectable on resting 
cells the implication being that they can be easily activated. CTLA-4 can bind the B7 
molecules on a T cell 20 times more avidly than the CD28 molecules, thus providing an 
inhibitory signal to the cell, the binding of CTLA-4 to the B7 molecules is essential in 
limiting the proliferative response of activated T cells. The activation of effector memory T 
cells is less complicated and they can be activated upon TCR engagement with little or no co­
stimulation thus providing a quick antigen recall response.
Naive T cells require more co-stimulatory signals than effector T cells and can only be 
efficiently activated through binding to an APC. APCs bind to naive T cells through 
interaction between LFA-1, CD2 and ICAM-3 on the T cell and ICAM-1, ICAM-2, LFA-3 
and DC-SIGN on the APC, the interaction between ICAM-3 and DC-SIGN is unique only to 
DCs. Upon TCR engagement with MHCipeptide a conformational change in LFA-1 greatly 
increases its affinity for ICAM-1 and ICAM-2 resulting in a more stable interaction between 
the cells. This association between the APC and T cell can persist for several days, leading to 
T cell proliferation, the resulting progeny adhere to the APC and differentiate into armed 
effector cells. Once the naive T cell is activated, it expresses a number of proteins that drive 
clonal expansion and differentiation. One such protein is CD40 ligand (CD40L), which is 
present on the T cell and binds CD40 present on the APC. CD40 and CD40L belong to the 
TNF family of receptor and upon binding an activating signal is transmitted resulting in the 
expression of the B7 molecules. Another pair of proteins that contribute to the co-stimulation
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o f  T cells is the 4 - IBB protein on the T cell and the 4 - IBB ligand present on the APC, the 
binding o f these proteins again results in activation o f both the APC and T cell. The c o ­
stimulatory m olecules required for T cell activation are shown in figure 1.3. Follow ing the 
successful activation o f the T cell, the cells then proliferate and produce armed effector T 
cells that are capable o f  killing infected cells.
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Figure 1.3 Co-stimulatory molecules required for T cell activation
Represented are the co-stimulatory receptors involved in T cell activation. Following the 
engagement of MHCipeptide with the TCR, the CD8 co-receptors cluster bringing the 
cells into closer proximity. The engagement of the CD28 molecules with the B7 
molecules produces a positive signal initiating a cascade of cell signalling pathways, 
CD45 is also essential in signal transduction. Additional positive signals are required to 
activate naive T cells, these are provided by the LFA-3 and ICAM-1 molecules.
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1.6 Cell mediated immune response
A primary immune response is initiated following T cell activation. Approximately 48 hours 
after the activation of a naive T cell, it enlarges and begins undergoing repeated rounds of cell 
division. The interaction of the CD28 and B7 molecules triggers the cell to enter the G! phase 
of cell division, inducing the expression of IL-2 and the IL-2 receptor, cytokines can be 
detected 1-2 hours after TCR engagement. Activated T cells continue to divide 2-3 times a 
day, for 4-5 days resulting in the generation of large clones of progeny cells which 
differentiate into memory or effector T cells.
1.6.1 Effector CD8+ T cells
Following the successful engagement of the CTL-target the CTLs become functional effector 
cells that can destroy target cells. As well as being able to kill target cells, CTLs also secrete 
the cytokines IFNy and TNF(3 that are capable of modulating the immune response, IFNy can 
directly inhibit viral replication and can increase the expression of MHC class I molecules, 
both cytokines can activate macrophages and recruitment them to the site of infection. 
Effector CTLs are capable of killing target cells using two mechanisms, the first involves the 
pore forming protein perforin, the second involves the release of several serine proteases 
termed granzymes. The engagement of the TCR causes the golgi stacks and storage granules 
to move near the junction of the two cells. The perforin proteins and granzymes are then 
released from the T cell by exocytosis, moving into the junctional space between the cells.
Perforin is a 65kD protein that forms pores with an internal diameter 5-20nm in the 
membrane of target cells. As a monomer perforin makes contact with the target cell 
membrane, where it undergoes a conformational change exposing an amphipathic domain that 
is inserted into the membrane. In a process requiring Ca2+ the perforin monomers polymerise 
forming pores within the target cell membrane. The formation of a pore in the membrane of 
the target cell allows ions and water to enter the cytosol, leading to osmotic swelling and cell 
lysis. Perforin is also involved in granzyme B mediated killing, whereby the formation of 
pores allows the granzymes to enter the cell. Additionally, many cells express the mannose 6- 
phosphate receptor that can also bind granzyme B. These receptor:granzyme B complexes are 
then internalised into vesicles within the cell, perforin forms pores in these membranes 
thereby releasing the granzymes.
CTLs can kill target cells with the use of granzymes. Once in the target cell, granzymes 
initiate a cascade of reactions resulting in the fragmentation of both host and viral DNA, 
granzyme is also an initiator of the caspase pathway leading to cell death. Some T cells lack 
both granzyme and perforin, but utilise alternative means to kill target cells via Fas. Fas is a
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member of the TNF receptor family, it is a transmembrane protein that can induce cell death 
upon ligation of its natural ligand, Fas ligand, this is a member of the TNF family, which can 
be found on the membrane of CTLs. The ligation of the Fas ligand on the CTL, with Fas on 
the target cell, results in the activation of an initiator caspase. Fas is associated with a protein 
known as FADD (Fas-associated protein with death domain), which associates with caspase 8 
initiating the apoptotic pathway. The granzyme/Fas pathway results in the target cell 
undergoing apoptosis, the Fas pathway is also used to destroy activated T cells once the 
infection has been resolved and can prevent T cells from killing indiscriminately, this process 
is crucial in areas such as the eyes and testes where these activated T cells could cause 
irreparable damage.
The cell mediated immune response is crucial in preventing CMV disease, a deficiency of 
functional CMV specific CD8+ T cells correlates with the development of CMV disease in 
immunosuppressed patients (Boeckh et al. 2003; Reusser et al. 1991). The major target 
antigens for the cell mediated immune response has been identified as being the coat protein 
pp65 (Wills et al. 1996), this structural protein provides an ideal target for cytotoxic T cells 
(CTL) as they are introduced into the cell during viral entry and can be detected before viral 
gene expression has commenced (Riddell et al. 1991). Other target antigens have also been 
suggested which could enhance the immune response, including pp28, IE1 and ppl50 (Gyulai 
et al. 2000; Kern et al. 1999b). The majority of the studies conducted to examine the CMV 
specific cell mediated immune response has focused on pp65, recently there has been a 
renewal of interest in the IE1 antigen (Gyulai et al. 2000; Kern et al. 1999b) with the 
demonstration that both pp65 and IE1 specific T cells can be found (Gyulai et al. 2000; Kern 
et al. 2000) in CMV positive individuals, these were found to be functional both in terms of 
cytotoxicity (Gyulai et al. 2000) and IFNy production (Kern et al. 2000; Kern et al. 1999b). In 
HSCT patients the adoptive transfer of CMV specific CD8+ T cell clones has been used to 
restore CMV specific immunity (Riddell et al. 1992; Walter et al. 1995). However, it became 
clear in these early trials that the maintenance of these CMV specific CD8 T cells was 
dependent upon the presence of a CD4+ T cell response, and in those patients who lacked 
sufficient CD4+ T cell reconstitution the CD8+ T cell responses declined a few weeks after 
adoptive transfer (Walter et al. 1995).
1.6.2 Effector CD4+ T cells
Unlike the CD8+ T cells, CD4+ T cells are not capable of directly killing infected cells, 
although their helper functions are essential in the production and modulation of the immune 
response. The importance of CD4+ T cells is highlighted in HIV positive individuals, where a 
gradual drop in the absolute number of CD4+ T cells leads to the development of life-
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threatening opportunistic infections. The CD4+ T cells are therefore referred to as helper T 
cells due to their ability to modulate the immune response through the vast array of different 
cytokines they secrete, two CD4+ T helper cell subsets called TH1 and TH2 which can be 
distinguished according to the pattern of cytokines they secrete (Carter and Dutton 1996; 
Romagnani 1997). Both the TH1 and TH2 cells secrete IL-3 and GM-CSF, in addition TH1 
cells secrete IL-2, TNF|3 and IFNy and are more associated with providing help for the cell 
mediated immune response in particular the activation of CD8+ T cells and the generation of 
delayed hypersensitivity reactions. The TH1 cells are also associated with the production of 
excessive inflammation and tissue damage, which can occur as a result of infection or injury. 
The Th2 cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13 they activate eosinophils, provide help 
to B cells promoting the production of antibodies and also participate in allergic reactions. 
The cytokine profile of the two subsets determines their different functions, in the context of 
viral infections the TH1 cells are the dominant subset.
Th1 cells produce IFNy and IL-2, these cytokines play a dominant role in the cell mediated 
immune response by promoting the differentiation of pCTLs into fully functional CTLs that 
are capable of killing virally infected cells. The production of IFNy by TH1 cells can activate 
macrophages stimulating an increase in microbial uptake and up-regulating the expression of 
MHC class II molecules, in addition they secret IL-12 which further induces TH cells to 
differentiate into the TH1 subset. IFNy can also induce antibody isotype class switching to 
IgG, which is able to promote antibody-mediated phagocytosis and complement-mediated 
killing. IL-2 produced by TH1 cells encourages the proliferation of activated T cells with the 
production of new progeny that are capable of killing infected cells. The cytokines produced 
by the TH1 cells are the dominant cytokines produced during viral infections, these cytokines 
not only promote the cell-mediated immune response but also suppress the production of TH2 
cells.
The cytokines present in the environment of TH cells determines the subset that develops. If 
IL-4 is present the development of a TH2 subset is favoured, alternatively if IL-18 and IFNy is 
present then a TH1 subset develops. During an immune response IFNy is produced by the 
stimulation of T cells or NK cells, inducing a number of changes including the up-regulation 
of IL-12 production by DCs and macrophages, also increasing the expression of the IL-12 
receptor on activated T cells. IL-18 promotes the proliferation and IFNy production by NK 
cells and developing or fully differentiated T cells. Through cytokine production the TH cells 
are regulated such that depending on the type of infection only one TH subset will be present, 
this is known as cross regulation. The TH1 subset is important in dealing with viral infections, 
in particular they play a key role in controlling cytomegalovirus.
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The role of CD8+ T cells in controlling CMV in patients after HSCT has been the main focus 
of many studies aiming to restore CMV specific immunity. The adoptive transfer of CMV 
specific CD8+ T cells provide increasing evidence that CD4+ T cells play an important role 
in the control of infection. The first trial demonstrating the effectiveness of adoptively 
transferred CMV specific CD8 T cells was carried out by Riddell and co-workers (Riddell et 
al. 1992), who showed that adoptive immunotherapy with CMV specific T cell clones could 
rapidly restore CMV immunity. Subsequently, it has been demonstrated in the renal transplant 
setting that a functional CD8+ T cell response and antibody production alone were unable to 
control primary CMV infection, indicating that the CD4+ T cells are essential in the recovery 
from infection (Gamadia et al. 2003).
In the HSCT setting Peggs et al. demonstrated that the pre-emptive infusion of polyclonal 
CMV specific CD4+ and CD8+ T cells resulted in a 3-5 log in vivo expansion of the infused 
cells after an allogeneic stem cell transplant (Peggs et al. 2003). Work conducted by Einsele 
et al. demonstrated that a fall in the CMV viral load resulted from the transfer of CD4+ and 
CD8+ CMV specific T cells in seven patients after an allogeneic stem cell transplant (Einsele 
et al. 2002). The CD4+ T cell response against CMV has been analysed in healthy 
individuals, where strong proliferative responses were found against the coat protein pp65, 
other antigens such as gB, gH, IE72, IE82 and UL69 were also targeted (Beninga et al. 1995). 
These studies revealed the importance of CD4+ T cells in the immune response to CMV, 
which are particularly important post HSCT where high dose immunosuppressive drugs 
disrupt the fine balance between viral replication and cellular responses.
1.6.3 T cell differentiation
The recognition of viral peptides by naive T cells leads to their proliferation generating 
progeny, which differentiate into either memory cells or effector cells. Effector T cells are 
cytolytic and are capable of destroying infected cells through the use of cytoplasmic granules 
or by Fas-mediated killing. Upon the resolution of infection the effector memory cells are no 
longer required and die by apoptosis. If the same pathogen is encountered again the memory 
T cells that were previously generated mount a quick response resulting in the pathogen's 
destruction. Memory T cells differ from naive T cells, they have a less stringent requirement 
for activation requiring less co-stimulation and are able to secrete a more extensive set of 
cytokines ((Byrne et al. 1988; Merkenschlager et al. 1988; Picker et al. 1995; Sanders et al. 
1989). The discrimination between naive, effector and memory T cells relies on the 
expression of different cell surface molecules, the memory T cell population can be further 
divided into central memory cells (CCR7+) and effector memory cells (CCR7-) based on the 
expression of chemokine receptor CCR7. Traditionally, the phenotyping of T cells was
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determined by the relative expression of two isoforms of the cell surface molecules CD45 
(Akbar et al. 1988; Michie et al. 1992). The expression of CD45RA was associated with naive 
T cells that have had no previous encounters with antigen. Memory T cells were defined by 
the expression of CD45RO and absence of CD45RA. However, the phenotyping of T cells 
has been complicated by the discovery of a population of CD45RA+ T cells that have 
characteristics of primed T cells (Hamann et al. 1997; Kern et al. 1999a; Wills et al. 1999). 
These CD45RA+ primed cells have been shown to have cytotoxic properties and are able to 
produce IFNy and TNFa; however, these cells proliferate poorly in response to antigen 
stimulation. Antigen experienced CD45RA+ T cells have down-regulated CD27 which is 
thought to result from chronic antigen stimulation (Baars et al. 1995; De Jong et al. 1992).
In contrast to effector T cells, the phenotype of naive T cells is more straightforward, they 
express CD45RA, the co-stimulatory molecules CD27, CD28, and the chemokine receptor 
CCR7 which allows the homing of these cells into the secondary lymphoid organs. Following 
activation CCR7 and CD28 are down regulated while CD27 allows these cells to interact 
efficiently with other activated T cells. The discrimination of different T cell subsets is 
difficult due to the different levels of expression of the cell surface markers, the nomenclature 
is confusing with different groups defining subsets using different cell surface markers. The 
identification of an antigen experienced population of CD45RA+ T cells during persistent 
infections and how these arise is unclear at the moment. The current phenotype of effector, 
naive and memory T cells is summarised in figure 1.4.
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Figure 1.4 Phenotype of T lymphocyte populations
CD8+ T lymphocytes can be divided into distinct populations based on the expression of 
cell surface phenotypic markers. Upon antigen stimulation naive CD8+ T cells 
differentiate into either effector cells armed to kill target cells or memory cells that are 
reactivated upon antigen reencounter. Effector T cells can be further characterised by the 
relative expression of CD45RA which results from persistent antigen stimulation.
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1.7 Generation of T lymphocytes
T cells initially develop in the bone marrow before migrating to the thymus where they 
undergo a vigorous selection process resulting in the development of CD4+ and CD8+ T 
cells. B cells undergo a similar selection process although they are produced in the bone 
marrow where they also undergo positive and negative selection to emerge as mature B cells, 
capable of recognising extracellular pathogens.
1.7.1 T cell development
The thymus is the main source of all T cells, T cells developing in the thymus are known as 
thymocytes, 98% of these undergo apoptosis within the thymus. The pathway leading to the 
development and maturation of T cells is illustrated in figure 1.5. The developing T cell 
undergoes both negative and positive selection as part of its repertoire selection within the 
thymus, as a result it takes approximately 3 weeks for thymocytes to develop and differentiate 
into T cells. The positive selection process permits the survival of only those T cells whose 
TCR's are capable of only recognising self MHC molecules. The negative selection process 
eliminates T cells that react too strongly with self-MHC molecules with or without a self­
peptide, thus preventing the development of T cells capable of initiating autoimmune 
reactions.
Thymocytes that have just arrived at the thymus do not express any cell surface markers such 
as CD4 or CD8, or RAG-1 and RAG-2 that are required for TCR rearrangement, at this stage 
they are called double negative cells (DN). DN thymocytes then start to express c-kit, the 
receptor for the stem cell growth factor, CD44, an adhesion molecules involved in T cell 
homing and CD25 the a  chain of the IL-2 receptor is also expressed. Cells then stop 
expressing c-kit and reduce the expression of CD44, they then start expressing the 
recombinase genes RAG-1 and RAG-2 that are required for TCR rearrangement. At this stage 
95% of cells proceed to rearrange the TCR ap  genes and 5% rearrange their TCR yd genes. 
Cells first rearrange the (3 genes and then express the p chain, cells that fail to produce a p 
chain die. The newly synthesised p chain joins with a pre TCRa chain, which then associates 
with CD3 to form a pre TCR complex, after this stage the cells start to express both the CD4 
and CD8 receptors and are called double positive (DP) cells. The DP cells then proliferate, 
only the P chain has rearranged at this stage, the a  chain does not rearrange until the cells 
have stopped proliferating. Once the DP cells have finished proliferating the level of the 
RAG-2 protein increases allowing the rearrangement of the a  chain. The resulting T cell 
repertoire consists of T cells with the same P chain but different a  chains generating a more 
diverse repertoire. DP cells that express an aP  TCR-CD3 complex and survive thymic 
selection then develop into single positive CD4 or CD8 immature T cells that then leave the
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thymus into the circulation. The rearrangement o f the TCR genes generates a T cell repertoire 
containing 1018 T cells capable o f  recognising a wide range o f  pathogens.
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Figure 1.5 T Lymphocyte development
T lymphocytes develop in the thymus where they are known as thymocytes, surviving 
their maturation then undergo both positive and negative selection. Thymocytes just 
entering the thymus are called double negative cells (DN), at this stage they start to 
express the receptor for stem growth factor (c-kit), the T cell homing molecule (CD44) 
and the a  chain of the IL-2 receptor (CD25). Thymocytes then stop expressing c-kit, 
CD44 and CD25 and start to express the RAG genes required for TCR rearrangement. 
Following TCR rearrangement the TCR a  and (3 chains associate with CD3 to form the 
pre TCR complex, at this stage cells start to express both the CD4 and CD8 co-receptors 
(double positive, DP). Cells that survive thymic selection then develop into single 
positive CD4 or CD8 T cells and leave the thymus to enter the circulation.
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1.7.2 TCR rearrangement
The huge diversity of the T cell repertoire is due to the rearrangement of the TCR genes. Each 
immature T cell has two genes encoding for each chain of the TCR, however, only one of the 
a  chains and one of the (3 chains are functionally rearranged and expressed (Leiden and 
Thompson 1994), this phenomenon is called allelic exclusion. Prior to TCR rearrangement 
the TCR genes are in a non-functional germ line configuration consisting of variable (V), 
joining (J) and constant (C) segments, in addition the (3 chain also contains a diversity (D) 
segment, each segment is separated by intervening sequence of DNA. The genes encoding the 
(3 chain are located on chromosome 7 and the genes encoding the a  chain are located on 
chromosome 14. During TCR rearrangement the somatic rearrangement of these segments 
occurs, allowing them to come together to generate a unique TCR. The somatic 
rearrangement of the TCR V,D and J genes is performed by recombinases that recognise 
specific nucleotide sequences adjacent to each rearranging segment. The TCR rearrangement 
first begins with the |3 chain where the diversity is generated from the rearrangement of VDJ, 
VJ and VDDJ joins, the D segment is included in all three reading frame increasing the chain 
diversity. The diversity of the a  chain is generated by the joining of the V and J segments, 
additional diversity can be generated by the insertion of an N nucleotide at the joining sites. 
The resulting rearranged DNA is then transcribed into mRNA, which is translated into 
functional a  chains and (3 chains. The rearrangement of the TCR genes is not a process that is 
unique to T cells, B cells undergo a similar rearrangement of the genes encoding the 
immunoglobulins.
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1.8 Humoral Immune response: B cells
Apart from T cells, B cells also play an important role in viral infections by producing 
specific antibodies that are capable of binding to a particular antigen. B cells are generated in 
the bone marrow where the rearrangement of the immunoglobulin (Ig) genes occur, this 
generates an antibody diversity that exceeds 109, however, only a small proportion of this 
repertoire is displayed at any one time. Mature B cells then leave the bone marrow and 
migrate via the lymph and blood to the secondary lymphoid organs, notably the spleen and 
lymph nodes. Like T cells, many B cells are produced but very few of these mature, naive B 
cells only have a half-life of 3 days to 8 weeks, if they do not encounter a specific antigen 
they die by apoptosis. Approximately 90% of B cells produced in the bone marrow each day 
die without having matured. The loss of B cells in the bone marrow is due to negative 
selection which eliminates B cells that express auto reactive antibodies. This is a similar 
process to T cell selection, except B cells mature in the bone marrow whereas T cells mature 
in the thymus.
B cells that leave the bone marrow express membrane bound immunoglobulins (mlgD and 
mlgM), having a single antigen specificity. The antigen that is recognised by the membrane 
bound antibodies activates the B cell that then proliferates producing 32-64 progeny, these 
then differentiate into either plasma cells or memory cells. Plasma cells produce antibodies 
specific for the antigen recognised by the B cell, five main classes of antibodies can be found, 
IgG, IgM, IgE, IgD and IgA, although IgD is present in a membrane form it is not secreted by 
plasma cells, on B cells that have not undergone isotype switching both IgM and IgD are 
expressed, although to date the function of IgD is unclear. IgG is the predominant antibody 
present in blood, following the resolution of a viral infection, virus specific IgG can circulate 
for many years after and is the principle mediator of protection against reinfection. The 
second most important antibody in viral infections is IgM, which is produced early during an 
infection and is often diagnostic of a recent or chronic infection. Antibodies work by 
attaching to viral antigens present on the surface of virions thus neutralising infectivity and 
preventing the spread of the virus. Antibodies can also activate the complement pathway by 
coating the virus and facilitating its uptake by macrophages, highlighting the interaction of 
the innate and adaptive immune responses. The B cell response to antigens is either thymus 
independent or dependent, depending on the antigen present, thymus dependent activation 
requires a direct interaction between the B cell and a TH cell, whereas thymus independent 
activation requires only the cytokines produced by TH cells for activation. The involvement of 
Th cells in the activation of B cells highlights the overlap between the cell mediated and 
humoral immune responses resulting in the destruction of an invading pathogen.
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Antibodies directed against CMV can be detected following the resolution of the primary 
infection and then persist for life. The predominant target for neutralising antibodies is the 
coat glycoprotein gB, other minor target antigens have also been identified, such as gH and 
pp65. The importance of CMV specific antibodies in the pathogenesis of the virus remains 
unclear. The humoral immune response is likely to play an important role in preventing the 
blood borne spread of the virus. The occurrence of intrauterine CMV infection is highest if 
the infection has been transmitted by primary infection of the mother compared with recurrent 
maternal infections (Fowler et al. 1992). This finding indicates that maternal primary 
infection with CMV is more detrimental to the foetus than virus reactivation, but the humoral 
immune response alone does not provide this protection, as the cell-mediated response is also 
important in controlling the virus. In the solid organ transplant setting the passive transfer of 
high titre immunoglobulin specific for CMV reduces the severity of CMV disease (Plotkin et 
al. 1994). The use of CMV specific immunoglobulin to treat CMV pneumonitis in bone 
marrow transplant (BMT) recipients has shown mixed results. One study conducted by 
Blacklock et al. (Blacklock et al. 1985) showed that among 18 BMT recipients with CMV 
pneumonitis who were treated with CMV specific immunoglobulin 9 patients survived, 
however, a subsequent study conducted by Reed et al. (Reed and Meyers 1987) was unable to 
confirm these findings. Since the advent of GCV that is used pre-emptively to treat CMV 
infections the use of CMV specific immunoglobulin has decreased, some centres use 
immunoglobulin in combination with GCV in patients with established CMV disease with 
some improvements in outcome. Antibodies directed against CMV are probably important in 
preventing the blood borne spread of the virus they play a minor role in the overall immune 
response against the virus which is dominated by the cell mediated immune response. B cells 
do represent an overlap between the humoral and cell mediated response due to their 
dependence on TH cells for activation, although the cell mediated immune response is the 
most important in controlling CMV the innate and humoral responses do enhance these 
antiviral responses.
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1.9 Innate immune response: Natural Killer (NK) cells
NK cells are part of the innate immune response and play an important role in the initial 
response to viral infections. The generation of a T cell response and the emergence of specific 
CTLs takes at least 7 days, during this time the NK cells are able to non specifically kill 
infected cells and produce numerous cytokines that promote the development of either TH1 or 
Th2 cells. NK cells are derived from the bone marrow and make up approximately 15% of the 
circulating lymphocytes (Cooper et al. 2001), however, they differ from T cells as they 
exhibit non-specific cytotoxicity and are important in the immune defence against both 
viruses and tumours. People who lack NK cells, can suffer from life-threatening infections 
caused by viruses such as VZV and CMV (Biron et al. 1989).
The NK population shows a high level of heterogeneity with regard to the cell surface 
molecules they express. The majority of NK cell express the adhesion molecule CD56, CD2 
and CD 16 a receptor for the Fc region of immunoglobulin G (IgG). NK cells express many 
different receptors that are capable of providing inhibitory or activating signals, it is the 
balance between the inhibitory and activating signals that are thought to result in NK 
mediated killing. Numerous inhibitory receptors have been identified but the exact receptors 
that produce an activating signal are not clear, some activating receptors have been suggested 
such as the C-type lectin proteins, also NKp30, NKp44 and NKp46 which appear to play an 
important role in the activation of NK cells. The inhibitory receptors present on the NK cell 
prevent NK cell mediated killing, proliferation and cytokine production. Two major 
inhibitory receptors have been identified, the first type is the C-type lectin inhibitory receptors 
(CLIR) and the second is the killer cell inhibitory receptors (KIR). The CLIR receptor is 
CD94/NKG2 that binds to HLA-E on the surface of target cells (Braud et al. 1998). HLA-E is 
not expressed on the cell surface unless it has bound a peptide derived from the classical HLA 
molecules (HLA-A, -B, -C), thus HLA-E serves as an indicator of the level of MHC class I 
synthesis, if adequate amounts of HLA-E are expressed the binding of the CD94/NKG2 with 
HLA-E provides an inhibitory signal preventing the activation of the NK cell. In cells 
infected with a virus such as CMV the amount of MHC expressed is initially up-regulated due 
to the presence of IFNy, but later goes down due to the actions of US2, US3 and US11, thus 
preventing viral peptides from being expressed on the cell surface. A reduction in HLA-E 
prevents CD94/NKG2 from binding resulting in the activation of the NK cell. Through this 
mechanism NK cells are able to kill cells that have a reduced level of MHC expression on 
their cell surface such as tumour cells and virus infected cells (Karre et al. 1986).
NK cells kill in a similar way to T cells, using both Fas mediated killing and granzymes 
(Yokoyama and Scalzo 2002), however, unlike T cells, NK cells constitutively express
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granzymes and consequently appear under the microscope as large granular cells. Once an 
NK cell adheres to a target cell, degranulation occurs with the release of perforin and 
granzymes leading to the apoptosis of the target cell. The expression of FasL on the surface of 
the NK cell enables the killing of target cells expressing Fas. NK cells produce numerous 
cytokines that are able to promote either a TH1 or TH2 response depending on the pathogen. 
Unlike T cells, NK cells do not generate any immunological memory and recognise target 
cells in a non-MHC restricted fashion, because of the cytokines they produce they are 
important in both innate and adaptive immune responses.
The fine balance between the immune response and CMV maintains the virus in a latent state 
which is characterised by periodic reactivations. CMV has developed strategies to overcome 
the immune response enabling it to persist in the host, such strategies reduce the expression of 
viral peptides on the surface of infected cells. More recently GCV and FOS resistant strains of 
CMV have been identified leading to increasing difficulties in treating infections. In the 
immunocompetent host CMV rarely causes disease and primary infection is often sub 
clinical, in immunocompromised individuals primary infection or the reactivation of latent 
virus can cause life-threatening disease. CMV is a significant problem in patients undergoing 
HSCT due to the profound immunodeficiency experienced in the first few months post 
transplant, the occurrence of GVHD means these patients are at high risk of developing CMV 
disease. The chances of reactivating CMV largely depends on the type of transplant received 
and complications occurring post transplant.
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1.10 Haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation (HSCT) has been used to treat a variety of 
haematological malignancies and autoimmune diseases. The decision to perform a HSCT 
requires that a number of risk factors be taken into account such as age, disease, remission 
state, and the availability of a suitable donor. The pre-transplant conditioning destroys the 
patients own immune and haematopoietic system, in this process a large proportion of any 
existing malignancy is also eradicated. Following conditioning, patients are then transfused 
with stem cells from either a matched unrelated donor or a matched sibling donor. The 
infused stem cells leave the circulation and home to the extra cellular spaces within the bone 
marrow. There is profound immune deficiency in the first 3-12 months following 
transplantation, full reconstitution can take up to two years. A persistent deficiency in the 
immune system function leads to an increased risk of infection (Storek et al. 1997), disease 
relapse (Maraninchi et al. 1987) and the development of a secondary malignancy (Curtis et al. 
1997).
1.10.1 Conditioning regimens
The aim of conditioning regimens is to eradicate the existing haematological disease and 
provide room for the donor stem cells, immunosuppression needs to be sufficient to prevent 
the rejection of the incoming donor stem cells and long-term engraftment is required to 
prevent disease relapse. The most common reasons for HSCT failure are disease relapse, 
graft-versus-host disease (GVHD), infection and toxicity.
Due to improved conditioning regimens HSCT is an option that is now available for patients 
who by previous guidelines were at high risk of transplant related mortality (TRM). The early 
transplants involved high intensity myeloablative conditioning followed by the harvest of 
bone marrow from a matched donor which was subsequently infused into the recipient, due to 
the toxic nature of the conditioning regimens these protocols were only performed on young 
people with a low risk of TRM. The development of reduced intensity conditioning (RIC) 
provides a feasible option for older patients who are at high risk of TRM, RIC is non- 
myeloablative and therefore avoids the toxicities associated with myeloablative regimens. 
RIC protocols have reduced the early toxic deaths that resulted from the traditional 
myeloablative regimens, these accounted for 50% of all deaths during the first 100 days post 
transplant. The choice of drugs to use in conditioning regimens does vary between different 
transplant centres according to recommendations and previous experience. The work 
presented in this thesis was conducted in collaboration with the Royal Free hospital (London), 
at this centre myeloablative conditioning protocols usually consist of total body irradiation 
(TBI) with or without cyclophosphamide (Cy) and RIC protocols use fludarabine (Flu) and
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melphalan (Mel). Due to these improved conditioning regimens more people are eligible for 
HSCT resulting in a higher chance of curing their haematological malignancies.
Apart from the improvements made with the conditioning regimen, changes have also 
occurred with respect to the source of stem cells. Traditionally stems cells were harvested 
from the bone marrow under general anaesthetic and subsequently infused intravenously into 
the recipient. Recently, G-CSF has been used to mobilise stem cells than can then be 
collected from the peripheral circulation. The use of peripheral blood stem cells (PBSC) 
offers the advantage that collection is simpler and can be performed in the hospitals out 
patients department. A higher number of cells can be obtained from PBSC's, however, the 
long-term side effects of G-CSF is unknown and in some donors their stem cells do not 
mobilise adequately with G-CSF resulting in them being harvested from the bone-marrow. 
PBSC's are increasingly being used due to the relative ease that they can be obtained, with 
minimal invasive treatment required for the donor. Another source of stem cells is cord blood 
cells, these have only been successfully used in the paediatric HSCT setting due to the 
relatively small number of cells obtained, a number of cord blood banks are being set up in 
order to try and increase the potential number of grafts available. The availability of a HLA 
matched donor is the main constraint at the moment in particular with patients from ethnic 
minorities, despite searching many bone marrow registers worldwide a matched donor may 
never be found. Because of this limitation an increase in haploidentical transplants has 
occurred in latter years.
1.10.2 Histocompatibility matching
The tissue compatibility of a donor is determined by the highly polymorphic genes of the 
major histocompatibility complex (MHC) known as the HLA system. The HLA genes are the 
most polymorphic of the human genome accounting for a total of 1615 alleles identified in 
the worldwide population. The HLA genes encode for cell surface MHC molecules that 
present foreign peptides to T cells, thus initiating a cell mediated immune response. The 
immune response to MHC molecules presents the greatest barrier in transplantation, the 
accurate testing and matching of HLA alleles is important in determining the best potential 
donor. The role of HLA-A/B/C/DR mismatches between the donor and recipient influences 
the risk of graft failure (Morishima et al. 2002; Petersdorf et al. 1998) and the occurrence of 
acute GVHD (Petersdorf et al. 2003). Although the HLA matching of the donor and recipient 
improves the success rate of the transplant, it does not prevent the rejection of the graft, if an 
unrelated donor is used it is unlikely that both donor and recipient will have identical MHC 
genotypes; minor histocompatibility antigens can also trigger graft rejection. Thus, the 
engraftment of donor-derived stem cells relies mainly on immunosuppressive drugs to 
prevent the graft from being rejected.
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1.10.3 Immune reconstitution post HSCT
As previously mentioned HSCT recipients experience a long period of profound immune 
deficiency. Engraftment of the transplanted stem cells usually occurs within the first month 
post transplant, engraftment is achieved when a neutrophil count of 0.5xl09/L is obtained on 
two consecutive days, until then patients are at particularly at risk of developing life- 
threatening bacterial infections. When myeloid and lymphoid cells are of donor origin the 
patient is said to be 100% donor chimeric (McSweeney and Storb 1999), however, in some 
patients this is difficult to achieve and can only be achieved by the infusion of lymphocytes 
derived (DLI) from the donor into the patient. The rate of immune reconstitution depends on 
many factors such as age, type of transplant, stem cell source and complications encountered 
post transplant. Older recipients have less thymic activity than younger patients resulting in 
delayed immune reconstitution with few naive T cells being generated. The number and 
diversity of T cells infused with the graft impacts on the development of the T cell repertoire, 
in recipients of T-cell depleted (TCD) grafts the reconstitution of the T cell repertoire is 
slower when compared to non-TCD recipients. The monitoring of immune reconstitution post 
transplantation is essential in determining the patient's risk of developing infections or 
relapsing post transplant.
Infections encountered by the recipient post transplantation largely reflect the immune defects 
present at the time. Infections during the first month post transplant largely reflect 
deficiencies in granulocytes and mononuclear cells, where as, infections occurring late post 
transplant are largely due to poor T cell and B cell reconstitution. The importance of T cells 
post transplantation is highlighted by the use of donor lymphocyte infusions (DLI) to either 
induce 100% donor chimerism in recipient's post transplant or to cure patients who relapse 
their original leukaemia or lymphoma. Approximately 20-80% of patients who relapse post 
transplant can be cured with the use of DLI, however, this treatment is associated with the 
risk of developing GVHD and is therefore not suitable for those patients who have developed 
GVHD. This graft versus leukaemia (GvL) effect that is often seen in patients receiving a DLI 
demonstrates the importance of T cells in preventing relapse and is further highlighted by the 
increased risk of relapse associated with TCD transplants (Goldman et al. 1988). In patients 
that show poor T cell reconstitution, donor derived lymphocytes can be given to the recipient 
to encourage or improve T cell numbers and recovery, although this comes with the risk of 
the patient developing GVHD.
After a myeloablative transplant the first cells to reconstitute are those of the innate immune 
response notably granulocytes, NK cells, marcrophages and monocytes. The cells of the 
innate immune response are able to provide some protection against viral infections, however,
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since T cells and B cells are still severely reduced in number, without these cells patients are 
still at risk of developing life-threatening infections from opportunistic pathogens. Within one 
year post transplant the B cells numbers start to normalise, the antibody levels early post 
transplant are low, but antibodies specific for pathogens encountered post transplant start to 
increase. When CD4+ T cell and B cell reconstitution is sufficient, the vaccination for 
pathogens not encountered post transplant (tetanus, measles, mumps) is recommended. The 
reconstitution of the T cell repertoire is characterised by the appearance of memory T cells 
that are either of donor origin in non TCD transplants, or residual T cells in the recipient that 
have survived the conditioning regimen, these memory T cells expand and are able to respond 
rapidly to pathogens that they are specific for. To obtain a diverse T cell repertoire that is 
capable of responding to a wide variety of pathogens the reconstitution of naive T cells is 
required, the rate of naive T cell reconstitution is largely dependent on a functional thymus. 
The rate of immune reconstitution is largely affected by the development of GVHD and its 
treatment as well as any infectious complications encountered.
57
Chapter 1
1.11 Complications post HSCT
One of the major problems encountered by HSCT recipients is the development of GVHD 
and subsequently infections can occur due to continued immune deficiency. The occurrence 
of acute GVHD is a major cause of early TRM and chronic GVHD is a major cause of 
morbidity and mortality 100 days post transplant. The high TRM due to GVHD is not only 
due to it's direct effects but also due to it's treatment resulting in further profound 
immunodeficiency, allowing for the occurrence of opportunistic infections.
1.11.1 Graft vs. Host disease
GVHD is the consequence of interactions between antigen presenting cells (APCs) from the 
recipient and mature T cells from the donor. The T cells from the donor react with host APCs 
(alloreactivity) causing organ damage. There are two pathways involved in the presentation of 
alio reactive antigens, a direct allorecognition pathway and an indirect allorecognition 
pathway. In direct allorecognition effector T cells bind directly to the allogeneic MHC class I 
molecules in mismatched grafts, in this pathway naive T cells are activated by APCs that bear 
both the allogeneic MHC molecules and have co-stimulatory activity. Donor derived APCs 
present in the graft migrate to the lymph node following infusion where they activate any 
residual T cells bearing the corresponding TCR. Following T cell activation these then leave 
the lymph nodes and migrate back to the graft where they attack the foreign cells, resulting in 
graft destruction. Indirect allorecognition is caused by the uptake of donor proteins by the 
recipients own APCs, these are subsequently presented to T cells by self-MHC molecules. 
Among the presented proteins are the minor H antigens and peptides derived from the foreign 
MHC itself. Two models have been proposed that could generate alloreactive T cells, the 
peptide independent model, whereby T cells recognise polymorphic residues on the surface of 
MHC molecules, and the peptide dependent mechanism where peptides bound to MHC 
molecules are recognised. Recent evidence demonstrates that the peptide dependent 
mechanism is mainly responsible for the generation of alloreactive T cells (Whitelegg et al. 
2005).
Acute GVHD occurs before 100 days post transplant, the median incidence of grade II-IV 
acute GVHD is about 40% but can range from 10-80% depending on risk factors. The main 
risks associated with the development of acute GVHD are the recipient's age, conditioning 
regimen, CMV status, donor HLA matching and NK cell alloreactivity. Chronic GVHD 
occurs after 100 days post transplant and is more likely to develop in those recipients who 
have also had acute GVHD. The median incidence of chronic GVHD is 30-45%, the main 
organs affected by both chronic and acute GVHD are the skin, gastrointestinal tract and the 
liver, in 80% of cases the skin is the most frequently affected organ. The treatment of GVHD
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involves the use of potent immunosuppressive therapy aimed at reducing the function of T 
cells. Methotrexate is most commonly used in combination with Cyclosporine A (CsA) that 
specifically inhibits T cell proliferation and IL-2 production, it primarily works by inhibiting 
the activity of calcineurin thereby preventing the translocation of NFAT into the nucleus and 
subsequent IL-2 transcription. CsA is commonly given a few days before transplant to reduce 
or prevent graft rejection. Other drugs are available to treat GVHD such as Tacrolimus, which 
works in a similar manner to CsA by blocking the activity of NFAT, Mycophenolate Mofetil 
(MMF), which inhibits the synthesis of guanine nucleotides and thus has a potent cyostatic 
effect on lymphocytes. Corticosteroids such as prednisolone are most commonly used to treat 
chronic GVHD, they work by binding intracellular glucocorticoid receptors that then act as 
transcription factors binding to the glucocorticoid promoters at target gene promoters thus 
preventing their transcription. A number of drugs can be used to prevent or reduce the 
severity of GVHD, these can be used individually or in combination to provide a more potent 
therapy.
To reduce the risk or severity of GVHD, mature T cells can be depleted from the graft prior to 
infusion, thereby, removing potentially alloreactive T cells. If a graft is T cell depleted prior 
to infusion any T cells that subsequently mature in the recipient through processing in the 
thymus are tolerant to the recipients antigens. T cell depletion is commonly carried out in 
transplants where there is an increased risk of GVHD possibly due to HLA mismatches or in 
older patients who have a high TRM, but a higher rate of relapse occurs in recipients who 
receive T cell depletion. Early retrospective studies revealed that leukaemic relapse after 
HSCT was less frequent in those patients who had developed GVHD post transplant (Weiden 
et al. 1979). These studies indicated that cells from the donor could exert an anti-leukaemic 
effect, these findings have proven particularly important when determining transplant 
conditioning regimes. With some leukaemia's such as chronic myeloid leukaemia (CML) 
where a graft-versus-leukaemia (GvL) effect has been demonstrated a non-TCD transplant 
might be preferred.
In this thesis 18 patients were recruited from the Royal Free Hospital, thirteen patients were 
TCD using Campath-IH and the remaining five patients did not receive any form of TCD. 
Campath-IH is a humanised monoclonal antibody against the cell surface marker CD52, this 
marker is highly expressed on lymphocytes and monocytes, which can then be depleted from 
the graft prior to infusion. The use of T cell depleting reagents implies that no pathogen 
specific T cells are transferred to the recipient, who is consequently at high risk of developing 
life-threatening opportunistic infections post transplant.
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1.11.2 Infectious complications post HSCT
Apart from GVHD HSCT recipients as mentioned above are also prone to opportunistic 
infections. The HSCT recipients are the most immunosuppressed patients within a hospital 
and are therefore at high risk of developing nosocomial infections from pathogens in the 
surrounding environment. During the neutropenic phase immediately post transplant 
recipients are at particular risk of developing bacterial infections in particular from 
Streptococcus and gram negative bacteria, these infections can be life-threatening leading to 
sepsis. Late post transplant patients are still profoundly hypogammaglobulinemic and are 
therefore unable to mount an immune response to encapsulated bacteria and are most 
susceptible to infections caused by H.influenzae and S.pneumoniae. Apart from bacterial 
infections, fungal infections present one of the most serious infectious complication following 
HSCT, in particular infections caused by Aspergillus (Marr et al. 2002). The incidence of 
infections caused by Aspergillus can vary depending on the incidence of GVHD, however, 
this generally ranges between 0-20% and is the most common cause of death in patients who 
have undergone allogeneic HSCT (Cordonnier et al. 2003). Aspergillus infects the lungs 
causing aspergillosis that is characterised by the spread of the fungus through the lungs 
causing respiratory failure, this may even disseminate throughout the whole body. The risk of 
developing aspergillosis is highest in those patients who develop GVHD and is mainly 
associated with the used of steroid therapy. Despite improvements in the treatment of 
aspergillosis it still carries a 50% mortality rate in those who develop the disease.
Viral infections are another major problem encountered post allogeneic HSCT that can be 
life-threatening, especially when infecting the lungs, liver or CNS. The respiratory viruses 
such as respiratory syncytial virus (RSV), parainfuenza virus, rhino virus and influenza virus 
are commonly encountered post HSCT. These respiratory viruses cause pneumonia more 
frequently than Cytomegalovirus, the mortality due to RSV can be as high as 80%. The 
Herpes viruses can also cause serious disease post transplant, these viruses establish life long 
latency in those infected and due to HSCT conditioning regimens all pre existing transplant 
immunity against these viruses is lost, as a result recipients are at increased risk. The 
reactivation of Herpes simplex virus can present a problem in seropositive patients causing 
painful mucosal lesions, other viruses such as Varicella-zoster virus (VZV) and Adenovirus 
can also reactivate to cause disease. The reactivation of Epstein-Barr virus (EBV) can cause a 
life-threatening lymphoproliferative disease post HSCT, although monitoring EBV viral loads 
allows for the early detection of infection prior to disease. Cytomegalovirus (CMV) is another 
Herpes virus that can cause significant problems post HSCT, historically CMV disease was 
the main cause of death post HSCT, however, due to improvements in the treatment and 
detection of this virus mortality has been falling. Despite this CMV still presents a problem
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post HSCT due to the occurrence of ganciclovir resistant strains and the possible association 
of CMV and GVHD. The risk of CMV infection is greatest in those recipients who are on 
steroid therapy for GVHD, received a graft from a matched unrelated donor, or if the graft 
was T cell depleted. In this thesis the CMV specific immune reconstitution in HSCT 
recipients was investigated, although as described other bacterial or fungal infections do also 
represent a problem post transplant, the reactivation of CMV occurs in the majority of HSCT 
recipients. The ability of CMV to avoid immune detection and persist in the host has been a 
major area of research a greater understanding of the virus and its replication has led to the 
development of potent antiviral drugs to prevent CMV disease in high-risk groups. It is 
therefore useful to characterise target epitopes for vaccination and to improve strategies to 
further reduce the problems due CMV so that it no longer impacts on the outcome of HSCT 
therefore allowing the focus to shift to some of the other pathogenic viruses.
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1.12 Cytomegalovirus
Cytomegalovirus can be a cause of life-threatening disease in immunocompromised 
individuals. A number of different patients groups succumb to CMV infections notably HIV 
positive individuals, HSCT recipients and solid organ transplant recipients, CMV is also a 
major cause of congenital deformities when the mother acquires the virus during pregnancy 
that then infects the foetus causing serious CNS damage. In common with other herpes 
viruses, CMV establishes a life long latency in the host characterised by periodic 
reactivations, approximately 40 of its open reading frames (ORFs) show a high degree of 
similarity to proteins encoded by alpha and gamma herpes viruses (Chee et al. 1990; Karlin et 
al. 1994).
1.12.1 CMV structure
The CMV virion particle is 150-200nm in diameter and consists of a lOOnm diameter 
icosahedral nucleocapsid containing a 230kbp, double stranded linear DNA genome 
surrounded by a protein layer called the tegument, which is enclosed by a lipid bilayer 
containing a large number of viral glycoproteins. These viral glycoproteins play an essential 
role in the maturation of the virus but are also important in virus entry and cell-to-cell spread 
(Britt and Mach 1996). The structure of the virus is shown in figure 1.6. Cells infected with 
CMV in culture produce the mature virion and two other types of particles; non-infectious 
particles and dense bodies, the non-infectious particles are defective viral particles that lack 
DNA but contain enveloped immature capsids and the viral assembly protein (AP) that is 
normally absent from mature nucleocapsids. The dense bodies are enveloped particles that 
lack a nucleocapsid and viral DNA, but contain several tegument proteins with pp65 being 
the must abundant one. The relative amount of the different particles produced depends on the 
viral strain and the number of passages in culture (Courcelle et al. 2001).
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Figure 1.6 Cytomegalovirus (CMV) virion structure
The structure of CMV a showing the viral genome and nucleocapsid surrounded by a 
tegument layer containing the pp65 antigen, the tegument layer is enclosed by the lipid 
bilayer that contains the viral glycoproteins. (Source: (Gandhi and Khanna 2004).
1.12.2 Virus binding and entry
Virus entry is rapid and efficient in both perm issive and non-perm issive cells types. The 
efficient replication o f  the laboratory CM V strain (A D  169) is only observed in a restricted 
range o f human cells notably lung or skin fibroblasts, clinical isolates preferentially replicate 
in endothelial ce lls, it is thought that a post penetration block is thought to restrict the 
replication o f  the virus in non-perm issive cells (Sinzger et al. 2000). CM V infects cells by 
interacting with an epidermal growth factor receptor (EGFR) and the coreceptor alphavbeta3 
inducing subsequent signalling pathways (W ang et al. 2005; W ang et al. 2003). Viral entry is 
accom plished through a cascade o f  interactions between the viral and cellular protein, this 
results in the fusion o f  the viron envelope with the cellular plasm a membrane in a pH  
independent mechanism. The viron attaches to the host cell by the low  affinity binding o f  gB  
to heparan proteoglycans (Compton et al. 1993), the affinity o f  this binding is increased by 
the association o f  other viral glycoproteins w ith yet unidentified receptors (Theiler and 
Compton 2001).
The m ost important glycoproteins for virus entry include gB, gN , gO, gH, gM  and gL, the 
disruption o f the ORFs encoding gB, gH, gL and gM results in the failure to produce mature 
virions in fibroblasts, only the gO glycoprotein appears to be dispensable (H obom  et al.
63
Chapter 1
2000). These glycoproteins associate to form three complexes called gCI, gCII and gCIII, 
these are highly conserved among the herpes viruses (Gretch et al. 1988). The gCI complex is 
composed of homodimeric gB molecules, the gCIII complex contains a heteroligomeric 
complex of gH, gL and gO (Theiler and Compton 2001), both of these complexes are 
essential for viral entry. The gCII complex results from the association of gM and gN (Kari et 
al. 1994). The gCI complex is involved in the initial interaction of the virion with the host 
cell, gB is the major cell surface heparan sulphate proteoglycan binding glycoprotein. The 
gCIII complex is involved in the final stages of virus entry via the pH independent fusion 
between the virion envelope and the host cell membrane (Huber and Compton 1998). All 
three of these complexes induce neutralising antibodies, although for diagnostic purposes the 
serostatus of an individual is determined by the detection of gB specific immunoglobulin, 
which is the most abundantly expressed. The virus can penetrate the host cell very quickly 
and within an hour post infection (p.i) the tegument protein pp65 can be detected. Due to the 
presence of pp65 following viral entry it is used as the target antigen in antigenemia assays 
for the rapid detection of CMV infections. Following virus entry changes in host gene 
expression and cellular expression occurs and the expression of the CMV genome 
commences.
1.12.3 CMV genome and gene expression
The CMV genome is the largest of all herpes viruses containing 230kbp arranged in unique 
long (UL) and unique short (US) repeat regions. The laboratory CMV strain, AD 169, has 
been completely sequenced, its genome analysis has revealed that it encodes for 225 ORFs 
(Chee et al. 1990; Novotny et al. 2001), subsequent analysis has also shown that 19 genes 
were missing when compared with the clinical strains (Cha et al. 1996), the genome of the 
clinical CMV strain Merlin has also recently been fully sequenced (Dolan et al. 2004). In 
accordance with other herpes viruses, approximately 25% of the ORFs encode for proteins 
related to the replication of the viral DNA, the remaining 75% of ORFs are thought to encode 
for proteins involved in the maturation and structural organisation of virions. To date only a 
few of these 225 ORFs have been assigned functional roles (Novotny et al. 2001), many 
ORFs still remain to be characterised.
The expression of the CMV genome is initiated shortly after the virus has entered the host 
cell, mechanism's which control genome expression are not fully understood but are likely to 
involve proteins synthesised in three distinct stages post infection. The first proteins to be 
synthesised are the immediate early proteins (IE), these are required for the transcription of 
the second set of genes, the early genes (E). The IE proteins are synthesised within the first 
hour post infection, these include the major IE (MIE) UL122 and UL123 genes that encode
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for the IE1 and IE2 proteins, the MIE proteins act as transactivators and auto stimulators that 
are required for the expression of other CMV genes, they also regulate the expression of a 
large number of host genes as well (Fortunato and Spector 1999). The early appearance of 
IE1 and IE2 proteins in the host cell makes them ideal antigens to be presented and processed 
into viral peptides that can be present on the cell surface in association with MHC class I 
molecules, however, it was found that pp65 present in the tegument inhibited the presentation 
of IE1, therefore in CMV infected pp65 expressing fibroblasts there should be no presentation 
of IE1 (Gilbert et al. 1996). Despite the finding that pp65 can prevent IE1 peptides from being 
presented on the cell surface, a number of IE1 specific CTLs can be found in healthy CMV 
seropositive individuals (Gyulai et al. 2000; Kern et al. 2000), demonstrating that during the 
reactivation of latent CMV IE1 could be processed before pp65, which is expressed in the late 
stages of gene expression.
The IE proteins initiate the expression of the early genes, the early proteins allow DNA 
replication to proceed and appear 8-24 hours after infection. Early proteins provide essential 
enzymatic function within the cell, such as the DNA polymerase (UL55) and a protein kinase 
(UL97) which phosphorylates the antiviral nucleosides, ganciclovir and aciclovir. Mutations 
can occur within the UL97 gene preventing the activation of ganciclovir and thus allowing 
resistant strains to develop. Following the early genes, the late genes are then expressed, the 
late proteins are produced 24-48 hours post infection, these proteins play a structural role in 
virion formation. Some late genes are transcribed at early times but are only translated after 
DNA replication has occurred. The most well studied late protein is the tegument protein 
pp65 (UL83) that can be found both in mature virions and dense bodies, although pp65 is 
expressed in the late stage of gene expression it is present in the tegument of mature virions 
and upon virus penetration into a host cell, pp65 can then be processed into viral peptides by 
the proteasome and presented on the cell surface in association with MHC class I. Unlike the 
IE1 antigen, pp65 does not rely on viral genome expression and during a primary infection 
peptides derived from pp65 can be found on the host cell surface, as a result a high number of 
pp65 specific CTLs can be found in the circulation (Wills et al. 1996). The pp65 and IE1 
antigens are attractive targets for the cell mediated immune response, whilst the coat protein 
gB is considered the main target antigen for the humoral immune response.
The development of a CMV vaccine suitable for all at risk groups relies on the understanding 
of the immune response to the virus and thus the best candidate antigens for selection and 
inclusion into a vaccine. The current treatment of CMV infection involves the use of potent 
antiviral drugs, however, these drugs can have serious side effects and the recent emergence 
of drug resistant strains of CMV may mean that in future that the mortality rate due to CMV 
increases, as less treatment options are available.
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1.13 Aims of the thesis
The recent advances in medicine have created more treatment options for previously life- 
threatening diseases such as leukaemia, which together with the success of haematopoietic 
stem cell transplantation have improved the chances of curing leukaemia and providing better 
overall survival. During and post HSCT the recipient is heavily immune suppressed to 
prevent the rejection of the incoming graft, however, during this period life-threatening 
opportunistic infections can occur. Currently there are two options available for the treatment 
of CMV infections, firstly the antiviral drugs ganciclovir and foscamet can be administered, 
however, drug resistant strains of CMV have been reported, in those patients who fail to 
respond to antiviral drugs CMV specific T cells can be transferred from the donor to try and 
control CMV replication. The adoptive transfer of CMV specific T cells can only be carried 
out if the donor is still available and is CMV seropositive.
Thus the aim of this thesis is to identify the CMV antigens that are important in controlling 
CMV replication in patients undergoing HSCT and to identify immunogenic peptides that 
could be incorporated into a peptide vaccine.
• Firstly, HSCT patients will be monitored longitudinally post HSCT for CD8+ T cell 
responses to the CMV antigens Immediate early 1 (IE1) and phosphoprotein 65 
(pp65), in addition the CD4+ T cell response to CMV lysate will also be determined. 
The functional responses of both CD4+ and CD8+ T cells will be determined by 
measuring the amount of IFNy produced following antigen stimulation through the 
use of intracellular staining for IFNy.
• The epitope mapping of new CD8+ T cell epitopes derived from the IE1 and pp65 
antigens will be performed in a large cohort of healthy individuals of mixed HLA 
types. We were particularly interested in identifying new epitopes presented in the 
context of HLA alleles present within the Asian and Afro-Caribbean populations.
• We will utilise HLA/peptide tetramers to identify the frequency of T cells specific for 
CMV peptides in the peripheral circulation of healthy individuals, HSCT and 
Common Variable Immunodeficiency (CVID) patients. The phenotype of the T cell 
subsets in healthy individuals, CVID and HSCT patients will also be assessed.
• The relative dominance of CMV peptides will be investigated in HLA- 
A*0201/B*0702 positive individuals and peptide specific T cells will be generated in 
vitro from these individuals to investigate this phenomenon.
The findings from this PhD thesis serve to demonstrate the importance of a functional T cell 
response to CMV in patients undergoing HSCT, the results presented here demonstrate the 
problems involved in selecting peptides to be incorporated into a CMV vaccine.
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Chapter 2 
Methods
2.1 Patient Studies
2.1.1 Recruitment and ethical approval
Two studies were conducted that required written consent from the participants. The first 
study was to identify new CMV epitopes from a cohort of healthy volunteer donors, the 
second study conducted monitored functional CD4+ and CD8+ T cells responses to CMV in 
patients post HSCT. The ethical approval required and the sample collection for each is 
described separately below.
2.1.2 Epitope mapping study recruitment
Volunteers who had joined the Anthony Nolan Trusts' stem cell transplantation donor register 
were contacted with respect to participating in this study. They were selected according to 
their HLA type and CMV serology, we only contacted volunteers who had never been 
approached about becoming a potential stem cell donor and also those who had little time left 
on the register due to age constraints. Initially an information sheet and consent form (see 
appendix section 1) were sent to these individuals, to those who provided written consent a 
blood taking pack was subsequently sent. All donors gave approximately 20mls of venous 
blood which was taken at their local health centre or at the Anthony Nolan Trusts' head office. 
All blood samples were returned by an overnight mail delivery. The histocompatibility 
laboratories at the Anthony Nolan Trust, London, performed the HLA typing and CMV 
specific ELISA.
2.1.3 Healthy laboratory volunteer recruitment
Blood samples were obtained from healthy laboratory staff from the Anthony Nolan Trust, 
Haematology and Virology departments at the Royal Free hospital (London) and from 
clinicians at Southampton General Hospital. All volunteers were informed of the study and 
verbal consent was obtained. All volunteers were typed for all major HLA antigens (HLA-A, 
HLA-B, HLA-C, HLA-DR) at the allelic level by molecular techniques. HLA typing and the 
CMV ELISA was performed by the histocompatibility laboratories at the Anthony Nolan 
Trust, London.
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2.1.4 Recruitment of patient's post-HSCT
HSCT patients were recruited from the Royal Free Hospital (London) with the approval from 
the local ethical approval authorities (GM AN97/1). These patients were given an information 
sheet about the study (see appendix section 1) and the attending clinician answered any 
questions. Written consent was obtained from all patients who participated in this study (see 
appendix section 1). The patients who were recruited were undergoing allogeneic HSCT as 
treatment for either haematological malignancies or immunological defects. Only those 
patients who were CMV seropositive prior to transplant or received a graft from a CMV 
seropositive donor were considered eligible for this study. The patients and donors were typed 
for all major HLA antigens at the allelic level by molecular techniques. HLA typing and the 
CMV specific ELISA was performed by the histocompatibility laboratories at the Anthony 
Nolan Trust, London.
Eighteen patients being treated for haematological malignancies and immunological disorders 
by allogeneic HSCT were recruited to take part in this study between July 2004 and 
September 2005. All the patient details are summarised in table 2.1. The monitoring of CMV 
specific reactivity was commenced post HSCT after engraftment and when there was 
sufficient recovery of lymphocyte numbers, initially patients were monitored fortnightly as an 
inpatient and then at each outpatient visit.
2.1.5 Blood collection protocols
Blood samples were obtained once engraftment was confirmed and sufficient immune 
reconstitution had taken place. Blood samples were obtained at the same time as other routine 
tests were performed both from inpatients and later from patients attending the out patient 
clinic. 20ml blood was collected into tubes containing 200(11 heparin (Monoparin (lOOOU/ml) 
CP Pharmaceuticals, UK) to prevent the blood from coagulating. All samples were processed 
either on the day of collection or the following day.
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Patient Disease Age,
years
Sex Donor/Patient 
CMV serology
Stem cell source Conditioning Campath-IH 
in vivo/in graft
GvHD
prophlaxis
Follow 
up, days
1 ALL 19 M -/+ MUD PBSC Flu, Cyclo and TBI No/Yes CsA 129
8 EP 60 M -/+ RIC MUD PBSC Flu and Melph Yes/No Tacrolimus 236
2 MM 49 F -/+ Sib RIC alio PBSC Flu and Melph Yes/No CsA 336
15 AML 35 F -/+ Sib BM Cyclo and TBI No/No MTX and CsA 216
3 AML 47 M -/+ Sib PBSC Cyclo and TBI No/Yes CsA 208
17 NHL 56 M -/+ MUD RIC alio PBSC Flu and Melph Yes/No CsA 179
22 FasL 32 M -/+ Sib RIC alio PBSC Flu and Melph Yes/No CsA 103
7 CML 57 F +/+ RIC MUD PBSC Flu and Melph Yes/No CsA 245
19 ALL 27 M +/+ Sib BM TBI No/No MTX and CsA 142
4 AML 32 M +/+ Sib RIC alio PBSC Flu and Melph Yes/No CsA 325
5 AML 9 M +/+ Sib PBSC Cyclo and TBI No/No MTX and CsA 256
12 HL 19 F +/+ Sib RIC alio PBSC Flu and Melph Yes/No CsA 188
11 CLL 53 M +/+ Sib RIC alio PBSC Flu and Melph Yes/No CsA 114
13 AML 58 F +/+ RIC MUD PBSC Flu and Melph Yes/No CsA 231
6 ALL 17 M +/+ Sib PBSC Cyclo and TBI No/No MTX and CsA 183
18 AML 44 M +/+ Sib PBSC Cyclo and TBI No/No MTX and CsA 167
16 NHL 53 M +/- Sib RIC alio PBSC Flu and Melph Yes/No CsA 188
21 AML 35 F +/- Sib RIC alio PBSC Flu and Melph Yes/No CsA 124
Table 2.1 Patient characterstics
This table summarises the characteristics of the eighteen patients that were recruited to participate in the post HSCT study. These 
patients were all undergoing HSCT at the Royal Free hospital London, UK
AML, acute myeloid leukaemia; ALL , acute lymphoblastic leukaemia; NHL, non-hodgkins lymphoma; CML, chronic myeloid leukaemia; HL, 
hodgkins lymphoma; CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; EP, erythropoietic porphyria; FasL, fas ligand deficiency; MTX, 
methotrexate; CsA, cyclosporin A; Cyclo, cyclophosphamide; TBI, total body irradiation; Flu, Fludarabine; Melph, melphalan; RIC, reduced intensity 
conditioning; MUD, matched unrelated donor
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2.1.6 Pre transplant conditioning
Eighteen patients were recruited post HSCT, 11 patients from this cohort received reduced 
intensity conditioning prior to transplantation, this is primarily a reflection on the age of the 
patients and the presenting disease. Conditioning consisted of total body irradiation (n=7) or 
melphalan and fludarabine (n=ll), the majority of patients received T cell depletion with 
either Campath in vivo (n=l 1) or "in the bag" (n=2); five patients received no form of T cell 
depletion. The majority of patients within this cohort received T cell depletion to reduce or 
prevent the occurrence of GVHD, this primarily reflects the conditioning regime at the RFH 
and as consequence these patients are at a higher risk of developing infectious complications 
post transplant.
2.1.7 CMV serology
Seven patients were CMV seropositive prior to transplant and received a graft from a CMV 
seronegative donor (R+/D-) of these seven patients three received a graft from a matched 
unrelated donor. Nine patients were CMV seropositive prior to transplant and received a graft 
from a CMV seropositive donor (R+/D+) of these two patients received a graft from a 
matched unrelated donor. Both of these patient groups were considered to have the highest 
risk of reactivating CMV post transplantation. Two patients were CMV seronegative prior to 
transplant and received a graft from siblings who were CMV seropositive.
2.1.8 Graft versus host disease (GVHD) and antiviral prophylaxis
The five patients that received no form of T cell depletion were given Methotrexate (MTX) 
and Cyclosporin A (CsA) post transplantation as immunosuppression. The Thirteen patients 
that were T cell depleted received Cyclosporin A alone as immunosuppression. One of the 
thirteen T cell depleted patients (patient 8) was also receiving Tacroliminus as 
immunosuppression for a prior liver transplant, this was continued post HSCT until the 
induction of tolerance for the transplanted liver occurred. T cell depletion is used to prevent 
or reduce GVHD, however, seven patients developed confirmed or suspected GVHD that was 
treated with methylprednisolone or prednisolone.
From the start of conditioning until engraftment all patients were given intravenous acyclovir 
(800mg, 4 times a day) to suppress the replication of herpesviruses notably Varicella Zoster 
virus, Herpes Simplex Virus and Cytomegalovirus. CMV DNAemia was assessed by routine 
quantitative PCR performed by the Virology department at the Royal Free hospital; the 
minimum limit of detection is 200 copies/ml blood. CMV reactivations were treated when 
two consecutive positive results were obtained or in some cases the decision to treat was left 
to the discretion of the consulting clinician.
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2.2 Cell separation and culture 
2.2.1 Peripheral blood mononuclear separation
Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood by density 
gradient centrifugation. An equal volume of blood was layered over an equal volume of 
lympholyte (Cedarlane laboratories, Canada) in a sterile 20ml universal tube (Bibby Sterilin, 
UK). The tubes were then centrifuged at 2200rpm for 20 minutes without the brakes applied 
to prevent the lymphocyte layer being disturbed. Lymphocytes were then collected from the 
interface layer using a Pasteur pipette. Lymphocytes were then transferred into a 50ml Falcon 
tube (Beckton Dickinson, USA), RPMI 1640 medium (BioWhittaker, UK) was added and 
then the cells were centrifuged at 1800rpm for 10 minutes, this washing step was performed 
to remove any contaminating lympholyte solution. Cells were then washed once more and 
resuspended in 10ml RPMI 1640 medium containing 10% foetal calf serum (FCS), lU/ml 
penicillin and 1 p.g/ml streptomycin (all Bio Whittaker, UK) in preparation for counting and 
subsequent use or cryopreservation.
2.2.2 Cell counting and viability
Cells were counted using the Trypan Blue exclusion method. A 10pl aliquot of the cell 
suspension was mixed with 10pl of 0.4% Trypan Blue solution (Sigma, UK) and transferred 
to a haemocytometer counting chamber (0.1mm depth, Webster Scientific International, UK). 
The number of live and dead cells was determined by using a phase contrast microscope 
(DMLB, Leica) where the live cells appear translucent and the dead cells appear blue.
2.2.3 Cell Cryopreservation
Cells to be cryopreserved were transferred into a 50ml Falcon universal (Beckton Dickinson, 
USA) and centrifuged at 1600rpm for 5 minutes. The supernatant was then discarded and the 
cells were resuspended in a freezing solution which consisted of 90% Foetal Calf Serum 
(FCS, Bio Whittaker, UK) and 10% Dimethylsulphoxide (DMSO, BDH, UK). Cells were 
then pipetted into 1.5ml cryotubes (Nunc®, Denmark) that contained at least 5xl06 cells, 
these aliquots were rapidly frozen by placing into a "Mr Frosty" (Fisher scientific, UK) and 
subsequently transferred to -80°C overnight. The next days these aliquots were then 
transferred into liquid nitrogen for long-term storage.
2.2.4 Thawing Cryopreserved Cells
When cells were required from liquid nitrogen storage, an aliquot was taken and rapidly 
thawed at 37°C to prevent the formation of ice crystals. Cells were then transferred into a 
50ml Falcon tube (Beckton Dickinson, USA) containing 50ml RPMI 1640 (BioWhittaker,
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UK), to remove the freezing mix cells were then centrifuged at 1600rpm for 5 minutes. A cell 
count was then carried out to determine the cell viability.
2.2.5 Cell Culture
The cell lines used were maintained in RPMI 1640 medium (with L-Glutamine, 
Bio Whittaker, UK) supplemented with lU/ml penicillin, lp,g/ml streptomycin and 10% FCS 
(all BioWhittaker, UK), this medium will be referred to as complete medium. Cells were 
maintained in sterile 25, 75 or 175 cm2 culture flasks (Falcon, UK) and incubated in a 
humidified 5% C 02 incubator (IG 150, Jouan, France). The medium was changed to new 
medium every 2-3 days depending on the cell density or if the culture became acidic as 
indicated by the pH indicator in the medium. All cell-based work was performed in a class II 
microflow cabinet.
2.2.6 Cell lines 
T2 cells
T2 cells are unable to present endogenously processed antigens due to a deletion of the genes 
for transporters associated with antigen presentation (TAP1/TAP2). These cells constitutively 
express HLA-A*0201 and HLA-B*5101 and have been used to test the ability of HLA- 
A*0201 molecules to bind to predicted immunogenic peptides. The T2 cells have also been 
transfected with HLA-B*0702 were used to facilitate the identification of HLA-B*0702 
restricted epitopes. T2 cells are easily maintained in culture for long periods, they only 
require complete media every 3-4 days and splitting as necessary.
Transfected cell lines
The T2 cell line was used throughout the project for the presentation of CMV peptides to 
generate a CTL response. When possible T2 cells that had been transfected with other HLA 
types were used to confirm the HLA restriction of newly identified epitopes or they were used 
to generate CMV specific T cells. T2 cells that had been transfected with HLA-B*0702 
(T2B7) were obtained from Dr L Barber (ANRI), in these cells the HLA-B*0702 sequence 
was inserted into the expression vector pBJNeo (see appendix section 2). This vector allows 
the gene of interest to be expressed in mammalian cells; the vector carries a neomycin gene 
that confers resistance to the antibiotic geneticin (G418) when translated. The T2 cells were 
transfected by electroporation, the cells were maintained in complete media containing 
1 mg/ml G418 antibiotic.
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To confirm the expression of HLA-B*0702 the ME1 antibody that specifically recognises 
HLA-B*0702 was used to label the HLA-B*0702 molecules on the cell surface. An anti 
mouse IgG secondary antibody was used that was conjugated to FITC, this antibody is 
directed against the species that the ME1 antibody was raised in. All transfected T2 cells that 
were used in assays were screened for the expression of HLA under investigation prior to use. 
The T2B7 cells were stained with the ME1 and secondary antibody (see section 2.3) and 
subsequently acquired by flow cytometry. The T2 cells were stained with the HLA-A*0201 
specific antibody BB7.2 and the secondary antibody and acquired by flow cytometry.
Geneticin (G418)
The geneticin sulphate antibiotic (G418, PAA Laboratories GmgH, Austria) was used to 
maintain the selection of cell lines that were transfected with the pBJNeo vector (see 
appendix section 2). This vector contains a neomycin resistance gene that when translated 
confers resistance to G418. The G418 was dissolved at a concentration of 40mg/ml in PBS 
and filtered through a 0.45pm filter (Sartorius, UK) prior to being used at a final 
concentration of 1 mg/ml.
2.2.7 Hybridoma cell lines
Hybridoma cell lines were used to produce the human HLA monoclonal antibodies that were 
used for cell staining these cell lines had been produced by previous students. Hybridoma cell 
lines are generated from the fusion of a B cell producing a specific antibody with a 
continuously growing plasmacytoma, the resulting fusion is an immortalised antibody 
producing cell line. The hybridoma cell lines used were grown in complete media to a volume 
of approximately 2 litres over a period of 3-6 weeks. To harvest the antibodies the cells were 
centrifuged at 1700rpm for 10 minutes at 4°C and the supernatant was then carefully 
removed. The supernatant was then concentrated down to approximately 100ml using an 
ultrafiltration stirred cell (Amicon®, UK) under nitrogen gas pressure. The molecular weight 
cut off size of the membrane (Millipore, Bedford, USA) is 10,000 ensuring that the antibody 
cannot pass through. The supernatant containing the antibodies was then titrated to determine 
the saturating amount to use in cell staining methods. The antibodies obtained from 
hybridoma cell lines are listed in table 2.2.
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Antibody
Name
Cell surface marker Secondary antibody
W6/32 MHC class I pan antibody Mouse anti-human IgG FITC
conjugate
BB7.2 HLA-A*0201 Mouse anti-human IgG FITC
conjugate
ME1 HLA-B*0702 Mouse anti-human IgG FITC
conjugate
Table 2.2 Unconjugated primary antibodies used
This table summarises the hybriboma cell lines that were used and the specificity 
of antibodies that were purified from each cell line.
2.2.8 Generation of Epstein-Barr virus transformed B-cell lines (LCL)
Epstein-Barr virus (EBV) transformed B-cell lines were generated by infecting B cells with 
EBV supernatant and were maintained in culture for 6-8 weeks prior to use. To generate EBV 
stocks the marmoset producer cell line B95-8 was grown exponentially. After 3 days the cells 
were pelleted, the supernatant was then harvested, filtered and stored for short term use at 
-80°C or cryopreserved in liquid nitrogen for long term storage.
For EBV transformation of healthy donor B cells at least lxlO7 PBMCs were used, these were 
pelleted by centrifuging at 1500rpm for 5 minutes and the supernatant was then discarded. 
The cell pellet was then resuspended in 1ml EBV supernatant and incubated in a humidified 
5% C 02 incubator for 1.5 hours. After the incubation period 5ml complete medium 
containing 1 % phytohemagglutinin (PHA) was added and 2ml pipetted into each well of a 24 
well plate. Cells were cultured in a humidified 5% C 02 incubator for a week, half of the 
medium was exchanged for fresh medium every 3 days. After a week in culture PHA was 
removed from the cell cultures by centrifugation of the cells at 1500rpm for 5 minutes. The 
cell lines were then expanded in 25-75cm2 flasks over 4-6 weeks. The generation of EBV 
transformed cells was confirmed by testing for the expression of the B cell markers CD 19, 
CD20 and the co-stimulatory molecules CD86, HLA-DR. Cells were either used directly or 
cryopreserved for subsequent use. These EBV cell lines were used to determine the HLA 
restriction of newly identified CMV peptides. The EBV cell lines that were used are listed in 
table 2.3.
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Cell line name HLA type Source
WT49 A*0205, B*5801 Workshop cell line
BTB A*0201, B*270502 Workshop cell line
WEWAK1 A*1101, A*2402, B*2704, B*1506 Workshop cell line
BRUG A*0301, A*1101, B*2702, B*2705 Workshop cell line
GILL A*0201, A*2902, B*4402, B*2705 Generated
SR A*2402, A*6801, B*1501, B*2705 Generated
ISMAIL A*3201, A*3303, B*5201, B*5801 Generated
SC A*0201, A*1101, B*0702, B*4001 Generated
Table 2.3 EBV transformed cell lines used or generated from healthy donors
This table summaries the HLA type of the EBV cell lines. EBV cells were either obtained 
from the Workshop cell line bank or were specifically generated for this project from 
healthy donors.
In addition to the in house generated EBV cell lines, other EBV cell lines were obtained from 
the International HLA Workshop EBV cell line bank. The International HLA Workshop was 
set up in 1964 to help identify and clarify human leukocyte antigens (HLA), the EBV cell line 
bank is maintained at the Anthony Nolan Research Institute (London), and is available to 
other HLA research laboratories.
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2.3 Cell staining and sorting
2.3.1 Cell surface staining using fluorescently conjugated antibodies
The PBMCs used were fresh or from cryopreserved stocks. Cells were centrifuged at
1500rpm for 5 minutes and washed in PBS containing 5mM sodium azide and 1% FCS (wash
buffer), the cells were then centrifuged again at 1500rpm for 5 minutes. The cell pellet was 
resuspended in 50pi wash buffer in a 48 well V bottoms plate (Nunc®) and incubated with a 
directly conjugated antibody for 30 minutes in the dark at 4°C. Some antibodies non- 
specifically bind to cells expressing an Fc receptor, in order to prevent this occurring a 
blocking reagent was used first followed by staining with the antibody specific for the 
required cell surface marker. The cells were resuspended in 20pi of FcR blocking reagent 
(Miltenyi Biotech, Germany) and incubated in the dark at room temperature for 10 minutes. 
Cell surface staining antibodies were then added directly to the well without washing. After a 
30 minute incubation, the cells were washed twice and fixed with 200pl of PBS containing 
1 % paraformaldehyde. The cells were then either stored in the dark at 4°C or were acquired 
on a FacsCalibur flow cytometer running Cellquest software (Beckton Dickinson, UK). The 
antibodies used were either directly conjugated to a fluorochrome or were unconjugated and 
required a secondary conjugated antibody (table 2.4). The immunoflurescent dyes used are 
excited by light of one wavelength and emit a different wavelength of light as fluorescence. 
The fluorochromes used and their excitation and emission wavelengths are listed in table 2.5.
Abbreviation Complete name Emission peak (nm)
FSC Forward Scatter 488
SSC Side Scatter 488
FITC Fluorescin isothiocyanate 530
PE Phycoerythrin 585
PerCP Peridinin chlorophyll protein 670+
APC Allophycocyanin 661
Table 2.5 Emission wavelengths of the fluorochromes used
This table summarises the emission peaks of the conjugated antibodies used throughout 
this project.
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Cell surface 
marker
Function Cell population Antibody
source
CD3 Associated with the T 
cell receptor complex
T cells, Thymocytes BD
CD4 MHC class II co­
receptor
Thymocytes subset, TH1 
and Th2 T cells, monocytes 
and macrophages
BD
CD8 MHC class I co- 
recptor
Thymocytes subset, 
cytotoxic T cells
BD
CD19 B cell activation and 
proliferation
B cells BD
CD27 Co stimulation 
activation signal for T 
and B cells
Thymocytes subset, T cells, 
NK cells and some B cells
BD
CD28 Co stimulatory signal T cell subsets, activated B 
cells
Diaclone
CD45RA Lymphocyte
signalling
T cell subsets, B cells, 
monocytes
BD
CD45RO Lymphocyte
signalling
T cell subsets, B cell 
subsets, monocytes, 
macrophages
BD
CD56 Adhesion molecule NK cells BD
CD57* Non MHC restricted 
cytotoxicy after 
activation
T cell subsets, NK cells, B 
cells and monocytes
BD
CD80 Co stimulator for T 
cell activation
B cell subsets BD
CD83 Unknown Dendritic cells, B cells, 
Langerhans' cells
BD
CD86 Co stimulator for T 
cell activation
Activated B cells, 
monocytes and dendritic 
cells
BD
CD69 Activation Activated T and B cells, 
activated macrophages and 
NK cells
BD
CCR7* Chemokine receptor memory and naive T cells 
and mature dendritic cells
R&D
HLA-DR HLA class II surface 
marker
BD
*FcR blocking reagent used with these conjugated antibodies
Table 2.4 Fluorochrome conjugated antibodies
This table summarises all the fluorochrome conjugated antibodies that were used to 
characterise cell subsets throughout this project. All these antibodies were mouse anti­
human monoclonal antibodies and were purchased from Beckton Dickinson (BD, UK) 
unless indicated.
77
Chapter 2
2.3.2 Cell surface staining using unconjugated primary antibodies
For the labelling of HLA molecules on the cell surface unconjugated antibodies were 
produced from the hybridoma cell lines listed in table 2.2. The staining for HLA molecules 
was performed as a two-step procedure. Initially cells were stained using a primary 
unconjugated antibody (W6/32 or ME1, table 2.2) and incubated on ice for 30 minutes. The 
HLA specific antibodies had been titrated to determine the optimal volume to use for a given 
cell number. Titration of antibodies was performed through the use of cells that expressed the 
HLA allele of interest. The expression of HLA-A*0201 on the T2 cells was checked using the 
HLA-A*0201 specific antibody BB7.2. The expression of HLA-B*0702 on the transfected 
T2 cells was checked using the HLA-B*0702 specific antibody ME1, a negative expressing 
HLA cell line (K562) was also included. The absence of HLA molecules on the surface of 
K562 cells was confirmed by using the pan-MHC class I antibody W6/32. All the cell lines 
were stained with various amounts of antibody to determine the optimal amount for use. After 
a 30 minute incubation, cells were washed twice with PBS and were then stained with the 
secondary antibody an anti-mouse IgG (FITC conjugate, Sigma, UK) at a 1:20 dilution. The 
specificity of the secondary antibody was checked by incubating cells with only the 
secondary antibody. The cells were then incubated on ice for 30 minutes in the dark at 4°C. 
Following the incubation step, the cells were washed twice in PBS to remove any unbound 
antibody, they were subsequently fixed with 200pl of PBS containing 1% paraformaldehyde. 
The stained cells were then either stored in the dark at 4°C or were acquired by flow 
cytometry.
2.3.3 Tetramers
HLA peptide tetramers are powerful tools for studying antigen specific T cells. Tetramers 
allow for the direct visualisation of antigen specific T cells by flow cytometry and are 
sufficiently sensitive to overcome the low affinity of the T cell receptor for MHCipeptide. 
HLA tetramers are complexes of four biotinylated MHC molecules, which are folded with a 
specific peptide and bound to a fluorochrome. Mixing the biotinylated MHCipeptide complex 
with streptavidin results in the formation of an MHCipeptide tetramer. These HLAipeptide 
tetramers allow for the quantification of peptide specific T cells regardless of function. HLA 
peptide tetramers also allow for the phenotyping of tetramer positive T cells, but no 
information regarding the function of the T cells can be gained. The drawback of using HLA 
tetramers is that the number of tetramer positive CD8+ T cells does not always correlate 
absolutely with the number of functional CMV specific T cells, it has been shown that not all 
tetramer positive cells are functional in terms of their ability to produce IFNy (Ozdemir et al. 
2002).
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For tetramer staining, lxlO6 cells, either fresh or cryopreserved were incubated with lpg of 
the relevant tetramer in 50pl staining buffer (PBS containing 1% heat inactivated FCS and 
5mM sodium azide) at 37°C for 30 minutes in the dark. Cells were then washed in the 
staining buffer and counter stained with 3 pi anti CD8 PerCP and 3 pi anti CD3 FITC mAb 
(Beckton Dickinson, USA) for 30 minutes at 4°C in the dark. Two washing steps were then 
performed and the cells were then fixed in PBS containing 1% Paraformaldehyde. All 
samples were acquired within 48 hours on a FacsCalibur flow cytometer running Cellquest 
software (Beckton Dickinson, USA).
2.3.4 Intracellular cytokines
Intracellular staining for cytokine production is a qualitative and quantitative method for 
measuring antigen specific T cells. Intracellular staining is a method that assesses the 
functionality of T cells following antigen stimulation. This method provides many advantages 
over traditional methods of measuring T cell function such as H3-Thymidine incorporation 
and 51Cr release assay. These traditional methods are long and labour intensive and the results 
cannot be quantitatively compared. The intracellular detection of cytokines is more sensitive 
than other assays such as the enzyme-linked immunospot (ELISPOT) assay that can be 
affected by the production of high levels of background IFNy. Intracellular staining unlike 
ELISPOT can identify different cell populations simultaneously such as CD4+ and CD8+ T 
cells.
Intracellular staining for cytokine production was performed following the activation of T 
cells, the protein transport inhibitor Brefeldin A is included in order to block cytokine export 
thus allowing the accumulation in the endoplasmic reticulum of the relevant cytokine under 
investigation. The cells are fixed and permeabilised with a mixture of mild detergents. High 
affinity anti-cytokine antibodies that penetrate the cell and bind the intracellular cytokine 
molecules are used. The method used to quantitatively assess T cell responses to the CMV 
antigens is described below.
50ml venous heparinized blood was obtained from fully HLA typed individuals. Following 
density centrifugation, cells were washed and adjusted to l-2xl06 PBMCs in 400pl complete 
media. The co-stimulatory antibody CD28 (R&D, UK) was added at a concentration of 
lug/ml in the presence of peptide (lOpg/ml). Peptide and the co-stimulatory antibody were 
added at time zero along with lOpg/ml Brefeldin A (Sigma, UK). Anti CD28 was added to 
cells stimulated with CMV lysate and incubated for 1 hour prior to the addition of Brefeldin 
A. A pre incubation of PBMCs with CMV lysate was required prior to the addition of 
Brefeldin A, this pre incubation step of PBMCs with CMV lysate allows for the processing of
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antigens in the MHC class II antigen processing pathway. The addition of Brefeldin A would 
prevent the processing of whole antigen by blocking the transport of peptides to the 
endoplasmic reticulmn. Cells were then incubated at 37°C in a humidified 5% C02 
atmosphere for 12 hours. After the incubation period, cells were washed twice in staining 
buffer consisting of PBS and 1% heat inactivated FCS, 0.09% sodium azide, pH 7.5). Anti- 
CD8 PerCP, anti-CD3 PE (Beckton Dickinson, UK) were used to stain the cells prior to 
permeabilisation. Cells were resuspended in 50pl staining buffer, 3 pi of each antibody was 
added and incubated at 4°C, in the dark for 30 minutes. The cells were then washed twice in 
the staining buffer, resuspended in 100pi Cytofix/Cytoperm solution (PharMingen, UK) and 
incubated at 4°C in the dark for 20 minutes. The cells were washed twice in 1 x Perm/Wash 
Solution (PharMingen, UK) to maintain the permeabilised state of the cells. The 
permeabilised cells were resuspended in 50pl 1 x Perm/Wash Solution to which 0.5pl anti 
human IFNy FITC (PharMingen, UK) was added and incubated at 4°C in the dark for 30 
minutes. The permeabilised cells were then washed twice in 1 x Perm/Wash Solution, fixed in 
1% Paraformaldehyde and acquired on a FacsCalibur flow cytometer running Cellquest 
software (Beckton Dickinson, USA).
23 .5  Intracellular staining data acquisition and analysis
Cells that were stained using the intracellular staining method were acquired by flow 
cytometry. Initially, a side scatter verses forward scatter dot plot was set up, a gate was then 
drawn around the lymphocyte population. From the lymphocyte gate a dot plot was set up 
with CD3 verses CD8, at this stage it was important to draw a large gate that included dim 
CD8 and CD4 cells which can appear as a smear coming off the main population, these cells 
are activated and as a result have down regulated their TCR complex. From the CD3 and 
CD4/CD8 gate another plot was set up with side scatter verses IFNy, in some cases the 
expression of the activation marker CD69 was plotted against IFNy.
2.3.6 Anti human CD28
CD28 is used as a co-stimulatory molecule by T cells following engagement of the MHC and 
T cell receptor (TCR), it serves to enhance the signalling effect of MHC and TCR co-ligation 
and therefore the monoclonal anti-human CD28 antibody was used to enhance T cell 
activation following antigenic stimulation through its binding to CD28. For intracellular 
staining, anti CD28 was used at 1 p,g/ml and was added at the same time as the antigen.
2.3.7 Polyclonal Stimulation
As a positive control for the intracellular staining and real time PCR methods, cells were 
stimulated with either staphylococcus enterotoxin B (SEB, Sigma, UK) or purified
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phytohaemagglutinin (PHA, Abbot Murex). SEB and PHA are strong mitogenic stimulants 
that promote cytokine release and rapid cell proliferation. Both reagents were used at a 
concentration of lpg/ml culture.
2.3.8 Cell separation
The separation of cells was performed using Miltenyi Biotech MicroBeads (Germany) that 
allowed for the positive or negative selection of cell populations. MicroBeads were used for 
the separation of cells, these MicroBeads were directly conjugated to anti CD8 FITC. The 
method used to separate CD8+ T cells from PBMC populations is described below.
Cell sorting for CD8 positive T cells
CD8+ T cells were positively selected using a CD8+ T cell isolation kit (Miltenyi Biotech, 
Germany). PBMCs were resuspended in 80pl wash buffer (PBS containing 0.5% bovine 
serum albumin (BSA) and 2mM EDTA) per 107 cells, 20(0,1 of the anti-CD8 MicroBeads was 
added and the cells were then incubated at 4°C in the dark for 15 minutes. The cells were 
subsequently washed once in buffer then centrifuged at 1600rpm for 5 minutes at 4°C. The 
cell pellet was then resuspended in 500p,l of buffer and magnetic separation was carried out as 
described below.
Magnetic separation
The MS columns (Miltenyi Biotech, Germany) were used for the positive selection of cells. 
According to the manufacturers guidelines the maximum number of labelled cells that can be 
used with these columns is 107 cells and only a maximum of 2xl08 cells in total. The columns 
were placed in a magnetic field and rinsed with 500pl wash buffer. The cell suspension was 
then applied to the column and allowed to run through. Unlabelled cells do not bind to the 
column and were collected. Three additional washes were then performed using 500pl of 
wash buffer per sample, the unlabelled cells (unlabelled fraction) were collected. The column 
was then removed from the magnetic field and placed in a sterile universal. To elute the 
labelled cells, 1ml buffer was applied to the column and forced through using the plunger 
supplied with the column, this was repeated twice more to ensure that all labelled cells were 
collected (labelled fraction). To determine the purity of the sorted cells, the unlabelled cell 
fraction was acquired by flow cytometry and compared with the labelled fraction.
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2.4 Immunological assays
2.4.1 T2 assays
T2 cells carry the HLA-A*0201 allele but lack both TAPI and TAP2 genes and are only able 
to bind exogenously added peptides. The expression of HLA-A*0201 on the cell surface is 
low but detectable, the binding of an exogenously added peptide stabilises the MHC class I 
molecules on the surface. These cells were used to test the ability of peptides to bind HLA- 
A*0201 or HLA-B*0702. To measure the increase in fluorescence related to an increased 
MHC class I expression, pan class I antibodies were used either against all MHC class I 
molecules (W6/32) or against specific molecules such as HLA-A*0201 (BB7.2) and HLA- 
B*0702 (ME1). For each test performed a no peptide control was used to compare the shift in 
fluorescence, a positive control was also used which was a peptide known to bind to the 
particular HLA molecule.
For each MHC stabilisation assay at least lxlO6 cells were pulsed with 10-100pg/ml peptide 
overnight at 37°C in a humidified 5% C 02 incubator. Following overnight incubation, the 
cells were washed twice in PBS before cell surface staining was performed using either the 
ME1 or BB7.2 antibodies. The cells were centrifuged at 1500rpm for 5 minutes. The pellet 
was resuspended in 100pi PBS containing 5mM sodium azide and 1% FCS (wash buffer), 5pi 
of the unconjugated primary antibody was then added and incubated at 4° for 30 minutes. The 
cells were washed twice to remove all unbound antibodies. The MHC stabilisation assays 
were performed using a secondary antibody, this was a sheep anti mouse IgG (whole 
molecule, Sigma, UK) conjugated to FITC (Sigma, UK). After two further washes, the cells 
were resuspended in lOOpl wash buffer and incubated with a 1:20 dilution of the secondary 
antibody in the dark at 4° for 30 minutes. The cells were then washed twice to remove all 
unbound antibodies, fixed in 200pl 1% paraformaldehyde and acquired on a FacsCalibur flow 
cytometer.
2.4.2 Epitope mapping using EBV transformed B cell lines (LCL)
To confirm the HLA restriction of newly identified CMV epitopes EBV transformed B cell 
lines were utilised these cells were chosen as they expressed the identical HLA allele under 
investigation and would therefore be expected to present the appropriate peptide. The EBV 
transformed B cell lines that were used are listed in table 2.3, PBMCs were obtained from 
consenting healthy volunteer controls.
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The LCL's were pulsed with the relevant peptide for 1 hour, a no peptide negative control was 
also included. The LCL's were pulsed with lOpg of peptide at 37°C in a humidified 5% C 02 
incubator. Following peptide pulsing, cells were washed twice in RPMI and then irradiated at 
96Gy to ensure no proliferation occurred once in culture. The co-stimulatory antibody CD28 
(R&D, UK) was added at a concentration of lpg/ml and 10pig/ml Brefeldin A (Sigma, UK) 
was also added once the antibody had been allowed to bind. Brefeldin A is used to prevent the 
export of intracellular IFNy. Both the PBMCs and LCL's were adjusted to the numbers listed 
in table 2.6.
Peptide PBMC cell number EBV cell number
No peptide 5x10s 5x10s
Test peptide lxlO6
Test peptide lxlO6
Test peptide (1:1) 5x10s 5xl05
Table 2.6 Cell ratio used for identifying the HLA restriction of newly identified 
CMV peptides
This table shows the conditions that were used to determine the presenting HLA-allele of 
newly identified CMV peptides. A no peptide negative control was included to determine 
the background IFNy levels.
The ratio of PBMCs to LCL's was varied to establish the best ration that provided the optimal 
T cell stimulation (table 2.6) but IFNy secretion did not increase above a ratio of 5:1 (E:T). 
Both the LCL's and PBMCs were then mixed and incubated overnight at 37°C in a humidified 
5% C 02 incubator. Performing a short overnight incubation allows insufficient time for an 
allogeneic reaction to occur, this prevents the masking of an anti peptide response. After 
overnight incubation the cells were washed twice in PBS and stained according to the 
intracellular staining method previously described. To confirm that the LCL's were not 
secreting any IFNy an anti-CD19 PE conjugated antibody was used and the amount of IFNy 
produced was determined by flow cytometry and gating on the CD 19+ cells. Samples were 
then washed and then fixed in 1% Paraformaldehyde and acquired on a FacsCalibur flow 
cytometer.
2.4.3 Generation of CMV specific CTL's
Peptide specific T cells were generated from healthy volunteers using T2 cells as antigen 
presenting cells. 50mls blood was obtained from healthy volunteers, PBMCs were isolated by 
density gradient centrifugation as described previously. T2 cells were adjusted to lx l0 6/ml 
and peptide pulsed with 50pg/ml peptide overnight in a 6 well plate, in a 37°C humidified 5% 
C 02 incubator. The T2 cells were then irradiated at 96Gy to ensure that they did not 
proliferate once in culture, two wash steps were then performed with PBS to ensure that all 
excess peptide was removed. The T2 cells were then adjusted to 0.4xl06/ml using IMDM
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media (Iscoe's Modified Dulbeco's Media, Gibco, Invitrogen, UK) containing 10% FCS, 2% 
AB serum, lU/ml penicillin and lp,g/ml streptomycin. IMDM media was used as it is a highly 
enriched media that is ideal for high density rapidly proliferating cultures. To confirm that the 
peptides were binding to the HLA molecules on the cell surface an MHC stabilisation assay 
was performed using the method described previously.
Prior to the initiation of the cultures with T2 cells, the PBMCs were tetramer stained in order 
to establish a basal tetramer level at day 0. For each cell line negative controls were set up to 
assess the background level of tetramer staining at the different time points, these included T2 
cells with no peptide and T2 cells pulsed with an irrelevant peptide. The tetramer staining was 
validated through the use of CMV seronegative volunteers and also by using tetramers 
specific for other CMV epitopes.
After 7 days in culture, the cells were counted and tetramer staining was performed to 
determine the level of expansion of tetramer positive cells. After 7 days the cells were 
stimulated for a second time. Another batch of peptide pulsed T2 cells were prepared on the 
6th day these were left overnight and irradiated as on day 0. The cells were then adjusted and 
added at the same ratio of 5:1 (PBMC:T2). In order to compensate for cytokine exhaustion 
20IU/ml IL-2 and 20ng/ml IL-7 was added, these were also added when the cells were split or 
if additional media was required. Following the 2nd stimulation cell expansion was visible 
and the cultures needed splitting every second day. The cultures were incubated in a 37°C 
humidified 5% C 02 incubator and checked microscopically every day to ensure a high cell 
density was maintained. At the end of a further 7 days the cells were counted and tetramer 
staining was performed to determine the percentage of tetramer positive cells.
2.4.4 Interleukin-2
Recombinant human Interleukin-2 (IL-2) was used to promote the proliferation of T cells 
after specific antigen stimulation. IL-2 was added to each T cell culture 7 days after the first 
stimulation (section 2.4.3) at a final concentration of 20IU/ml culture.
2.4.5 Interleukin-7
Human Interleukin-7 (IL-7) plays an important role in memory CD8+ T cell homeostasis by 
promoting the survival and division of these cells in culture. IL-7 was added to each T cell 
culture 7 days after the first antigen stimulation (section 2.4.3) at a final concentration of 
20ng/ml culture.
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2.4.6 Thymidine incorporation assay
In order to measure cell proliferation in response to antigenic stimulation, a thymidine 
incorporation assay was utilised. This assay measures incorporation of 3H thymidine into 
cellular DNA as the cell enters the S phase of the cell cycle. Thymidine is a nucleic acid 
component of DNA, as the cells divide, 3H thymidine is equally incorporated into the DNA of 
the daughter cells. The incorporation of 3H thymidine into DNA is then quantified by |3- 
scintillation counting.
The thymidine incorporation assay was used to test newly identified peptide candidates. Cells 
were plated out at lxlO5 in triplicate in a U bottom 96 well plate, peptides were added at 
lOpg/well and the plates were then incubated in a 37°C humidified 5% C 02 incubator for 24 
hours. A positive control was included which was a well-characterised peptide epitopes 
known to induce cell proliferation as well as staphylococcus enterotoxin B. As a negative 
control, cells with no peptide were included. The cells were all cultured in complete media 
with 10% AB serum, which was used instead of FCS to reduce non-specific background 
proliferation.
Following a 24-hour incubation lpCi/well of 3H thymidine was added and the cells were 
incubated for an additional 24 hours. Cells were then harvested with an automatic cell 
harvester (Harvester 96®, Tomtec, Orange, USA). The cells were then deposited onto a glass 
fibre filter membrane (Printed Filtermat A, Wallac, Turku, Finland). The membrane was then 
dried in a microwave and placed into a plastic bag (Sample Bag, Perkin Elmer life Science, 
Wallac). The edges of the bag were heat sealed (Heat Sealer, Wallac) leaving a small hole for 
the addition of 5ml of scintillant (Optiphase "Supermix", Wallac, Turku, Finland) which 
solubilises the 3H thymidine. The bag was then heat sealed and placed into a cassette holder. 
The P-particle emissions from the 3H thymidine was then counted using a 1450 Microbeta 
plus Liquid scintillation counter (Wallac).
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2.5 Biochemistry
2.5.1 Solubilisation of peptides
All peptides were provided as a freeze-dried product that was stored at -20°C until dissolved. 
The peptides were all solubilised using dimethylsulfoxide (DMSO) and were typically 
reconstituted at a concentration of 5-10mg/ml. For all stimulation experiments the final 
concentration of DMSO had to be 1% or below. All peptides were subsequently stored at 
-20°C until required.
2.5.2 Synethetic peptides
Synthetic peptides were used extensively throughout this project. The peptides used for each 
project section are described separately.
Peptides used for HLA tetramer production
The synthetic peptides used for the production of HLA tetramers were obtained from Alta 
Biosciences (The University of Birmingham, UK). All peptides were synthesised on an ABI 
synthesiser using F moc chemistry and subsequently purified by high performance liquid 
chromatography (HPLC). The purity of the peptides was greater than 90% as determined by 
mass spectroscopy. The synthetic peptides that were used for tetramer production are listed 
below in table 2.7.
Peptide sequence CMV antigen Position HLA restriction
NLVPMVATV pp65 495-503 HLA-A*0201
VLEETSVML IE1 316-324 HLA-A*0201‘
YSEHPTFTSQY pp65 363-373 HLA-A*0101
TPRVTGGGAM pp65 417-426 HLA-B*0702
CRVLCCYVL IE1 309-317 HLA-B*0702
‘This tetramer was produced at the Tetramer core facility, Emory University, Atlanta, USA.
Table 2.7 Antigenic peptides used for HLA tetramer production
The sequence o f the CMV peptides used for the production of HLA tetramers. These 
peptides were purchased from Alta Biosciences, University of Birmingham, UK and had 
a purity o f more than 90%. Throughout this project these peptides will be referred to 
according to the first three amino acids (in bold).
2.5.3 Post HSCT monitoring study
For the monitoring of CMV specific immune responses in patients undergoing HSCT, peptide 
mixes were purchased for the CMV antigens IE1 and pp65. These PepMixes™ (Jerini, 
Germany) contain 15nmol (approximately 25p,g) of each peptide spanning the full length of 
the antigens, all these peptides were 15mers that overlapped by 11 amino acids. For the IE1 
antigen there were 120 peptides and for pp65 there were 138 peptides. The PepMixes™ were 
provided as freeze dried material that was dissolved in 125 pi DMSO. 5 pi was then used per
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stimulation ensuring that the amount of DMSO was below 1%. Reconstituted PepMixes were 
aliquoted and stored at -20°C until required.
2.5.4 Epitope mapping study
In order to identify new CMV epitopes, peptides pools were constructed that spanned the 
whole sequence of both IE1 and pp65, for IE1 there were 8 peptide mapping pools and for 
pp65 there were 9 peptide mapping pools. The sequence of each antigen is shown in figure 
2.1. A full list of the peptides in each pool is shown in the appendix (section 2). Each peptide 
pool contained 15-16 peptides that overlapped by 11 amino acids, these peptide pools were all 
produced on a micromole scale by Jerini (Germany) and were resuspended in 500pl DMSO. 
Initial epitope mapping studies were performed using these peptide pools. PBMCs from each 
individual tested were stimulated overnight with 2.5pil of each pool, and the amount of IFNy 
produced was measured either by intracellular staining or RT PCR. For peptide pools that 
gave a positive response the individual peptides that made up that pool were synthesised and 
tested on the same individuals. A positive response to a peptide mapping pool was defined by 
determining the mean response to all the mapping pools, and then any value that was three 
times the mean was regarded as positive. The further definition of the 9mer peptide was 
performed using algorithms and testing the candidate peptide by using matched LCL's or 
proliferation assays.
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IE1 Antigen
Pooll
1 MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSL
-j- Pool 2
51 GDPLFPELAEESLKTFEQVTEjpCNENPEKDVLAELVKQIKVRVDMVRHRI
101 k e h m l k k y t q t e e k f t g a f n m m g g c l q n a l d ] [ il d k v h e p f e e m k c ig l t m
Pool 3 -,r
151 q s m y e n y iv p e d k r e m w m a c ik e l h d v s k g a a n k l g g a l q a J[k a r a k k d e l
Pool 4
201 RRKMMYMC YRNIEFFTKNS AFPKTTNGCSQAMAALQNLPQCSPDEIMAYA
•v Pool 5
251 QJIKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMTMYG
Pool 6
301 GISLLSEF CRVJ[LCC YVLEETS VMLAKRPLITKPE VIS VMKRRIEEICMKV
351 f a q y il g a d p l r v c s p s v d d l ](r a ia e e s d e e e a i v a y t l a t a g v s s s d s l
Pool 7 -,r
401 v s p p e s p v p a t i p l s s v i v a e n s d q e e s e q s J[d e e e e e g a q e e r e d t v s v k
Pool 8
451 SEPV SEIEE VAPEEEEDGAEEPT ASGGKSTHPM VTRSKADQ J 
pp65 Antigen
Pooll
1 MESRGRRCPEMISVLGPISGHVLKAVFSRGDTPVLPHETRLLQTGIHVRV
Pool 2
51 SQPSLILV SQYTPDSTPCHRGjbNQLQVQHTYFTGSEVEN V SVN VHNPTGR
101 SICPSQEPMSIYVYALPLKMLNIPSIN VHHS}[PS AAERKHRHLP VADAVIHAS
Pool 3 „
151 GKQMWQARLTVSGLAWTRQQNQWKEPDVYYTSAFVFPTigjpVALRHVVC
Pool 4
201 AHELVCSMENTRATKMQ VIGDQYVKVYLESFCEDVPSGKLFMHVTLGSD V
Pool 5
251 EJ[EDLTMTRNPQPFMRPHERNGFTVLCPKNMIIKPGKISHIMLDVAFTSHE
Pool 6
301 HFGLLCPKSIPJpLSISGNLLMNGQQIFLEVQAIRETVELRQ YDPVAALFF
351 FDIDLLLQRGPQYSEHPTFTSjjYRIQGKLEYRHTWDRHDEGAAQGDDDVW
Pool 7
401 TSGSDSDEELVTTERKTPRVTGGGAMAGASTJ[S AGRKRKS ASS ATACTSGV
Pool 8
451 MTRGRLKAESTVAPEEDTDEDSDNEIHNPAVFTWPPWQAGI JIl ARNLVPMV
Pool 9
501 ATV QGQNLKYQEFF WD ANDIYRIF AELEGVW QP AAQPKRRRHRQD ALPGP 
551 CIASTPKKHRG]
Figure 2.1 Overlapping peptide pools for the CMV antigens LEI and pp65
This figure shows the sequences of the CMV antigens IE1 (accession number PI 302) and 
pp65 (accession number P06725) derived from the AD 169 strain. The peptide pools 
boundaries are shown, the full peptide composition of these peptide pools is shown in the 
appendix (section 2).
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2.6 Tetramer Production
For the production of HLA tetramers the method used was based on that previously described 
by Ogg et al. (Rowland-Jones S 2000) and is described in the following paragraphs. All the 
reagents used to make the buffers used below were purchased from either Sigma (UK) or 
BDH(UK).
2.6.1 Cloning of modified HLA heavy chains
All the modified HLA heavy chains that were used in this project had been previously 
produced at the Anthony Nolan Research laboratories or by our collaborators. Briefly, the 
cDNA encoding for the extracellular portion of the HLA heavy chains was cloned into the 
pET-3d vector (Novagen, Cambridge Bioscience, UK), the map of this vector is shown in the 
appendix (section 2). Only the extracellular portion of HLA heavy chain was amplified, this 
was then modified by the addition of a biotinylation site at the C-terminal end. The addition 
of the biotin allows for the attachment of streptavidin that is coupled to the fluorescent marker 
phycoerythrin (PE). The biotin ligase enzyme, BirA was used to biotinylate the HLA 
monomers. Following the biotinylation of the monomers the streptavidin that has four biotin 
binding sites induces the formation of the tetramers. The structure of a tetramer is shown in 
figure 2.2. These pET-3d HLA heavy chain constructs were transformed into BL21pLysS 
(Novagen, UK) bacterial cells for protein expression. The |32M chain was provided in the 
PHN1 vector in the Escherichia coli strain XA90 (a gift from Dr Don Wiley).
2.6.2 Induction of protein expression
Transformed Escherichia coli strain BL21pLysS was inoculated into 30ml LB medium (lOg 
tryptone, 5g yeast, lOg NaCl per litre distilled water) containing lOOpg/ml ampicillin (Sigma, 
UK) and incubated overnight in a shaking incubator at 37°C. 30mls of the overnight culture 
was removed and inoculated into a flask containing one litre of LB medium containing 
lOOpg/ml ampicillin and placed in a shaking incubator at 37°C until the optical density 
reached 0.6-0.9 at a wavelength of 600 nm. Prior to the induction of protein expression a 1ml 
sample of the uninduced culture was taken to run on SDS-PAGE at a later stage. Protein 
expression was induced by the addition of Isopropyl p-D-thiogalactopyranoside (IPTG, 
Alexis Corporation Ltd, UK) to the culture at a final concentration of 1M. After a further 4 
hours incubation, a post induction sample was taken and the bacteria were then harvested by 
centrifuging at 4,000rpm for 30 minutes at 4°C. The supernatant was poured off, and the 
bacterial pellet was resuspended in 50ml phosphate buffered saline (PBS, Bio Wittaker, USA) 
then stored at -20°C for future use.
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Streptavidin PE
MHC class I
Figure 2.2 HLA peptide tetramer complex
This figure illustrates the com position  o f  a HLA tetramer refolded with a peptide. The 
biotinylated M HC heavy chains are refolded with a peptide and then coupled to form a 
tetram er v ia  b ind ing to streptavidin. The streptavidin m olecu le  is coup led  to the 
fluorochrom e R-phycoerythrin (PE) that allow s for the visualisation o f  tetramer by flow  
cytom etry.
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2.6.3 Inclusion body purification
Proteins synthesised as inclusion bodies in E.coli strains such as BL21pLysS need to be 
purified from other bacterial proteins. This was achieved by the following method. Bacterial 
cells were disrupted using sonication, dispersed in bursts of 30-60 seconds, with samples 
being kept cold on ice to prevent heat build up. The lysis process was aided by the addition of 
25mg lysozyme (Sigma, UK), sonication was continued until the culture lost its viscocity. 
The culture was then centrifuged at 13,000rpm for 30 minutes at 4°C to pellet the inclusion 
bodies. The pellet was then washed three times in 50ml Triton wash buffer (0.5% (v/v) Triton 
X-100, 50mM Tris pH 8, lOOmM NaCl, 0.1% (w/v) sodium azide, ImM EDTA, ImM DTT) 
and centrifuged at 13,000rpm for 30minutes at 4°C, a further wash was then performed with 
50ml resuspension buffer (50mM Tris pH 8, lOOmM NaCl, ImM EDTA, ImM DTT) and 
pelleted by centrifugation at 13,000rpm for 30 minutes at 4°C. The resulting inclusion bodies 
were solubilized overnight in 30ml urea buffer (8M Urea, 0.1M NaH2P04, 0.01M Tris pH 8, 
O.lmM EDTA, O.lmM DTT) and then centrifuged at 10,000rpm for 30 minutes. The 
concentration of the expressed protein was assessed by SDS-PAGE and BCA assay (Pierce, 
UK) as described in the next section.
2.6.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE allows for the separation of proteins according to their molecular weight. After 
the reduction of any disulphide bonds by heating and the addition of p-mercaptoethanol, SDS, 
a strong anionic detergent, then coats the polypeptide chains. The binding of SDS masks the 
true native ionic charge of the protein such that at neutral pH, the charge of the protein is 
related to its molecular mass. Proteins are then separated by gel electrophoresis, where the 
degree of separation is proportional to the molecular mass of the protein.
To determine the molecular weight of the purified heavy and |32-microglobulin chains each 
was run on a 15% SDS PAGE gel. The gels were prepared using the BioRad Mini protein gel 
electrophoresis apparatus and were made up of a 15% casting gel that was overlaid by a 5% 
stacking gel. The reagents and volumes that were used are listed below in table 2.8. To create 
an even surface Isopropanol was laid over the casting gel until it had set, the stacking gel was 
poured and wells were created by inserting a gel comb.
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Reagent Casting gel Stacking
Solution A (92.02g/l Tris, 2% (w/v) SDS) 5ml 2.5ml
30% Acrylamide-0.8% Bisacrylamide, 10ml 1.65ml
(Protogel, National Diagnostics)
Distilled H20 5ml 5.45ml
N-N-N'-N' tetramethylethylene diamine 20pl 20 pi
(TEMED, BDH)
5% (w/v) Ammoinum persulphate (APS, BDH) 220pi 380pl
Table 2.8 SDS PAGE gel electrophoresis components
This table summarises the reagents that were used to make up the 15% SDS PAGE gels. 
The casting and stacking gels were prepared in 50ml Falcon tubes.
The samples to be run on a SDS PAGE gel were transferred to a 0.5ml eppendorf tube and 
centrifuged for 5 minutes at 13,000rpm, the pellet was then resuspended in 4x loading buffer 
(2.5ml Solution A, 0.1% (w/v) SDS, 1% (w/v) sucrose, 0.1% (w/v) Bromophenol blue) 
containing 4% (v/v) (3 mercaptoethanol. To reduce the disulphide bonds within the proteins 
all samples were incubated at 100°C for 5 minutes in the presence of p mercaptoethanol. The 
samples were then loaded into the wells of the pre cast SDS PAGE gel along with high and 
low molecular weight markers (BioRad, UK). The gels were run at 150volts for 30-40 
minutes in SDS buffer (250mM Glycine, 25mM Tris, 0.1% (w/v) SDS). Once the blue dye 
front had run to the bottom of the gel, the gels were removed from the plates and stained in 
Coomassie brilliant blue (1% (w/v) Coomassie blue R in destain (methanol:glacial acid:water 
4:1:6) solution) for 15 minutes. The gels were then destained by placing them into destain 
solution (methanol:glacial acid:water 4:1:6), they typically took 4-8 hours to destain. The gels 
were then vacuum dried on a gel dryer for 2 hours (Gel Dryer, model 583, BioRad, UK).
The SDS PAGE method allows for the assessment of protein expression in E.coli, it can also 
be used to determine the efficiency of the protein purification steps. An example of an SDS 
PAGE gel is shown in figure 2.3, the size of the protein bands was determined from the 
molecular weight ladder, ovablumin and lysozyme were also used to confirm the size of the 
P2microglobulin chains (|32M chain).
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Figure 2.3 SDS PAGE analysis of E.coli inclusion body preps
A coom assie stained 15% SD S-PA G E  gel loaded with high M W  markers (lane l)1 .2 5 p g  
L ysozym e (lane 2) 0 .6 p g  L ysozym e (lane 3) 1 .2 5 p g  O valbum in (lane 4) 0 .6p g  
Ovalbum in (lane 5). The inclusion  body preparation aliquots (5 p i) o f  human H LA- 
B *0702  heavy chain (lane 6) and B *0702  heavy chain (lane 7 ), sm aller aliquots (2p l)  
w ere also run in lane 8 for B *0702  heavy chain and lane 9 for A *0201 heavy chain. An  
aliquot (5p l) o f  the human p2M chain was run in lane 9. Other contam inating bacterial 
protein bands are also visib le on the SDS gel.
2.6.5 Measurement of protein concentration
The protein concentration in solution was measured using the M icro BCA™ assay kit (Pierce, 
UK). This assay utilises bicinchoninic acid (BCA) that detects Cu+1 that is formed when Cu+2 
is produced by proteins in an alkaline solution. The purple-coloured reaction product strongly 
absorbs at 562nm , the colour change is linear with increasing protein concentration. The 
protein concentration o f  a sample was determined by preparing a standard curve o f know  
protein concentrations and reading o ff the absorbance at 562nm  from the unknown sample. 
Bovine serum albumin (BSA ) is provided in the BCA kit at a concentration o f  2m g/ml, serial 
dilutions o f  B SA  were made ranging from 0 p g /p l-3 2 p g /p l, each dilution was prepared in a 
total volum e o f  5 00p l sterile H20  in 1.5ml eppendorf tubes. To prepare the BCA working  
reagent 25 parts o f  M icro BC A ™ R eagent M A and 24 parts o f  M icro BCA™  Reagent MB  
were m ixed with 1 part o f  M icro BCA™  Reagent MC. To each tube 5 00p l o f the BCA  
working reagent was added and all tubes were then incubated in a water bath at 60°C for 60 
minutes. The absorbance o f each sample was measured at 562nm  and the absorbance reading 
o f the blank was subtracted from each sample reading. A standard curve was then prepared 
and the protein concentration o f  the unknown samples was determined.
2.6.6 Refolding of HLA/peptide complexes
After the production and extraction o f the recombinant proteins they are assem bled into their 
monomeric form as fo llow s. 30m g (32M chain was added to the pre-cooled refolding buffer 
(lOOmM Tris pH 8, 400m M  L-Arginine HC1, 5mM reduced glutathione, 0.5m M  oxid ized
HLA-A*0702 h ea v y  cha in
Hum an BjM cha in
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glutathione, 2m M  ED T A ), fo llow ed by 8mg peptide and then 30m g H LA heavy chain. The 
refolding procedure was improved by the slow  addition o f  the H LA heavy chain over several 
hours this reduced aggregate formation by keeping the H LA heavy chain saturated with the 
peptide and (32M  chain. The refolding o f  the heavy chain, |32M  and peptide was allow ed to 
proceed for 48 hours. The refolding mixture was then centrifuged for 20 minutes at 4,000rpm  
at 4°C to rem ove any aggregated com plexes. The refolding mixture was then concentrated  
dow n to 20m l using an ultra filtration stirred cell (A m icon ® , U K ) under nitrogen gas 
pressure, and then further concentrated to 5ml using a vivaspin colum n (V ivascience, UK).
2.6.7 Biotinylation of folded HLA proteins
A buffer exchange using the BirA buffer (lOOmM Tris pH 7.5 , lOOmM NaCl, 5m M  M gC l2) 
was then performed on the concentrated refold. Tw o PD 10 colum ns w ere used (Pharmacia, 
UK), the colum ns were first equilibrated in filtered BirA buffer, 2.5m l refolding mixture was 
then added to each colum n, the proteins were eluted by the addition o f  3.5m l BirA buffer. The 
eluted mixture w as then centrifuged at 10,000rpm  for 5 m inutes to rem ove any aggregated  
material. The biotinylation reaction was initiated by the addition o f  lOOmM D-biotin (Sigm a, 
U K ), lOOmM ATP (Sigm a, U K ) and 1 m g/m l BirA, the reaction was left overnight at room  
temperature.
2.6.8 Purification of Biotinylated HLA monomers
To purify the m onom er com plexes, the sam ple was concentrated to 2m l using a 0 .2pm  
vivaspin colum n (V ivascience, U K ) and then centrifuged at 13,000rpm  for 5 m inutes. The 
sample was then loaded onto a gel filtration colum n (FPLC) (Pharmacia, U K ) attached to an 
AK TA Purifier. The run program was set up on an IBM  operating system  2 running U nicom  
3.10 Software. The colum n was packed with 100ml Superdex™  75 matrix (Pharmacia, UK ) 
that a llow s for the separation o f  proteins on the basis o f  m olecular w eight ranging from  
3x 103-7x 104. The colum n w as equilibrated in a high salt buffer (20m M  Tris-H Cl pH 8.0, 
150mM  NaC l) prior to loading the sam ple. The flow  rate o f  the colum n was set to run at 
1 ml/minute, the pressure lim it was set at 0.3m PA  and 3ml fractions were collected throughout 
the run. A  purification trace was obtained for each sample illustrating the conductivity and 
relative absorbance o f  each fraction at 280nm . (A sample trace is shown in figure 2 .4 .) The 
high salt buffer used allow s for the separation o f  biotin w hich is seen as an increase in  
conductivity when eluted. Fractions corresponding to each peak were concentrated to 100- 
500pl using 0 .2p m  vivaspin colum ns (V ivascience, UK). The protein concentration was then 
determined and a native gel was run to determine the efficiency o f  the biotinylation reaction.
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Figure 2.4 FPLC purification trace of HLA-B*0702 refolded complexes
FPLC purification o f  H L A -B *0702  heavy chain refolded with |32M chain and the TPR  
peptide. The m onom er com plexes w ere purified after biotinylation. The sam ple was 
loaded onto the FPLC colum n and 3ml fractions were collected. The relative absorbance
(m illi-absorbance units, m A U ) w as measures at 280nm  ( ------ ) and plotted against the
fraction number (x axis), this allow ed for the determination o f  each fraction com position.
The elution o f  biotin was determined by an increase in conductivity ( ------) corresponding
to a peak in absorbance. The largest proteins are eluted from the colum n first, for this 
refold the peak 1 corresponds w ith aggregated material; peak 2 correctly refolded  
material; peak 3 ex cess  |32M chain; peak 4 excess biotin. A lso  later eluted from  the 
colum n w as excess peptide.
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2.6.9 Determination of biotinylation efficiency by native gel electrophoresis
The efficiency of the biotinylation reaction was determined by analysing the samples on a 
native gel, which allows for the detection of a shift in the biotinylated monomers compared 
with non-biotinylated monomers. The casting and stacking solutions were prepared in 50ml 
Falcon tubes according to the recipe shown in table 2.9. The addition of APS causes the rapid 
polymerisation of the gels and was therefore added last just prior to pouring the gels. The 
native gel was prepared using the BioRad Mini protein gel electrophoresis equipment.
Reagent Casting gel Stacking
30% Acrylamide-0.8% Bisacrylamide, 8ml 1.7ml
(Protogel, National Diagnostics)
Distilled HzO 14.5ml 6.8ml
1.5M Tris HC1 pH 8.8 7.5ml -
1M Tris HC1 Ph 6.8 - 1.25ml
TEMED (BDH) lOpl lOpl
5% (w/v) Ammonium persulphate (APS, BDH) lOOpil lOOpl
Table 2.9 Native gel electrophoresis components
This table summarises the reagents that were used to make up the native gels.
The resolving gel was overlaid with the stacking gel and left to polymerize, in order to create 
an even surface Isopropanol was laid over the resolving gel until it had set. The stacking gel 
was then poured; wells were created by inserting a gel comb. The gels were then run at 150 
volts for 30 minutes to remove any excess salts in the running buffer (24.8mM Tris, 192mM 
Glycine) that might affect the protein migration through the gel. The protein concentration of 
the FPLC peaks was determined by BCA assay (as previously described).
To confirm that the HLA monomers were biotinylated the formation of a tetramer complex 
was performed by the addition of extravidin (Sigma, UK). At least 2pg of HLA monomer was 
used; the biotinylated monomer as well as the non-biotinylated monomer were incubated with 
and without 3-6pi extravidin (Sigma, UK) and left for 1 hour at room temperature. An equal 
volume of the native gel-loading buffer (50mM Tris pH 8.8, 0.1% (w/v) Bromophenol blue, 
10% v/v glycerol) was added to each sample. The samples were then loaded onto the gel and 
run at 150 volts for 1 hour, the gels were then stained with coomassie blue and vacum dried 
for analysis. A shift in the mobility of the biotinylated sample when compared to the non- 
biotinylated sample indicates that the biotinylation has been successful. The biotinylated 
monomer forms a tetramer complex after the addition of extravidin which results in a 
decreased mobility on the gel when compared with non-biotinylated monomers, an example 
of a native gel is shown in figure 2.5.
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Biotinylated HLA complexes
Unbiotinylated Heavy chain
Figure 2.5 Native gel shift assay
A  native gel shift assay carried out on H LA -B*0702/TPR  that had been incubated at a 4:1 
molar ratio w ith streptavidin for one hour. A  native gel was then run to determ ine the 
level o f  biotinylation o f  the com plexes. A pre biotinylation sample (2pg) was run (lane 1) 
and com pared with the biotinylated sam ple (2p g) in lane 2. There is a "shift" o f  the 
biotinylated HLA com plex compared with the unbiotinylated HLA monomer sample.
2.6.10 Generation of HLA-tetramer complexes
The formation o f  a tetramer com plex is necessary to overcom e the relatively low affinity of 
the T cell receptor for peptide/HLA. This tetramer structure is formed by the addition of 
streptavidin which has four biotin binding sites. To allow  for the direct visualisation of 
tetramer positive T cells by flow  cytometry the streptavidin is fluorescently conjugated. The 
HLA com plex is biotinylated by the BirA enzym e, which adds the biotin at the C-terminal 
ends. The streptavidin is then added and forms strong non-covalent bonds with the biotin 
inducing the formation o f a tetramer complex.
The tetramerisation o f the biotinylated HLA monomers was performed using phycoerythrin 
(PE) conjugated to streptavidin (B iogenesis, UK). The biotinylated monomers were then 
placed on a shaker at lOrpm at 4°C whilst 0.375 pg o f  streptavidin PE was added per pg of 
HLA monomer. The amount o f  streptavidin PE added was calculated according to the 
molecular weights o f  the streptavidin PE and the HLA monomers. The Streptavidin PE was 
added in 1/10 aliquots slow ly over hourly intervals. The tetramer was then stored in 0.1%  
sodium azide in suitable aliquots and stored at 4°C in the dark.
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2.7 Molecular Biology
2.7.1 Isolation of total RNA
It was important when isolating mRNA to maintain an RNase free environment in order to 
prevent the degradation of the RNA. The total RNA was isolated using the RNeasy mini kit 
(Qiagen, Germany).
To isolate total RNA a maximum of 107 cells were pelleted for 5 minutes at 13,000rpm. The 
cell pellet was disrupted by the addition of 350|xl RLT buffer and resuspended by vortexing 
for one minute. The cell lysate was then homogenised by passing it at least 5 times through a 
20-gauge needle fitted to a sterile syringe. To the cell lysate 350pl of 70% ethanol was added 
and mixed well by pipetting. This homogenised lysate was then applied to an RNeasy mini 
column, placed in a 2ml collection tube, centrifuged for 15 seconds at 10,000rpm and the 
flow through discarded. After centrifuging, 350pl RW1 buffer was added to the column, this 
was centrifuged for 15 seconds at 10,000rpm and the flow through discarded. DNase 
digestion was performed directly on the membrane by adding 10p,l DNase to 70pl RDD 
buffer (Qiagen, Germany) this was pipetted onto the column and incubated for 15 minutes at 
room temperature. Following DNase digestion the column was centrifuged at 10,000rpm for 
15 seconds and then washed by the addition of 350pil RW1 buffer. The column was 
transferred into a new collection tube, 500p,l RPE buffer was added, the tube was then 
centrifuged for 15 seconds at 10,000rpm, the flow through was then discarded. Another 500pi 
RPE buffer was added and the column centrifuged at 10,000rpm for 2 minutes, this step was 
repeated to ensure that the silica gel membrane was dry. To elute the RNA, the column was 
placed in a new collection tube, 50pl RNase-free water was pipetted directly on to the 
membrane and the column was then centrifuged for 1 minute to elute the RNA. Measuring the 
optical density at a wavelength of 260nm assessed the RNA concentration, to generate cDNA 
10pl of RNA in solution was used this was sufficient to ensure that a good yield would be 
obtained.
2.7.2 Synthesis of complementary strand DNA (cDNA)
In order to perform real time PCR using RNA as a template, it first has to be reverse 
transcribed into cDNA. This was performed by the use of moloney murine leukemia virus 
reverse transcriptase (M-MLV RT, Promega, UK) that allows for the synthesis of cDNA from 
long messenger RNA templates (>5kb). The master mix was first produced (Table 2.10).
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Reagent Volume (xl)
Random Oligo primers (500pg/ml) l\i\
dNTPs (lOmM)
Isolated mRNA S\i\
Table 2.10 Reverse transcription master mix
This table summarises the reagents used to make up the reverse transcription reaction 
master mix that was subsequently heated to 65°C prior to adding the rest o f the 
components. All the reagents were purchased from Promega, UK.
To melt any secondary structures within the RNA template, the master mix was incubated at 
65°C for 5 minutes and then rapidly chilled on ice to prevent these structures from reforming. 
Following this incubation step, the remaining reagents required for reverse transcription were 
added to each tube (table 2.11):
Reagent Volume (xl)
5 x buffer 4pl
0.1MDTT 2pl
RNase inhibitor (RNasin (400U/pl) 1 pil
M-MLV Reverse transcriptase (200U/pl) lpil
Table 2.11 Reagents used for the synthesis of complementary DNA (cDNA)
Reverse transcriptase reaction was performed to generate cDNA on the total mRNA. All 
the reagents used were purchased from Promega, UK.
A negative control was used for each sample that contained no M-MLV RT, the tubes were 
then placed in a PCR machine (Peltier Thermal cycler) and the following program was run.
37°C 50 minutes
70°C 10 minutes
All samples were stored at -20°C for future use.
2.7.3 Polymerase Chain Reaction (PCR)
PCR results in the selective amplification of a chosen region of DNA. Amplification is 
carried out by the enzyme DNA polymerase I, this enzyme is derived from the bacterium
Thermus aquaticus and is thermostable meaning it is not denatured by the heat steps involved
in the PCR reactions. The selective amplification of DNA relies on the design of two short 
oligonucleotides at the borders of the region to be amplified. These oligonucleotides must 
hybridise to the DNA and act as primers for the polymerase enzyme. To perform a PCR 
reaction, the enzyme is added to the template DNA along with the primers. This mixture is 
then heated to 94°C to disassociate the base pairs, this releases the single stranded DNA to act 
as a template again this is called the denaturation step. The following step is the annealing 
step, the melting temperature (Tm) of the primer dictates the temperature that the annealing is 
carried out at. The DNA-DNA annealing is temperature dependent, the temperature must be
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low enough to allow for the specific annealing of the primer to the target sequence but not to 
low that results in non specific binding of the primer. The melting temperature of the primers 
can be calculated using the following equation:
Tm = ( 4 x ( G  + C) )  + ( 2 x ( A  + T) ) ° C
The annealing temperature is usually set to 10°C above the Tm of the primers. The final step is 
the extension step, this is the step when DNA synthesis occurs, the optimal temperature for 
Taq polymerase to work at is 74°C. This cycle of denature-annealing-extension is repeated 
25-30 times. The PCR products obtained are then run on an agarose gel (section 2.7.4).
To confirm that amplified product had been obtained, a PCR was performed specific for the 
expression of a housekeeping gene. The PCR primers were designed to amplify the 
housekeeping gene HPRT (reference sequence NM_000194). The sequences of these primers 
(Sigma-Genosys, UK) are shown in table 2.12: -
Primer sequence:housekeeping gene HPRT
Forward HPRT primer (5'-3') 
CAGTCAACAGGGGACATAAAATTTG
Reverse HPRT primer (5'-3') 
TGAACTCTCATCTTAGGC
Table 2.12 Primer sequences for PCR of the housekeeping gene HPRT
The oligo primers used for the amplification of HPRT. These oligo primers were 
designed in house by Dr Katie Mathews and were purchased from Alta Biosciences, 
Birmingham University, UK.
The PCR reaction was set up using the reagents listed in table 2.13, all these reagents were 
first thawed on ice prior to use.
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Reagent Supplier Volume (xl)
Reverse HPRT Primer Sigma-Genosys, UK 0.2pl
(lOOpmol/pl)
Forward HPRT Primer Sigma-Genosys, UK 0.2pl
(lOOpmol/pl)
10 x buffer Promega, UK 5 pi
dNTP's (lOMm) Bioline, UK lpl
cDNA - 2pl
Taq Polymerase (5 Units/pl) Promega, UK 0.5pl
dH20 - 41.lpl
Total volume 50 pi
Table 2.13 Reagents used for the PCR amplification of HPRT
The PCR reaction that was used is shown in the table below: -
Temperature (°C) Time Purpose
94 5 minutes Denaturing
94 1 minute "'i Denaturing
55 1 minute 36 cycles Annealing
72 1 minute Extension
72 10 minutes Extension
4 Hold Storage
Table 2.14 PCR program used to amplify HPRT
This table summarises the PCR cycle conditions that were used to amplify the HPRT 
gene.
2.7.4 DNA electrophoresis
DNA electrophoresis is used to separate and identify DNA fragments by running them 
through an agarose gel. At a neutral pH DNA molecules have an overall negative charge per 
unit length, these molecules then move towards an anode in an electrical field. The rate of 
movement of the fragments is dependent upon the pore size of the gel and this is determined 
by the percentage of agarose used. To resolve small DNA fragment a high percentage of 
agarose is used (2%) and for larger fragments this percentage is reduced. The location of the 
DNA bands in the gel were visualised by adding 6pl of the fluorescent dye ethidium bromide 
with the gel. The gel was then poured into a sealed tray and a 30 well comb was then placed 
at the top of the gel. Once the gel had solidified TBE buffer was poured over the gel and the 
samples were loaded into the wells. These bands were then visualised under a UV light and a 
photograph taken using the molecular analyst® software (BioRad, USA).
Following the completion of the PCR reaction, the samples were run on a 2% agarose gel 
which was prepared by dissolving 2g agarose (Invitrogen, UK) in 100ml Tris-boric acid- 
EDTA buffer (TBE, Biowhittaker, USA), lOpl of hyperladder V (Bioline, UK) was loaded 
into the first well of every gel, then 30pl of each sample was added to 6pl orange G loading
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buffer (Pel Freez, UK) and loaded into the remaining wells. The agarose gel was then run at 
120 volts for 50 minutes. A  DNA agarose gel showing the HPRT PCR reaction products is 
presented in figure 2.6.
N o reverse transcriptase + reverse transcriptase
Size r ' S’ -s - +
Figure 2.6 DNA agarose gel of the amplified HPRT gene
The HPRT gene is 345bp, this gel confirms that am plifiable cD N A  was generated.
A  known positive and negative control was included as w ell as no M -M LV RT.
2.7.5 Relative Quantification of mRNA using real time reverse transcription PCR (RT
PCR)
Quantitative gene expression assays are now the most com m only used method for measuring 
gene expression patterns (Bustin 2002) by measuring the amount o f  mRNA expressed. Once 
the mRNA has been transcribed into cD N A , the amount o f  IFNy m RNA expressed can be 
determined using RT PCR reaction. The RT PCR method measures the amount product 
during the exponential phase o f the PCR reaction. There are three phases in a PCR reaction; 
the first phase is the exponential phase, during the exponential phase there is an exact 
doubling o f  the product in every cycle, the amplification o f  the product at this stage is highly 
specific and very precise. The second stage is the linear phase, during this phase the reaction 
components are being consum ed, subsequently the reaction slow s and as a result there is a 
high variability in the results obtained. The last stage is the plateau phase, during this phase 
the reaction has stopped and as a result no product is produced. Traditional PCR and detection  
on an agarose gel is performed at the plateau phase, any quantification carried out at this stage 
is unreliable. The PCR phases are shown in figure 2.7. The RT PCR method is more reliable 
as it can quantify the amount o f D N A  product in the exponential phase.
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Figure 2.7 Real time PCR amplification plot
This figure sum m arises the stages o f  the RT PCR reaction and illustrates the detection  
levels o f  the traditional PCR and the RT PCR.
RT PCR reaction
To quantify the relative expression o f  the IFNy gene the assays-on-dem and™  (Applied  
Biosystem s, U SA ) gene expression kits were used, these kits contain pre-designed, quality 
controlled, validated assays that are ready to use. These assays contain TaqMan MGB (Minor 
Groove Binder) probes (FAM  dye labelled) with the primers and probes specific for the gene 
o f interest. The TaqM an® probe is designed to anneal to a specific part o f the template 
between the forward and reverse primers. The probe sits in the path o f the D N A  polymerase 
as it starts to copy the cD N A . The probe is specially designed with a high-energy dye termed 
the reporter at the 5' end and a low  energy dye termed the quencher at the 3' end. When these 
two dyes are in close proximity there is a transfer o f energy from the high dye to the low , this 
is termed florescent resonance energy transfer (FRET). When the probe is intact and excited  
by light and the two dyes are in close proximity the energy transfer results in the reporter dye 
em ission being suppressed by the quencher dye. However, as the D N A  polymerase progresses 
its 5' nuclease activity cleaves the probe, the distance between the two dyes then increases 
causing the transfer o f  energy to stop. Because the reporter and quencher dyes have been  
separated, the em issions from the reporter dye increases w hile the em ission s from the 
quencher decreases. The changes in the em issions from the two dyes is then detected by the 
instrument and displayed by the software, this change is illustrated graphically in figure 2.8.
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Figure 2.8 Fluorescent emissions of the reporter and quencher dyes
T his figure sum m arises the em ission  o f  the quencher dye (left) and the reporter dye  
(right). W hen the probe is intact the proxim ity o f  the quencher at the 3' end greatly  
reduces the fluorescence emitted by the reporter at the 5' end. W hen the probe binds to 
the target sequence it is cleaved by the 5' nuclease activity o f  Taq polym erase, resulting 
in the separation o f  the reporter dye from the quencher, w hich increases the reporter dye 
signal.
The software then calculates the level o f  gene expression, as described in the next section. 
The RT PCR method is illustrated in figure 2.9.
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Figure 2.9 Methods involved in the relative quantification of IFNy gene expression
This diagram summarises all the steps involved in the relative quantification of IFNy 
gene expression using Real time PCR.
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Comparative CT method for relative quantification of gene expression
For this study the relative quantification of IFNy cDNA was used. The relative quantification 
method measures the change in expression of the target gene in a test sample relative to a 
calibrator sample. The calibrator sample is usually an untreated control; in this study the no 
peptide control was used as the calibrator sample. The relative quantification method provides 
an accurate comparison between the initial level of a template in each sample. There are many 
advantages to using relative quantification, firstly there is no need for a standard curve but a 
validation experiment is performed instead. The validation experiment demonstrates the 
efficiency of the target and reference amplifications, the efficiency of both amplifications 
must be equal. Following the RT PCR reaction, the software calculates the threshold cycle 
(CT), which is the number at which the amount of amplified target reaches a fixed threshold. 
The amount of target, normalised to an endogenous control and relative to a calibrator is 
given by:
2 ‘AACt
For this project a fellow colleague had already performed the validation experiment. The 
method used for the identification of new CMV peptides using RT PCR is described in the 
next section.
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Identification of new CMV peptides using RT PCR
In these experiments the RT PCR method was used in the identification of new CMV 
epitopes, this method was used as in some healthy volunteers the level of IFNy detected by 
intracellular staining was very low and it was not possible through lack of sensitivity to 
distinguish a clear positive response. The relative quantification of IFNy mRNA by real time 
PCR offers increased sensitivity as well as the opportunity to measure other cytokines at a 
later date or in parallel.
Following the synthesis of cDNA, the relative quantification of IFNy mRNA was then carried 
out. The amount of IFNy mRNA produced in response to peptide stimulation was determined 
relative to an endogenous housekeeping gene. An endogenous housekeeping gene was used in 
conjunction with the target gene and allows for you to normalise the quantification of cDNA, 
for this reason it is important that the levels of the housekeeping gene remain relatively 
constant. Typical housekeeping genes used include p-actin, GAPDH and ribosomal RNA 
(18S). For this project the housekeeping genes GAPDH and 18S were measured.
For the identification of new CMV peptide epitopes using RT PCR, PBMCs were first sorted 
by the use of MicroBeads and then stimulated with antigen. Following stimulation mRNA 
was isolated and transcribed into cDNA (as described above), the cDNA was used either neat 
or diluted and added to the master mix (Table 2.15).
Master Mix Reagents Volume (xl)
2 x Taqman universal master mix (Applied 12.5 pi
Biosystems)
Assay-on-demand™ (IFNy or endogenous house 1.25 pi
keeping gene, Applied Biosystems)
Sterile H20 10.25 pi
Total final volume 24pl
Table 2.15 Relative Quantitative real time PCR components
This table summarises the reagents used for the qualitative real time PCR for the 
amplification of IFNy and housekeeping gene transcripts. All reagents were purchased 
from Applied Biosystems, UK and were used according to the manufacturers guidelines.
The master mix was prepared in triplicate for each sample to be tested and 24pi was 
dispensed into each well of a 96 well optical reaction plate (Applied Biosystems, USA). The 
master mix and samples were stored on ice throughout the preparation stage, lp l of each 
cDNA sample was added either neat or diluted 1:5-1:1000, the plate was centrifuged for 3 
minutes at 1600rpm to collect all the contents in the bottom of the wells. The plate was then 
run in an ABI thermal cycler (Applied Biosystems 7500 Real Time PCR system, USA) using 
the conditions listed in table 2.16.
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Temperature (°C) Time Purpose
50 2 minutes UNG activation
95 10 minutes Taq activation
95
60
15 seconds 1 ^  
1 minute J
Denaturation
Annealing
Table 2.16 Relative Quantitative real time PCR run conditions
This table summarises the real time PCR run conditions that were used for the 
amplification of IFNy and a housekeeping gene.
The assay-on-demand™ reagent includes ROX that normalises the assay against pipetting 
errors that could affect the overall fluorescent signal. The ABI software automatically 
calculates the average AACt for each sample triplicates using the following calculation: -
ACt = target Ct - endogenous Ct
target = gene of interest (eg. IFNy) 
endogenous = house keeping gene (GAPDH, 18S)
AACt is then calculated:
AACt = ACt (sample) - ACt calibrator (background control)
To convert the data into arbitrary units the following equation is used:
2'AACt
The software automatically calculates the position of the baseline and threshold, for each run 
performed this was also manually checked. An example of the amplification plots obtained 
from both a housekeeping and target gene is shown in figure 2.10 and figure 2.11. An 
example of a gene expression plot is shown in figure 2.12, this plot shows the expression 
level or folds difference of the target gene relative to the calibrator. The software also allows 
one to remove outliers that could affect the calculated CT ensuring the highest accuracy is 
obtained.
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Chapter 3 
The role of CMV specific CD4+ and CD8+ T cell responses in 
protection against CMV reactivation in HSCT recipients
3.1 Introduction
Infection due to cytomegalovirus (CMV) can cause morbidity and mortality in the post HSCT 
setting in those who acquire or reactivate CMV. Approximately 60-70% of patients 
undergoing HSCT will reactivate CMV and without prompt antiviral therapy 20-30% will go 
on to develop CMV end organ disease (Boeckh M 1998). In these patients there is profound 
immune deficiency in the first 3-12 months post transplantation during which time there is an 
increased risk of CMV reactivation and full immune reconstitution can take up to two years. 
Those patients who go onto develop graft-versus-host-disease (GVHD) are most at risk of 
developing uncontrollable CMV replication. The treatment of GVHD involves the use of 
immunosuppressive therapy aimed at reducing the severity of symptoms and preventing graft 
loss but such therapy leaves patients more immune suppressed and more likely to develop 
CMV disease.
The development of HLA class I-peptide tetrameric complexes that recognise specific T cell 
receptors allow for the identification of T cells specific for a given peptide (Altman et al. 
1996; Ogg and McMichael 1998). It is now possible, with the use of such tetramers, to 
directly analyse and quantify CMV specific T cells in the peripheral blood. The longitudinal 
monitoring of patients post HSCT with tetramers has shown that there is an inverse 
relationship between CMV specific T cells and the development of viremia (Aubert et al. 
2001; Cwynarski et al. 2001; Gratama et al. 2001). The drawback of using HLA class I- 
peptide tetramers is that the number of tetramer positive CD8+ T cells does not always 
correlate with the number of functional CMV specific CD8+ T cells, ie. not all tetramer 
positive cells are functional in terms of their ability to produce IFNy (Ozdemir E 2002). In 
order to construct HLA tetramers information is required about the viral epitope presented 
and the HLA antigen presenting the peptide.
Tetramers have been extensively used to study MHC class I restricted antigen specific T cells 
including those specific for CMV and have therefore broadened our knowledge of the role of 
cytotoxic T cells in CMV infections. The role of CD4+ T cells has not been established due to 
technical difficulties associated with the production of HLA class II tetramers such that only a 
limited number are currently available.
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The aim of this chapter is to examine the functional CMV specific immune reconstitution in 
patients undergoing HSCT. CD4+ and CD8+ T cell responses to CMV antigens were 
examined post HSCT in a cohort of patients of mixed HLA alleles. Due to the current lack of 
published information about CD4+ T cell epitopes, CMV lysate was used to stimulate a 
CD4+ T cell response as it incorporates all of the potential antigens known to induce a CD4+ 
T cell response. The CD8+ T cell response to the CMV antigens IE1 and pp65 were 
determined using PepMixes™ containing overlapping peptides that span the sequence of both 
antigens. To date the only studies conducted looking at CMV specific T cells post HSCT have 
used HLA tetramers and have focused only on the pp65 antigen. This study will look at the 
functional T cell responses to the CMV antigens post HSCT and the effects that GVHD, T 
cell depletion and steroid therapy have on these responses.
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RESULTS 
3.2 Detection and quantification of CMV specific IFNy producing T cells in HSCT 
patients 
3.2.1 HSCT patient recruitment
Eighteen patients undergoing haematopoietic stem cell transplantation (HSCT) for 
haematological and immunological diseases were recruited at the Royal Free Hospital 
(London). Patient characteristics and transplant details are summarised in chapter 2 (Table 
2.1). The presenting diseases in this cohort were acute myeloid leukaemia (AML=7), acute 
lymphoblastic leukaemia (ALL=3), non-Hodgkins lymphoma (NHL=2), chronic myeloid 
leukaemia (CML=1), Hodgkin's lymphoma (HL=1), chronic lymphocytic leukaemia 
(CLL=1), multiple myeloma (MM=1), Fas ligand deficiency (Fas=l) and erythropoietic 
porphyria (EP=1). The median follow up was 188 days (range 103-336 days) post HSCT. 
Eleven patients underwent reduced intensity conditioning and seven patients received fully 
myeloablative conditioning. The majority of the patients received an HLA identical sibling 
transplant (n=13) and five patients received a fully HLA matched unrelated transplant. 
Thirteen patients received Campath as a form of T cell depletion either in the bag (n=2) or in 
vivo (n=ll) and five patients received no form of T cell depletion. Patients were monitored 
closely for signs of GVHD and upon diagnosis were treated accordingly with intravenous 
methylpredinisolone or oral prednisolone. GVHD prophylaxis consisted of Cyclosporin A 
with or without methotrexate. Due to the difference in transplant regimes and the relatively 
small number of patients it was not possible to account for all the many variables among this 
cohort but patients could be grouped according to T cell depletion, steroid therapy and CMV 
reactivation.
3.2.2 Immune reconstitution post HSCT
The age range of patients in this cohort was large (9-60yrs); the younger patients had a 
quicker immune reconstitution than the older patients, children have a greater amount of 
thymic activity than adults resulting in a quicker recovery of naive T cells (Klein et al. 2001). 
HSCT and the conditioning regimens involved are known to affect thymic function and 
subsequent T cell lineages. The role of CD4+CD25+ T regulatory cells after HSCT is under 
debate due to the amount of conflicting data published, these cells are naturally occurring, 
whose function is to suppress auto reactive T lymphocytes thus controlling normal immune 
responses (Fehervari and Sakaguchi 2004; Piccirillo and Shevach 2004). Following HSCT, T 
regulatory cells have been implicated in playing a role in development of GVHD, recently 
Zorn et al. (Zorn et al. 2005) analysed CD4+CD25+ T regulatory cells in thirty patients with
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chronic GVHD and found that they contributed towards the development of chronic GVHD. 
During this study we were not able to examine the role of CD4+CD25+ T regulatory cells in 
patients post HSCT but clearly it would be interesting to investigate these cells in the context 
of CMV.
Among this cohort we looked at the general immune reconstitution in these patients prior to 
analysing the CMV specific immune reconstitution. The main factors influencing immune 
reconstitution among this cohort includes age, T cell depletion and steroid therapy. By 
obtaining the absolute lymphocyte counts we could calculate the absolute number of CD4+ 
and CD8+ T cells at each time point, the absolute number of NK cells for each time point 
were provided by Dr J Luxton (ANRI). When comparing the T cell counts between the 
different age groups obtained at +50 days, +100 days and +150 days post HSCT no 
significant difference was seen when comparing the counts using the Mann-Whitney U test, 
this may have been because the age range of the patients is large (9-60 years; median 39.5 
years) and there are only four patients under 30 years of age included.
When looking at the effect of T cell depletion on the T cell counts, significant differences 
were observed between the patient group that received T cell depletion and the group that 
received no form of T cell depletion. At +50 days post transplant a significant difference 
(P=<0.05) in the absolute lymphocyte, CD4+ and CD8+ counts was observed between the 
two patient groups. By +100 days post transplant a significant difference (P=<0.05) between 
the CD4+ and CD8+ T cell counts was observed, however, there was no significant difference 
in the absolute lymphocyte counts between the two groups. Furthermore on +150 days post 
transplant no significant difference (P=>0.05) in the counts was observed between the two 
groups. The difference between the counts for the two groups could be due to the effects of 
Campath-IH, which specifically depletes CD52+ cells from either the graft or pre 
administration. Some patients did have a normal absolute lymphocyte count (range 1.0- 
2.0xl09/l) early post transplantation. At +50 days post HSCT three out of five non T cell 
depleted patients had normal absolute lymphocyte counts, while only one TCD patient out of 
thirteen had a normal lymphocyte count. By +100 days post HSCT four out of five non T cell 
depleted patients and three out of thirteen TCD patients had normal lymphocyte counts. At 
day 150+ two out of four non TCD patients and three out of nine TCD patients had normal 
lymphocyte counts, at these later time points some patients had died or were discharged from 
the clinic and therefore no lymphocyte counts could be obtained. The effect of Campath-IH 
on T cell reconstitution have been previously documented (Morris et al. 2003), the data 
presented here also demonstrates that Campath-IH effects the T cell counts up to +50 days 
post transplant.
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The effect of Campath-IH is mainly restricted to those CD52+ cells, notably lymphocytes, 
NK cells do not express CD52 and therefore avoid the depleting effects of Campath-IH. The 
NK cell reconstitution was good in comparison to the T cell counts, by +50 days post HSCT 
the median NK cell count among this cohort was 195xl09/l, at +100 days post HSCT this had 
increased to 347xl09/l, at day +150 days post HSCT the NK count had reached a plateau at 
315x109/1. This data indicates that early post transplantation the NK cells are likely to play a 
significant role in the immune response to both pathogens and tumours.
3.2.3 CMV replication post HSCT
In this study, CMV replication (>200 genomes/ml blood) occurred in 56% of patients; of 
these 34% were CMV seropositive before transplant (R+) and received a graft from a CMV 
seronegative donor (D-), the remaining 22% were CMV seropositive before transplant (R+) 
and received a graft from a CMV seropositive donor (R+). None of the R-/D+ or the non T 
cell depleted patients experienced detectable CMV replication post transplantation. The 
median day of detection of CMV PCR replication was day 20 (range 2-53) and the maximum 
viral load in this group was 5.13 logi0 copies/ml blood. The clinical details for each patient 
post HSCT are summarised in table 3.1. During the course of this study none of the patients 
developed confirmed CMV disease as determined by the antigenemia assay for the pp65 
antigen. However, following this study patient 17 developed confirmed CMV retinitis. 
Subsequent analysis showed that in this patient the virus was resistant to ganciclovir and 
therefore foscamet was used to control viral replication.
Seven patients in this cohort received steroid therapy for the treatment of confirmed or 
suspected GVHD. The severity was grade II and was mainly localized to the skin. Steroids act 
by suppressing the CD4+ T cell function, this leaves patients more immune suppressed which 
inevitably increases the chances of CMV reactivation. The reactivation of CMV occurred in 
four out of the six patients; the median number of days after the commencement of steroid 
therapy until a CMV PCR positive result was 8 (range 0-19). The two patients that did not 
reactivate CMV despite steroid therapy received no form of T cell depletion as part of their 
transplant regime.
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Patient Donor/Patient 
CMV serology
Stem cell source First PCR+ 
post SCT 
(days)
Number of 
infectious episodes8
Steroid therapy 
commenced (days)
Campath-IH 
in vivo/in graft
Transplant outcome
1 -/+ MUD PBSC 2 3 None No/Yes CR
8 -/+ MUD PBSC 16 1 None Yes/No CR
2 -/+ Sib Mini-allo PBSC 50 1 +42 Yes/No CR
15 -/+ Sib BM None 0 +62 No/No CR
3 -/+ Sib PBSC 38 2 None No/Yes Relapsed
17 -/+ MUD mini alio PBSC 5 1 +18 and +110 Yes/No CR
22 -/+ Sib Mini-allo PBSC 17 1 None Yes/No Mixed chimerism
7 +/+ MUD PBSC 53 1 +133 Yes/No CR
19 +/+ Sib alio BM None 0 None No/No Relapsed
4 +/+ Sib Mini-allo PBSC None 0 None Yes/No CR
5 +/+ Sib PBSC None 0 None No/No CR
12 +/+ Sib Mini-allo PBSC 20 1 +165 Yes/No CR
11 +/+ Sib Mini-allo PBSC 20 1 +148 Yes/No CR
13 +/+ MUD PBSC 46 1 None Yes/No CR
6 +/+ Sib PBSC None 0 None No/No CR
18 +/+ Sib alio PBSC None 0 None No/No CR
16 +/- Sib Mini-allo PBSC None 0 None Yes/No CR
21 +/- Sib Mini-allo PBSC None 0 +38 No/No Relapsed RIP+233
Table 3.1 CMV reactivation post HSCT and transplant outcome
This table summarises the reactivation of CMV among the 18 patients and the transplant outcome. The number of CMV infectious episodes8 is 
defined as the detection of two consecutive CMV PCR+ results until the detection of two consecutive negative CMV PCR results.
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3.2.4 Assessing functionality of CMV specific T cells
Only patients that reached at least 100 days post transplantation were included in this study as 
all patients were lymphopenic in this early stage, thus at high risk of reactivating CMV. 
Monitoring of CMV specific responses was commenced as early as possible after 
engraftment. For the majority of patients this was before +50 days (n=12) but due to post 
transplantation complications, monitoring could not be commenced in six patients until later 
(+60-100 days). To quantify T cell responses to CMV, purified CMV lysate was used to 
determine the amount of IFNy produced by responding CD4+ T cells following an overnight 
stimulation, in addition peptide pools that span the whole antigen sequence for the IE1 and 
pp65 antigens were used to determine the amount of IFNy produced by responding CD8+ T 
cells following peptide stimulation. The functional responsiveness of CMV specific T cells 
was determined in the eighteen patients post HSCT.
Heparinised blood was obtained from all consented patients following the recovery of 
sufficient lymphocyte counts. PBMCs were isolated and stimulated separately with the IE1 
PepMix, pp65 PepMix and CMV lysate (see section 2.3.4). Following peptide stimulation all 
samples were acquired by flow cytometry, the initial gate was set up on the lymphocyte 
population and subsequent gates were set up on the CD3+CD8+ or CD3+CD4+ lymphocytes. 
Due to the down regulation of CD3-TCR complex upon activation the gates were set up on 
SEB stimulated cells, gating for IFNy producing cells versus side scatter was used to 
determine the amount of IFNy produced. The activation of CD4+ and CD8+ T cells was 
confirmed by including an anti human CD69 PE antibody that would detect the expression of 
the early activation marker CD69 on the cell surface. An example of CD69 staining is shown 
in figure 3.1. The percentage of CD8+ T cells producing IFNy was assessed from the 
CD3+CD8+ T cell gate and subsequently a side scatter verses IFNy plot was created, in this 
example (Figure 3.1, panel A) 33.6% CD8+T cells produced IFNy in response to the pp65 
PepMix. From the IFNy gate another plot was created to assess the level of CD69 expression 
on the cell surface (Figure 3.1, panel B), this revealed that only 60% IFNy positive T cells 
were also expressing CD69. Approximately 40% of the IFNy producing CD3+CD8+ T cells 
did not express the activation marker CD69 or it was down-regulated as illustrated in figure
3.1 (panel C) by the disappearance of the CD69 negative population below the axis. In this 
study the amount of IFNy produced by CD3+CD8+ or CD3+CD4+ T cells was determined, 
CD69 was not used, as it would lead to an underestimation of the true number of IFNy 
producing T cells, on reflection CD25 might have been a better marker of activated T cells.
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Figure 3.1 Expression of CD69 on CD3+CD8+ T cells following antigen stimulation
PBM C s from patient 12 were stimulated with pp65 PepM ix. IFNy and C D 69 were then 
measured. Panel A  show s the percentage o f  C D 3+C D 8+ T ce lls  producing IFNy. The 
FAC s plot shown in Panel B is gated on the IFNy producing ce lls  in panel A  and show s 
the percentage o f  IFNy C D 3+ C D 8+  T ce lls  that a lso  up-regulate C D 69. The dow n  
regulation o f  C D 69 can also been seen in panel C w hich is gated on the C D 3+C D 8+ T  
cell population.
In contrast to HSCT recipients in healthy individuals the amount o f  IFNy produced by T cells 
follow ing peptide stimulation does correlate with C D 69 expression, many groups gate on 
IFNy+CD69+ cells to show the activated phenotype o f  these cells (Dunn et al. 2002; He et al. 
2001). Because HSCT patients are at high risk o f developing opportunistic infections post 
transplantation it is possib le that the expression o f  C D 69 has already been up regulated in 
response to other antigens. A lso it is possible that as HSCT patients undergo a "cytokine 
storm" their T cells are non-specifically activated by these cytokines leading to an initial 
increase in CD69 expression that is later down regulated.
CD8+ T cell responses to the CM V antigens pp65 and IE1 were determined in all consented  
patients post HSCT along with the CD4+ T cell responses to CM V lysate; CM V lysate was 
used as it would incorporate all potential antigens that could stimulate CD4+ T cells. The 
CD4+ T cell response to CM V lysate was determined by Dr Hubertus Buyck (Centre o f  
V irology, RFH) at each sam pling tim e point. An exam ple o f  the flow  cytom etry plots  
obtained on three representative patients at different time points is shown in figure 3.2.
The level o f  functional T cell responses to the CM V antigens varies between the three 
patients (Figure 3.2). Patient 15 received no form o f  T cell depletion and was considered at 
medium risk o f  reactivating CMV due to the CM V seropositive status o f the recipient prior to 
transplantation. Patient 13 was T cell depleted in vivo  and was at highest risk o f  reactivating 
CMV because she was CM V seropositive pre transplant and received PBSC from a CM V  
seropositive match unrelated donor (M U D ). Patient 6 received no form o f  T depletion and 
was considered relatively low  risk o f reactivating CMV post transplant, because o f  his age 
immune reconstitution is likely to be quicker compared to the other two patients.
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C CD4+ T cell response to the IE1 PepMix
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E CD4+ T cell response to CMV lysate 
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Figure 3.2 Intracellular staining for IFNy production by CMV specific T cells following 
antigen stimulation
PBMCs were isolated from patients post HSCT and stimulated with pp65 (Panels A-B),
IE1 (Panels C-D) PepMixes and CMV lysate (Panel E). The amount of IFNy produced in 
response to antigen stimulation was determined using intracellular staining and analysed 
by flow cytometry. Lymphocytes were gated on CD3+CD8+ or CD3+CD4+ and an IFNy 
gate was established versus side scatter are shown. The CD4+ T cell responses to CMV 
antigens are shown in three representative patients (Panels A, C and E) at +50, +100 and 
+150 days post HSCT. The CD8+ T cells responses to the pp65 and IE1 antigens are 
shown in three representative patients (Panels B and D). The patient characteristics are 
described in chapter 2 (Table 2.1). The background IFNy production (no antigen) was 
subtracted from all the samples.
Figure 3.2 (Panel A -E) illustrates the T cell responses to CM V antigens at +50, +100 and 
+150 days post HSCT in the three patients. Patient 15 had a very rapid response to the CM V  
antigens by day +50 (Figure 3.2, panel A ), T cell responses were detectable in response to the 
pp65; IE1 antigens and the CM V lysate. This patient received a non T cell depleted bone 
marrow from a CM V seronegative sibling donor. Despite being at relatively high risk o f  
reactivating CM V due to steroid therapy and a seronegative donor, no detectable CM V  
replication occurred post HSCT. Patient 13 had very poor immune reconstitution with only  
1051 CD8+ T cells and 2349 C D 4+ T cells acquired at +50 days (Figure 3.2, panel A ), by 
+100 days post HSCT only 581 C D 8+ T cells and 2161 CD4+ T cells were acquired (Figure 
3.2, panel B), this patient received T cell depleted PBSC from a m atched unrelated CM V
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seropositive donor and is at considerable risk of reactivating CMV post transplant. CMV 
replication was detectable in patient 13 at +46 days post transplantation resulting in a CD8+ T 
cell response to pp65 only (Figure 3.2, panel B) and a CD4+ T cell response to CMV lysate 
(Figure 3.2, panel E). Interestingly, patient 13 has no T cell response to IE1 possibly resulting 
in poor viral control. Patient 6 showed a very rapid immune reconstitution achieving a 
lymphocyte count within normal range (1.0-3.5xl09/L) by +110 days post HSCT. Patient 6 
received non T cell depleted PBSC from a matched CMV seropositive sibling, it is likely that 
because he received no form of T cell depletion the transferred T cells resulted in rapid 
immune reconstitution. A very small number of T cells responded to the CMV antigens, less 
than 0.5% T cells produced IFNy in response to any CMV antigen post transplantation 
(Figure 3.2, panels A-E). As CMV specific T cells have been transferred from the donor at 
the time of transplant this small number is sufficient to prevent the virus from reactivating.
In this study the absolute numbers of responding CD4+ and CD8+ T cells were calculated in 
response to each antigen using the absolute T cell counts. The percentage of responding T 
cells would not have been an accurate measure due to the variable levels of immune 
reconstitution within this patient cohort. In the samples obtained post transplant the number of 
cells acquired tends to be low and a high background of IFNy production was detected, the 
background amount of IFNy produced was deducted from all the antigen stimulations. The 
high background levels could be due to the effects induced by drug therapy and tissue damage 
giving rise to the phenomenon known as "cytokine storm". In all patients approximately 100 
positive CD8+ or CD4+ T cells were acquired from the early post HSCT samples the 
outcome being that statistically these results were less reliable. This is a downfall of this type 
of study but cannot be overcome as patients can be lymphopenic for up to a year post HSCT, 
in the majority of patients at least 10,000 positive CD4+ or CD8+ T cells could be acquired 
from approximately 4 months after post HSCT.
124
Chapter 3
3.3 Effect of T cell depletion on CMV specific responsiveness
We first investigated the effect of T cell depletion in those who experienced CMV replication 
(at >200 CMV genomes/ml blood) compared to the non T cell depleted individuals who did 
not experience CMV infection. In the patients who were CMV seropositive (n=ll) before 
transplant and received Campath-IH either in vivo or "in the bag", CMV reactivation 
occurred in 10 of these patients. To investigate the T cell responses to the CMV antigens post 
HSCT the absolute number of T cell responding to the CMV antigens was determined in 
those patients considered at high risk of reactivating CMV due to recipient CMV 
seropositivity (n=16). The median number of responding T cells to CMV antigens during the 
first 100 days after HSCT was compared with the median observed in those patients who 
experienced no detectable CMV reactivations. All the patients who had detectable CMV 
replication within the first 100 days post transplant had reduced responses to the CMV 
antigen pp65 and CMV lysate. Six patients experienced no CMV replication (figure 3.3) of 
these five received no form of T cell depletion indicating that the transfer of T cells from the 
donor prevented the reactivation of CMV in these recipients. The immune response to the 
CMV antigen pp65 and CMV lysate in those patients who experienced no CMV replication 
was greater (>1x106/L T cells responding to any CMV antigen) than in the patients who 
experienced CMV replication (Figure 3.3). Figure 3.3 compares the immune response to the 
CMV antigens in the first 100 days post transplant in those recipients who reactivated CMV 
in the first 100 days post transplant and those who did not reactivate CMV post transplant. A 
significant difference was observed in the CD4+ T cell response to pp65 and CMV lysate 
(Figure 3.3, panel B) and the CD8+ T cell response to pp65 (Figure 3.3, panel B) when 
compared using the Mann-Whitney U test. No significant difference was found with the T 
cell response to IE1 in those who experienced CMV reactivation compared with those who 
did not experience any CMV reactivation events, but a clear difference could be seen where 
those who reactivated CMV had no CD8+ T cell response to IE1 while those who 
experienced no CMV reactivations had a CD8+ T cell response to the IE1 antigen.
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Figure 3.3 Comparative analysis of T cell responses to CMV antigens in CMV 
reactivating verses non-reactivating patients
The numbers of T cells responding to the CMV antigens were compared in those patients 
who experienced no CMV reactivation and those who experienced CMV replication. The 
median absolute number of responding T cells was calculated from all the time points 
before +100 days post HSCT in all patients. Box plots show the responses to the CMV 
antigens (median, box extends from 25th-75th percentile). The CD8+ T cell responses to 
pp65 and IE1 (Panel A) and the CD4+ T cell responses to IE1 (■ ), pp65 (■ ) and CMV 
lysate (■ ) were determined (Panel B). The responses to all CMV antigens in the first 100 
days post HSCT were compared between the two groups using the Mann-Whitney U test.
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The reactivation of CMV generated a CD4+ T cell response to CMV lysate and also a CD8+ 
T cell response to pp65 or IE1; this immune response either peaked during reactivation or 
shortly after, representative plots are shown in figure 3.4.
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Figure 3.4 M onitoring functional CMV specific T cells in recipients of T cell 
depleted grafts
The absolute number of CD3+CD4+ and CD3+CD8+ T cells (x l06/l blood) producing 
IFNy in response to pp65 (□ ), IE1 (A)  and CMV lysate (X), and the quantitation of CMV 
viral load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Representative 
patients are shown; panel A shows patient 13 after a matched unrelated peripheral blood 
stem cell transplant; panel B shows patient 1 after a matched unrelated peripheral blood 
stem cell transplant. A lso illustrated on the graph are periods of treatment with 
ganciclovir ( ts/ / s .a ) .
As can be seen in figure 3.4 less than lxlO6 T cells responded to any CMV antigen prior to 
the onset of detectable CMV replication. Patient 13 had no T cell responses to the CMV 
antigens prior to +57 days post HSCT (Figure 3.4, panel A), on +46 days CMV replication is 
detected in the peripheral blood, this patient was then treated with a course of ganciclovir to 
reduce the viral load. Eleven days after the reactivation of CMV a CD4+ T cell response
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against CMV lysate develops alongside a CD8+ T cell response to pp65. In this patient the 
CMV viral load is reduced by the ganciclovir and the expanded CMV specific T cells prevent 
any further reactivations from occurring. The generation and maintenance of a potent T cell 
response against CMV prevents the virus from reactivating, however, not all patients develop 
and maintain good T cell responses. As illustrated with patient 1 (Figure 3.2, panel B) peak T 
cell responses can be detected after the reactivation of CMV although these responses are not 
maintained resulting in continued viral replication. In this patient a small CD8+ T cell 
response against IE1 and pp65 starts to develop at +100 days post HSCT, but this response is 
not expanded or maintained and the virus reactivates again at +120 days. Prior to the 
reactivation of CMV no CD4+ T helper responses against CMV lysate can be detected 
although a response does start to appear after CMV replication is detected at +120 days. 
These two patients are representative of the patients who reactivated CMV post HSCT, all 
patients had no detectable CD4+ T helper response to CMV lysate prior to virus reactivation. 
Some patients reactivated CMV more than once (n=2) and in these patients no CMV specific 
T cell responses were maintained against the virus, it is possible that memory T cells were not 
generated but further phenotypic analysis would be required to confirm this. Before the first 
CMV reactivation event no CD4+ or CD8+ T cell responses against CMV were detected in 
these patients, although in those who went on to reactivate CMV again CD8+ T cell responses 
against pp65 or IE1 were detected but in these patients in the absence of a CD4+ T cell 
response they could not prevent viral reactivation.
Due to the lack of responses to the CMV antigens we wished to examine the percentage of the 
T cell repertoire occupied by CMV specific cells. In order to accomplish this we utilized the 
CD4+ or CD8+ gates on the flow cytometry plots to calculate the absolute number of CD4+ 
or CD8+ T cells. The percentage of responding T cells was then calculated using the data 
obtained from the absolute number of T cells responding to each CMV antigen. The 
percentage of the T cell repertoire occupied by CMV specific T cells responding to pp65, IE1 
and CMV lysate was determined for all the patients. Shown in figure 3.5, panel A and panel 
B, is two representative plots on patients 1 and 13, panel C shows the results for all patients at 
+100 days post HSCT. The reactivation of CMV in patient 13 shows that the percentage of 
the CD4+ T cell repertoire that responded to the CMV lysate increased to 10% (Figure 3.5, 
panel A), however, in the same patient 60% of the CD8+ T cell repertoire responded to pp65 
and only 10% responded to IE1. In all those patients who only experienced one CMV 
reactivation event a high percentage of the T cell repertoire contained T cells specific for 
CMV as can be seen with patient 13 (Figure 3.5, panel A). Following the reactivation of 
CMV the percentage of the T cell repertoire occupied by CMV specific T cells increases this
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1 0 0 1.12 1.64 0
2 0.08 0.05 0 4.92 0.07
3 0.04 0 0 0.79 0.16
4 0.15 0.03 4.77 1.96 4.41
5 0.14 0.04 2.66 0.68 0.49
6 0.56 0 0.04 0.44 0.09
7 0.57 0.06 10.49 1.83 1.73
8 0 0 0 4.55 0
11 0 0 0.64 19.60 0.30
12 0.25 0 0 10.80 0.04
13 2.38 0.16 14.46 57.73 0.80
15 1.70 0.09 3.31 3.22 0.33
16 0.72 0.53 0 0.59 0.31
17 0 0 0 2.45 0
18 0.01 0.02 1.66 0.21 0
19 0.42 0.24 1.76 0.77 0.29
21 0.13 0 0.09 0.78 0
22 0.19 0 0.54 0.04 0.05
Figure 3.5 Monitoring expansions of the CD4+ and CD8+ T cell pool in response to the 
CMV antigens
The percentage of the CD3+CD4+ and CD3+CD8+ T cell pool producing IFNy in 
response to pp65 ( □ ) ,  IE1 (A) and CMV lysate (X), and the quantitation of CMV viral 
load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Representative 
patients are shown; panel A shows patient 13 after a matched unrelated peripheral blood 
stem cell transplant; panel B shows patient 1 after a matched unrelated peripheral blood 
stem cell transplant, panel C shows the results for all 18 patients at +100 days post 
HSCT. Also illustrated on the graph are periods of treatment with ganciclovir (vss/7\ \.
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is probably due to the expansion of effector T cells armed and focused on destroying CMV 
infected cells. The percentage of the T cell repertoire taken up by CMV specific T cells 
gradually decreases following the resolution of CMV viremia and is probably due to the 
disappearance of effector T cells and the subsequent generation of memory T cells. The 
gradual, reduction in the percentage of the T cell repertoire taken up by CMV specific T cells 
could also decrease as other T cells become established with other specificities. Two patients 
experienced more than one CMV reactivation event, in these patients the percentage of the T 
cell repertoire occupied by CMV specific T cells was lower than that seen in those who 
experienced one reactivation event. Patient 1 (Figure 3.5, panel B) experienced three CMV 
reactivation events post HSCT, the percentage of the CD4+ T cell repertoire that responds to 
the CMV lysate was only 0.5% (Figure 3.5, panel B), in the same patient 9% of the CD8+ T 
cell repertoire responded to pp65 and 0.5% responded to IE1. In patient 1 the percentage of 
the T cell repertoire taken up by CMV specific T cells did increase following the reactivation 
of CMV, however, this percentage dropped quicker than that observed in patient 13 (Figure 
3.5, panel A), possibly indicating that no memory T cells were generated. These results 
demonstrate that following the reactivation of CMV a large percentage of the developing 
CD4+ and CD8+ T cell repertoire is occupied by responding CMV specific T cells but in 
those who experience uncontrollable CMV replication this percentage is lower and not 
maintained.
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3.4 CMV specific responsiveness following non T cell depleted HSCT
In the five patients that received non T cell depleted grafts, both CD4+ and CD8+ T cell 
responses to CMV could be detected early post transplant (<50 days), with peak T cell 
responses to the CMV antigens despite the absence of detectable CMV replication as shown 
in figure 3.6. In contrast, patients who had received T cell depleted grafts showed no response 
to the CMV antigens early post transplantation (Figure 3.4) and 10 out of 13 of these T cell 
depleted patients went on to reactivate CMV. Interestingly, two patients (patients 4 and 16) 
from the T cell depleted group that did not reactivate CMV had CD8+ T cell responses to 
both pp65 and IE1. Patient 16 was CMV seronegative and received a graft from a sibling 
matched CMV seropositive donor and was consequently considered at low risk of reactivating 
CMV due to the transfer of CMV specific T cells from the donor. In contrast patient 4 was 
CMV seropositive and received a graft from a CMV seropositive sibling donor and was 
therefore considered at high risk of reactivating CMV. Patient 4 had a high T cell response to 
the CMV antigens with 12.7xl06/l CD8+ T cells responding to pp65, 23.3xl06/l CD8+ T cells 
responding to IE1 and 1.7xl06/l CD4+ T cells responding to CMV lysate. The CD4+ T cell 
response to the IE1 and pp65 antigens was below Ix l06/1 but despite receiving a T cell 
depleted graft this patient did not reactivate CMV post HSCT probably due to the high level 
of T cell responsiveness maintained to the CMV antigens.
The non T cell depleted patients had high T cell responses to the CMV antigens in the 
absence of detectable CMV replication. Figure 3.6 shows the magnitude of these peaks in the 
T cell response varied indicating that in the non T cell depleted group viral control can be 
achieved with a small number of responding CMV specific T cells. In patient 6 (Figure 3.6, 
panel A) the peak absolute number of CD8+ T cells that responded to pp65 was 1x106/L on 
day +95 and the CD4+ T cell response to CMV lysate was 0.01xl06/L which was sufficient to 
prevent detectable CMV replication. The magnitude of response was higher with patient 18 
(Figure 3.6, panel B), at the peak of the response the absolute number of CD8+ T cells that 
responded to pp65 was 12xl06/L on day +77, the peak CD4+ T cell response to CMV lysate 
at the same time point was 5.7xl06/L. It is possible that the lower number of T cells 
responding to the CMV antigens in patient 6 were sufficient to prevent the reactivation of 
CMV, this patient received non T cell depleted PBSC from a younger sibling, therefore it is 
likely that naive T cells contained within the graft could have resulted in quicker immune 
reconstitution, resulting in better virus control. Studies carried out using tetramers to monitor 
die CMV specific immune reconstitution post HSCT assigned a level of 1x107/L tetramer 
positive T cells as providing protection against developing CMV disease (Cwynarski et al. 
2001). However, in this study it is not possible to assign a level of protection against the 
development of CMV disease as some patients had less than 1x106/L T cells that responded to
131
Chapter 3
the CM V antigens but did not experience detectable viral replication indicating that many 
factors influence the reactivation o f CMV.
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Figure 3.6 Functional CMV specific T cell responses in patients receiving non T cell 
depleted grafts
The absolute number of CD3+CD4+ and CD3+CD8+ T cells (x l0 6/l blood) producing 
IFNy in response to pp65 (□ ), IE1 (A) and CMV lysate (X), and the quantitation of CMV 
viral load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Representative 
patients are shown; panel A shows patient 6 after a matched sibling peripheral blood stem 
cell transplant; panel B shows patient 18 after a matched sibling peripheral blood stem 
cell transplant.
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3.5 Effect of steroid therapy on CMV specific responsiveness
The development of GVHD is one of the main complications encountered following 
allogeneic HSCT, although the exact triggers for GVHD are not clear it involves the 
interaction between antigen presenting cells of the recipient and mature T cells of the donor 
resulting in an allogeneic type of response. The occurrence and severity of GVHD is the main 
factor delaying immune reconstitution, the standard treatment for GVHD is 
immunosuppression aimed at reducing the symptoms, however, this also reduces the 
lymphocyte numbers. The development of acute GVHD is a major factor that contributes to 
the development and severity of CMV infection (Miller et al. 1986). Among our cohort seven 
patients developed GVHD assessed as being grade I-II and mainly confined to the skin, all 
seven patients were initially treated with methylprednisolone that was later switched to 
prednisolone, gradually the dose was reduced to maintenance levels.
Out of the seven patients that received steroid therapy for GVHD five went on to reactivate 
CMV shortly after the commencement of treatment (mean 11.4 days), in these patients CMV 
replication always occurred after the development of GVHD. The effect of steroid therapy 
and the subsequent reactivation of CMV can be seen in figure 3.7, in this example patient 17 
developed GVHD at +18 days post HSCT and received intravenous methylprednisolone, 
fifteen days later CMV replication was detected in the peripheral blood. This patient had a 
CD4+ T cell response to the CMV lysate that dropped upon the initiation of steroid therapy. 
At +40 days post HSCT 1.4xl06/L CD8+ T cells responded to pp65 and 1.8xl06/L CD8+ T 
cells responded to IE1. At +50 days post HSCT there was peak in the CD4+ and CD8+ T cell 
response to IE1 and pp65 despite the patient being on steroid therapy, it is not clear from the 
clinical details what has led to this peak in response. Prior to the reactivation of CMV at +60 
days post HSCT a sharp drop in the number of T cells responding to the CMV antigens 
probably led to the reactivation of CMV. This patient is representative of the five patients that 
received steroid therapy for GVHD and who then went onto reactivate CMV, in all patients a 
drop in the T cell response to the CMV antigens was detected prior to CMV replication. 
Following this study patient 17 went on to develop CMV retinitis suggestive of poor T cell 
reconstitution, the virus was demonstrated to be resistant to ganciclovir and treatment was 
changed to foscamet. A similar decrease in functional T cell responses was observed in one of 
the two patients (patient 15) that received non T cell depleted grafts and steroid therapy for 
GVHD. Unfortunately, the T cell response to the CMV antigens could not be determined in 
the second patient (patient 21) before steroid therapy was commenced at +38 days post 
HSCT. Patient 15 received a non T cell depleted graft and following the commencement of 
steroid therapy a reduction in both T cell numbers and function was observed (Figure 3.8, 
panel A), however, a higher level of T cell responsiveness to the CMV antigens was observed
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Figure 3.7 Changes in the number of functional CMV specific T cells during 
uncontrolled CMV reactivations and steroid therapy
The absolute number of CD3+CD4+ and CD3+CD8+ T cells (x l0 6/L blood) producing 
IFNy in response to pp65 (□), EE1 (A) and CMV lysate (X), and the quantitation of CMV 
viral load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Patient 17 is 
shown after a RIC matched unrelated peripheral blood stem cell transplant. Also 
illustrated are periods of treatment with ganciclovir ( Y////1 ); methylprednisolone ( i - i ); 
prednisolone ( I I).
when compared with the patients that received T cell depleted grafts. Prior to the 
commencement of steroid therapy at +46 days post HSCT patient 15 had 11.3xl06/L CD4+ T 
cells that responded to CMV lysate, 19.4xl06/L CD8+ T cells responded to pp65 and no T 
cell response was detected against the IE1 antigen. During steroid therapy 3.2xl06/L CD4+ T 
cells responded to CMV lysate, 3.0xl06/L CD8+ T cells responded to pp65 and 0.27xl06/L 
CD8+ T cells responded to IE1 (+74 days post HSCT). This data shows that the patients that 
received non T cell depleted grafts did not reactivate CMV during steroid therapy because 
they maintained enough CMV specific T cells to prevent the virus from reactivating. This 
leads to the possibility that in the patients that reactivated CMV this might possibly be as a 
result of a drop in the functional T cell response to the CMV antigens. Although the patients 
who received non T cell depleted grafts did experience the same loss in T cell function they 
did maintain functional CMV specific T cells possibly reflecting the better immune 
reconstitution in these patients.
The T cell response to the CMV antigens gradually returns once the steroid dosage is reduced. 
Among this cohort the seven patients that developed confirmed or suspected GVHD were 
started on a high dose of steroids (2mg methylprednisolone per kg body weight). This initial 
high dose results in the loss of T cell responses to the CMV antigens but in parallel does 
reduce GVHD, as the GVHD symptoms resolve the steroid dosage is gradually reduced. The
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Figure 3.8 Effect of steroid therapy on the number of T cell responding to the CMV 
antigens
The absolute number of CD3+CD4+ and CD3+CD8+ T cells (x l0 6/l blood) producing 
IFNy in response pp65 (□ ) , IE1 ( A)  and CMV lysate (X), and the quantitation of CMV 
viral load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Patient 15 is 
shown after receiving bone marrow from a sibling donor (Panel A) and patient 7 is shown 
after a matched unrelated peripheral blood stem cell transplant (Panel B). Also illustrated 
on the graph are periods of treatment with methylprednisolone ( t "aa V. prednisolone 
d  I): with ganciclovir (ZZZZ2) and valganciclovir ( EZZZZ2).
lower steroid dosage results in the gradual return of the T cell responses to the CMV antigens 
although this recovery was facilitated by the reactivation of the virus as shown in figure 3.8 
(Panel B). In figure 3.8 (Panel B) patient 7 was treated with steroids for suspected or 
confirmed GVHD at +133 post HSCT, the high initial steroid dose caused a loss of T cell 
responses to the CMV antigens, however, as the dosage was tapered these T cell responses 
gradually returned. By +200 days post HSCT 20x106/L CD4+ T cells responded to CMV 
lysate (Figure 3.8, panel B), 26xl06/L CD8+ T cells responded to pp65 and 7xl06/L
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responded to IE1 (Figure 3.8, panel B). The return of the T cell responses to the CMV 
antigens was boosted by CMV replication detected at +180 days. Among the five patients that 
reactivated CMV while on steroid therapy we found that the CD8+ T cell response recovered 
faster and to a greater magnitude than die CD4+ T cell response.
The loss in absolute number of T cells and the reduced production of IFNy in response to 
antigen stimulation led us to investigate the cause. The initiation of steroid therapy caused a 
large fall in the functional responsiveness of T cells. In the example shown in figure 3.8 
(Panel B) the number of CD4+ T cells responding to CMV lysate fell by 65% following the 
commencement of steroid therapy, the number of CD8+ T cells responding to the IE1 antigen 
fell by 94%. We therefore examined the effect of steroid therapy on the absolute lymphocyte 
counts to determine whether die fall in T cell responses was due to the lack of T cell function 
or as a consequence of reduced T cell numbers. The most effective way of quantifying the 
number of CMV specific T cells that were functional would have been to use HLA/peptide 
tetramers and to then stimulate the T cells and to quantify the number of responding cells, but 
unfortunately no tetramer staining could be performed on these patients due to low T cell 
counts. Also the patients that received steroid therapy were of mixed HLA types and no HLA 
matched tetramers were available at the time for the antigen involved. Therefore in order to 
monitor the loss of T cell numbers associated with steroid therapy the absolute number of 
CD4+ and CD8+ T cells were determined for all seven patients. The absolute number of 
CD4+ and CD8+ T cells were calculated from the full blood counts performed at the RFH 
and then by using the %CD3+CD4+ or %CD3+CD8+ gate on the flow cytometry plots. The 
absolute number of lymphocytes determined by this method was compared with the number 
determined by using fluorospheres', overall there was no significant difference between the 
counts obtained by each method. As shown in figure 3.9, the number of CD4+ and CD8+ T 
cells declined upon the initiation of steroid therapy. Prior to the commencement of steroid 
therapy patient 7 had an absolute CD4+ T cell count of 1700xl06/L and a CD8+ T cell count 
of 900x106/L, following the initiation of steroid therapy at +134 the absolute CD4+ T cell 
count had dropped to 400x106/L and the CD8+ T cell count had dropped to 450x106/L (Figure 
3.9). These results are representative of all those patients who had received steroid therapy 
post HSCT, allowing us to draw the following conclusion that the initiation of steroid therapy 
causes a drop in the T cell response to the CMV antigens, this drop in T cell responses is also 
accompanied by a decrease in the absolute number of T cells. In this study, we were unable to 
establish whether CMV specific T cells were dysfunctional, in terms of their ability to 
produce IFNy upon stimulation, due to the administration of steroids although this is the most 
likely explanation. Once the steroid dosage is gradually reduced the number of CD8+ T cells
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increases fo llow ed by the number o f  CD4+ T cells, indicating that the cells are present but 
incapacitated by administration o f steroids. During these periods o f  steroid therapy patients 
become lymphopenic and are at an increased risk o f developing life-threatening infections.
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Figure 3.9 Effect of steroid therapy on absolute T cell counts
The absolute number of CD3+CD4+ ( ■ ) and CD3+CD8+ ( ■ ) T cells (x l06/l blood) and 
the quantitation of CMV viral load ( • )  (log,0 genomes/ml of blood) are shown as days 
post HSCT. Patient 7 is shown after a matched unrelated peripheral blood stem cell 
transplant. Also illustrated on the graph are periods of treatment with ganciclovir (ZZZZZl)', 
valganciclovir (E2ZZ3) methylprednisolone ( l. . .  _ j  ) and prednisolone ( < i ).
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3.6 Assessment of the dominance of different CMV antigens in the control of CMV 
replication
The immune response to the different CM V antigens (pp65, IE1 and CM V lysate) was 
compared to determ ine whether a specific T cell response to a g iven antigen was more 
dominant in controlling CM V replication. Peak C D 4+ T cell responses to CM V lysate were 
observed at the same time as a detectable CD8+ T cell response to either pp65 or IE1 (Figure 
3.4), this m ight be expected as the lysate contains both pp65 and IE1. The C D 8+ T cell 
response to IE1 in three patients was detectable prior to the response to pp65, a representative 
plot is shown in figure 3.10.
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Figure 3.10 Num ber of CD8+ T cells responding to IE1 and pp65 in CMV 
seropositive recipients receiving a graft from a CMV seropositive donor
The absolute number of CD3+CD8+ T cells (x l0 6/l blood) producing IFNy in response to 
pp65 (□ ), IE1 (A) and CMV lysate (X), and the quantitation of CMV viral load ( • )  (log]0 
genomes/ml of blood) are shown as days post HSCT. Representative data on patient 6 is 
shown after a matched sibling peripheral blood stem cell transplant.
The three patients that exhibited this phenomenon were CM V seropositive before transplant 
and received a graft from a CM V  seropositive donor but not all those who were R +/D +  
showed the same pattern o f  response and there was no HLA allele in com m on to all three 
individuals. Nine patients showed CD 8+T cell responses to both IE1 and pp65 simultaneously 
with more than lx lO 6 C D 8+ T cells responding to each antigen. Five other patients only had a 
C D 8+ T cell response to pp65 (m ore than lx lO 6 C D 8+ T cells responding), all o f  these 
patients reactivated CM V post HSCT.
The relative risk o f  having only a C D 8+ T cell response to pp65 was calculated for fourteen 
patients. For this analysis a C D 8+ T cell response was defined as more than 1x 106/L C D 8+ T 
cells producing IFNy in response to IE1 or pp65, this excluded 4 patients (patients 6, 16, 21,
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22). This data is presented below in a contingency table (Table 3.2). Those patients who 
demonstrated CD8+ T cells responses to only pp65 were 65% (risk difference) more likely to 
reactivate CMV than those who had CD8+ T cell responses to both pp65 and IE1. The 
relative risk of having only a CD8+ T cell response to pp65 was 3.0, this indicates that 
individuals who only have a response to pp65 are three times more likely to reactivate CMV 
than those who had CD8+ T cell responses to both antigens. Although from figure 3.3 no 
significant difference could be found between the T cell response to IE1 in those who 
reactivated CMV and those who did not in the first 100 days post transplant, the data 
presented here in table 3.2 reveals that having both a T cell response to pp65 and IE1 provides 
better protection from CMV reactivations. The implication of this in relation to vaccination 
strategies with peptides will be covered in the discussion.
CD8+ T cell responses to CMV reactivation (number No CMV reactivation
CMV antigens of patients) (number of patients)
pp65 5 0
pp65 and IE1 3 6
Table 3.2 Frequency of HSCT patients responding to the IE1 and pp65 antigens
The number o f HSCT recipients who have CD8+ T cell responses to both pp65 and IE1 
antigens and those who have only a CD8+ T cell response to pp65. The relative risk of 
having only a CD8+ T cell response to pp65 was determined and is described below.
The Pearson correlation coefficient was applied to the patient data in order to determine 
whether there was a positive correlation between the T cell responses to the different 
antigens. The CD8+ T cell response to pp65 showed a positive correlation (P=0.0483) with 
the T cell response to IE1 but this was only in 4 patients, two of which reactivated CMV post 
HSCT. The CD4+ T cell response to CMV lysate showed a positive correlation with the 
CD8+ T cell response to pp65 but this was only observed in 4 patients interestingly all 
reactivated CMV post HSCT. The CD4+ T cell response to CMV lysate showed a positive 
correlation with the CD8+ T cell response to IE1 but this was only observed in 4 patients, two 
of these reactivated CMV post HSCT. These results demonstrate that the T cell responses to 
the CMV antigens showed a positive correlation in only a few patients and there was no 
overall protection from CMV gained in these patients.
The longitudinal monitoring of patients post HSCT revealed that at the time of their first 
CMV reactivation, a reduced immune response to the CMV antigens could be detected 
compared with those who did not experience any CMV replication. Among the 10 patients 
who reactivated CMV, the CD4+ response to CMV lysate was between 0-0.192 x l06/L, a
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similar reduction could be seen in the CD 8+ T cell response (range 0-0.75 x l0 6/L). However, 
two patients had > 1x 106/L CD8+ T cells that responded to pp65 both prior and during the 
onset o f  increasing viral load but this response did not prevent the virus from reactivating. 
The data presented in figure 3.11 reveals that the CD 8+ T cell response to pp65 alone could  
not prevent the virus from reactivating in these patients but the response to the CM V lysate 
would be more valuable as a stim ulus for providing protection against the virus as a 
vaccination strategy.
Days post HSCT
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Figure 3.11 Role of CD4+ T cell responses in maintaining pp65 immunity against 
CMV
The absolute number of CD3+CD4+ and CD3+CD8+ T cells (x l0 6/l blood) producing 
IFNy in response to pp65 (□ ), IE1 (A) and CMV lysate (X), and the quantitation of CMV 
viral load ( • )  (log10 genomes/ml of blood) are shown as days post HSCT. Shown is 
patient 12 after a RIC matched sibling peripheral blood stem cell transplant. Also shown 
on the graph are periods of treatment with ganciclovir (?ss/7i) and prednisolone ( i " i ).
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3.7 Discussion
In this study, CMV specific immune reconstitution was monitored in patients undergoing 
HSCT as a treatment for a variety of haematological malignancies and immunological 
deficiencies. The CD4+ and CD8+ T cell IFNy responses to CMV antigens was measured 
using CMV lysate to stimulate the CD4+ T cells, IE1 and pp65 peptide pools (PepMix™) 
were used to stimulate both the CD4+ and CD8+ T cells. These peptide pools and the CMV 
lysate represent all potential CD4+ T cells epitopes. CMV lysate would include epitopes 
derived from the viral coat protein, gB, that has already been described as stimulating an 
effective CD4+ T cell response (Landini 1988; Landini and Michelson 1988). Previous data 
(Dunn et al. 2002; Kern et al. 2002) has shown that 15mer peptides are able to stimulate both 
CD4+ and CD8+ T cells simultaneously, we were therefore able to describe both CD4+ and 
CD8+ T cell responses to the pp65 and IE1 antigens. The use of peptide pools and CMV 
lysate meant that this study was not confined to those individuals who are HLA-A*0201 but 
allowed for the recruitment of patients with a variety of HLA haplotypes.
Previous studies (Aubert et al. 2001; Cwynarski et al. 2001; Gratama et al. 2001) have 
monitored the absolute number of tetramer positive T cells in patients post HSCT, their 
findings showed that in those individuals who had at least 1x107/L tetramer positive CD8+ T 
cells were protected from reactivating CMV (Cwynarski et al. 2001). However, these studies 
were limited to HLA-A*0201 and HLA-B*0702 individuals as these were the only tetramers 
available at the time. A further study conducted by Ozdemir et al. demonstrated that not all 
tetramer positive cells are functional with respect to IFNy production (Ozdemir E 2002). We 
therefore monitored responses to the CMV antigens by using intracellular staining for IFNy 
and assessed both the CD4+ and CD8+ T cell responses.
In our cohort of 18 patients, 10 reactivated CMV at a median of 20 days post HSCT; none of 
these patients developed CMV disease, in those who reactivated CMV deficiencies in both 
CD4+ and CD8+ T cell responses to the CMV antigen pp65 and CMV lysate were detected 
within the first 100 days post transplant. In two patients (patients 1 and 12) who subsequently 
experienced a second reactivation, a CD8+ T cell response to pp65 was present (0.3- 
22.8x106/l) before an increasing viral load was detected. This CD8+ T cell response to pp65 
did not protect these patients from reactivating CMV, in addition there was also no 
simultaneous peak of CD4+ T cell response (0-0.3xl06/l) to CMV lysate. These findings 
highlight the importance of a CD4+ T cell response and this can be more predictive than the 
CD8+ T cell response in determining the degree of protection provided against CMV. The 
reactivation of CMV stimulated both CD4+ and CD8+ T cell responses either during or 
shortly after an increasing viral load, indicating that the maintenance of this response would
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further protect against any other reactivation events. Patients who experience a delay in CD4+ 
T cell reconstitution would be at increased risk of reactivating CMV post transplantation, a 
low number of CD4+ T cells has been shown to be associated with an increased infection rate 
(Small et al. 1997; Storek et al. 2000), it would also appear that the same occurs in patients 
post HSCT with CMV infections.
The maintenance of an immune response against CMV was also affected by steroid therapy, 
in this cohort seven patients required steroid therapy for the treatment of either confirmed or 
suspected GVHD. Steroids had a rapid affect on CD8+ T cell function with a reduction in the 
magnitude of response to CMV antigens after the commencement of treatment. This affect 
was less marked on the CD4+ T cell response to lysate, which was reduced by 65% in patient 
7. Steroids specifically block T cell activation via their direct negative effects on IL-2 and IL- 
6. Patients receiving steroid therapy shortly after transplant are more likely to develop 
infections from bacteria, fungus and viruses (Sayer et al. 1994). The effect of steroids is 
primarily aimed at suppressing the function of CD4+ T cells and therefore CD8+ T cells 
indirectly. The rapid effect that steroids have on CD8+ T cells highlights the dependency of 
these cells on CD4+ T cells. The non T cell depleted patients (n=2) did not reactivate CMV 
despite die use of steroids, reflecting the better immune reconstitution in these patients and 
the potential transfer of CMV specific T cells from the donor. The occurrence of CMV 
pneumonitis has been shown to correlate with the presence and severity of GVHD (Myers et 
al. 1975), it has been suggested that GVHD serves as a host element necessary for the 
development of CMV disease although this does remain a controversial theory. Among the 
patients recruited in this study 10 reactivated CMV, half of these did develop GVHD, 
however, it is difficult to determine if this was as a direct result of GVHD or it treatment with 
steroid therapy.
Among this cohort the reactivation of CMV occurred at a median of 8 days after the 
commencement of steroid therapy, this could be attributed to the rapid loss of function of the 
CD8+ T cells and subsequently also the CD4+ T cells. Due to low lymphocyte counts in the 
patients who were receiving steroid therapy it was not possible to perform tetramer staining to 
establish what proportion of the CMV specific T cells were functional in terms of IFNy 
production. However, upon calculating the absolute number of CD4+ and CD8+ T cells it 
was clear that steroid therapy caused a huge decrease in T cell numbers. The same trend was 
seen in a patient (patient 15) that received a non T cell depleted graft and subsequently 
received steroid therapy for the treatment of GVHD, although the T cell count and function 
was reduced, this was less profound than in the patients that received T cell depleted grafts. 
One study (Ozdemir E 2002) has shown that steroids result in a significant impairment in
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CMV specific CD8+ T cell TNFa production but not in the frequency of CD8+ T cells. The 
data presented here shows that there is reduced IFNy production by both CMV specific CD4+ 
and CD8+ T cells along with a decrease in frequency. These results highlight the detrimental 
affect that steroids have on the immune response to CMV and demonstrate that those patients 
who receive T cell depleted grafts and develop GVHD are at the highest risk of reactivating 
CMV.
Five patients in this cohort received no form of T cell depletion as part of their transplant 
protocol; none of these patients reactivated CMV post transplantation, probably as a result of 
the transfer of functional T cells from the donor in the D+/R+ D+/R- groups. In non T cell 
depleted individuals viral replication probably does occur as peaks in responses to the CMV 
antigens can be detected, although immune reconstitution in these patients is good due to the 
transfer of functional T cells from the donor. The limit of detection of the CMV PCR test is 
200copies/ml blood, it is therefore possible that viral load does fluctuate below the level of 
detection and is enough to generate an immune response that subsequently prevents the viral 
load increasing any further.
Historically, longitudinal monitoring of CMV specific T cells has been conducted with the 
use of HLA tetramers; to date no such study has been conducted with the IE1 antigen. The 
importance of the immune response to the IE1 antigen has recently been shown by 
longitudinal monitoring of patients post solid organ transplantation (Bunde et al. 2005). 
Because the IE1 antigen is a product of the immediate early phase of the viral replication 
cycle it is a potential target for the immune response, following the demonstration that pp65 
can inhibit the presentation of IE1 (Gilbert et al. 1996) the search for potential CMV epitopes 
shifted from EE1 to pp65. However, in some individuals IE1 specific CD8+ T cells can still be 
detected (Gyulai et al. 2000; Kern et al. 2000; Kern et al. 1999) and an increasing amount of 
research is now being conducted on the IE1 antigen. Within this cohort nine patients had 
CD8+ T cell responses to both IE1 and pp65, while five patients had a CD8+ T cell response 
to pp65 only, with the remaining four patients no significant CD8+ T cell response (>1x106/L 
responding CD8+ T cells) against either antigen could be detected. The patients that had a 
CD8+ T cell response to both pp65 and IE1 exhibited better viral control when compared to 
the five patients that had only a response to pp65 who were 65% (relative risk difference) 
more likely to reactivate CMV. Interestingly all the patients whose T cell responses to IE1 
peaked before pp65 were CMV seropositive prior to transplant and received a graft from a 
CMV seropositive donor, but a larger study would need to be performed in order to determine 
the significance of these findings.
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There are many factors that effect CMV specific immune reconstitution post HSCT two of the 
main ones are treatment with ganciclovir and GVHD and its treatment (Bowden et al. 1987; 
Heagy et al. 1991; Li et al. 1994). Recent strategies aimed at depleting T cells from the donor 
graft can reduce the incidence of acute or chronic GVHD (Spencer et al. 1995) making more 
patients eligible for transplant. T cell depletion strategies are associated with delayed immune 
reconstitution, increase in relapse and graft failure. Delayed immune reconstitution leaves 
patients at more risk of developing infectious complications notably fungal and viral 
infections. In our study CMV replication occurred only in those patients who received T cell 
depletion either in the graft or in vivo. In this study no protective number of CMV specific 
CD4+ or CD8+ T cells could be assigned as has been shown with longitudinal tetramer 
monitoring studies (Aubert et al. 2001; Cwynarski et al. 2001). The monitoring of functional 
CMV specific T cell responses has shown that in some patients the number of T cells 
producing IFNy in response to antigen stimulation was low but was, however, enough to 
prevent CMV replication. There are many factors that effect patients post HSCT and some 
patients had more problems with fungal infections than with viral infections. A much larger 
study would need to be conducted to investigate the immune response to CMV antigens post 
HSCT but this study does highlight some trends with regard to functional immune responses 
to CMV.
There are currently only a few antiviral drugs available to treat CMV disease or reduce CMV 
viraemia the main drug used is ganciclovir that is given either pre-emptively or 
prophylactically, in the case of persistent viremia foscamet can also be used. However, there 
is an increasing number of drug resistant strains of CMV being reported (Erice et al. 1998; 
Hamprecht et al. 2003; Julin et al. 2002), other options such as the adoptive transfer of CMV 
specific T cells should be available. Although the incidence of CMV disease in the HSCT 
setting is decreasing with the advent of ganciclovir and foscamet, the vims has been reported 
to contribute indirectly towards the development of alloreactive T cells causing GVHD 
(Gluckman et al. 1997). The most serious cases of CMV infection have been seen in 
combination with GVHD and this raises the question about the contribution of CMV in the 
development of GVHD, to date the evidence supporting this association is lacking.
Our results indicate that both a helper T cell response and a cytotoxic T cell response are 
important in preventing CMV disease in HSCT recipients. An understanding of the 
replication cycle of CMV has already identified several key antigenic proteins, which should 
be considered in the design of a vaccine. The gB protein has been identified as the main focus 
for antibody production, with pp65 currently being considered as the main target for CTL 
responses, but this situation may change depending on the combination of HLA alleles that an
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individual expresses. The incorporation of other CMV proteins such as ppl50 and IE1 may 
well be mandatory and could provide better protection if used in a vaccine formulation. The 
results presented in this chapter reveal that in HSCT recipients that had a CD8+ T cell 
response to both pp65 and IE1 there was better viral control and they were less likely to 
reactivate CMV than those who only had a CD8+ T cell response to IE 1 or pp65 alone.
The development of a CMV vaccine could not only reduce the incidence of CMV disease in 
immunocompromised patients but could reduce the 17,000 cases of congenital CMV that 
occur each year in the USA and Europe (Plotkin 1999). In the HSCT setting the development 
of a CMV vaccine should be investigated for immunotherapy in patients receiving allografts. 
Clearly it would not be wise to vaccinate HSCT recipient's prior to transplant as the 
conditioning regimes and in particular cyclosporine A would destroy any CMV specific T 
cells that were generated. However, the HSCT donors could be immunised prior to harvest 
resulting in a higher number of CMV specific T cells being transferred to the recipient. In 
transplants where the donor is CMV seronegative and the recipient is CMV seropositive, the 
donor could be vaccinated a few months prior to harvest resulting in the transfer of CMV 
specific T cells. In transplant regimes that involve the T cell depletion of the graft to reduce 
the occurrence of GVHD no CMV specific T cells would be transferred to the recipient. The 
adoptive transfer of CMV specific T cells has been used to generate CMV specific T cells in 
vitro from the donor and adoptively transferred into the recipient to prevent the development 
of CMV disease. The vaccination of CMV seronegative donors would allow for CMV 
specific T cells to be generated in vitro and to be transferred into the recipient if required. The 
adoptive transfer of CMV specific CD4+ and CD8+ T cells is required to provide long-term 
protection against CMV disease, in patients with poor CD4+ reconstitution transferred clones 
are lost within weeks of transfer (Walter et al. 1995). The adoptive transfer of CMV specific 
T cells is a long and laborious method that is expensive and is not logistically feasible for all 
transplant centres to perform. Newer strategies have been employed using tetramers to isolate 
CMV specific CD8+ T cells (Cobbold et al. 2005) then transferring these to the recipient with 
minimal ex vivo manipulation, other strategies have isolated CD4+ and CD8+ CMV specific 
T cells by selecting T cells producing IFNy in response to antigen stimulation then 
transferring these to the recipient. These newer strategies produce CMV specific T cells 
quicker than previous methods, which can then be transferred to a recipient if required. 
Overall, we have shown that CMV specific CD4+ T cells are important post HSCT, and a 
CD8+ T cell response against pp65 and IE1 provides better viral control post transplant. We 
have conducted the first longitudinal study that examines the T cell IFNy responses to the 
CMV antigens in patients post HSCT and have determined the effects of post transplantation 
therapy on T cell responsiveness.
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Chapter 4
Identification of CD8+ T cell epitopes from the Cytomegalovirus
antigens pp65 and IE1
4.1 Introduction
Over the last two decades numerous studies have been conducted to identify the major CMV 
target antigens that induce cell mediated immune responses. A large body of work has been 
performed to identify the CMV peptides that are presented in association with different HLA 
molecules. These studies have provided new information about the immune response to CMV 
and have led to the development of more sophisticated reagents to study the different aspects 
of this response. The majority of these studies have concentrated on cytotoxic T lymphocytes, 
mainly due to a lack of available reagents for helper T lymphocytes and evidence of their 
importance is only becoming apparent in the last five years.
The recognition of virally infected cells by CD8+ T cells requires that the viral proteins be
*
processed into peptides by the cell's proteasome complex. The peptides that are generated for 
loading onto Major Histocompatibility Complex (MHC) class I molecules are typically 8-10 
amino acids long. These virally derived peptides are then transported in a TAP dependent 
manner into the endoplasmic reticulum for loading onto MHC class I molecules; this 
antigenic complex is then transported to the cell surface. A large body of work has been 
performed to identify the CMV peptides that are presented in association with different 
human leukocyte antigen (HLA) molecules. This has led to the development of new rapid 
methods both cellular and computer generated for predicting CMV epitopes and an increasing 
list of known CMV epitopes.
The major antigen targeted by CMV specific cytotoxic T lymphocytes (CTL) was identified 
as being the coat phosphoprotein 65 (pp65) (Wills et al. 1996). This coat protein is an ideal 
target for CTLs as it is introduced into the cell during viral entry and is rapidly available for 
processing in the MHC class I pathway. The pp65 antigen does not require viral gene 
expression (Riddell et al. 1991) and is therefore one of the first antigens to be presented on 
the surface of infected cells. To date, most of the CD8+ T cell epitopes identified originate 
from pp65 and cover HLA alleles that are predominant in the Caucasoid population. Other 
target antigens have also been suggested that could enhance the immune response, including 
pp28, IE1, and ppl50 (Gyulai et al. 2000; Kern et al. 1999b). Currently many groups are
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starting to look at these other antigens by using various epitope mapping techniques, as a 
result of this additional CMV peptides are being identified although at a slow rate due to the 
complexity of the work.
The aim of this chapter is to identify new MHC class I restricted CMV epitopes using the best 
available method. In chapter 3 the importance of the CMV antigen IE1 was highlight in a 
cohort of patients who had undergone HSCT, those patients that had detectable CD8+ T cell 
responses to both IE1 and pp65 had better virus control. This data revealed that a boosting of 
both pp65 and IE1 specific CTLs would be required to provide better overall viral control. 
The aim of this chapter is to identify new MHC class I restricted CMV peptides focusing 
mainly on the immediate early 1 (IE1) antigen and also to identify peptides restricted by HLA 
alleles that are predominant in the Afro Caribbean and Asian populations.
4.1.1 Methods used to identify CMV epitopes
A number of different epitope mapping methods have been used to screen CMV antigens for 
new epitopes. The original methods used were laborious and very often under-estimated the 
true frequency of CMV specific T cells, with the advent of new more sensitive assays a 
number of different methods are available and are described below:-
Limiting dilution assay (LDA)
The method used to identify the first pp65 epitope (Diamond et al. 1997) was a limiting 
dilution assay; this method measures those CTLs that are capable of expanding in a bulk 
culture maintained over 2-3 weeks. The cytotoxic potential of these CTLs is then measured 
using a standard chromium release assay. This method was the only method originally 
available to map new CMV epitopes, however, subsequently it was shown that it under 
estimated the true frequency of circulating CTLs, also it is very laborious and time 
demanding to perform therefore the throughput is relatively low.
Antigen expressing viral vectors
Epitopes can also be identified with the use of recombinant viral vectors containing the 
sequence of the antigen under investigation. Such a strategy was employed by Diamond et al. 
(Diamond et al. 1997) to identify the minimal pp65 cytotoxic epitope NLVPMVATV. In this 
study, truncations of pp65 were expressed in vaccinia viral vectors. These truncations were 
then screened using a T cell clone that was reactive to pp65; overlapping peptides were then 
used to identify the minimal cytotoxic epitope. This method is time consuming and very 
laborious, it also requires that one has specific clones available which need to have been 
characterised initially.
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Overlapping peptides
The use of peptides that cover the entire length of a protein is a relatively new and rapid 
method that can identify new peptides presented by a range of different HLA molecules. By 
using overlapping 15mer peptides both CD4+ and CD8+ restricted epitopes can be identified, 
previous data (Dunn et al. 2002; Kern et al. 2002) has shown that 15mer peptides are able to 
stimulate both CD4+ and CD8+ T cells simultaneously. The responsiveness of T cells may be 
assessed by using various different methods; the most commonly employed involves the 
detection of IFNy production following peptide stimulation. The development of a cytokine 
flow cytometry method (CFC) allows the precise assessment of T cells responding to a given 
peptide. Incubation with the secretion inhibitor Brefeldin A allows cytokines to accumulate 
within cells, and intracellular staining identifies those cells producing the cytokine of interest. 
CFC allows for the gating of both CD4+ and CD8+ T cells that are then acquired by flow 
cytometry; this is an advantage over the ELISPOT method that relies on the separation of 
specific cell populations prior to peptide stimulation. The overlapping peptide method for 
identifying new CMV epitopes is now coming to the fore as an efficient and reliable method 
for epitope prediction.
Transgenic mice
Transgenic mice expressing the human HLA-A*0201 gene have been used to identify 
peptides that are restricted by HLA-A*0201. The mouse model HHD II contains a defect in 
its own MHC class I genes such that any antigenic peptides generated can only be presented 
in association with human HLA-A*0201. This mouse model is restricted to HLA-A*0201, 
however, there are a lot of other HLA alleles in the population thus restricting their use. This 
method has been used to identify the IE 1 peptide TMYGGISLL (Gallez-Hawkins et al. 2003) 
but does require some prior knowledge of possible peptides which can be predicted by the 
MHC allele algorithm programs.
MHC stabilization assay
The TAP-negative (HLA A2, B51) cell line, T2, has been extensively used to test the ability 
of MHC molecules to bind to predicted immunogenic peptides. Due to defective TAP 
molecules, T2 cells are unable to transport endogenous peptides, and only peptides that are 
added exogenously can bind to MHC molecules on the cell surface. The ability of synthetic 
peptides to stabilise MHC molecules on the cell surface of T2 cells can be measured by the 
increase in immnuofluorescence associated with the stabilisation of the MHC molecules. T2 
cells constitutively express HLA-A*0201 on the cell surface but they have also been 
transfected with additional HLA class I molecules to facilitate the identification of HLA- 
restricted peptides (Elkington et al. 2003; Smith and Lutz 1996; Takiguchi et al. 1994;
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Zweerink et al. 1993). The MHC stabilisation assay requires some prior knowledge of 
possible peptide targets which can be obtained from predictive algorithm programs and is 
restricted to the transfected alleles available.
Algorithm programs
Algorithm programs have been used extensively to identify the peptide with the highest 
affinity for a particular HLA molecule from all possible peptides in a given antigen 
(Elkington et al. 2003; Frankenberg et al. 2002; Gallez-Hawkins et al. 2003). These programs 
predict putative MHC class I restricted potential epitopes from the amino acid sequence of a 
given antigen. Each peptide is then assigned a score according to the strength of binding to 
the MHC molecule. Some of the most commonly used programs include SYFPEITHI 
(Rammensee et al. 1999) and BIMAS.
The BIMAS database was created by Dr Kenneth Parker (NIAID and NIH, USA) and uses 
information from amino acid and position coefficient tables to predict epitopes (Parker et al. 
1992). These tables have been created by Dr Parker and apart from HLA-A*0201, the data in 
these tables are not available anywhere else. The coefficient tables rank the contribution that 
an individual amino acid has on the peptide binding to MHC class I molecules. All amino 
acids are designated with a value of one, the dominant anchor residues have values greater 
than one while unfavourable amino acids have a value of less than one. The auxiliary anchor 
residues can have values greater than one but are not as high as the anchor residues. Some 
amino acids can have a value of one where nothing is known about the amino acid at that 
position and whether it would make the peptide binding favourable or not. This database does 
have some drawbacks namely it only has information on 28 HLA A and B alleles. Because 
this database only looks at the individual amino acids within a sequence it does not take into 
account the combination of amino acids and the possible favourable or unfavourable impact 
they may have on peptide binding. Due to the lack of information about the possible impact 
that the auxiliary anchor residues may have, epitope mapping using this database can only be 
a guide to possible peptides.
The SYFPEITHI database like the BIMAS database predicts peptides based on a scoring 
system that determines the ability of a peptide to bind to a HLA molecule according to the 
presence of a particular amino acid at the anchoring position (Rammensee et al. 1999). A 
favourable amino acid at either anchoring position is allocated a value of 10, while the 
auxiliary residues are allocated a value of 6, unfavourable amino acids have a negative value, 
the resulting score for the peptide is the combination of these values. The SYFPEITHI 
database can be used as a guide to predict the most likely epitopes contained within a
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sequence, however, like the BIMAS database it does not take into account the combination of 
amino acids and the possible favourable or unfavourable impact they may have on peptide 
binding. Again for some of the more uncommon HLA molecules information regarding the 
natural ligands are unknown and therefore this results in unreliable predictions based on 
calculations rather than experimental evidence.
Peptide epitopes can also be predicted from information related to the proteasome cleavage 
sites contained within an antigen. A number of programs are available the most popular ones 
are PAPROCC and NetChop. The PAPROCC (www.paproc.de) database was developed at 
the Tubingen University (Kuttler et al. 2000; Nussbaum et al. 2001), this database is a 
computer theoretical model for the cleaving of substrate by the human 20S and yeast 
proteasomes. The experimental data for the human 20S proteasome looked at the cleavage of 
enolase and ovalbumin by the human erythrocyte proteasome. The PAPROCC database can 
be used to predict the C-terminus of the peptide but is not reliable to use for the prediction of 
the N-terminus as it is unable to take into account any cytosolic proteases that can trim the 
peptide. The NetChop database (www.cbs.dtu.dk/services/NetChop/) was developed at the 
Center for Biological Sequence analysis at the Technical University of Denmark (Kesmir et 
al. 2002), this database is a neural network-based that has been trained using human 
proteasome 20S ligands. The rationale behind using ligands is that they are the closest to a 
naturally processed in vivo product. The MHC class I ligands used were obtained from 
publicly available databases (Kesmir et al. 2002), the current NetChop version is three times 
larger than the previous edition. The creators of NetChop have compared their database with 
other publicly available databases (Saxova et al. 2003) and found that their database could 
predict 73% of the naturally cleaved C-terminus ligands. One of the main criticisms of 
proteasomal cleavage databases is that the proteasomal-generated fragments may not be 
transferred to the endoplasmic reticulum and bind MHC class I molecules. These databases 
can be useful in narrowing down the number of possible candidate peptides that bind to a 
particular MHC molecule, however, caution should be taken as these peptide prediction 
programs do not always represent in vivo peptide processing. Viruses such as CMV have 
developed strategies to prevent the presentation of viral peptides on the surface of infected 
cells.
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RESULTS
The identification of new CMV epitopes focused on the IE1 and pp65 antigens, the 
importance of T cell responses to these two antigens was highlighted in chapter 3 in HSCT 
recipients post transplantation. Due to the immune suppressed nature of HSCT recipients it 
was not feasible to use these patients to identify new CMV epitopes, we therefore recruited 
healthy individuals and identified new epitopes mainly from this cohort.
4.2 Functional responses to the CMV antigens pp65 and IE1
To determine the feasibility of identifying new CMV epitopes derived from the IE1 and pp65 
antigens, a preliminary study was conducted to assess the level of immune responsiveness to 
these antigens in a cohort of 29 healthy donors. PBMCs from each donor were stimulated 
separately overnight with the pp65 PepMix and the IE1 PepMix using the methods described 
in chapter 2 (section 2.3.4). Following overnight stimulation the amount of IFNy produced in 
response to each antigen was determined using intracellular staining for IFNy, a 
representative plot is shown in figure 4.1 demonstrating how the CD8+ T cells producing 
IFNy were gated on the flow cytometry plots, the results for the whole cohort are shown in 
figure 4.2.
As can be seen from figure 4.2 significant levels of IFNy were produced in response to the 
pp65 and IE1 PepMixes in CMV seropositive healthy donors. There was no IFNy produced in 
response to either of the PepMixes in those donors who were CMV seronegative thus 
demonstrating that the immune responses measured were specific to the CMV antigens. There 
was a varied range of CD8+ T cell responses to both the pp65 (range 0.01- 
3.609%CD3+CD8+IFNy+ T cells) and IE1 (0.01-4.222%CD3+CD8+IFNy+ T cells) antigens 
indicating that some individuals maintain a higher level of responsiveness to these antigens 
while others have a level that is barely detectable. By comparing the responses to both pp65 
and IE1 using the Mann-Whitney U test there was no significant difference found between the 
responses to the two antigens, demonstrating that a similar frequency of CTLs against both 
antigens is present in healthy donors, this has also been described in the literature (Gyulai et 
al. 2000; Kern et al. 2000). It can therefore be concluded that the levels of response found to 
the IE 1 and pp65 antigens in healthy donors are high enough to enable the epitope mapping of 
both antigens, and that healthy individuals have TCR repertoires that utilise both antigens to 
deal with CMV reactivations as opposed to just pp65 which was originally thought to be the 
case.
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Figure 4.1 Example of the gating strategy for IFNy responses to IE1 and pp65 in a healthy CMV seropositive individual
Shown are IFNy responses to the IE1 PepM ix (far left), pp65 PepM ix (left), polyclonal stimulus (SEB) and in the absence o f  antigen (right). IFNy 
producing C D 8+ T cells are determined as a percentage o f the C D 3+C D8+ T cell population. Chapter 4
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Figure 4.2 Functional IFNy responses to the CMV antigens pp65 and IE1 in healthy 
individuals
Responses to the CMV antigens pp65 ( ■ ) and IE1 (A ) were determined in a cohort of 25 
CMV seropositive and 4 CMV seronegative healthy individuals. The amount of IFNy 
produced in response to peptide stimulation was represented as a percentage of the 
CD3+CD8+ T lymphocyte population. For all donors the background level of IFNy (no 
peptide control) was subtracted from the overall result. There was no statistically 
significant difference between the CD8+ T cell responses to the two antigens (/>=0.391) 
when tested using Mann-Whitney U test.
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4.3 Overlapping 15mer peptides to identify new CMV epitopes
In order to use overlapping 15mer peptides to identify new epitopes for C D 8+ T cells, it was 
necessary to demonstrate that these would bind to MHC class I m olecules. To investigate the 
binding affinity o f 15mer peptides, T2 cells were pulsed with a FITC labelled 9mer peptide 
(N L V PM V A T V ) and 15mer peptide (A G IL A R N L V PM V A T V ). These 9mer and 15mer 
peptides were labelled with FITC on the carboxyl terminal end. T2 cells were pulsed with 
50p g  peptide overnight, the follow ing day, excess peptide was washed o ff  and the samples 
were acquired and analysed by flow  cytom etry. A M HC stabilisation assay was also  
performed to confirm  the peptide binding abilities o f  the 9m er and 15mer peptides. The 
results o f  the 9mer and 15mer peptide binding experiments are show in figure 4.3.
A
c3
oo
FITC c h a n n e l
B
ARNLVPMVATVQGQNNLPMVATV AGILARNLVPMVATV
Anti HLA-A*0201 (BB7.2) FITC
Figure 4.3 Determination of binding capacity of 9mer and 15mer peptides to bind 
HLA-A*0201
In panel A FITC labelled NLVPMVATV (------ ) and AGILARNLVPMVATV (----- ) were
used to determine if 15mer peptides can bind HLA-A*0201; a no peptide ( ----- ) control
was used to determine any background FITC. Panel B shows the T2 binding assay 
performed to determine if 15mer peptides can stabilise HLA-A*0201 on the surface of 
T2 cells. The NLVPMVATV; AGILARNLVPMVATV and ARNL VPM V AT V OGON 
peptides were used. The 15mer peptides contain the NLVPMVATV peptide; the 
anchoring residues are shown in red.
The 15mer peptides can bind to MHC class I m olecules on the cell surface, but the binding is 
dependent on the location o f the anchoring residues. Both o f  the fluorescently labelled 9mer 
and 15mer peptides could bind to H LA-A*0201 m olecules on the surface o f T2 cells (Figure 
4.3, panel A). The ARNLVPM VATVQ G Q N peptide could not stabilise MHC class I on the 
cell surface but the A G ILA R N LV PM V A TV  peptide could  (Figure 4 .3 , panel B ), both
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peptides contain the NLVPMVATV peptide sequence that is known to bind HLA-A*0201 the 
anchoring residue are leucine in position 2 and valine in position 9. The 
ARNLVPMVATVQGQN peptide has the anchoring residues in the middle of the peptide and 
may explain why this peptide is unable to stabilise MHC class I molecules on the cell surface. 
The AGILARNLVPMVATV peptide contains the valine anchor residue at position 15 this 
results in the binding of this peptide. Longer 15mer peptides can bind to MHC class I 
molecules, the ends of the binding groove are closed and therefore peptides can either bulge 
centrally from the binding cleft (Guo et al. 1992; Horig et al. 1999) or occasionally can 
extend beyond the C terminal anchor site (Collins et al. 1995). The AGILARNLVPMVATV 
peptide binds to the MHC class I binding cleft indicating that it is most likely that this peptide 
bulges away from the cleft because the peptide terminates with the valine residue at the C 
terminal anchor site. It is also possible that some trimming of this 15mer peptide could occur 
due to the presence of aminopeptidase's at the cell surface and in the surrounding medium. 
The conclusion from figure 4.3 is that 15mer peptides can bind to MHC class I molecules, 
which is comparable to the binding of a 9mer peptide.
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4.4 Scanning for the immunogenic portion of pp65 and IE1
In order to identify new CMV epitopes, 31 healthy individuals were recruited from the 
laboratories at ANRI, Royal Free Hospital (London) and from Southampton General 
Hospital, all participants were informed of the study and verbal consent was obtained. To 
increase the HLA diversity of the group and confirm identified epitopes, additional healthy 
individuals were recruited from the Anthony Nolan Stem Cell donor register, written consent 
was obtained from this group of individuals (chapter 2, section 2.1.2). The diversity of the 
HLA alleles within the whole cohort is shown in figure 4.4, a full list of the individual HLA 
types can be found in the appendix (section 3). In addition six HSCT were recruited due to 
their uncommon HLA alleles, these recipients were all at least 12 months post transplant, the 
patient characteristics are listed in table 4.1. In the early post transplant period high levels of 
circulating cytokines can be detected this created high background levels that made the 
identification of new immunogenic peptides impossible. However, 12 months following 
HSCT the production of IFNy in response to the CMV peptides was higher in the HSCT 
recipients when compared to healthy donors. Because these HSCT recipients are 
immunocompromised detectable CMV viral replication can occur post transplantation, 
resulting in the continued stimulation and expansion of these CMV specific CTLs that can be 
easily detected in vitro.
To scan for new CMV epitopes the amino acid sequence of IE1 and pp65 were broken down 
into mapping pools containing 15mer peptides that overlap by 11 amino acids. To map the 
IE1 antigen there were 8 mapping pools and 9 mapping pools for pp65, each mapping pool 
contained approximately 15 peptides. The full list of peptides contained within each mapping 
pool can be found in the appendix (section 2). Each mapping pool spans approximately 50 
amino acids of the protein sequence. In order to determine the portion of the antigen that 
elicits an immune response PBMCs from each healthy donor was stimulated with both the 
IE1 and pp65 panel of mapping pools in addition to both no peptide and SEB controls. The 
stimulation conditions used were as previously described in chapter 2 (section 2.3.4).
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Figure 4.4 Distribution and frequency of HLA alleles within a cohort of 31 healthy 
donors
This figure summarises the HLA alleles among a cohort of healthy individuals used in 
this study. High resolution HLA typing was performed to determine each allele subtype.
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Patient Disease Age,
years
Donor/Patient
CMV
serology
Stem cell source Conditioning Campath-IH 
in vivo/in graft
GvHD
prophlaxis
40 AML 32 +/+ RIC sib PBSC Flu and Melph Yes/No None
41 AML 58 +/+ RIC MUD PBSC Flu and Melph Yes/No CsA
43 AML 44 +/+ Sib PBSC Cyclo and TBI No/No MTX and CsA
46 Lymphoma 55 + Autologous PBSCs Melph No/No None
48 CML 57 +/+ RIC MUD PBSC Flu and Melph Yes/No CsA
49 AA 19 +/+ Sib BM Cyclo Yes/No MTX and CsA
Table 4.1 HSCT Patient characteristics
This table summarises the characteristics of the HSCT patients recruited to the study from the Royal Free 
Hospital, London. AML, acute myeloid leukaemia; AA, Aplastic Anaemia; CML, chronic myeloid leukaemia; 
MTX, methotrexate; CsA, cyclosporin A; Cyclo, cyclophosphamide; TBI, total body irradiation; Flu, 
Fludarabine; Melph, melphalan; RIC, reduced intensity conditioning; MUD, matched unrelated donor
Chapter 4
Chapter 4
4.5 Identification of predominant immunogenic 15mer peptides
In order to determine the portion o f  the pp65 and IE1 proteins that contained the dominant 
epitopes the mapping pools corresponding to each antigen were tested on PBM Cs from all 31 
healthy individuals. The amount o f  IFNy produced after overnight incubation with each  
individual mapping pool was measured by intracellular staining (chapter 2, section 2.3.4). A  
representative staining plot is shown in figure 4.5 and the results for the w hole cohort is 
shown in figure 4.6.
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Figure 4.5 Example of peptide stimulation using peptide mapping pools to scan for 
the immunogenic portion of the IE1 antigen
PBMCs were stimulated with the IE1 peptide mapping pools overnight as described in 
chapter 2 (section 2.3.4). The flow cytometry plots shown are a representation of the 
results obtained with the 8 IE1 mapping pools. IFNy producing CD8+ T cells are 
determined as a percentage of the CD3+CD8+ T cell population.
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The CD8+ T cell responses to the pp65 and IE1 antigens are located towards the carboxyl end 
of the antigens (Figure 4.6). The greatest diversity in CD8+ T cell responses were found in 
response to the pp65 antigen with the majority of the cohort responding to mapping pools 5-9. 
The CD8+ T cell responses to the IE1 antigen were less diverse and responses were mainly 
confined to mapping pools 4 and 6. The responses to the IE1 antigen was greater in donors 
expressing HLA-B*0702 when compared with non-B*0702 donors (Figure 4.7), this was 
statistically significant (P=0.0001, Mann-Whitney U test), however there was no significant 
difference seen (P=0.6936, Mann-Whitney U test) when comparing the responses of the same 
groups to pp65. The range of CD8+ T cell responses between the donors varied with some 
donors having a high level of responsiveness to the CMV antigens while for others the 
response was just above background levels.
One of the problems encountered with the mapping pool data was how to define the level of 
immune responsiveness. For some healthy donors only 0.5% CD8+ T cells produced IFNy in 
response to a mapping pool, but other individuals had more than 2% CD3+CD8+ T cells that 
produced IFNy in response to a mapping pool. Clearly there is a huge variation in the levels 
of responsiveness to the CMV antigens among this cohort. A possible explanation is that 
there could have been a recent or on going CMV reactivation. Among HSCT patients a high 
level of responsiveness to the IE1 and pp65 PepMixes was observed in chapter 3, these 
patients frequently experience detectable CMV reactivations that then drives and maintains a 
high level of immune responsiveness to the virus. To account for these differences the mean 
response to the pp65 and IE1 mapping pools was determined for each healthy donor, a 
positive response was then defined as a level three time the mean for that particular antigen.
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CD8+ T cell IFNy response to the IE1 mapping pools
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Figure 4.6 Scanning of IFNy T cell responses to the IE1 and pp65 mapping pools for 
the study cohort
The responses to the IE 1 (panel A) and pp65 (panel B) mapping pools were determined 
in a cohort of 31 healthy CMV seropositive individuals. PBMCs from each individual 
were stimulated overnight with each IE1 and pp65 mapping pool. The amount of IFNy 
produced was determined by intracellular staining for IFNy. The number of CD8+ T cells 
producing IFNy in response to the mapping pools was represented as a percentage of the 
CD3+CD8+ population. The background (absence of antigen) level of IFNy produced 
was subtracted from the result obtained for each pool. The bars indicate the median IFNy 
T cell responses to each mapping pool. The amount of IFNy produced in response to the 
mapping pools was below 0.1% in CMV seronegative healthy individuals (data not 
shown).
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Figure 4.7 IFNy responses specific for the pp65 and IE1 antigens in HLA-B*0702 
positive and negative individuals
PBM C s from  healthy donors were stimulated with the IE1 (A) and pp65 ( ■ )  PepM ixes 
overn ight, the am ount o f  IFNy produced w as ca lcu la ted  as a percen tage o f  the 
C D 3+C D 8+ T cells. The background IFNy responses in the absence o f  peptide have been  
subtracted; the bars indicate the median response to the tw o antigens. The IFNy response 
to the IE1 antigen in the H L A -B *0702 positive group was significantly higher than in the 
non H L A -B *0702 group (P = < 0 .0001 , M ann-W hitney U test) but there was no significant 
difference in the IFNy responses to pp65 betw een the tw o groups (P=0 .6 9 3 6 , M ann- 
W hitney U test).
4.5.1 Identification of 15mer peptides derived from IE1 and pp65
Once the overall responses to the mapping pools had been determined from the cohort o f  
healthy donors, farther studies were carried out to identify specific epitopes derived from the 
IE1 and pp65 antigens. The majority o f  the CD8+ T cell epitopes identified to date are mainly 
derived from the pp65 antigen. Over the last decade there has been an increasing number o f  
CM V epitopes identified that could be included in a peptide vaccine. It has been estim ated  
that epitopes for four more HLA types need to be identified in order to achieve 90% coverage 
in the Afro-Caribbean and Asian populations (Longmate et al. 2001). D ue to the recently  
highlighted importance o f  the IE1 antigen in chapter 3 and also recently in the literature 
(Bunde et al. 2005) w e were interested in identifying new IE1 epitopes w hile also identifying  
new pp65 epitopes to provide better coverage o f the Afro-Caribbean and Asian populations.
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Various methods have previously been used to identify new CMV epitopes, which were 
described in section 4.1. The mapping of epitopes using overlapping peptides allows for the 
rapid identification of peptides presented in association with all HLA molecules and thus is 
the most suitable method to use. This section will focus on the identification of immunogenic 
15mer peptides from pp65 and DEI. The definition of the 9mer peptides is described in section
4.7.
The identification of 15mer immunogenic peptides was conducted in those donors who 
showed a strong response to either a pp65 or IE1 mapping pool. The individual peptides that 
made up the mapping pool under investigation were synthesised as individual 15mer peptides 
and each peptide was then used to stimulate PBMCs overnight, the amount of IFNy produced 
was determined using the intracellular staining method (chapter 2, section 2.3.4). From the 
data obtained in figure 4.6 the immune response to IE1 is mainly focused on mapping pools 4 
and 6, for the pp65 antigen the immune response was mainly focused on mapping pools 4, 5 
and 6, therefore the identification of immunogenic 15mer peptides focused on these five 
mapping pools. The results from the overnight stimulation with the individual 15mer peptides 
from each mapping pool are shown in figure 4.8 for the IE1 antigen mapping pools (4 and 6), 
figure 4.9 and for the pp65 antigen mapping pools (4 and 5) and figure 4.10 for the pp65 
antigen mapping pool 6.
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Figure 4.8 IFNy responses to the individual 15mer peptides that make up IE1 
mapping pool 4 and pool 6
PBMCs from two healthy donors (donors 13 and 31) and three HSCT patients (donors 
40, 46 and 48) were assayed for CD8+ T cell IFNy responses to each individual peptide 
making up mapping pool 4 (panel A). PBMCs from two healthy donors (donors 6 and 29) 
were assayed for CD8+ T cell IFNy responses to each individual peptide making up 
mapping pool 6 (panel B). The background IFNy responses in the absence of peptide 
have been subtracted from each peptide stimulation assay. The number of IFNy positive 
cells are represented as a percentage of the CD3+CD8+ T cells.
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Figure 4.9 IFNy responses to the individual 15mer peptides that make up pp65 
mapping pool 4 and pool 5
PBMCs from two healthy donors (donors 23 and 31) and one HSCT patient (donor 43) 
were assayed for CD8+ T cell IFNy responses to each individual peptide making up 
mapping pool 4 (panel A). PBMCs from two healthy donors (donors 15 and 26) and one 
HSCT patient (donor 41) were assayed for CD8+ T cell IFNy responses to each 
individual peptide making up mapping pool 5 (panel B). The background IFNy responses 
in the absence of peptide have been subtracted from each peptide stimulation assay. The 
number of IFNy positive cells are represented as a percentage of the CD3+CD8+ T cells.
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Figure 4.10 IFNy responses to the individual 15mer peptides that make up pp65 
mapping pool 6
PBMCs from a healthy donor (donors 26) were assayed for CD8+ T cell IFNy responses 
to each individual peptide making up mapping pool 6. The background IFNy responses in 
the absence of peptide have been subtracted from each peptide stimulation assay. The 
number of IFNy positive cells are represented as a percentage of the CD3+CD8+ T cells.
From figure 4.8 (Panel A) it can be seen that C D 8+ T cell from two healthy donors and three 
patients responded to individual 15mer peptides contained within the IE1 antigen mapping 
pool 4. Within the IE1 antigen mapping pool 4 a number o f  different peptides stimulated an 
IFNy response (Figure 4 .8 , panel A) indicating that a number o f  different potential epitopes 
are contained within this peptide pool. The HLA phenotype o f  the two healthy donors and 
three patients is different and there is not one HLA alleles com m on to all five individuals, 
indicating that the peptides are binding to different MHC m olecules. The sequence o f  the 
15mer peptides that generated an IFNy response in these healthy individuals and HSCT  
patients are listed in table 4 .2 . The definition o f  the epitope from these 15mer peptides is 
described in section 4.7.
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Donor HLA Peptide 15mer peptide sequence
13 A 0201, A 2902, B4401, B2705 IEA13 FPKTTNGCSQAM AAL
31 A 0 2 0 1, A 0 3 0 1, B0702, B 1801 IEA13
IEB4
40 A 29, A68, B49, B50 IEA9 YRNIEFFTKNS AFPK
46 AO 101, B0801 IEA5
IEA6
ARAKKDELRRKM M YM
KDELRRKM M YM CYRN
48 A 2402, A 3101, B5101, B2705 IEA6
IEA7
KDELRRKM M YM CYRN
RRKMMYMCYRNIEFF
Table 4.2 15mer peptides identified from IE1 mapping pool 4
This table summarises the sequence of the 15mer peptides from the IE1 antigen mapping 
pool 4 that stimulated an IFNy T cell response.
From figure 4 .6 it can be seen that 19 individuals had high C D 8+ T cell responses to the IE1 
antigen mapping pool 6, all these individuals possess the H L A -B *0702 allele. The individual 
15mer peptides that make up mapping pool 6 were tested individually on two H LA -B*0702  
healthy donors (donors 6 and 29), these two donors were chosen due to the high amount o f  
IFNy produced by their C D 8+ T ce lls  in response to this m apping pool and the easy  
availability o f  sam ples. From the data presented in figure 4 .8 the HLA restriction o f  the 
epitope contained with the IE1 antigen mapping pool 6 is likely to be H LA -B*0702 restricted. 
Both donors 6 and 29 showed a C D 8+ T cell response to the peptides IEB6 and IEB7 (Figure
4.8, Panel B). Sm aller C D 8+ T cell responses were detected in PBM Cs from donor 29 to 
other peptides contained within mapping pool 6 but these were not dominant responses and 
were not above the mean level o f  responsiveness for this mapping pool. The peptide sequence 
o f  the IEB6 and IEB7 peptides is LSEFCRVLCCYVLEE and CRVLCCYVLEETSVM  
respectively. From the data presented (Figure 4 .8) the most im m unogenic peptide is IEB7, 
w hich is likely to be restricted by H L A -B *0702, further experim ents were performed in 
section 4.7 to confirm the HLA restriction.
The response to the pp65 antigen mapping pools was more diverse than the responses 
detected against the IE1 antigen with a number o f different individuals having C D8+ T cells  
that responded to the pp65 mapping pools 5-9 (Figure 4.6). The amount o f IFNy produced in 
response to m apping pool 4 ranged from 0-0.882%  (% CD3+CD8+IFNy+ T cells). The 
individual 15mer peptides that make up pp65 mapping pool 4 were used to stimulate a C D8+  
T cell response in two healthy individuals (donors 23 and 31) and one HSCT recipient (donor 
43). From figure 4 .9  (Panel A ) it can be seen that CD8+ T cells from each donor only  
responded to one or tw o 15mer peptides contained within pp65 mapping pool 4, the sequence 
o f these peptides is listed below  in table 4.3. Both healthy donors 23 and 31 responded to the 
sample peptide (PD 10), both o f these individuals have two HLA alleles in com m on which are
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HLA-A*0201 and B *0702. The HSCT recipient responded to two different 15mer peptides 
(PPD2 and PPD3) although a higher amount o f IFNy was produced in response to the PPD2 
peptide, it is likely that the 9mer peptide is truncated over the two peptides.
Donor HLA Peptide 15mer peptide sequence
23 A 0201, A l 101, B0702, B3501 PPD10 SGKLFM HVTLGSDVE
31 A 0 2 0 1, A 0 3 0 1, B0702, B 1801 PPD10 SGKLFM HVTLGSDVE
43 A 0205, A0217, B5001, B3501 PPD2
PPD3
VCSM ENTRATKM QVI
ENTRATKM QVIGDQY
Table 4.3 15mer peptides identified from pp65 mapping pool 4
This table summarises the sequence of the 15mer peptides from the pp65 antigen
mapping pool 4 that stimulated an IFNy T cell response.
From figure 4.9 (Panel B) it can be seen that there was a high level o f  responsiveness to pp65 
mapping pool 5 (range 0-2.892%  CD3+CD8+IFNy+ T cells). The individual 15mer peptides 
that make up mapping pool 5 were used to stimulate a C D 8+ T cell response using PBMCs 
from two healthy donors (donors 15 and 26) and one HSCT recipient (donor 41). Donors 26  
and 41 were chosen because their HLA alleles are associated with the afro-Caribbean and 
Asian populations and w e are particularly interested in identifying new CM V epitopes from  
these populations.
From the data shown in figure 4 .9  (Panel B) donors 15 and 41 showed responses to at least 
two 15mer peptides. C D 8+ T cells from donor 15 produced the m ost IFNy in response to 
peptide PPE11 with a smaller response detected to PPE12. It is reasonable to hypothesise that 
the 9mer peptide is within the PPE 11 peptide sequence and a truncated form exists within the 
PPE12 peptide. Follow ing peptide stimulation C D8+ T cells from donor 41 produced IFNy in 
response to four 15mer peptides, the sequence o f the 15mer peptides that CD8+ T cells from 
donors 15 and 41 responded to are listed in table 4.4. Unfortunately, CD8+ T cells from  
donor 26 did not produce much IFNy in response to the individual 15mer peptides, there was 
no IFNy produced above background levels (no peptide control). The peptide stimulation and 
subsequent IFNy detection using the intracellular staining method is not sensitive enough to 
detect a true positive response in donor 26, therefore real time PCR was used for the relative 
quantification o f gene expression was performed (section 4.6.4).
168
Chapter 4
Donor HLA Peptide 15mer peptide sequence
15 A 3201, A 3303, B5201, B5801 PPE11
PPE12
HIMLDVAFTSHEHFG
DVAFTSHEHFGLLCP
41 A 2402, A l 101, B5101, B2704 PPE3
PPE7
PPE9
TRNPQPFMRPHERNG
TVLCPKNMIIKPGKI
IIKPGKISHIMLDVA
Table 4.4 15mer peptides identified from pp65 mapping pool 5
This table summarises the sequence of the 15mer peptides from the pp65 antigen
mapping pool 5 that stimulated an IFNy T cell response.
From figure 4 .10 the amount o f IFNy produced by CD8+ T cells in response to mapping pool 
6 ranged from 0-0.6%  (CD3+CD8+IFNy+ T cells). Because the level o f  responses to pp65 
pool 6 is smaller when compared to the pp65 mapping pools 4 and 5 epitope mapping was 
conducted in only one healthy donor (donor 26). Previously, PBM Cs from donor 26 were 
used to identify 15mer peptides from pp65 mapping pool 5 but the level o f IFNy produced 
was too low  to be detected by intracellular staining. H owever, donor 26 had a stronger IFNy 
response to mapping pool 6 compared to pool 5 which allow ed for the identification o f the 
individual stimulating 15mer peptide. The highest amount o f IFNy produced by C D8+ T cells  
was in response to the peptides PPC5-PPC7, with the maximal amount produced in response 
to peptide PPC6, it can also be seen that there was a response to peptide PPC2 (Figure 4.10). 
C D 8+ T cells  from  donor 26 responded to a least three peptides contained within pp65 
mapping pool 6, it can therefore be assumed that there are a few  CM V epitopes contained  
within this pool. The sequence o f the individual 15mer peptides that stimulated CD8+ T cells  
from this donor is listed below  in table 4.5.
Donor HLA Peptide 15mer peptide sequence
26 A 1101, A 6 8 0 1, B 3 5 0 1, B3503 PPC2
PPC5
PPC6
PPC7
VELRQ YDPV A ALFFF 
FFFDIDLLLQRGPQY  
IDLLLQRGPQ Y SEHP 
LQRGPQ Y SEHPTFTS
Table 4.5 15mer peptides identified from pp65 mapping pool 6
This table summarises the sequence of the 15mer peptides from the pp65 antigen 
mapping pool 6 that stimulated an IFNy T cell response.
4.5.2 Identification of immunogenic 15mer peptides using RT PCR to detect IFNy 
production
For som e o f  the healthy donors the amount o f  IFNy produced in response to peptide  
stimulation was too low  to enable the level o f  responsiveness to be determined. Three tim es 
the mean o f  all the peptide responses w as calculated, any response above this lev e l is 
regarded as a positive response. For donor 26 a response to pp65 m apping pool 5 w as
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detected (0.66% CD3+CD8+IFNy+ T cells). But subsequently when the individual peptides 
that make up this pool were used to stimulate the PBMCs no functional response was 
detected. To detect IFNy production in response to the individual 15mer peptides 
quantification of mRNA using real time reverse PCR (RT PCR) was used to quantitate the 
level of mRNA gene expression. The relative quantification method measures the change in 
expression of the target gene (IFNy) relative to an endogenous housekeeping gene.
Although the RT PCR method is more laborious and expensive its increased sensitivity could 
improve the detection of IFNy. The RT PCR method used is described in chapter 2 (section 
2.7.5) briefly; the CD8+ T cells were MicroBead sorted (chapter 2, section 2.3.8) to ensure 
that the IFNy mRNA measured was only from the CD8+ T cells. Following MicroBead 
sorting the cells were then stimulated overnight with the individual 15mer peptides. The 
transport inhibitor Brefeldin A was added alongside anti-CD28. Although the mRNA 
accumulates in the intracellular compartment of the cell the release of IFNy could result in the 
non-specific activation of other CD8+ T cells in the vicinity. Following a 12-hour incubation, 
the mRNA was isolated and reverse transcribed into cDNA, the RT PCR reaction was then set 
up using the assays-on-demand™ reagent. The amount of IFNy mRNA present was 
quantitated using the comparative CT method for the relative quantification of gene 
expression. The expression of the housekeeping gene GAPDH was used as the calibrator and 
the relative expression of the IFNy gene was quantified relative to GAPDH.
PBMCs from donor 26 were stimulated overnight with the individual 15mer peptides that 
make up pp65 mapping pool 5 using the methods already described above. The results of the 
individual peptide stimulations and subsequent quantification using RT PCR are shown in 
figure 4.11 (Panel A). As can be deduced from figure 4.11 (Panel A), four peptides (D ll, 
D12, E4, and El 1) produced a high AACT value, the level of mRNA expression in response to 
the other peptides was relatively low in comparison. The expression of IFNy mRNA was 
relative to the endogenous housekeeping gene GAPDH and the AACT value obtained for the 
no peptide control was subtracted from all samples. Because of the high standard error bars 
obtained, the RT PCR reaction was repeated on the cDNA samples for six of the peptides. 
The repeated RT PCR results are shown in figure 4.11 (Panel B), from these results it can be 
seen that donor 26 responded to the peptides D ll, D12 and E ll. The high standard error 
values previously obtained for peptide E4 (Figure 4.11, panel A) suggested that it was 
showing as a false positive and when repeated the AACT value was relatively low in 
comparison (Figure 4.11, panel B). This data demonstrates that the RT PCR method for the 
relative quantification of IFNy mRNA is more sensitive than the intracellular staining method
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and can be used to identify new epitopes that cannot be identified with the intracellular 
staining method, however, the RT PCR method is very laborious and due to the high cost of 
the reagents it is not feasible to use this method to identify new epitopes from all the donors.
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Figure 4.11 Relative quantification of IFNy gene expression following peptide 
stimulation
CD8+ T cell were isolated from PBMCs obtained from donor 26. CD8+ T cells were 
stimulated overnight with the individual 15mer peptides, mRNA was isolated and 
complementary DNA (cDNA) was synthesised. The quantification of IFNy gene 
expression was assessed using the assay-on-demand reagents and calculated using the 
comparative CT method. The standard error bars are shown for each peptide (panel A), 
RT PCR was performed in triplicate for each peptide. Due to the high standard error 
values obtained the Real time PCR reaction was repeated for 6 peptides (panel B).
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4.7 Prediction of HLA class I binding CMV peptide epitopes
To identify immunogenic peptides derived from the identified 15mer peptides algorithm 
databases were used for some HLA alleles. These databases predict putative MHC class I- 
restricted potential epitopes from the amino acid sequence of a given antigen, the background 
to these databases is described in section 4.1.1. For the identification of the minimal 
immunogenic peptide, two algorithm databases were used in conjunction with two 
proteasomal databases to help in the definition of CMV peptides.
4.7.1 Predicting 9mer and lOmer peptides using HLA class I peptide binding 
databases
The HLA peptide binding programs BIMAS and SYFPEITHI were used to predict the 9mer 
or lOmer peptides from the sequence of the already identified 15mer peptides (see section 
4.6). The 15mer peptides from both pp65 and IE1 were entered into each database. The 
BIMAS database calculates peptides based on a coefficient table, the coefficient value is 
calculated by measuring the rate of dissociation of the B2-microglobulin chain from the HLA 
peptide complex. The SYFPEITHI database ranks amino acids according to their specific 
position in the peptide, with the favourable anchor residues being allocated higher values.
Due to the difference in how the BIMAS and SYFPEITHI databases predict peptides they 
were both used to screen for the 9mer or lOmer peptides from the already identified 15mer 
peptides. The peptide sequence of the 15mer peptides were entered individually into each 
database, the peptides predicted using the SYFPEITHI database are listed in table 4.6 and for 
the BIMAS database the predicted peptides are listed in table 4.7. The two highest ranked 
peptides and associated HLA class I molecule are shown in each table for each individual 
15mer peptide. The main limitation of these databases is the relatively small number of HLA 
class I molecules included, the SYFPEITHI database only has data on 14 HLA alleles while 
the BIMAS database contains information on 29 HLA alleles. The relatively small number of 
HLA alleles meant that not all 15mer peptides could be screened for each donor, and the more 
uncommon HLA alleles were not included in the database. For donor number 26, the 
SYFPEITHI database could not be used because it contained no HLA alleles that this donor 
has, for donor 40 neither the BIMAS or SYFPEITHI databases could be used, this donor has a 
HLA type more associated with the Asian population and these databases contain no 
information regarding three of the HLA alleles. Peptides were screened for in donors who had 
at least two HLA alleles in either two databases. This only excluded donor 40, for this donor 
information regarding each HLA allele would be required before attempting to predict the 
most likely 9mer or lOmer peptide from the sequence of the identified 15mer peptide.
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Donor Peptide Peptide sequence Peptide
SYFPEITHI^
Score HLA restriction
29 IEB6 LSEFCRVLCCYVLEE FCRVLCCYVL 13 B*07
CRVLCCYVL 11 B*07
48 IEA6 KDELRRKMMYMCYRN RRKMMYMCY 23 B*2705
IEA7 RRKMMYMCYRNIEFF J MCYRNIEFF 15 B*2705
46 IEA5 ARAKKDELRRKMMYM ELRRKMMYM 24 B*08
IEA6 RRKMMYMCYRNIEFF , RAKKDELRR 14 B*08
13 IEA13 FPKTTNGCSQAMAAL GCSQAMAAL 16 B*2075
GCSQAMAAL 14 A*0201
31 IEA13 FPKTTNGCSQAMAAL GCSQAMAAL 14 A*0201/B*0702
NGCSQAMAAL 12 B*0702
IEB4 NLPQCSPDEIMAYAQ SPDEIMAYA 18 B*0702
LPQCSPDEI 16 B*0702
41 PPE3 TRNPQPFMRPHERNG QPFMRPHE 17 B*51
NPQPFMRPH 12 B*51
PPE7 TVLCPKNMIIKPGKI 1 KPGKISHI 26 B*51
PPE9 IIKPGKISHIMLDVA J MIIKPGKI 18 B*51
23 PPD10 SGKLFMHVTLGSDVE FMHVTLGSDV 19 A*0201
GKLFMHVTL 16 A*0201
31 PPD10 SGKLFMHVTLGSDVE FMHVTLGSDV 19 A*0201
GKLFMHVTL 16 A*0201
Table 4.6 Predicted binding of CMV pp65 and IE1 peptides to HLA class I 
molecules using the SYFPEITHI peptide binding algorithm
The 15mer peptides identified were screened for potential 9mer or lOmer epitopes using 
the SYFPEITHI peptide binding algorithm (fcwww.syfpeithi.de). The 15mer peptides 
were derived from the CMV antigens pp65 and IE1. The two highest ranking peptides are 
shown for each 15mer peptide together with the suggested HLA restriction element.
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Donor Peptide Peptide sequence Peptide
BIMAS3
Score HLA restriction
29 IEB6 LSEFCRVLCCYVLEE FCRVLCCYVL 40.000 B*07
YVLEETSVM 12.437 B*07
48 IEA6 KDELRRKMMYMCYRN RRKMMYMCY 3000.000 B*2705
IEA7 RRKMMYMCYRNIEFF LRRKMMYMCY 1000.000 B*2705
46 IEA5 ARAKKDELRRKMMYM ELRRKMMYM 80.000 B*08
IEA6 RRKMMYMCYRNIEFF LRRKMMYMC 0.020 B*08
13 IEA13 FPKTTNGCSQAMAAL GCSQAMAAL 10.000 B*2705
KTTNGCSQAM 9.000 B*2705
31 IEA13 FPKTTNGCSQAMAAL GCSQAMAAL 4.000 B*0702
TTNGCSQAM 1.000 B*0702
IEB4 NLPQCSPDEIMAYAQ LPQCSPDEIM 30.000 B*0702
LPQCSPDEI 8.000 B*0702
15 PPE11 HIMLDVAFTSHEHFG VAFTSHEHF 20.000 B*5801
PPE12 DVAFTSHEHFGLLCP TSHEHFGLL 4.800 B*5801
41 PPE3 TRNPQPFMRPHERNG QPFMRPHERN 11.000 B*51
QPFMRPHER 2.000 B*51
PPE7 TVLCPKNMIIKPGKI ' KPGKISHIML 60.500 B*51
PPE9 IIKPGKISHIMLDVA KPGKISHIM 18.150 B*51
23 PPD10 SGKLFMHVTLGSDVE FMHVTLGSDV 231.067 A*0201
SGKLFMHVTL 4.000 A0201/B*0702
31 PPD10 SGKLFMHVTLGSDVE FMHVTLGSDV 231.067 A*0201
SGKLFMHVTL 4.000 A0201/B*0702
43 PPD2 VCSMENTRATKMQVI KMQVIGDQY 4.000 B*3501
PPD3 ENTRATKMQVIGDQY NTRATKMQVI 1.200 B*3501
26 PPC2 VELRQYDPVAALFFF DPVAALFFF 20.000 B*3501
RQYDPVAAL 4.000 B*3501
PPC5 FFFDIDLLLQRGPQY 1 GPQYSEHPTF 30.000 B*3501
PPC6 IDLLLQRGPQYSEHP GPQYSEHPT 2.000 B*3501
PPC7 LQRGPQYSEHPTFTS J
PPD11 FMHVTLGSDVEEDLT 1 DVEEDLTMTR 600.000 A*6801
PPD12 TLGSDVEEDLTMTRN J DVEEDLTMT 12.000 A*6801
PPE11 HIMLDVAFTSHEHFG DVAFTSHEH 24.000 A*6801
DVAFTSHEHF 3.600 A*6801
Table 4.7 Predicted binding of CMV pp65 and IE1 peptides to HLA class I 
molecules using the BIMAS peptide binding algorithm
The 15mer peptides identified were screened for potential 9mer or lOmer epitopes using 
the BIMAS peptide binding algorithm Cwww.bimas.dcrt.nih.gov/molbio/hla_bind). The 
15mer peptides were derived from the CMV antigens pp65 and IE1. The two highest 
ranking peptides are shown for each 15mer peptide together with the suggested HLA 
restriction element.
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As can be seen from tables 4.6 and 4.7 there is a degree of agreement between the BIMAS 
and SYFPEITHI databases. Both databases predicted the same peptide for the majority of the 
donors, the highest ranked peptide was the same for both databases although different 
peptides were predicted for the majority of the second highest ranked peptides. For donor 41 
there was a discrepancy between the peptides predicted by both databases, this maybe a 
reflection on how the peptides are predicted. The highest peptide predicted by BIMAS is the 
RRKMMYM peptide and is predicted to bind HLA-B*2705 in agreement the SYFPEITHI 
database which also ranks this peptide high. The RRKMMYM was also predicted to bind to 
HLA-B*0801 (data not shown), the binding of this peptide was increased by including 
glutamic acid and leucine residues at the N-terminal end of the peptide. This similarity in 
peptide sequence reflects the similar binding motifs reported for both the HLA-B*2705 and 
HLA-B*0801 molecules.
4.7.2 Predicting 9mer and lOmer peptides using Proteasomal cleavage databases
To further elucidate the 9mer or lOmer peptides from the already identified 15mer peptide 
(section 4.6), proteasomal cleavage prediction programs were used. These databases predict 
the peptide fragment produced by the human proteasome. The two programs used were 
PAPROCC and NetChop. The PAPROCC uses a database that is based on theoretical 
cleavage sites based on experimental data from the human 20S proteasome. The NetChop 
database predicts cleavage sites based on a database of known MHC class I ligands that are 
obtained from publicly available databases.
The peptides predicted using the HLA class I peptide binding databases SYFPEITHI and 
BIMAS (section 4.7) were further screened using the NetChop and PAPROCC proteasomal 
cleavage databases, the results for each peptide are listed in table 4.8. The PAPROCC 
database eliminated 10 peptides as not being produced as a result of a carboxyl terminal 
cleavage, none of the 10 peptides eliminated by the PAPROCC database were eliminated by 
the NetChop database. The NetChop database only excluded 5 peptides as not being 
generated by the human 20S proteasome. A degree of agreement between the two databases 
was observed with only a few peptides. The RRKMMYMCY and LRRKMMYMCY peptides 
were scored highly by both the NetChop and PAPROCC databases, the same was observed 
with the SPDEIMAYA peptide. Conversely, the DVAFTSHEH peptide obtained the highest 
score with the PAPROCC database but with the addition of a phenylalanine residue at the 
carboxyl terminal end the resulting peptide was ranked higher with NetChop than the 
PAPROCC database. Overall the proteasomal cleavage sites were predicted for 39 peptides, 
the two databases only agreed on the cleavage sites for 9 peptides. This discrepancy meant 
that these databases could not be relied on for predicting the most likely cleavage sites.
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Further experiments were conducted to determine which 9mer or lOmer peptides CD8+ T 
cells responded to in terms proliferation and IFNy production.
15mer peptide Predicted peptide" Protein PAPRocC4* NetChopc
IEB6 FCRVLCCYVL IE1 NC 0.92
YVLEETSVM IE1 67.01 (III) 0.93
CRVLCCYVL IE1 12.24 run 0.92
IEA6+IEA7 RRKMMYMCY IE1 105.23 (III) 0.94
LRRKMMYMCY IE1 105.23 (III) 0.94
MCYRNIEFF IE1 32.08 (III) NC
IEA5+IEA6 ELRRKMMYM IE1 188.40(1) 0.60
LRRKMMYMC IE1 291.76(1) NC
RAKKDELRR IE1 75.79 011) NC
IEA13 GCSQAMAAL IE1 350.97 (1) 0.59
KTTNGCSQAM IE1 26.54 (III) 0.68
TTNGCSQAM IE1 NC 0.68
NGCSQAMAAL IE1 350.97 (I) 0.59
IEB4 LPQCSPDEIM IE1 75.83 (III) NC
LPQCSPDEI IE1 75.83 (III) NC
SPDEIMAYA IE1 180.81 (III) 0.96
PPE11+PPE12 VAFTSHEHF pp65 34.72 (I) 0.87
TSHEHFGLL PP65 21.22(1) 0.93
PPE3 QPFMRPHERN pp65 130.31 (I) NC
QPFMRPHER pp65 130.31 (I) 0.95
QPFMRPHE pp65 130.31 (I) NC
NPQPFMRPH pp65 NC 0.61
PPE7-PPE9 KPGKISHIML pp65 19.00(111) 0.93
KPGKISHIM pp65 NC 0.92
KPGKISHI pp65 111.80(111) 0.86
MIIKPGKI pp65 2.52 (III) NC
PPD10 FMHVTLGSDV pp65 156.92 (III) 0.75
SGKLFMHVTL pp65 39.59 (II) 0.95
GKLFMHVTL PP65 39.59 (II) 0.95
PPD2+PPD3 KMQVIGDQY pp65 61.38 (III) 0.86
NTRATKMQVI DP65 94.81 (II) NC
PPC2 DPVAALFFF pp65 154.81 (III) 0.91
RQYDPVAAL pp65 211.78(1) 0.97
PPC5-PPC7 GPQYSEHPTF pp65 120.72 (III) 0.88
GPQYSEHPT DP65 120.72 (III) NC
PPD11-PPD12 DVEEDLTMTR pp65 84.00 (I) 0.94
DVEEDLTMT pp65 84.00 (I) NC
PPE11 DVAFTSHEH pp65 250.39 (I) 0.69
DVAFTSHEHF pp65 NC 0.94
Table 4.8 Proteasomal cleavage predictions for the selected 15mer peptides
Proteasomal cleavage prediction of the algorithm predicted peptides was determined 
using two publicly available proteasome cleavage databases. The PAPRocCb database 
can be found at www.paproc.de and the NetChopc database can be found at 
www.cbs.dtu/services/Netchop. The 9mer or lOmer peptides are ranked from the BIMAS 
and SYFPEITHI databases" according to their cleavage potential at the C-terminal end. 
Values represent the cleavage options for the specified peptides. NC=No cleavage.
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4.8 Definition of CMV derived peptides
Following the prediction of 9mer and lOmer peptides (section 4.7) further experiments were 
conducted to assess the CD8+ T cell response to these peptides in vitro. In order to assess 
these peptides an MHC stabilisation assay was performed on peptides that were ranked to 
bind either HLA-A*0201 or HLA-B*0702. Peptides were also assessed in terms of their 
ability to induce cell proliferation or IFNy production. For some of the less common HLA 
alleles the potential antigenic peptide was examined using published information on the 
peptide binding specificities for each HLA molecule (Marsh 2000).
Because of the large number of potential peptides that have been predicted using the binding 
algorithm program and proteasomal cleavage databases (section 4.7), only a few of the highly 
ranked peptides were further characterised. Due to financial constraints and the availability of 
PBMCs from the healthy donors only three 15mer peptides were further tested to identify the 
9mer peptide, but clearly a huge number of antigenic peptides could be defined. The further 
assessment of the predicted peptides is described separately below for each antigen and HLA 
allele.
4.8.1 Definition of IE1 derived peptide binding to HLA-B*0702
The data presented in figure 4.2 shows that the frequency of CD8+T cells responding to the 
IE1 and pp65 antigens are similar. The data presented in figure 4.6 demonstrates that the 
CD8+ T cell response to IE1 is focused on mapping pools 4 and 6. Due to the high level of 
IENy produced in response to mapping pool 6, the individual 15mer peptides that make up 
this mapping pool were tested in two donors (donors 6 and 29). The response to IE1 mapping 
pool 6 was focused on two 15mer peptides (IEB6 and IEB7) and these peptides appeared to 
be presented in association HLA-B*0702. By comparing the responses to IE1 in HLA- 
B*0702 donor with non HLA-B*0702 donors a significant difference (P=<0.05, Mann- 
Whitney U test) was observed (Figure 4.7) with the HLA-B*0702 positive individuals 
producing more IFNy in response to the IE 1 antigen compared to the pp65 antigen.
From the results obtained from the peptide binding algorithm (Tables 4.6 and 4.7) databases 
and information on the proteasomal cleavage (Table 4.8) sites the FCRVLCCYVL peptide 
was ranked the highest by both the BIMAS and SYFPEITHI databases. The YVLEETSVM 
and CRVLCCYVL peptides were ranked second by the BIMAS and SYFPEITHI databases 
respectively, these peptides were predicted as binding in the context of HLA-B*0702, the 
majority of die donors that produced IFNy in response to IE1 mapping pool 6 were HLA- 
B*0702 (Figure 4.6). The peptide binding specificity of HLA-B*0702 reveals that a proline 
anchor residue is preferred at position two and a leucine anchor residue at position nine
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(Marsh 2000). The described CMV peptide TPRVTGGGAM contains a proline anchor 
residue at position two but does not contain a leucine anchor residue at position nine. The 
binding motif of HLA-B*0702 reveals that the YVLEETSVM peptide would not be able to 
bind as it does not contain either of the two required anchor residues. The other two peptides 
were tested individually for their ability to bind to HLA-B*0702 using a MHC stabilisation 
assay (chapter 2, section 2.4). T2 cells that had been transfected with the pBJNeo vector 
containing the DNA sequence of HLA-B*0702 (T2B7 cells) were used to test the ability of 
the FCRVLCCYVL and CRVLCCYVL to stabilise the HLA-B*0702 molecules on the cell 
surface. The TPRVTGGGAM (referred to as TPR) peptide wa,s used as a positive control, 
T2B7 cells without peptide was used as a negative control. The binding of synthetic peptides 
is measured by an increase in immunofluorescence associated with the stabilisation of the 
MHC molecules on the cell surface. Neither of the two candidate peptides (FCRVLCCYVL 
and CRVLCCYVL) was able to stabilise the MHC molecules on the cells surface (Figure 
4.12, panel A). The T2B7 cells that were pulsed with the TPR peptide showed an increase in 
the stabilisation of the MHC molecules on the cell surface, but no increase was seen with the 
candidate peptides or the 15mer peptide (IEB6) that they are derived from. However, T2B7 
cells were pulsed with a higher amount of each peptide (100p,g of each peptide) and the 
CRVLCCYVL was able to stabilise the MHC molecules on the cell surface (Figure 4.12, 
panel B). The stabilisation of the MHC molecules on the cell surface with the CRVLCCYVL 
peptide maybe because the amount of peptide used was so high, such an amount would not 
reflect the true in vivo situation. It can therefore be concluded that these peptides either do not 
bind to HLA-B*0702 or they bind with such low affinity that there is no detectable 
stabilisation of the MHC molecules using the MHC stabilisation assay.
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No peptide IQug TPRVTGGGAM
10ug LSEFCRVLCCYVLEE 10ng FCRVLCCYVL 10ng CRVLCCYVL
Anti HLA-B*0702 (ME1) FITC
No peptide
100pg CRVLCCYVL
100ng TPRVTGGGAM
100|ig FCRVLCCYVL
 ►
Anti HLA-B*0702 (ME1) FITC
Figure 4.12 MHC stabilisation of T2 cells transfected with HLA-B*0702 using 
putative HLA-B*0702 peptides
The candidate H L A -B *0702 restricted peptide C R V LC C Y V L  and FCR VLC CY VL were 
tested in an M HC stabilisation assay using T 2 ce lls  that expressed  the H L A -B *0702  
allele (referred to as T 2B 7 cells). T 2B 7 ce lls  w ere pulsed  overnight with lO pg o f  the 
15mer peptide (panel A , bottom  left), the candidate peptide FCR VLC CY VL (Panel A , 
bottom  m iddle) and C R V L C C Y V L  (Panel A , bottom  right). A s a positive control the 
pp65 peptide TPR V TG G G AM  was used w hich is known to bind H L A -B *0702 (Panel A , 
top right) and a no peptide control (Panel A , top left) w as used as a negative control. 
N eith er o f  tw o  candidate p ep tides bind to H L A -B * 0 7 0 2  (Panel A ). The M HC  
stabilisation assay w as repeated using lOOpg o f  the candidate peptides (Panel B). At 
lOOpg on ly  the C R V L C C Y V L  peptide stabilised  the expression  o f  the H L A -B *0702  
m olecules on the cell surface (Panel B , bottom left). To assess the stabilisation o f  HLA- 
B *0702 m olecules at the cell surface the flow  cytom etry plots acquired for the no peptide 
controls (— ) were overlaid with the plots acquire for each peptide under test (— ). Show n  
on the x-axis is the ce ll surface staining with the anti H L A -B *0702 antibody (M E1) and 
the cell counts are shown on the y-axis.
3H thymidine proliferation assay to confirm peptide responses
To test the CRVLCCYVL peptide further, a proliferation assay was performed using the 
thymidine incorporation assay (chapter 2, section 2.4.6). The thymidine incorporation assay  
measures cell proliferation fo llow ing antigenic stimulation by measuring the amount o f  3H 
thym idine incorporated into the D N A  o f  rapidly proliferating cells. The C R V LC C Y V L  
peptide was added to PBM Cs and incubated for 24 hours, the 3H thym idine was then added
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and the cells were left for a further 24 hours. The full details o f  the method used are described 
in section 2 .4 .6 . PBM Cs from three donors (6, 29, 49) w ere pulsed separately with the 
CRVLCCYVL and TPR peptides, SEB was used as a positive control to ensure that the cells  
could proliferate in response to antigenic stimulation.
The CRVLCCYVL peptide induced cell proliferation in one o f  the three donors tested, the 
highest level o f  proliferation was seen in donor 29 . This data dem onstrates that the 
CRVLCCYVL peptide can induce cell proliferation upon stimulation (Figure 4.13), however, 
the peptides tested did not induce a high level o f proliferation in donors 49 and 6 indicating 
that additional co-stim ulation was required to induce optim al activation and subsequent 
proliferation.
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Figure 4.13 Proliferative response of PBMCs following stimulation with HLA- 
B*0702 restricted CMV peptides
PBM C s w ere obtained from  3 healthy donors and w ere pulsed with the C R V LC C Y V L  
( ■  ),or the T PR V T G G G A M  ( ■  ) peptide for 24 hours, the amount o f  3H thym idine  
incorporated into the ce lls  w as determ ined using a 0  counter. A  negative (no antigen, 0 )  
and a positive control (Polyclonal stim ulus, SEB ■ )  were also included. The mean counts 
per minute (cpm ) obtained for each peptide are shown.
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D espite the inability o f  the CRVLCCYVL peptide to induce cell proliferation in all the 
donors tested it could induce IFNy production by CD8+ T cells in donors 12 and 31 who have 
the H L A -B *0702 alle le  (Figure 4 .1 4 ), dem onstrating that this peptide is presented in 
association with the H L A -B *0702 m olecule. H ow ever, the CRVLCCYVL peptide does 
appear to have a low  affinity for either the T ce ll receptor or the H L A -B *0702 m olecule  
because it could not stabilise H L A -B *0702 in an MHC stabilisation assay. Attempts to 
produce a H L A -B *0702 tetramer refolded with the CRVLCCYVL peptide also failed this has 
also been attempted by another group (M oss 2004). Despite the MHC stabilisation assay and 
the attempts to produce a HLA tetramer with the CRVLCCYVL peptide, functional responses 
to this peptide can be detected in healthy donors and HSCT recipients. The response to this 
peptide can be greater than other already identified CM V epitopes derived from the pp65 
antigen, such as the TPR peptide. The C D 8+ T cell IFNy response to IE1 mapping pool 6 in 
H L A -B *0702 donors is due to this peptide but questions remain to be answered regarding its 
binding ability.
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Figure 4.14 Response of CMV seropositive donors to the putative HLA-B*0702 
peptide CRVLCCYVL
P BM C s from  donors 31 and 12 w ere stim ulated with the C RV LC C Y V L IE1 derived  
peptide. Intracellular staining for IFNy w as performed fo llow in g  overnight incubation  
with the peptide. From the C D 3+C D 8+ T cell gate the percentage o f  IFNy producing T  
cells were determined.
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4.8.2 Definition of IE1 derived peptide binding to HLA-B*2705
The second largest CD8+ T cell response to the IE1 antigen was seen against mapping pool 4 
(Figure 4.6), the majority of those who responded to this mapping pool expressed either the 
HLA-B*2705 or HLA-B*0801 alleles. The identification of the immunogenic peptide was 
carried out using the individual 15mer peptides that make up IE1 mapping pool 4 (Figure 
4.8). From the results obtained using the peptide binding algorithm (Tables 4.6 and 4.7) 
databases and information on the proteasomal cleavage (Table 4.8) sites six peptides were 
suggested as probable candidates for binding in the context of HLA-B*2705 or B*0801. The 
peptides suggested to bind both HLA-B*2705 and B*0801 were very similar and the same 
peptide (ELRRKMMYM) was suggested as binding to both HLA alleles (table 4.6 and table 
4.7), for this to be possible the binding motifs for both HLA alleles must be similar in order to 
accommodate the same peptide. The HLA binding motifs for both HLA-B*2705 and B*0801 
(Marsh 2000) is shown in figure 4.15. The peptide binding motifs for HLA-B*0801 and 
B*2705 reveals that the ELRRKMMYM peptide suggested by the BIMAS and SYFPEITHI 
databases would not be able to bind either HLA-B*0801 or B*2705. The ELRRKMMYM has 
already been described in die literature as binding to HLA-B*0801(Kem et al. 1999b; Wills et 
al. 2002), but there is some confusion about whether an aspartic acid should be at position 
one. As a peptide has already been identified for binding to HLA-B*0801 the identification of 
the peptide that binds to HLA-B*2705 was performed.
HLA-B*0801
1 2 3 4 5 6 7 8 9  
K K
HLA-B*2705
1 2 3 4 5 6 7 8 9
R
Figure 4.15 Peptide-binding motifs for HLA-B*0801 and B*2705 allele
Published binding motif for HLA-B*0801 and B*2705 (Marsh 2000).
3H thymidine proliferation assay to confirm peptide responses
Because some of the information within the algorithm databases is based on theoretical 
evidence, various truncations of the 15mer peptides were made and tested in a HLA-B*2705 
positive individual, these truncations were tested in a 3H thymidine proliferation assay 
(section 2.4.6) using PBMCs from donor 48 (HSCT recipient). The results of the 3H 
thymidine proliferation assay using the four potential peptides are shown in figure 4.16.
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NP SEB DELRRKMMY RRKMMYMCY DELRRKMMYM ELRRKMMYM
Candidate peptides
Figure 4.16 Proliferative response of PBMCs following stimulation with the 
candidate CMV peptides
PBMCs were obtained from donor 48 and were pulsed with four peptides for 24 hours. 3H 
thymidine was then added and the cells were incubated for a further 24 hours. The cells 
were then harvested and the amount of 3H thymidine incorporated into the cells was 
determined using a |3 counter. A negative (no peptide, NP) and a positive control 
(Polyclonal stimulus, SEB) were also included. The mean counts per minute (cpm) 
obtained for each peptide are shown.
The RRKM M YM CY peptide induced the highest level o f  proliferation compared to the other 
three peptides (Figure 4 .16), however, the levels were relatively low  which may be because 
this donor is a H SCT recipient and still im m unocom prom ised, unfortunately, there were no 
healthy H L A -B *2705  donors available w ithin this cohort to test this peptide on. The 
RRKM M YM CY peptide fits the peptide binding specificity for the H LA -B*2705 m olecule, 
having an arginine residue at position two. Although the other three peptides seem  to induce 
cells to proliferate they are unlikely to associate with H LA -B*2705 with such a high affinity 
as they lack the required arginine anchor residue at position two.
Confirming HLA restriction using EBV transformed B cell lines
To test the HLA restriction o f  the RRKM M YM CY peptide an EBV transformed B cell line 
(LCL) was used that matched the H LA -B*2705 allele but mismatched all other HLA alleles. 
The HLA o f  donor 48 is H L A -A *2402, A *3101, B *5101, B*2705 and the HLA type o f  the 
LCL BTB line is H L A -A *0201, B *2705, the only HLA allele in common to both donor 48  
and the cell line is B *2705. C D 3+C D 8+ T cells from donor 48 can only produce IFNy in 
response to peptides presented in the context o f  B*2705, overnight peptide stimulation would
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not be long enough to generate an allo-reaction against the mismatched HLA alleles. Various 
controls were included to account for any IFNy that could be produced by the BTB cells, 
these included BTB cells pulsed with the RRKMMYMCY peptide as well as a no peptide 
control. The method used is described in chapter 2 (section 2.4.2). Briefly, PBMCs were 
mixed at a 1:1 ratio with peptide pulsed BTB cells and incubated overnight. Intracellular 
staining for IFNy was then performed, the CD3+CD8+ T cells were analysed by flow 
cytometry to determine the amount of IFNy produced in response to the RRKMMYMCY 
peptide, a CD 19+ gate was also set up to determine the amount of IFNy produced by the BTB 
cells, the results are shown in figure 4.17.
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A
Tube Peptide BTB cells PBMCs
1 No peptide 5xl05 5x10s
2 RRKMMYMCY 5xl05 5xl05
3 RRKMMYMCY None lxlO6
4 RRKMMYMCY lxlO6 None
B
CD3+CD8+ gated cells
1 2 3
0.71%0.23%
ISo
CO
<D
T3
CO
0.37%
CD 19+ gated cells
1 2 4
0 .1% 0.39% 0.4%
Intracellular IFNy
Figure 4.17 Confirmation of HLA restriction for peptide RRKMMYMCY using the 
BTB EBV transformed cell line
The HLA restriction of the RRKMMYMCY peptide was confirmed using the BTB EBV 
transformed B cell line. BTB cells were pulsed with the RRKMMYMCY peptide 
overnight and then mixed with PBMCs from donor 48. Panel A shows the ratio of 
BTB:PBMCs used; Panel B shows the results of the intracellular staining for IFNy 
following peptide stimulation, the numbers refer to the tube numbers shown in panel A. 
The amount of IFNy produced was assessed from a CD3+CD8+ gate and then expressed 
versus side scatter. To determine if any background IFNy is produced by the BTB cells a 
CD 19+ gate was set up and the amount of IFNy produced was assessed versus the side 
scatter.
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The RRKMMYMCY is presented in the context of HLA-B*2705, CD8+ T cells from donor 
48 produced IFNy (0.71%) in response to BTB cells pulsed with the RRKMMYMCY peptide. 
CD8+ T cells from donor 48 produced IFNy in response to the peptide only (0.37%) but the 
amount was higher with the BTB cells due to the co-stimulatory molecules present on the 
BTB cells. The peptide pulsing of PBMCs relies on the presentation of the peptide by any 
antigen presenting cells within the PBMCs; LCL's are good antigen presenting cells as they 
can provide co-stimulatory signals required for T cell activation such as the B7 molecules. 
The amount of IFNy produced by the CD8+ T cells in response to the RRKMMYMCY 
peptide (0.37%) was not very high, there are a number of reasons for this, notably this donor 
is a HSCT recipient and has chronic GVHD which has required steroid therapy, the PBMCs 
used in figure 4.17 had been cryopreserved and it is therefore possible that some antigen 
presenting cells were lost due to the freezing process.
4.8.3 Definition of pp65 derived peptide binding to HLA-B*5801
The HLA-B*5801 allele is associated with the Afro-Caribbean and Asian populations and has 
been suggested (Longmate et al. 2001) as one of the four possible HLA types that contribute 
to achieving the 90% coverage of the Afro-Caribbean and Asian populations. Among this 
cohort donors 2 and 15 are HLA-B*5801, donor 15 showed a huge CD8+ T cell response to 
pp65 mapping pool 5 (2.4% CD8+ T cells producing IFNy). Two 15mer peptides PPE11 and 
PPE12 induced IFNy production following overnight stimulation (Figure 4.9), only CD8+ T 
cells from donor 15 produced IFNy upon stimulation with the PPE11 and PE 12 peptides.
From the BIMAS database two 9mer peptides were predicted to bind HLA-B*5801, the 
VAFTSHEHF peptide was ranked the highest with a score of 20, the second peptide 
TSHEHFGLL obtained a relatively low score of 4.8 (Table 4.7). The peptide binding 
algorithm programs contain peptide information on a relatively limited number of HLA 
alleles, the SYFPEITHI database does not contain any binding algorithm information on the 
HLA-B*5801 allele, therefore only the BIMAS database could be used. The proteasomal 
cleavage databases were used to determine what 9mer peptides would be generated following 
proteasomal cleavage. The VAFTSHEHF and TSHEHFGLL peptides were also shown to be 
generated from proteasomal cleavage (Table 4.8) but there was a disagreement between the 
values obtained with the PAPRocC and NetChop databases. The PAPARocC database ranked 
the VAFTSHEHF peptide highest but the NetChop database ranked the TSHEHFGLL highest 
(Table 4.8). The peptide binding motif described for HLA-B*5801 (Figure 4.18) was used to 
determine the most likely 9mer peptide from the two candidate peptides.
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HLA-B*5801
1 2 3 4 5 6 7 8 9
A  W
T F
S
Figure 4.18 Peptide-binding motifs for HLA-B*5801 allele
Published binding motif for HLA-B*5801 (Marsh 2000).
From figure 4 .18  it can be concluded that both the TSHEHFGLL and VAFTSHEHF could  
bind to the peptide binding groove o f  H LA -B*5801. Both o f these peptide were further tested 
by stimulating PBM Cs from donor 15 and measuring the amount o f IFNy produced by the 
intracellular staining method. From figure 4 .19  it can be seen that only the VAFTSHEHF  
peptide was able to induce an IFNy C D8+ T cell response (Figure 4.19), further investigations 
were performed to determine the HLA restriction o f  this peptide. Because there is not much 
data available on the peptide binding m otifs for the different HLA alleles o f donor 15, LCL's 
were used as APCs.
VAFTSHEHF
1.80%
-T.™, ........... .....■ I' irt| ■   
 ►
Intracellular IFNy FITC
Figure 4.19 IFNy responses for putative HLA-B*5801 restricted peptide
PBMCs from donor 15 were stimulated with the VAFTSHEHF and TSHEHFGLL pp65 
derived peptides. Intracellular staining for IFNy was performed following overnight 
incubation with the peptide. From the CD3+CD8+ T cell gate the percentage of IFNy 
producing T cells were determined. The negative control (no peptide) was subtracted 
from each sample.
Confirming HLA restriction using EBV transformed B cell lines
To test the HLA restriction o f  the VAFTSHEHF peptide LCL's were used that matched the 
H LA-B*5801 allele but m ism atched all other HLA alleles. The HLA o f  donor 15 is H LA- 
A *3201, A *3303, B *5201 , B *5801 and the HLA type o f the EBV transformed B cell line 
W T49 is H LA -A *02, B *5801, the HLA-B*5801 allele is in common to both donor 15 and the
TSHEHFGLL
0.25%
rr^T
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cell line. CD3+CD8+ T cells from donor 15 can only produce IFNy in response to peptides 
presented in the context of B *5801. Various controls were included to account for any IFNy 
that could be produced by the WT49 cells, these included WT49 cells pulsed with the 
VAFTSHEHF peptide and a no peptide control. The method used is described in chapter 2 
(section 2.4.2).
The VAFTSHEHF peptide is presented in the context of HLA-B*5801 (Figure 4.20), CD8+ T 
cells from donor 15 produced IFNy (3.47%) in response to WT49 cells pulsed with the 
VAFTSHEHF peptide (Figure 4.20, panel B). CD8+ T cells from donor 15 produced IFNy in 
response to the peptide only (2.07% CD8+ T cells producing IFNy) but the amount produced 
was higher with the WT49 cells due to the co-stimulatory molecules on the cell surface 
resulting in the improved T cell activation. These results demonstrate that the VAFTSHEHF 
peptide is presented in the context of HLA-B*5801 but only CD8+ T cells from donor 15 
responded to this peptide. CD8+ T cells from donor 2 who was also B*5801 only produced 
0.01% IFNy in response to mapping pool 5 but the main CD8+ T cell response in this donor 
was focused on the pp65 mapping pool 9 where 0.54% CD3+CD8+ T cells produced IFNy. 
This finding demonstrates that the VAFTSHEHF peptide is not immunodominant in all 
individuals who are B*5801 due to certain combinations of HLA alleles.
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A
Tube Peptide WT49 cells PBMCs
1 No peptide 5x10s 5x10s
2 VAFTSHEHF 5xl05 5xl05
3 VAFTSHEHF None lxlO6
4 VAFTSHEHF lxlO6 None
B
▲
CD3+CD8+ gated cells
1 2 3
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Intracellular IFNy
Figure 4.20 Confirmation of HLA restriction for the putative peptide VAFTSHEHF 
using the WT49 EBV transformed B cell line
The HLA restriction of the VAFTSHEHF peptide was confirmed using the WT49 EBV 
transformed B cell line. WT49 cells were pulsed with the VAFTSHEHF peptide 
overnight and then mixed with PBMCs from donor 15. Panel A shows the ratio of 
WT49:PBMCs used; Panel B shows the results of the intracellular staining for IFNy 
following peptide stimulation, the numbers refer to the tube numbers shown in panel A. 
The amount of IFNy produced was assessed from a CD3+CD8+ gate and then expressed 
versus side scatter. To determine if any background IFNy is produced by the WT49 cells 
a CD 19+ gate was set up and the amount of IFNy produced was assessed versus the side 
scatter.
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4.8.4 CMV specific T cell responses described in the literature
Due to the many different methods that have been used to identify CMV epitopes (Table 4.9 
and 4.10) there have been conflicting reports on true cytotoxic epitopes. Studies that have 
relied on the limiting dilution assay to quantify antigen specific T cells are less sensitive and 
have been superseded by more accurate assays. The limiting dilution assay was the only assay 
available in the early 1990s for the identification of CMV epitopes and was used for the 
identification of the HLA-A*0201 NLVPMVATV peptide (Wills et al. 1996). However, the 
limiting dilution assay under estimates the true frequency of antigen specific T cells and after 
several rounds of antigenic stimulation the phenotype of the expanded CTL population will 
have changed. Another drawback to the limiting dilution assay is that in the context of CMV 
the relative dominance of a peptide cannot be assessed a peptide response that is not 
detectable without in vitro stimulation is clearly a subdominant peptide.
Other groups have relied solely on algorithm databases to identify potential epitopes and 
these are then tested for functional or cytotoxic activity (Elkington et al. 2003; Frankenberg et 
al. 2002; Gallez-Hawkins et al. 2003; Khan et al. 2002a; Kuzushima et al. 2001). Caution 
should be taken when using algorithm databases to scan for potential epitopes because for 
some HLA alleles the information regarding the peptide binding motifs is based on theoretical 
evidence. Only with some of the more common HLA alleles eg. HLA-A*0201 is the 
information provided based on experimental evidence. The data already presented in this 
chapter reveals that there is disagreement between the epitopes predicted by the various 
different databases.
As more CMV epitopes are being identified a confusing picture is emerging about the best 
peptides to include in a peptide vaccine. Many groups use different techniques to identify 
epitopes this produces results which conflict with observations found by other groups. The 
IE1 HLA-A*0201 TMYGGISLL peptide was identified (Gallez-Hawkins et al. 2003) using 
algorithm databases. Subsequent testing was performed using an MHC stabilisation assay, in 
addition transgenic HHD II mice (containing human MHC class I) were vaccinated with the 
TMYGGISLL peptide and cytotoxicity was shown in vitro by chromium release assay. 
However, another study (Elkington et al. 2003) demonstrated that although the TMYGGISLL 
peptide did stabilise HLA-A*0201 in a stabilisation assay it failed to induce IFNy production 
in an ELISPOT assay using a panel of HLA-A*0201 donors.
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HLA
restriction
Sequence Epitope mapping method Assessment of functionality References
A*0101
A*1101
A*1101
A*68
B*0702
A*2402
YSEHPTFTSQY
GPISGHVLK
SVLGPISGHVLK
FVFPTKDVALR
RPHERNGFTVL
FTSQYRIQGKL
Overlapping 15mer peptides Cytotoxicity assay using peptide pulsed 
EBV transformed LCLs as targets.
(Longmate et al. 
2001)
A*02
A*02
VLGPISGHV
MLNIPSINV
T2 stabilisation assay and 
peptide competition assay
Cytotoxicity activity against CMV 
infected fibroblasts. IFNy production 
measured by ELISPOT assay
(Solache et al. 
1999)
A*0201 NLVPMVATV pp65 truncations expressed in 
vaccinia viruses; used in 
combination with algorithm 
databases
Cytotoxicity activity against CMV 
infected fibroblasts. Peptide 
immunisation of transgenic mouse 
model.
(Diamond et al. 
1997; Solache et 
al. 1999)
A*2402 QYDPVAALF Algorithm databases, T2 
stabilisation assay, limiting 
dilution cultures.
T cell clones: cytotoxicity activity 
against CMV infected fibroblasts; 
vaccinia viruses expressing pp65.
(Kuzushima et al. 
2001)
B*0702
B*0801
B*3501
TPRVTGGGAM
DANDIYRIF
VFPTKDVAL
Limiting dilution cultures and 
tested using overlapping 
peptides.
T cell clones: cytotoxicity assay 
against peptide pulsed autologous 
LCL cells.
(Wills etal. 1996)
B*3501 IPSINVHHY Alkali hydrolysis of pp65 
protein.
Screening pp65 alkali digests. 
Cytotoxicity assay using fibroblasts 
incubated with alkali digests.
(Gavin et al. 1993)
Table 4.9 CMV pp65 CD8+ T cell epitopes described in the literature
This table summarises the different methods used in the literature to identify pp65 CD8+ T cell epitopes. 
Cytotoxicty assay: Chromimum release assay; BCL: B-lymphoblastoid cell lines.
HLA
restriction
Sequence Epitope mapping method Assessment of functionality References
A*0201 YILGADPLRV T2 stabilisation assay, 
Algorithm databases.
Cytotoxicity activity against CMV 
infected fibroblasts and peptide pulsed 
T2 cells. IFNy production measured 
by ELISPOT assay.
(Frankenberg et al. 
2002)
A*0201 VLEETSVML Algorithm databases. Analysis of TCR Vf3 gene usage. IFNy 
production measured by ELISPOT 
assay. Cytotoxicity assay using CMV 
infected fibroblasts and peptide pulsed 
BLCs as targets.
(Khan etal. 2002)
A*0201 TMYGGISLL Algorithm databases, T2 
stabilisation assay.
Intracellular staining for IFNy 
production following peptide 
stimulation. Cytotoxicity assay using 
immunised transgenic mouse model.
(Gallez-Hawkins et 
al. 2003)
B*08
B*0702
(D)ELRRKMMY
M
CRVLCCYVL
Overlapping 15mer peptides Intracellular staining for IFNy 
production following peptide 
stimulation
(Kern et al. 1999; 
Wills et al. 2002)
B*18
B*18
B*18
ELKRKMIYM
CVETMCNEY
DEEDAIAAY
Transfected BLCs with 
pp65/IEl expressing constructs. 
Generated clones by limiting 
dilution assay.
Analysis of TCR V(3 gene usage. 
Cytotoxicity assay using pp65/IEl 
transfected LCLs.
(Retiere et al. 
2000)
Table 4.10 CMV IE1 CD8+ T cell epitopes described in the literature
This table summarises the different methods used in the literature to identify IE1 CD8+ T cell epitopes. 
Cytotoxicty assay: Chromimum release assay; BCL: B-lymphoblastoid cell lines.
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In this chapter we have identified new CMV peptides using overlapping 15mer peptides. To 
identify the immunogenic areas of the pp65 and IE1 antigens mapping pools were made, 
these each contained 15 truncated peptides that overlapped by 11 amino acids. These mapping 
pools were tested on a large cohort of 31 healthy individuals. The amount of IFNy produced 
in response to the mapping pools was determined using intracellular staining for IFNy 
following overnight peptide stimulation. From these mapping pools we could determine 
which pools contain the epitopes already identified in the literature (Table 4.11).
The majority of the CD8+ T cells responses were detected to the mapping pools covering the 
carboxyl terminal end of the antigen sequences (Figure 4.6). The majority of the epitopes 
identified in the literature are contained within mapping pools 5-9 (Table 4.11), unpublished 
data from our collaborators (Dr Buyck, Royal Free Hospital, London) regarding the 
identification of CD4+ T cell helper epitopes have shown that these are confined to pp65 
mapping pool 1,2 and 9. We therefore investigated the responses to already identified 
peptides by examining the response to the mapping pools that contain the epitopes sequence. 
We were particularly interested in already defined epitopes contained within mapping pools 
1-3, mainly because only a few epitopes have been defined for this part of the two antigens, 
other mapping pools towards the carboxyl terminal end contain numerous identified epitopes.
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HLA
allele
CMV
protein
Position Sequence Mapping pool 
located in
References
A*0101 pp65 363-373 YSEHPTFTSQY 7 (Longmate et al. 2001)
A*02 pp65 14-22 VLGPISGHV 1 (Solache et al. 1999)
A*02 pp65 120-128 MLNIPSINV 2 (Solache et al. 1999)
A*0201 pp65 495-503 NLVPMVATV 9 (Diamond et al. 1997; 
Solache et al. 1999)
A*1101 pp65 16-24 GPISGHVLK 1 (Hebart et al. 2002; 
Longmate et al. 2001)
A*1101 pp65 13-24 SVLGPISGHVLK 1 (Longmate et al. 2001)
A*2402 pp65 113-121 VYALPLKML 2 (Masuoka et al. 2001)
A*2402 pp65 328-336 QYDPVAALF 6 (Kuzushima et al. 
2001)
A*2402 pp65 369-379 FTSQYRIQGKL 7 (Longmate et al. 2001)
A*68 pp65 186-196 FVFPTKDVALR 4 (Longmate et al. 2001)
B*0702 pp65 417-426 TPRVTGGGAM 7 (Wills et al. 1996)
B*0702 pp65 265-275 RPHERN GET VL 5 (Longmate et al. 2001)
B*0801 pp65 515-523 DANDIYRIF 9 (Wills et al. 1996)
B*3501 pp65 123-131 IPSINVHHY 3 (Gavin et al. 1993)
B*3501 pp65 187-195 VFPTKDVAL 4 (Wills et al. 1996; 
Wills et al. 2002)
B*38 pp65 367-379 PTFTSQYRIQGKL 7 (Longmate et al. 2001)
B*3502 pp65 188-195 FPTKDVAL 4 (Longmate et al. 2001)
B*44XX pp65 511-520 EFFWDANDIY 9 (Wills et al. 1996)
A*0201 IE1 354-363 YILGADPLRV 6 (Frankenberg et al. 
2002)
A*0201 IE1 316-324 VLEETSVML 6 (Khan et al. 2002b)
A*0201 IE1 297-304 TMYGGISLL 5 (Gallez-Hawkins et al. 
2003)
B*08 IE1 198-207 (D)ELRRKMMYM 4 (Kern et al. 1999b; 
Wills et al. 2002)
B*0702 IE1 309-317 CRVLCCYVL 6 (Kern et al. 1999b)
B*18 IE1 199-207 ELKRKMIYM 4 (Retiere et al. 2000)
B*18 IE1 279-287 CVETMCNEY 5 (Retiere et al. 2000)
Table 4.11 Reported MHC class I restricted peptides and their location in the 
mapping pools
This table lists all the MHC class I restricted peptides derived from the pp65 and IE1 
antigens that have been described in the literature.
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We next investigated the relative dominance of published CMV epitopes (Table 4.11) among 
our cohort of healthy individuals. In order for an epitope to be considered for inclusion in a 
peptide vaccine it should be capable of inducing a functional response that should be 
detectable without any prior in vitro restimulation. Among our cohort we could not detect any 
CD8+ T cell responses to the peptides listed below in table 4.12:-
HLA
restriction
CMV
antigen
Mapping
pool
Epitope contained 
within pool
In vitro memory 
response*
HLA-A*0201 pp65 1 VLGPISGHV 1/16
HLA-A*0201 pp65 2 MLNIPSINV 0/16
HLA-A*2402 pp65 2 VYALPLKML 0/7
HLA-A*0201 IE1 5 TMYGGISLL 0/16
Table 4.12 Table of negative responses to published CTL epitopes for pp65 and IE1
This table lists four published CTL epitopes and the mapping pool they are contained 
within. The responses to the mapping pools containing the published CTL epitopes was 
determined by measuring IFNy production following peptide stimulation. A response4 is 
defined as more than 0.1% CD8+ T cells producing IFNy.
From table 4.12 it can be shown that there are no functional T cell responses to some of the 
peptides described in the literature. Among our cohort of healthy individuals only one donor 
showed a CD8+ T cell response (0.2% IFNy) to mapping pool 1, although these mapping 
pools only contain 15 peptides it is impossible to say which peptide has induced this response. 
All the other donors that were tested produced no IFNy (<0.1% CD8+ T cells producing 
IFNy) in response to the mapping pools listed (table 4.12), indicating that CD8+ T cells from 
these donors do not respond to the epitopes described within these pools. Only one or two 
epitopes have been identified from mapping pools 1-5 mainly because CD8+ epitopes are 
clustered towards the carboxyl terminal end of the protein. The number of epitopes contained 
within pp65 mapping pool 7 is four and consequently the majority of individuals respond to 
this mapping pool mainly due to the presence of epitopes restricted by common HLA alleles 
such as HLA-B*0702 and HLA-A*0101. The testing of each individual epitope would need 
to be carried out in a large cohort of mixed HLA alleles.
To make a successful vaccine the relative dominance of identified CMV epitopes needs to be 
established. An epitope such as VLGPISGHV that only induces an IFNy response in 1 out of 
16 healthy donors would not be a good candidate to include in a peptide vaccine. The relative 
immunodominance of different HLA subtypes would need to be considered, because of 
certain combinations of HLA alleles the relative dominance of an epitope can be altered.
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4.9 Discussion
The identification of viral antigenic peptides presented in association with HLA molecules on 
the surface of infected cells is a pre-requisite for the design of a peptide vaccine aimed to 
provide effective population coverage. Such peptides can also be used in the propagation of 
viral specific T cells for use in adoptive T cell therapy protocols.
The identification of viral peptides derived from the human cytomegalovirus was first 
conducted in 1993 (Gavin et al. 1993) by creating truncations of the CMV matrix protein 
pp65 and the major immediate early protein IE1 using an alkali hydrolysis method. Further 
studies carried out in the 1990s used the limiting dilution assay to generate peptide specific 
clones that could be tested for their ability to lyse CMV infected fibroblasts in a chromium 
release assay (Wills et al. 1996). The first CMV minimal cytotoxic epitope the pp65 peptide 
NLVPMVATV was then described, and was shown to stimulate CD8+ CTLs from normal 
healthy CMV positive individuals in the context of HLA-A*0201 (Diamond et al. 1997). In 
these early studies, the identification of CMV peptides focused on both pp65 and IE1, 
however, progress in the epitope mapping of the IE1 antigen slowed after the demonstration 
that IE1 specific T cells poorly lysed CMV infected autologous fibroblasts (Gilbert et al. 
1996). It was subsequently found that pp65 inhibited the presentation of IE1 and therefore in 
CMV infected fibroblasts there would be no presentation of IE1 (Gilbert et al. 1996). The 
focus of the epitope mapping studies shifted to pp65 and has so far resulted in the 
identification of at least 20 epitopes derived from the pp65 antigen.
Our own studies have demonstrated die presence of functional IE1 specific T cells in healthy 
individuals at a similar frequency as pp65 specific T cells. These IE1 specific T cells are 
capable of producing IFNy in responses to antigen stimulation, and in some donors the 
frequency of IE1 specific T cells was greater than the number of pp65 specific T cells. 
Published data has also demonstrated that both pp65 and IE1 specific T cells can be found 
(Gyulai et al. 2000; Kern et al. 2000) in CMV seropositive individuals and these were found 
to be functional both in terms of cytotoxicity (Gyulai et al. 2000) and IFNy production (Kern 
et al. 2000; Kern et al. 1999b). As demonstrated in chapter 3, the presence of both IE1 and 
pp65 specific T cells resulted in better viral control in HSCT patients. These results 
demonstrated the importance of IE1 specific T cells and therefore peptides derived from IE1 
would need to be included in a peptide vaccine.
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The identification of new CMV epitopes has progressed over the last decade leading to the 
use of more sensitive assays to study T cell responses. In this chapter intracellular staining for 
IFNy production was used, which allows the precise assessment of T cells responding to a 
given peptide. The intracellular staining method determines the frequency of responding T 
cells within 6 hours of peptide exposure. Incubation with the secretion inhibitor Brefeldin A 
allows cytokines to accumulate within cells, those producing the cytokine of interest are then 
identified by intracellular staining, IFNy production is most commonly measured (Kern et al. 
1999a; Kern et al. 1998). This method enables the gating of specific populations to allow for 
the direct visualisation of both CD4+ and CD8+ T cells, this is an advantage over the 
enzyme-linked immunospot (ELISPOT) method that relies on an additional step to separate 
the different populations prior to peptide stimulation. The intracellular staining method has 
superseded the ELISPOT method, however, the development of real time PCR to study gene 
expression patterns is now proving more sensitive and versatile than the current intracellular 
staining method.
To identify new CMV peptides, we used overlapping mapping pools that cover the pp65 and 
IE1 proteins, these pools allow for the rapid identification of new peptides in a HLA 
independent manner. New CD4+ and CD8+ restricted epitopes have been previously 
identified using this method (Dunn et al. 2002; Kern et al. 2002), although there maybe many 
more epitopes still to be defined. We have chosen to use 15mer peptides that overlap by 11 
amino acids, other groups have used a smaller overlap of 9 amino acids (Kern et al. 1999b) 
but this may result in some potential antigenic peptides being missed.
In our cohort of 31 healthy individuals we determined the functional IFNy responses to the 
IE1 and pp65 antigens using PepMixes™, these mixes contain overlapping 15mer peptides 
that cover the whole sequence of both antigens. From the results obtained smaller mapping 
pools were constructed that could be used to determine the immunogenic part of the proteins. 
These smaller mapping pools were used to stimulate PBMCs from healthy individuals and 
HSCT patients, the amount of IFNy produced by the CD8+ T cells was determined using the 
intracellular staining method. Once the immunogenic part of the antigen had been identified, 
the individual 15mer peptides making up each mapping pool were synthesised and tested on 
those individuals that had a good CD8+ T cell response to the mapping pool. These 
experiments identified 14 immunogenic 15mer peptides from 11 donors, for some individual's 
responses were detected against more than one 15mer peptide. For some peptides the 
immunogenic 9mer or lOmer peptide was located within the overlap between two 15mer 
peptides resulting in a positive response to adjacent peptides.
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Following the identification of 15mer peptides, the publicly available algorithm databases 
were consulted to try and define the 9mer peptide epitopes. There are two types of databases 
available (SYFPEITHI and BIMAS), these identify peptides based on their binding affinities 
to MHC class I molecules. The second type of database available (PAPROCC and NetChop) 
predict the peptides produced by the human proteasome. We used these databases in 
combination with experimental data to predict the 9mer peptide from the defined 
immunogenic 15mer peptide, there are only seven potential 9mer peptides contained within 
each 15mer peptide. The algorithm databases predicted the same peptide for the majority of 
the donors, but some discrepancies were seen with some peptides that may reflect the 
different ways these databases predict peptides. The proteasomal cleavage databases only 
predict the peptides that are generated as a result of carboxyl terminal end cleavage by the 
proteasome, these databases produced the most conflicting results, only 9 peptides were 
predicted with high scores by both the PAPROCC and NetChop databases. Overall these 
databases should be used with caution due to the discrepancy in the highest ranked peptides 
between the different databases. It is not the discrepancy over differently ranked peptides that 
causes most concern but the potential epitopes being missed. Problems with the use of 
algorithm databases to predict immunogenic peptides were also reported by Pelte et al. who 
recommended that these databases should not be used to screen for new epitopes (Pelte et al. 
2004).
The peptides predicted from the algorithm databases and the information published on the 
peptide bind motifs (Marsh 2000) of the different HLA molecules, 9mer and lOmer peptides 
were synthesised and tested in functional assays. This chapter focused on one pp65 peptide 
thought to bind in the context of B*5801 and two IE1 peptides thought to bind in the context 
of the HLA-B*0702 and B*2705 alleles. We were interested in the CRVLCCYVL peptide 
which we have shown to bind in the context of HLA-B*0702. An MHC stabilisation assay 
was performed using T2 cells that had been transfected with HLA-B*0702, interestingly, the 
CRVLCCYVL peptide only stabilised HLA-B*0702 when lOOpg peptide was used and 
attempts to generate a HLA-B*0702 tetramer with this peptide failed. Another group has also 
identified the CRVLCCYVL (Kern et al. 1999b) peptide by a matter of elimination using data 
obtained using overlapping peptide studies, however, no functional data was shown. The data 
presented in this chapter shows there is a high amount of IFNy produced by CD8+ T cells in 
response to the CRVLCCYVL peptide, which also induces cell proliferation. Unpublished 
data from another group (Moss 2004) showed that functional T cell responses against this 
peptide could be detected but they also failed to produce a HLA-B*0702 tetramer using this 
peptide. Functional CD8+ T cell responses are detected in HLA-B*0702 positive individuals 
against the CRVLCCYVL peptide but this peptide may have a low affinity for the T cell
199
Chapter 4
receptor or it may be presented in the context of a non classical HLA allele such as HLA-E or 
HLA-G. Further experiments are necessary in order to determine which HLA molecule 
presents this peptide and why such a high response is detected in HLA-B*0702 positive 
individuals. Other experiments that could be conducted include truncating the 9mer peptide to 
find the optimal sequence or testing CRV specific T cells in a cytotoxicity assay.
The second peptide derived from the IE1 antigen to be identified in this study is presented in 
the context of HLA-B*2705. To identify this HLA-B*2705 peptide, PBMCs from a HSCT 
recipient were used, these patients produce a high amount of IFNy in response to the IE1 and 
pp65 antigens making the identification of the 9mer peptide more straight forward. Even in 
the absence of detectable CMV replication the CD4+ and CD8+ T cell responses can easily 
quantitated in HSCT patients. The RRKMMYMCY peptide was rated highest by the 
algorithm and preoteasomal databases, subsequent functional assays revealed that this 9mer 
peptide could stimulate CD8+ T cells to produce IFNy and that cell proliferation could be 
detected using a thymidine incorporation assay. The ability of the RRKMMYMCY peptide to 
stabilise HLA-B*2705 on the surface of T2 cells could not be assessed due to the limited 
availability of antibodies directed against individual HLA alleles, at the time of this project 
only anti HLA-A*0201, HLA-B*0702 and pan HLA class I antibodies were available. The 
subsequent confirmation of the HLA restriction of the RRKMMYMCY peptide was carried 
out using an EBV transformed B cell line that only matched for HLA-B*2705. LCL's were 
pulsed with the peptide overnight and then used to present the peptide to PBMCs from a 
HLA-B*2705 positive donor. The amount of IFNy produced by the CD8+ T cells was 
determined by using the intracellular staining method. LCL's have not been used previously 
to identify the HLA restriction of newly identified peptides but this method is invaluable 
when the HLA alleles under study are relatively uncommon.
A study carried out by Longmate et al. demonstrated that at least four or more CMV CTL 
epitopes would need to be identified to attain 90% coverage of Afro-Caribbean and Asian 
populations (Longmate et al. 2001). Our cohort contains several individuals who were from 
Asian populations, we were therefore very keen to identify new CMV epitopes in these 
donors. From our data we have identified a new peptide that is derived from pp65 and 
presented in association with HLA-B*5801. The identification of the presenting HLA allele 
was complicated by the lack of available information regarding some of these more 
uncommon alleles. Only the BIMAS database contained information on the peptide binding 
specificity of HLA-B*5801 and the peptide ranked highest was in agreement with the 
PAPRocC proteasome cleavage database. Again, LCL's were used to confirm the HLA
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restriction of the VAFTSHEHF peptide. Interestingly CD8+ T cell from only one out of the 
two HLA-B*5801 positive donors responded to this peptide indicating that the presentation of 
CMV peptides may be influenced by the presence and combination of different HLA alleles 
expressed by a given individual.
In this study we have identified one new peptide derived from the IE1 antigen and one from 
pp65. Neither of these peptides have been described previously in the literature. The 
CRVLCCYVL peptide has been previously described in the literature although the CD8+ T 
cell response to this peptide has not previously been shown. A confusing pictures emerges 
from the assessment of this IE1 peptide, although IFNy and proliferative responses can be 
detected in response to the peptide, it did not bind HLA-B*0702 when using 10 pig of the 
peptide, suggesting that either this is not the HLA restriction of this peptide or die peptide has 
a very low affinity for the HLA-B*0702 molecule. The data presented in this project only 
demonstrates that CD8+ T cells respond to these newly identified peptides in terms of IFNy 
production, cytotoxcity assays would need to be performed to confirm that these are true 
epitopes. However, Kern et al. reported new epitopes on the basis of a CD8+ T cell IFNy 
responses only (Kern et al. 1999b). At the time of this project no effective targets were 
available to prove cytotoxicity in a chromium release assay, CMV infected fibroblasts cannot 
be used as DEI specific T cells cannot lyse CMV infected fibroblasts effectively (Gilbert et al. 
1996). It was subsequently found that pp65 inhibits the presentation of IE1, therefore in CMV 
infected pp65 expressing fibroblasts there would be no presentation of IE1 (Gilbert et al. 
1996). Some groups have overcome this problem by using viral vectors containing the 
sequence for the IE1 antigen and using these to infect target cells (Gyulai et al. 2000). We 
were also unable to test the cytotoxic potential of the pp65 peptide identified due to the 
absence of appropriate donors for fibroblast target cells. Further work is needed to prove that 
these peptides are true epitopes and can induce CD8+ T cell peptide specific killing.
There is currently some concern with regard to which peptides to include in a CMV vaccine 
mainly due to the various techniques currently being employed to identify new epitopes. 
Some of the studies conducted that used algorithm programs to screen for new epitopes have 
produced conflicting results and undoubtedly could have over looked some potential epitopes. 
The early studies carried out generated CMV specific clones using a limiting dilution assay 
and consequently the true frequency of peptide specific T cells would be under-estimated. In 
this study we created small mapping pools that cover the pp65 and IE1 antigens. With these 
pools we could determine what part of the antigen is most immunogenic in terms of IFNy 
production. Among our cohort of 31 individuals, we stimulated their PBMCs with each 
mapping pool and then measured the amount of IFNy produced using the intracellular staining
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method. We found that the majority of the CD8+ T cell responses were focused towards the 
carboxyl terminal end of the antigens whereas the CD4+ T cell responses were located at the 
amino and carboxyl terminal ends. We were able to identify which mapping pools contained 
epitopes that had already been described in the literature, from the data obtained in our cohort 
of 31 healthy individuals we determined the frequency of responses to some mapping pools 
containing previously described epitopes and found that these responses were so low that they 
would not be beneficial to include in a peptide vaccine.
In this study we have predominantly used intracellular staining for IFNy production although 
later real time PCR was used to detect changes in the level of gene expression in response 
peptide stimulation. The inability to detect IFNy production in some healthy donors using the 
intracellular staining method was a problem and it became difficult to discriminate responses 
that were very close to the background level. The real time PCR method was more sensitive 
and allowed for the relative quantification of IFNy expression in those donors with levels of 
IFNy production below the detection level for the intracellular staining method. However, the 
real time PCR method was more time consuming and required CD8+ T cells to be sorted prior 
to peptide stimulation. Only CD8+ T cells from one healthy donor (donor 26) produced very 
little IFNy in response to peptide stimulation, and in this donor the real time PCR was used to 
quantify the level of IFNy gene expression.
Overall we have identified two new peptides that induce CD8+ T cells to produce IFNy in 
response to peptide stimulation. However, we have illustrated how difficult it is to identify 
new CMV epitopes in particular when the dominance of a peptide is dictated by the presence 
or combination of particular HLA alleles. There appears to be a HLA hierarchy emerging 
with some HLA alleles eg. HLA-B*0702 presenting peptides that are more immunogenic 
than peptides presented by other HLA molecules. To develop a successful CMV peptide 
vaccine, the potential of these peptides to cross-react with T cells of other specificities would 
also need to be assessed. A CMV peptide vaccine should contain the minimal number of 
peptides required to provide protection among the target population, different peptide mixes 
should be used for the different populations, for example a peptide vaccine aimed at the 
Caucasoid population should contain peptides that are restricted by HLA alleles such as 
HLA-A*0101, A*0201, B*0702, B*0801 in contrast, if vaccinating the Asian populations 
peptides restricted by HLA alleles such A*2402 and B*5801 should be incorporated. By 
designing a CMV peptide vaccine for the different populations one can ensure that the 
minimal number of peptides are include and thus reducing the number of potentially cross­
reactive peptide. The successful development of a peptide vaccine to protect at risk 
populations would need to take all these issues into account.
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Chapter 5
Detection of CMV specific CD8+ T cells and the hierarchy in the 
presentation of CMV epitopes
5.1 Introduction
The development of HLA tetrameric complexes that recognise T cell receptors specific for a 
particular MHC class I restricted epitope allows for the identification of T cells specific for a 
given peptide. HLA-peptide tetramers consist of a HLA heavy chain containing the peptide 
binding groove and a light chain termed p2-microglobulin. Only the extracellular domain of 
the heavy chain is included and is modified by the addition of a biotinylation site at the C- 
terminal end. The heavy chain and p2-microglobulin chain are refolded in the presence of a 
peptide epitope, the resulting refolded complex is then biotinylated by the bacterial ligase 
enzyme BirA and subsequently purified by gel filtration. The tetrameric complex is generated 
by the addition of fluorescent streptavidin at a 1:4 ratio with the refolded complex. The 
method used for tetramer production in this chapter is described in chapter 2 (section 2.6).
HLA tetramers have been used to directly analyse and quantify the number of antigen specific 
T cell in the peripheral circulation, they have been used to detect virus specific T cells in the 
context of infectious diseases such as human immunodeficiency virus (Appay et al. 2000; 
Ogg et al. 1998), Epstein-Barr (Callan et al. 1998; Tan et al. 1999), influenza (Dunbar et al. 
1998), hepatitis C (Appay et al. 2002) and CMV (Aubert et al. 2001; Cwynarski et al. 2001). 
Tetramers have also been used to isolate and expand antigen specific T cells in 
immunotherapy strategies (Yee et al. 1999) and are able to overcome the relatively low 
affinity of T cell receptors for peptide/HLA complexes, for a given single complex the 
interaction has an off rate of 12-15 seconds at 25°C (Davis et al. 1998).
In this chapter the frequency of tetramer positive T cells was determined in three groups, 1) 
healthy individuals, 2) HSCT recipients, 3) CVID patients. The functional responsiveness to 
CMV antigens was studied in HSCT recipients (chapter 3), a brief description of the problems 
encountered with CMV post HSCT is described below. The healthy individuals were healthy 
laboratory volunteers based at the Anthony Nolan Research Institute (ANRI) and the Royal 
Free hospital (RFH). Patients with common variable immunodeficiency (CVID) were also 
recruited from the RFH (ethical consent number 04Q0501119) in collaboration with Dr 
Webster (Department of Immunology, RFH).
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CMV disease in the HSCT setting
Infection due to cytomegalovirus (CMV) can be a cause of morbidity and mortality in the 
post HSCT setting where it can cause life-threatening pneumonitis in those who acquire or 
reactivate CMV. Approximately 60-70% of patients undergoing HSCT will reactivate CMV 
and without prompt antiviral therapy 20-30% will go on to develop CMV end organ disease 
(Boeckh et al. 1998). It has been shown with HLA tetramers that there is an inverse 
relationship between CMV specific T cells and the development of viraemia (Aubert et al. 
2001; Cwynarski et al. 2001). These studies also revealed that there was a rapid expansion of 
CD8+ T cells at the onset of viraemia and subsequently that these levels dropped with the 
clearance of the virus. The recovery of CMV specific CD8+ T cell levels to greater than 
10x106/L has been previously associated with protection from the development of CMV 
disease (Cwynarski et al. 2001).
CMV and Common variable immunodeficiency (CVID)
Common variable immunodeficiency is a primary immunodeficiency disease (PID) that 
affects 1 in 25,000 Caucasians, it is the second most prevalent PID and is mainly a 
heterogeneous disease associated with low serum immunoglobulin levels of all isotypes (IgG, 
IgA and IgE), consequently patients are at increased risk of developing infections caused by 
encapsulated bacteria. A failure of B cells to differentiate into plasma cells in vivo is 
responsible for the hypo-immunoglobulinaemia seen in these patients which leads to an 
increased risk of bacterial infections (Cunningham-Rundles and Bodian 1999). Recent 
evidence has also suggested that there is a primary defect in the function of myeloid derived 
dendritic cells (Bayry et al. 2004; Scott-Taylor et al. 2004) resulting in impaired T cell 
activation and proliferation. The number of T and B cells in the peripheral circulation is 
within the normal range although the B cells fail to differentiate into plasma cells, in up to 
50% of CVID patients, defects in their cellular immune response have also been reported 
(Kondratenko et al. 1997). Patients with CVID cope relatively well with viral infections 
suggesting that the plasmacytoid dendritic cells are unaffected by the disease although there 
have been a few cases reported in the literature where CVID patients have developed CMV 
disease (Witte et al. 2000) or have had problems with EBV. Those CVID patients who are 
receiving immunosuppressive therapy to treat on going autoimmune conditions that have 
occurred, are more likely to develop CMV disease as a result. Currently there is no cure for 
CVID but patients are treated with intravenous immunoglobulin to prevent bacterial 
infections.
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The aims of this chapter were to determine the frequency of CMV specific T cells in healthy 
donors, CVID patients and HSCT recipients. Tetramers were produced for the HLA alleles 
A*0101, A*0201 and B*0702, these were refolded with peptides derived from the pp65 and 
IE1 antigens. The activation and differentiation of these tetramer positive T cells was 
determined by using fluorescently labelled antibodies against cell surface markers. The HLA 
hierarchy in peptide presentation was investigated in the context of HLA-A*0201/B*0702. 
CMV specific T cells were generated using CMV peptides described in the literature and 
newly described SPHERE peptides that are capable of binding to the T cell receptor with 
greater affinity. The functional response to CMV was investigated in a cohort of CVID 
patients, to date there have only been a few reports of CMV disease among these patients and 
we were therefore interested in looking at the T cell responses in this group.
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RESULTS
5.2 Frequency of CD8+ T cells specific for the IE1 and pp65 antigens
5.2.1 Detection of CMV specific T cells using HLA-peptide tetramers
Tetramers are able to detect 0.02% of CD8+ T cells (Rowland-Jones S 2000) and have been 
used to detect antigen specific T cells in a variety of infections. HLA-peptide tetramers were 
used to determine the frequency of CMV specific T cells circulating in the peripheral blood of 
healthy donors, HSCT recipients and CVID patients, HLA-A*0201, B*0702 and HLA- 
A*0101 heavy chains were refolded in the presence of CMV peptides derived from the pp65 
and IE1 antigens (table 5.1). The pp65 HLA-peptide tetramers were produced in-house; IE1 
HLA-peptide tetramer was from the Emory University, Atlanta, USA. The biotinylation of 
each tetramer was assessed by native gel electrophoresis (Chapter 2, section 2.6.9) and the 
specificity of each HLA-peptide tetramer was determined using CMV seronegative healthy 
donors and HLA mismatched CMV seropositive healthy donors. HLA tetramers were titrated 
in order to determine the opitimal amount of each to use.
Peptide CMV antigen HLA restriction
YSEHPTFTSQY pp65 HLA-A*0101
NLVPMVATV pp65 HLA-A*0201
TPRVTGGGAM pp65 HLA-B*0702
VLEETSVML IE1 HLA-A*0201
Table 5.1 Peptides derived from pp65 and IE1
This table summaries the four peptides that were selected to be refolded with HLA- 
A*0101, HLA-A*0201 and HLA-B*0702 to be made into HLA-peptide tetramers.
PBMCs were isolated and stained with the optimally determined amount of HLA-peptide 
tetramer. The tetramer staining was performed at 37°C; previous studies have shown that 
staining at 4°C increases the amount of non-specific staining (Whelan et al. 1999). The 
binding of the tetramer complex to the T cell receptor has been shown (Hoffmann et al. 2000) 
to diminish the binding of anti-CD3 antibody, resulting in a lower mean fluorescence signal 
thus showing that the tetramer has bound to the TCR. Following tetramer staining, the T cells 
were further characterised by staining for the cell surface markers CD3 and CD8.
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Tetramer positive cells were visualised by flow cytometry. The gating was performed on the 
live lymphocytes population (Figure 5.1, panel A, left) to exclude any dead cells that can 
non-specifically bind to the tetramer. Subsequent gating was performed on the CD3+ T cells 
(Figure 5.1, panel A, middle) and the percentage of tetramer positive T cells was assessed 
from the CD3+CD8+ T cells (Figure 5.1, panel A, right). The specificity of each tetramer was 
assessed using a panel of CMV seropositive and seronegative healthy individuals (Figure 5.1, 
Panels B-E). Each tetramer was able to detect discrete populations of peptide specific T cells 
in the CMV seropositive individuals (Figure 5.1, Panels B-E, upper plots) these populations 
were absent from the CMV seronegative individuals (Figure 5.1, Panels B-E, lower plots).
5.2.2 Frequency of IE1 and pp65 specific T cells
The frequency of CMV specific T cells detected in the peripheral blood was determined in 
our cohort of healthy individuals and compared to the frequency in CVID and HSCT patients. 
A representative tetramer plot for each group is shown in figure 5.2. For each tetramer tested 
discrete populations of tetramer positive T cells could be detected in the HSCT, CVID and 
healthy individuals (Figure 5.2), although the number of tetramer positive T cells did vary. 
The HSCT patients were lymphopenic (<1.0xl09/L lymphocyte count) for a long time 
following HSCT and therefore very few CD8+ T cells were acquired early post transplant. In 
some individuals two tetramer positive populations can be seen among the CD8+ T cells 
(Figure 5.2, panel C), these two populations are thought to represent T cells that have 
different T cell receptor affinities. Each tetramer was shown to be specific when tetramer 
staining was performed on PBMCs from CMV seronegative individuals; the percentage of 
CD8+ tetramer positive T cells detected in these individuals was below 0.1% (Figure 5.3 
Panels A and B, Figure 5.4 Panels C and D). Additionally, CMV seropositive individuals that 
were not of the same HLA as the tetramer were included to demonstrate the HLA specificity 
of each tetramer.
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Figure 5.1 Tetramer staining and gating strategy
Tetramer staining was performed on PBMCs from four healthy CMV seropositive and 
four CMV seronegative individuals. Tetramer staining was followed by cell surface 
staining for CD3 and CD8; all samples were acquired by flow cytometry. Initially a 
lymphocyte gate was set up (panel A, left) and CD3+ T cells were acquired on the CD3 
versus forward scatter (panel A, middle). From the CD3+ T cells the numbers of tetramer 
positive T cells were assessed as a percentage of the CD3+CD8+ cells (panel A, right). 
The specificity of each tetramer was assessed using CMV seropositive and CMV 
seronegative individuals (panels B-E).
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Figure 5.2 Detection of CMV specific T cells in healthy individuals, CVID and 
HSCT patients
Representative CMV tetramer staining of four healthy, CVID and HSCT patients using 
the pp65 and IE1 specific tetramers. Tetramer staining was performed using the HLA- 
A*0101/YSE, HLA-A*0201/NLV, HLA-B*0702 and HLA-A*0201/VLE tetramers. As 
shown in healthy individuals (panel A), HSCT patients (panel B) and CVID patients 
(panel C) discrete tetramer positive T cell populations can be seen with each tetramer. 
The percentage of tetramer positive T cells is represented as a percentage of CD3+CD8+ 
T cells.
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Figure 5.3 Comparison of tetramer positive CD8+ T cells specific for the NLV and 
TPR peptides in healthy individuals, CVID and HSCT patients
The CMV specific tetramer positive T cell frequencies in healthy individuals ( a ), CVID 
(▼ ) and HSCT patients (■ ). The number of tetramer positive T cells was determined in 
CMV seronegative ( • )  and HLA mismatched individuals (•). The percentage of tetramer 
positive T cells was determined using the HLA-A*0201/NLV tetramer (panel A) and 
HLA-B*0702/TPR tetramer (panel B). The frequency of tetramer positive T cells 
detected in the healthy individuals was compared with the frequency detected in the 
CVID and HSCT patients using the Mann-Whitney U test. The bars represent the median 
values obtained. The only statistically significant difference was the higher percentage of 
HLA-A*0201/NLV specific T cells detected in the HSCT patients compared with the 
healthy CMV seropositive individuals (P=0.05).
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Figure 5.4 Comparison of tetramer positive CD8+ T cells specific for the YSE and 
VLE peptides in healthy individuals, CVID and HSCT patients
The CMV specific tetramer positive T cell frequencies in healthy individuals ( a ), CVID 
( ▼ ) and HSCT patients (■ ). The number of tetramer positive T cells was determined in 
CMV seronegative ( • )  and HLA mismatched individuals (•). The percentage of tetramer 
positive T cells was determined using the HLA-A*0101/YSE tetramer (panel C) and 
HLA-A*0201/VLE tetramer. The frequency of tetramer positive T cells detected in the 
healthy individuals was compared with the frequency detected in the CVID and HSCT 
patients using the Man-Whitney U test. The bars represent the median values obtained.
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The frequency of tetramer positive T cells detected was highest among the HSCT patients 
(Figure 5.3) when compared with the healthy individuals and CVID patients, this is due to the 
reactivation of CMV experienced by these patient's. The frequency of NLV specific T cells 
detected in the circulation of the HSCT patients was higher compared to the healthy 
individuals (Figure 5.3, panel A and panel B), this was significant when using the Mann- 
Whitney U test (P=0.050). Among the HSCT patients the highest frequency of tetramer 
positive T cells was detected using the HLA-A*0201/NLV and HLA-B*0702/TPR tetramers, 
two individuals had T cells specific for the HLA-A*0101/YSE tetramer (>0.1% CD8 T cells, 
Figure 5.4, panel C) but only one individual had T cells specific for the IE1 HLA- 
A*0201/VLE tetramer (Figure 5.4, panel D). The patient who had T cells specific for the IE1 
peptide had a high frequency of tetramer positive T cells with at least 4% CD3+CD8+ T cells 
(Figure 5.4, panel D) detected using the IE1 tetramer. It is possible that the reactivation of 
CMV has increased the number of IE1 specific T cells in this patient. One of the CVID 
patients also had at least 4% CD3+CD8+ T cells specific for the VLE peptide (Figure 5.4, 
panel D), this could have been due to the reactivation of CMV although there is currently no 
information reported on the reactivation of CMV in the CVID patients.
Among these three groups the highest frequency of tetramer positive T cells detected in the 
peripheral circulation was in a HSCT recipient (Patient 32) where 67% of CD3+CD8+ T cells 
were specific for the HLA-A*0201/NLV tetramer. This HSCT recipient was +71 days post 
transplant and had only just cleared CMV from the blood. From the data obtained on this 
patient from chapter 3 we can calculate that 14.7xl06/L CD3+CD8+ T cells produced IFNy in 
response to the pp65 PepMix and 39xl06/L CD3+CD8+ T cells were detected with the HLA- 
A*0201/NLV tetramer. From these figures it can be shown that only 36% of tetramer positive 
T cells are functional in terms of IFNy production but because pp65 PepMixes were used it 
cannot be ruled out that the IFNy produced is not only in responses to the NLV peptide but 
may include other as yet undefined epitopes. The conclusion from this finding is that in 
agreement with already published work (Ozdemir E 2002), the number of tetramer positive T 
cells does not correlate with functional responses. The monitoring of patients longitudinal 
with tetramers does not provide an accurate assessment of true cellular immune responses to 
the CMV antigens and a more functional based assay would provide more reliable data.
5.2.3 Frequency of HLA-A*0201/NLV and HLA-B*0702/TPR specific T cells
The frequency of HLA-A*0201/NLV and HLA-B*0702/TPR tetramer positive T cells was 
compared using the results obtained from 15 healthy individuals. The amount of tetramer 
used was again titrated for each batch, positive and negative controls were included, we were 
therefore confident that both of these tetramers were specific for these peptides and presented
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in the context of HLA-A*0201 or HLA-B*0702 accordingly. The frequency of HLA- 
B*0702/TPR tetramer positive T cells that were detected was higher when compared with the 
HLA-A*0201/NLV tetramer (Figure 5.5). The difference in the number of tetramer positive 
CD8+ T cells detected with the HLA-A*0201/NLV and HLA-B*0702/TPR tetramers was 
statistically significant (P=0.0247) when using the Mann-Whitney U test. These results were 
also confirmed when measuring the amount of IFNy produced following overnight peptide 
stimulation (data not shown). The majority of these individuals have both the HLA-A*0201 
and HLA-B*0702 alleles, therefore it is probable that these individuals could only generate 
CD8+ T cells specific for the TPR peptide and not for the NLV peptide, this is probably the 
reason for the statistical difference. The dominance of the HLA-B*0702/TPR peptide in these 
HLA-A*0201/B*0702 individuals is investigated further in section 5.4.
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Figure 5.5 Com parison of TPR and NLV tetramer positive T cells in CMV 
seropositive healthy individuals
R epresentation  o f  the frequ en cy  o f  H L A -A *0201 /N L V  ( ■ ) sp ec ific  and H L A - 
B *0702/T P R  (a ) sp ecific  T ce lls  in a cohort o f  15 individuals. Bars indicate the median  
values obtained. The percentage o f  tetramer positive T cells detected is highest w ith the 
H L A -B *0702/T P R  tetramer when com pared with the H L A -A *0201/N L V  tetramer. This 
difference w as significant when tested using the M ann-W hitney U test (<0.05).
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5.2.4 Clinical evidence of CMV infection in CVID patients
Studies of CMV specific T cells in CVID patients was through collaboration with Dr D 
Webster (Department of Immunology, RFH). Three patients with CVID developed suspected 
CMV disease that was confirmed in one patient, and suspected in the second two. One patient 
developed severe chronic diarrhoea, biopsies taken from the colon in this patient showed 
evidence of active colitis and were positive by PCR for the CMV antigen glycoprotein B, 
however, the peripheral blood was negative for CMV and no CMV inclusions were seen in 
the biopsy material. This patient was given a 7-day intravenous course of ganciclovir 
followed by a 35-day course of valganciclovir, during this time there was a marked 
improvement in the patient's symptoms but following the cessation of valganciclovir there 
was a gradual relapse. A second patient also developed chronic diarrhoea; lymphocytes eluted 
from the biopsy material revealed that approximately 5% were specific for the CMV NLV 
peptide. The third CVID patient developed CMV enteritis with CMV inclusion bodies found 
in colonic macrophages, these inclusions stained positive for the early nuclear protein pp52. 
This patient subsequently developed a B cell lymphoma and following cytotoxic treatment 
CMV genomes were detected in the peripheral circulation.
5.2.5 T cell responses to CMV in patients with CVID
The functionality of CMV specific CD8+ T cells was investigated in chapter 3 in patients 
undergoing HSCT, initially the functionality of CMV specific T cells was first established in 
healthy individuals and subsequently a longitudinal study was conducted in these patients. 
The reactivation of CMV is associated with immune suppression such as in HSCT recipients 
and HIV positive individuals. We were therefore interested in determining whether the T cell 
response to CMV in patients with CVID could adequately control viral replication, given that 
CVID patients can also have defective T cell responses. The amount of IFNy produced by 
CD8+ T cells was determined following antigenic stimulation, the methods used are the same 
as those described previously in chapter 3 and outlined in chapter 2 (section 2.3.4). To 
determine the IFNy response to the CMV antigens IE1 and pp65, PepMixes were utilised, 
these contain overlapping 15mer peptides that cover the entire sequence of the two antigens. 
PBMCs were collected from the CVID patients at each hospital visit these were stimulated 
overnight with the different antigens in the presence of anti CD28 and Brefeldin A. Brefeldin 
A allows for the accumulation of cytokines within the cell, these can then be detected using 
fluorescently tagged antibodies.
The functional responsiveness of CD8+ T cells to the CMV antigens was determined in seven 
CVID patients and compared with healthy individuals (Figure 5.6). The CVID patients 
produced more IFNy in response to the IE1 antigen than the healthy individuals, this
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difference was significant (P=0.0099) when compared using the Mann-Whitney JJ test. 
However, although CD8+ T cells from the CVID patients also produced more IFNy in 
response to the pp65 antigen than the healthy donors this was not statistically significant 
(P=0.0714) when compared using the Mann-Whitney U test. Although no difference was 
detected with the number of VLE specific tetramer positive T cells between the CVID 
patients and healthy individuals (P=0.890, figure 5.4, panel D), there was a difference in IFNy 
production. Because only one IE1 tetramer was available for this study it is possible that other 
IE1 specific T cells were present that were specific for other peptides contained within the 
IE1 antigen. Overall these results indicate that the CVID patients do have a high level of 
responsiveness to the CMV antigens indicating that viral reactivation does occur in these 
patients, however, in some cases their immune response fails to prevent CMV disease.
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Figure 5.6 Comparison of IE1 and pp65 specific T cell responses between healthy 
individuals and CVID patients
Comparison of the frequency of IE1 specific ( a ) and pp65 specific (■ ) T cells in a cohort 
of healthy CVM seropositive individuals and CVID patients. The amount of IFNy 
produced in response to peptide stimulation with the IE1 or pp65 PepMixes was 
determined as a percentage gating on the CD3+CD8+ T cells. Bars indicate the median 
values obtained. There difference was a significant difference between the responses to 
IE1 when tested using the Mann-Whitney U test (Z^O.099), but there was no difference 
in the response to pp65.
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5.3 Phenotypic analysis of CD8+ T cells
To further characterise tetramer positive T cells, phenotypic analysis was performed using 
fluorescently conjugated antibodies against cell surface molecules. PBMCs were isolated 
from healthy individuals, CVID and HSCT patients. Tetramer staining was first performed 
followed by cell surface phenotyping, all samples were analysed by flow cytometry and the 
phenotype of T cells was expressed as a percentage of the CD8+ tetramer+ population.
5.3.1 Cell surface phenotyping of CMV specific CD8+ T cells
Traditionally the phenotyping of T cells was determined by the relative expression of two 
isoforms of the cell surface molecule CD45 (Akbar et al. 1988; Michie et al. 1992). The 
expression of CD45RA has been associated with naive T cells that have had no previous 
encounters with antigen. Memory T cells were defined by the expression of CD45RO and 
absence of CD45RA. However, the phenotyping of T cells has been complicated by the 
discovery of a population of CD45RA+ T cells that have characteristics of primed T cells 
(Hamann et al. 1997; Kern et al. 1999a; Wills et al. 1999). These CD45RA+ primed cells 
have been shown to have cytotoxic properties and are able to produce IFNy and TNFa; 
however, these cells proliferate poorly in response to antigen stimulation. The CD45RA 
primed T cells have been associated with chronic antigenic stimulation such as occurs in 
multiple myeloma (Sze et al. 2001), HIV and CMV (Wang et al. 1995) infections. Defining T 
cell subsets according to the expression of CD45RA/CD45RO is unreliable and recently 
defining T cell subsets has relied on the expression of the cell surface molecules CD27, 
CD28, CD45RA and CD57 (Brenchley et al. 2003; Hamann et al. 1999). In this section the 
phenotype of tetramer positive T cells was determined by the expression of CD27, CD28, 
CD45RA, CD45RO, CCR7 and CD62L. Phenotyping was performed on PBMCs from 
healthy individuals and HSCT patients when enough cells were available.
The phenotyping of tetramer positive T cells was performed in 3 healthy CMV seropositive 
donors and 3 HSCT patients, unfortunately, insufficient cells were obtained from the CVID 
patients due in part to the infrequent outpatient appointments these patients have and the 
relatively large number of cells required to measure the functional IFNy responses to CMV 
antigens. Following tetramer and cell surface staining all samples were acquired by flow 
cytometry, an initial live lymphocyte gate was set up on CD8+ tetramer+ T cells, from the 
tetramer gate the percentage of T cells expressing the different cell surface molecules was 
determined (Table 5.2). A representative flow cytometry plot is shown in figure 5.7 on 
PBMCs from one healthy individual, a CVID patient and a HSCT recipient. The flow 
cytometry plots (Figure 5.7) show that in some individuals there is no discrete population of
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Figure 5.7 Phenotypic characteristics of CMV specific tetramer positive T cells
Panels are representative of CMV specific tetramer staining and the phenotyping of the tetramer positive population. Panel A shows the tetramer 
staining and subsequent phenotyping of CD8+ T cells from a healthy individual, panel B shows the tetramer staining and subsequent phenotyping of 
CD8+ T cells from a CVID patient and panel C shows the tetramer and phenotyping of CD8+ T cells from a HSCT recipient. The CD8+ T cells were 
first gated and the relative expression of each cell surface marker from tetramer positive population was determined.
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positive T cells such as is the case with the tetramer staining illustrated in figure 5.4. When 
phenotyping tetramer positive T cells different cell surface markers are expressed at different 
levels resulting in a lack of discrete populations, it was therefore important that the quadrant 
gates were kept in the same place for each flow cytometry plot.
Donor Tetramer CD27 CD28 CD45RO CD45RA CD57 CCR7 CD62L
Healthy Individuals
1 B7/TPR - +/- - ++ + - -
2 B7/TPR ++ - - +++ + - +/-
3 B7/TPR ++ + + +++ + + +
HSCT patients
4 Al/YSE ++ + ++ + ++ +/- +
5 A2/NLV +/- + +++ - +++ +/- +/-
6 A2/NLV + - ++ - ++ - +
Table 5.2 Summary of phenotyping tetramer positive T cells
This table summarises the phenotype of HLA tetramer positive CD8+ T cells from 3 healthy 
CMV seropositive individuals and 3 CMV seropositive HSCT patients. PBMCs were stained 
with a HLA/peptide tetramer; subsequent staining was performed for CD8 and for the other 
cell surface markers listed. The percentage of tetramer positive T cells was determined from a 
CD8 gate. The percentage of T cells expressing the different markers was determined from the 
CD8+tetramer+ gate. Percentage positive greater than 75% +++, between 40-75% ++, 
between 20-40% +, between 10-20% +/- and below 10%-.
From the data shown in Table 5.2 the following can be see. In the HSCT recipients CD45RO 
is expressed at high levels on the tetramer positive T cells indicating that these are effector 
memory cells which is also confirmed by the down regulation of CD45RA, CCR7, CD27 and 
relatively low expression of CD28. These effector memory T cells are antigen reactive 
precursor cells (Merkenschlager and Beverley 1989) that are able to secrete IL-2, IFNy and 
TNFa in response to antigenic stimulation (de Jong et al. 1991). The presence of such a large 
number of effector memory T cells would indicate that these cells have recently encountered 
antigen. In the healthy individuals the expression of CD45RO was relatively low with less 
than 20% tetramer positive CD8 T cells expressing this molecule. In contrast in the healthy 
individuals the majority of the tetramer positive T cells expressed CD45RA, more than 75% 
tetramer positive T cells expressed this molecule. The expression of CD45RA on antigen 
experienced T cells indicate that these cells are antigen experienced and have reverted from
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being CD45RO+ CD45RA- to CD45RO- CD45RA+. These CD8+CD45RA+ T cells are 
antigen experienced T cells based on their tetramer staining but also they exhibit reduced 
expression of CD27 which can result from constant antigen stimulation (Baars et al. 1995; De 
Jong et al. 1992; Hintzen et al. 1993). These CD8+CD45RA+CD27- can exert potent 
cytotoxic activity upon encounter with antigen, they are reported (Hamann et al. 1997) to 
produce IFNy and TNFa, contain perforin and granzyme B, Fas ligand mRNA is also 
abundantly expressed. The CD45RA+CD27- CD8+ T cells also have reduced expression of 
CD28, this co-stimulatory molecule enables the efficient interaction with APCs. All three 
healthy donors have tetramer positive CD45RA+CD27- CD8+ T cells and maybe a product of 
persistent antigen stimulation. The HSCT patients have few tetramer positive 
CD45RA+CD27- CD8+ T cells, these patients have not experienced prolonged antigen 
stimulation although recent CMV reactivations have resulted in the generation of effector 
memory cells characterised by CD45RO expression.
It can also be shown (Table 5.2) that the tetramer positive T cells detected in the healthy 
individuals and HSCT have a typical memory phenotype. The CD62L and CCR7 molecules 
allow for the efficient homing of T cells to the secondary lymphoid where they encounter 
antigens. Upon antigen encounter the expression of CD62L and CCR7 is down regulated as 
the cells become memory T cells. The tetramer positive cells detected in the healthy 
individuals and HSCT all have low CD62L, CCR7 expression and a high level of CD57. The 
function of the CD57 molecules is currently unknown, although it has been shown that the 
expression of CD57 is the result of chronic stimulation of T cells. The number of CD57+ T 
cells increases in those infected with cytomegalovirus or HIV (Evans et al. 1999; Wang and 
Borysiewicz 1995) and this proportion increases with age (Tarazona et al. 2000). These 
CD57+ T cells are capable of cytokine secretion upon stimulation with CMV but fail to 
proliferate, the lack of CD28 expression on these cells is thought to be responsible for the 
inability of these cells to proliferate (Lloyd et al. 1997). It has also been reported that T cells 
lacking CD28 expression and CD45RA+CCR7- have a strong proliferative response to 
peptide pulsed APC's (Wills et al. 2002). From table 5.2 it can be seen that the tetramer 
positive T cells detected in the HSCT and healthy individuals highly express CD57. By 
phenotyping the CD8+ T cells populations of both CMV seropositive and CMV seronegative 
individuals distinct differences can be seen with regard to the expression of CD57 (Table 5.3).
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CD27 CD28 CD45RO CD45RA CD57 CD62L
CMV seronegative
Healthy donor 1 +++ - - ++ - ++
Healthy donor 2 +++ + - ++ +/- ++
CMV seropositive
Healthy donor 3 ++ ++ - +++ + ++
Healthy donor 4 ++ ++ - ++ + ++
CMV seropositive
HSCT recipient 5 + +/- + ++ ++ -
HSCT recipient 6 + +/- + ++ +++ -
CVID patient 7 - +/- ++ + ++ ND
CVID patient 8 ++ + ++ + ++ +
Table 53 Summary of phenotyping CD8+ T cell populations in CMV seropositive 
and seronegative individuals
This table summarises the phenotype of CD8 T cells from 2 CMV seropositive healthy 
individuals, 2 CMV seronegative healthy individuals, 2 HSCT patients and 2 CVID 
patients. The CVID patients do not produce any immunoglobulin and the CMV serostatus 
could not be established. PBMCs were stained with fluorescently tagged antibodies 
directed against the various cell surface markers and acquired by flow cytometry. 
Staining for CD62L could not be performed (ND) in one CVID patient due to the number 
of cells obtained. Percentage positive greater than 75% +++, between 40-75% ++, 
between 20-40% +, between 10-20% +/- and below 10%-.
53.2 Cell surface phenotyping of CD8+ T cells in CMV seronegative and seropositive 
individuals
CMV seronegative individuals have reduced expression of CD57 on the cell surface 
compared with CMV seropositive individuals (Table 5.3). This increased expression of CD57 
indicates that the chronic stimulation of T cells by CMV antigens has resulted in a marked 
change in the expression of CD57 when compared with the CMV seronegative individuals. 
High levels of CD57 can also be found on CD8+ T cells from the HSCT and CVID patients, 
although this could also be as a result of other forms of persistent antigen stimulation, such as 
other viruses or GVHD. The CMV serostatus of the CVID patients could not be established 
due to the absence of antibody production in these patients, although they do receive 
intravenous infusions of immunoglobulin that would include antibodies specific for CMV.
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From the data presented in table 5.3 the following observations can be made. The phenotype 
of the CD8 T cell repertoire in both healthy CMV seropositive and seronegative individuals 
differs from the phenotypes observed in the CVID and HSCT patients. The healthy 
individuals have a higher level of CD27 and CD62L expression on their CD8+ T cells 
compared with the CVID and HSCT patients. In contrast the percentage of CD8+ T cells 
expressing CD57 was lower in the two healthy individual groups when compared with the 
two patient groups, more than 40% CD8+ T cells in the patients expressed CD57 while less 
than 40% of CD8+ T cells expressed CD57 in the healthy individuals. There was also a 
marked difference in the expression of CD45RA between the patients and healthy individuals, 
the healthy individuals had a lower percentage of CD8+ T cells expressing CD45RO 
compared with the CVID and HSCT patients. CD45RO is expressed on effector memory cells 
and would therefore reflect the recent generation of effector memory T cells in response to 
antigenic stimulation. The CVID and HSCT patients would tend to experience more 
infections than the healthy individuals and this could result in more CD45RO+ T cells being 
generated. The expression of CD45RA and CD28 varied between the three groups, CD8+ T 
cells from the CVID patients expressed less CD45RA compared with the other groups and the 
healthy CMV seropositive had a higher percentage of CD8+ T cells expressing CD28.
The phenotype of the CD8+ T cells from healthy individuals did show differences depending 
on the CMV serostatus. The CMV seronegative healthy individuals had a much higher level 
of CD27 expression when compared to the healthy CMV seropositive individuals. But the 
CMV seropositive individuals had a higher level of CD28 and CD57 expression than the 
CMV seronegative individuals. Overall the CD8+ T cell repertoire from healthy individuals 
does differ from the CVID and HSCT patients. The CD8+ T cells from the patients have more 
characteristics associated with recent antigen exposure such as CD45RO+ and CD62L-. The 
healthy CMV seropositive individuals have CD8+ T cells that express more CD57 than the 
CMV seronegative individuals and this could be associated with chronic antigen exposure. 
Both the CMV seropositive and CMV seronegative individuals had a high percentage of 
CD8+ T cells that express CD62L indicating that these T cells can still home into the 
lymphoid tissue. This data also shows that there is a degree of heterogeneity with respect to 
the expression of the different cell surface markers and as the phenotyping of T cells becomes 
more complex with the inclusion of CD45RA antigen experienced T cells more markers are 
required to assign a particular phenotype.
222
Chapter 5
5.4 Generation of CMV specific T cell lines
The relative dominance of HLA-B*0702/TPR peptide over the HLA-A*0201/NLV peptide 
was demonstrated in section 5.2.3. The NLV peptide has been described in the literature as 
the dominant HLA-A*0201 CMV peptide that all HLA-A*0201 positive individuals respond 
to (Diamond et al. 1997; Kem et al. 1999b). However, from the data presented in figure 5.3 
this no longer seems to be the case. In those healthy individuals that are HLA- 
A*0201/B*0702 the CMV peptide TPR is presented in association with the HLA-B*0702 
molecule, very few or no T cells specific for the HLA-A*0201/NLV peptide can be detected 
in the peripheral circulation of these individuals. These findings indicate that there is a HLA 
hierarchy associated with the presentation of CMV peptides, in the context of HLA- 
A*0201/B*0702 the HLA-B*0702 TPR peptide is the dominant peptide presented. At the 
time of these finding there had been no report of this phenomenon in the literature but shortly 
after another group reported the same finding (Lacey et al. 2003) using different techniques. 
We therefore went on to investigate this phenomenon in more detail and to determine if these 
HLA-A*0201/B*0702 individuals have any T cells specific for the HLA-A*0201/NLV 
peptide and if these can be expanded ex vivo.
To generate CMV specific T cell lines a number of different peptides were used these are 
listed in table 5.4. The HLA-A*0201 NLV and HLA-B*0702 TPR peptides were used along 
with a no peptide control. The SP1 and SP6 peptides were also used, these peptides were 
obtained from Genzyme (USA) and although these peptides are not commercially available 
yet they were obtained in order to test their ability to generate an NLV specific peptide 
response. The SP1 and SP6 peptides are SPHERE (solid-phase epitope recovery) peptides are 
reported by the company to have a higher affinity for the T cell receptor (TCR) than the 
traditional NLV peptide. The SPHERE method identifies highly reactive altered peptide 
ligands from a large library and allows for the selection of peptides of a desirable 
immunogenic nature. The HLA restriction of each peptide was first confirmed using an MHC 
stabilisation assay (Chapter 2, section 2.4.1) using both T2 cells and T2 cells that have been 
transfected with HLA-B*0702 (T2B7), the results for each peptide is shown in Figure 5.8. 
The binding of the HLA-A *0201 restricted peptides was shown to bind only in the context of 
HLA-A*0201 (Figure 5.8, panel A), while the TPR peptide only binds to the HLA-B*0702 
molecules (Figure 5.8, panel B). The SP1 and SP6 peptides are also shown to bind to the 
HLA-A*0201 molecules on the surface of T2 cells (Figure 5.8, panel A) but not to HLA- 
B*0702 (Figure 5.8, panel B). From figure 5.8 it can be concluded that each peptide is HLA 
specific and no cross reactivity occurs.
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Figure 5.8 HLA-A*0201 and HLA-B*0702 MHC stabilisation assay 
The HLA-A*0201 and HLA-B*0702 cell surface expression on T2 cells was assessed 
after an overnight incubation with 50pg/ml of different antigenic peptides (described in 
chapter 2, section 2.4.1). The HLA-A*0201 expression was measured using the BB7.2 
antibody (panel A) and the HLA-B*0702 expression was measured using the ME1 
antibody (panel B). A negative control (No peptide) was included. The increase in MHC
expression was determined for each peptide (----- ), the increase in fluorescence was
determined by overlaying the no peptide plot ( ----- ) with the test peptide plot.
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Peptide sequence Peptide Abbreviation HLA Restriction
NLVPMVATV NLV HLA-A*0201
TPRVTGGGAM TPR HLA-B*0702
FLLPMIATV SP1 HLA-A*0201
FLDFSFWFV SP6 HLA-A*0201
Table 5.4 Peptides used to generate CMV specific T cell lines
This table summaries the four peptides that were used to generate CMV specific T cell
lines from HLA-A*0201/B*0702 individuals.
5.4.1 The use of T2 cells as Antigen presenting cells
Mature dendritic cells are the most potent stimulators of naive T cells and are very efficient at 
presenting antigens in the form of peptides on their cell surface. Mature dendritic cells have a 
high level of co-stimulatory molecules on their cell surface enabling the efficient presentation 
of antigenic peptides to T cells. To determine if HLA-A*0201/B*0702 individuals have any 
circulating T cells specific for the NLV peptide we initially used T2 cells as antigen 
presenting cells, dendritic cells would have been a better choice of APCs but due to the 
number of different peptides used insufficient dendritic cells could be generated. T2 cells 
unlike dendritic cells do not have high levels of co-stimulatory molecules on their cell surface 
and are therefore not able to stimulate naive T cells. However, as T cell lines were generated 
from CMV seropositive individuals only an antigen recall response was required and the 
unlimited supply of T2 cells made them a suitable choice for the generation of CMV specific 
T cells.
The method used to generate CMV specific T cells is described in detail in chapter 2 (section 
2.4.3) Briefly, T2 cells were pulsed overnight with 50pg peptide the following day the cells 
were washed and irradiated to prevent any cell proliferation once in culture. T2 cells 
constitutively express HLA-A*0201 on their cell surface and are negative for MHC class n. 
For the generation of TPR specific T cells T2 cells were used that expressed the HLA- 
B*0702 molecule, following transfection the expression of HLA-B*0702 was confirmed 
through the use of a HLA-B*0702 specific antibody (ME1). The PBMCs were prepared and 
mixed with the peptide pulsed T2 cells at a ratio of 5:1 (Effector:T2 cells). A negative control 
was set up which consisted of T2 cells with no peptide; this was used to assess the non­
specific expansion of T cells in response to T2 cells alone. The binding of the peptide to 
MHC molecules on the surface of the T2 cells was confirmed by performing an MHC 
stabilisation assay (Figure 5.8), this was performed for each stimulation for the duration of the
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experiment. To monitor the expansion of CMV specific T cells, tetramer staining was 
performed on days 0, 7 and 14 using the HLA-A*0201/NLV and HLA-B*0702/TPR 
tetramers. For the SP1 and SP6 peptides tetramers could not be made due to the limited 
amount of these peptides available from the company (Genzyme, USA). However, data 
reported by Genzyme indicates that the SP1 and SP6 peptides are recognised by CTLs 
specific for the NLV peptide and therefore should be detected using the HLA-A*0201/NLV 
tetramer. The amino acid sequence of each peptide used is listed in table 5.5 along with the 
properties of each amino acid. The sequence of the SP1 and SP6 peptides (Table 5.5) is very 
different from the NLV peptide but both peptides contain a leucine residue at anchor position 
2 and a valine residue at anchor position 9 as would be expected for HLA-A*0201 binding 
peptides.
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Peptide
HLA
restriction
Amino acid Position Amino acid 
property
NLVPMVATV A*0201 Asparagine 1 Hydrophilic
Leucine 2 Hydrophobic
Valine 3 Hydrophobic
Proline 4 Hydrophobic
Methionine 5 Hydrophobic
Valine 6 Hydrophobic
Alanine 7 Hydrophobic
Threonine 8 Hydrophilic
Valine 9 Hydrophobic
TERVTGGGAM B*0702 Threonine 1 Hydrophilic
Proline 2 Hydrophobic
Arginine 3 Hydrophilic
Valine 4 Hydrophobic
Threonine 5 Hydrophilic
Glycine 6 Hydrophobic
Glycine 7 Hydrophobic
Glycine 8 Hydrophobic
Alanine 9 Hydrophobic
Methionine 10 Hydrophobic
FLLPMIATV A*0201 Phenylalanine 1 Hydrophobic
Leucine 2 Hydrophobic
Leucine 3 Hydrophobic
Proline 4 Hydrophobic
Methionine 5 Hydrophobic
Isoleucine 6 Hydrophobic
Alanine 7 Hydrophobic
Threonine 8 Hydrophilic
Valine 9 Hydrophobic
FLDFSFWFV A*0201 Phenylalanine 1 Hydrophobic
Leucine 2 Hydrophobic
Apartate 3 Hydrophilic
Phenylalanine 4 Hydrophobic
Serine 5 Hydrophilic
Phenylalanine 6 Hydrophobic
Tryptophan 7 Hydrophobic
Phenylalanine 8 Hydrophobic
Valine 9 Hydrophobic
Table 5.5 Amino add sequence of the CMV peptides used
This table lists the amino acid sequence of the CMV peptides used in the generation of 
peptide specific T cells. The anchoring residue for the corresponding HLA is underlined 
and highlighted in red. The position and properties of each amino acid is also shown.
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5.4.2 Generation of HLA-A*0201/NLV specific T cells
The generation of CMV specific T cells was initially conducted using PBMCs from donor 29 
who is a healthy individual and whose HLA phenotype is HLA-A*0201, A*2901 B*0702, 
B*2703. The number of tetramer positive T cells was determined on days 0, 7 and 14, 
PBMCs were stimulated with peptide pulsed T2 cells on days 0 and 7. For the generation of 
an NLV specific T cell line, tetramer staining performed on day 0 revealed that only 0.02% 
CD8+ T cells were specific for the NLV peptide (Figure 5.9, top panel). T2 cells were pulsed 
with the NLV, SP1 and SP6 peptides, these cells were then irradiated and mixed at a 5:1 ratio 
(PBMCs:T2 cells) with the PBMCs. On day 7 tetramer staining was performed using the 
HLA-A*0201/NLV tetramer, the number of tetramer positive NLV specific T cells expanded 
with the NLV peptide had doubled to 0.17%, but the number of tetramer positive T cells was 
greatest following stimulation with the SP6 peptide where 0.74% CD8+ T cells were specific 
for the NLV peptide; the number of tetramer positive T cells expanded with the SP1 peptide 
was 0.27% (Figure 5.9, middle row). Following the second stimulation, tetramer staining was 
performed on day 14 using the HLA-A*0201/NLV tetramer. On day 14 the number of 
tetramer positive NLV specific T cells expanded using the NLV peptide had remained 
constant (0.16% CD8+Tetramer+) and the number of NLV tetramer positive T cells in the no 
peptide control culture was 0.04% CD8+ tetramer+ indicating that NLV specific T cells had 
been expanded in the NLV peptide stimulated culture (Figure 5.9, bottom row). The number 
of tetramer positive NLV specific T cells was highest in the culture generated with the SP1 
peptide where 3.05% CD8 T cells were specific for the NLV peptide; however, the number of 
tetramer positive T cells in the culture generated with the SP6 peptide had dropped to 0.04% 
(Figure 5.9, bottom row). These results show that in donor 29 NLV specific T cells do exist 
but they are not readily expanded using the NLV peptide but can be expanded with the 
SPHERE peptides SP1 and SP6.
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HLA-A*0201/NLV tetramer HLA-B*0702 tetramer
No peptide NLV SP1 SP6
Day 7
Day 14
HLA-A*0201/NLV tetramer
Figure 5.9 Generation of NLV peptide specific T cells using peptide pulsed T2 cells
NLV specific T cells were generated from a healthy HLA-A*0201/B*0702 CMV 
seropositive individual using peptide pulsed T2 cells. SPHERE peptides (SP1 and SP6) 
were also used and are reported to bind to the T cell receptor with a greater affinity than 
the NLV peptide. PBMCs were stimulated with the peptide pulsed T2 cells every 7 days 
as described in chapter 2. The expansion of the specific CD8+ T cells was determined by 
HLA/peptide tetramer staining each culture at day 0 (Top row), 7 (middle row) and 14 
(bottom row). The number of peptide specific T cells was expressed as a percentage of 
the CD3+CD8+ T cells.
5.4.3 Generation of HLA-B*0702/TPR specific T cells
To confirm that tetramer positive TPR specific  T ce lls could be expanded in donor 29 the 
same protocol as previously described was used but with T2 cells expressing H L A -B *0702  
(T2B7) to present the TPR peptide. Tetramer staining performed at day 0 revealed that 1.67% 
C D8+ T cells were specific  for the TPR peptide (Figure 5.10, top panel). On day 7 tetramer 
staining was performed using the H LA -B*0702/TPR  tetramer. Following the first stimulation  
the number o f  tetramer positive TPR specific T cells expanded by day 7 with the TPR peptide 
had trebled to 5.12%  w hile the no peptide control had decreased to 0.77%  (Figure 5 .10 , 
m iddle row). F ollow ing a second stim ulation, tetramer staining was performed on day 14 
using the H L A -B *0702/T PR  tetramer, the number o f tetramer positive TPR specific T ce lls  
expanded using the TPR peptide had increased to 12.0% w hile the no peptide control
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decreased to 0.28%  (Figure 5 .10 , bottom  row). The number o f H LA -B*0702/TPR  tetramer 
positive T ce lls  expanded using the TPR peptide was higher than the number o f  HLA- 
A *0201/N L V  tetramer positive T cells expanded using the N LV , SP1 or SP6 peptides. These 
results indicate that the traditional N L V  peptide is unable to expand N LV  specific T cells  
using the T2 cells to present the peptides, but H L A -A *0201/N L V  tetramer positive T cells  
can be expanded using the SPHERE peptides. The number o f  H LA -B*0702/TPR  tetramer 
positive T ce lls can be rapidly expanded using this system  indicating that these cells are 
preferential expanded in vivo  in response to antigen stimulation.
Day 0
No peptide TPR
Day 7
Day 14
HLA-B*0702/TPR tetramer
Figure 5.10 Generation of TPR peptide specific T cells using peptide pulsed T2B7 
cells
TPR specific T cells were generated from a healthy HLA-A*0201/B*0702 CMV 
seropositive individual using peptide pulsed T2B7 cells. PBMCs were stimulated with the 
peptide pulsed T2B7 cells every 7 days as described in chapter 2. The expansion of the 
specific CD8+ T cells was determined by HLA/peptide tetramer staining each culture at 
day 0 (Top row), 7 (middle row) and 14 (bottom row). The number of peptide specific T 
cells was expressed as a percentage of the CD3+CD8+ T cells.
Follow ing the generation o f  these C M V  specific T cell lines it was not possib le to perform  
any additional assays to determ ine the phenotype or the functionality o f  these cells m ainly 
due to the sm all number o f  ce lls  obtained. H ow ever, tetramer staining was perform ed to 
confirm the peptide specificity  o f  each culture. The cultures that had been generated with the 
H L A -A *0201 N L V , SP1 or SP 6 peptides were stained individually  w ith  the H L A -
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B*0702/TPR  tetramer, likew ise the TPR generated culture was also stained using the HLA- 
A *0201/N L V  tetramer. Interestingly, the cultures generated using the H LA-A*0201 restricted 
N LV , SP1 and SP6 peptides had generated discrete H L A -B *0702/T PR  tetramer positive  
populations (Figure 5 .11 , m iddle row). The culture generated using the NLV peptide only had 
0.16%  C D 8+ T ce lls  (Figure 5 .1 1 , bottom  row ) detected using the H L A -A *0201/N L V  
tetramer at day 14, but 8.43%  C D 8+ T cells  in this culture were detected using the HLA- 
B*0702/TPR tetramer (Figure 5.11, middle row). The same can also be seen with the SP1 and
0 .02%
No peptide NLV SP1
0.16% 8.43%
Day 0
SP6
0 .88% 4.07%
Day 14
No peptide
HLA-B*0702/TPR tetramer 
NLV SP1
0.16%
SP6
3.05% 0.04%
Day 14
HLA-A*0201/NLV tetramer
Figure 5.11 Tetram er staining o f NLV peptide specific T cells using HLA- 
A*0201/NLV and HLA-B*07027TPR tetramers
NLV specific T cells were generated from a healthy HLA-A*0201/B*0702 CMV 
seropositive individual using peptide pulsed T2 cells. SPHERE peptides (SP1 and SP6) 
were also used and are reported to bind to the T cell receptor with a greater affinity than 
the NLV peptide. PBMCs were stimulated with the peptide pulsed T2 cells every 7 days 
as described in chapter 2. The expansion of the specific CD8+ T cells was determined by 
HLA/peptide tetramer staining each culture at day 0 and 14. Both the HLA-B*0702/TPR 
(middle row) and HLA-A*0201/NLV (bottom row) tetramers were used to determine if 
only the NLV specific T cells were expanded with the NLV peptide. The number of 
peptide specific T cells was expressed as a percentage of the CD3+CD8+ T cells.
SP6 peptides but to a lesser degree, the culture generated with the SP1 peptide had only  
0.88%  C D 8+ T c e lls  (F igure 5 .1 1 , m iddle row ) detected using the H L A -B *0702/T P R  
tetramer, conversely 3.05%  o f  C D 8+ T cells were specific for the NLV peptide (Figure 5.11, 
bottom row) indicating that the large expansion o f the N LV  specific T ce lls  lim ited the 
expansion o f  the TPR specific  T ce lls. Unfortunately, staining using the H L A -B *0702/T P R
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tetramer was only perform ed on the cultures on day 14 due to the small number o f cells  
present on day 7. The only source o f  H L A -B *0702 presentation o f  the TPR peptide would  
have been the PBM Cs them selves, but you w ould have expected to see an expansion o f T 
cells in the negative controls (no peptide cultures). Tetramer staining was also performed on 
the culture generated with the TPR peptide using the H L A -A *0201/N LV  specific tetramer 
(Figure 5 .12). The number o f  H L A -A *0201/N L V  tetramer positive T cells in the culture 
generated with the TPR peptide was low  with only 0.27%  CD8 T cells specific for the NLV  
peptide (Figure 5.12, bottom row).
No peptide TPR
Day 14
HLA-B*0702/TPR tetramer 
No peptide TPR
Day 14
 ►
HLA-A*0201/NLV tetramer
Figure 5.12 Tetram er staining o f TPR peptide specific T cells using HLA- 
A*0201/NLV and HLA-B*0702/TPR tetramers
TPR specific T cells were generated from a healthy HLA-A*0201/B*0702 CMV 
seropositive individual using peptide pulsed T2B7 cells. PBMCs were stimulated with the 
peptide pulsed T2B7 cells every 7 days as described in chapter 2. The expansion of the 
specific CD8+ T cells was determined by HLA/peptide tetramer staining each culture at 
day 0 and 14. Both the HLA-B*0702/TPR (middle row) and HLA-A*0201/NLV (bottom 
row) tetramers were used to determine if only the TPR specific T cells were expanded 
with the TPR peptide. The number o f peptide specific T cells was expressed as a 
percentage of the CD3+CD8+ T cells.
These results reveal that C D 8+  T cells  specific  for the TPR peptide can be expanded in 
culture but m ost interestingly these TPR specific T cells can also be expanded using the NLV  
peptide. The C D 8+  T ce lls  specific  for the N L V  peptide can be expanded but only by using  
the SPHERE peptides, the small number o f  NLV  specific T cells present and the high number 
o f TPR specific T ce lls  could result in the expansion o f the TPR specific T cells in preference
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to the NLV specific T cells. These CM V specific T cell lines were generated in donor 29 and 
although these experim ents were repeated it had to be established that this phenomenon was 
not unique to this donor. W e therefore recruited three additional H L A -A *0201/B *0702  
healthy individuals, tw o were CM V seropositive and one was CM V seronegative and these 
experiments were repeated. Donor 29 was also included to demonstrate that these results were 
reproducible. An irrelevant H L A -A *0201 peptide w as also used to determine whether it was 
possible to expand these TPR specific T cells using an H LA -A *0201 peptide or whether it is 
only the N LV  and SPHERE peptides that can expand these cells. W e therefore used the HLA- 
A*0201 peptide SLLPAIVEL (SLL) that is a known self-peptide and has been described as 
binding in the context o f  H L A -A *0201. The binding o f  this SLL peptide to H LA-A*0201  
was confirmed using a T2 binding assay (Figure 5.13).
c
3Oo
TrrTTT
Anti HLA-B*0702 (ME1) FITC
Figure 5.13 HLA-A*0201 MHC stabilisation assay for the SLL peptide
The HLA-A*0201 cell surface expression on T2 cells was assessed after an overnight 
incubation with 50pg/ml o f the SLL peptide (described in chapter 2, section 2.4.1). The 
HLA-A*0201 expression was measured using the BB7.2 antibody (panel A). A negative 
control (No peptide) was included. The increase in MHC expression was determined for
the SLL peptide (------ ), the increase in fluorescence was determined by overlaying the no
peptide plot (----- ) with the test peptide plot.
5.4.4 Generation of NLV specific T cells in CMV seropositive and seronegative
individuals
The generation o f  C M V  sp ec ific  T ce lls  w as conducted in three H L A -A *0201/B *0702  
healthy individuals using the peptides listed in table 5.3 and in addition the SLL peptide was 
included. The protocol used is explained above and described in more detail in chapter 2 
(section 2.4.3). Tetramer staining was performed on days 0, 7 and 14 using both the TPR and
NLV tetramers, the results obtained are show n in figure 5.14 and figure 5 .15 . Tetramer
staining was performed using the H L A -A *0201/N L V  tetramer on day 7 revealed that the SP6
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Figure 5.14 Generation of NLV peptide CMV specific T cells from healthy individuals 
using T2 cells
PBMCs derived from four HLA-A*0201/B*0702 healthy individuals (x axis) were 
stimulated with peptide pulsed T2 cells every 7 days. Three healthy individuals are CMV 
seropositive (29, 25, 27) and one CMV seronegative (34). T2 cells (Expressing HLA- 
A*0201) were pulsed with the NLV ( ■ ) ,  SP1 ( ■ ), SP6 ( ■ ) and SLL ( ■ ) peptides and 
a negative no peptide control was included ( ■ ). PBMCs and peptide pulsed T2 cells 
were incubated at a 5:1 ratio, IL-2 and IL-7 cytokines were added after the second 
stimulation (day 7). Tetramer staining was performed on day 0 ( ), day 7 (Panel A) and
day 14 (Panel B) using the HLA-A*0201/NLV tetramer. Peptide specific T cells are 
expressed as a percentage of the CD3+CD8+ T cells.
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Figure 5.15 Generation of TPR peptide CMV specific T cells from healthy 
individuals using T2B7 cells
PBMCs derived from four HLA-A*0201/B*0702 healthy individuals (x axis) were 
stimulated with peptide pulsed T2B7 cells every 7 days. Three healthy individuals are 
CMV seropositive (29, 25, 27) and one CMV seronegative (34). T2B7 (Expressing HLA- 
A*0201 and HLA-B*0702) cells were pulsed with the NLV ( ■ ), SP1 ( ■ ), SP6 ( ■ ) and 
SLL ( ■ peptides and a negative no peptide control was included ( ■ ). PBMCs and 
peptide pulsed T2 cells were incubated at a 5:1 ratio, IL-2 and IL-7 cytokines were added 
after the second stimulation (day 7). Tetramer staining was performed on day 0 ( ) and
14 using the HLA-B*0702/TPR tetramer. Peptide specific T cells are expressed as a 
percentage of the CD3+CD8+ T cells.
peptide generated the highest number o f  H L A -A *0201/N L V  tetramer positive T cells (Figure 
5.14, panel A ) in all three CM V seropositive individuals. This result is in agreement with the 
previous experim ent performed on PBM Cs from donor 29 where the SP6 peptide generated 
0.74%  H L A -A *0201/N L V  tetramer positive T cells. The cultures generated using the SLL  
peptide contained less that 0.5%  C D 8+ T cells specific for the NLV peptide (Figure 5.14). In 
the culture set up using PBM Cs from a CM V seronegative donor less than 0.5% CD8+ T cells  
were specific for the N L V  peptide, indicating that the cells generated in the positive cultures 
are C M V sp ec ific . T h ese  resu lts reveal that in the three CM V seropositive H LA - 
A *0201/B *0702 individuals the cultures generated using the SP6 did contain C D 8+ T cells  
specific for the H L A -A *0201 N L V  peptide.
Follow ing a second stimulation tetramer staining was performed on all the cultures on day 14, 
both the H L A -A *0201/N L V  and H L A -B *0702/T PR  tetramers were used to determ ine the 
number o f  TPR or N L V  sp ecific  T ce lls  contained within the cultures generated with the
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NLV, SP1, SP6 or SLL peptides. The results shown in Figure 5.14 (panel B) demonstrate that 
the highest percentage of NLV specific T cells were contained within the cultures generated 
with the NLV peptide, this is in contrast to the results obtained on day 7 when the SP6 
peptide generated the highest number of NLV specific T cells. When tetramer staining was 
perfonned using the HLA-B*0702/TPR tetramer on the cultures generated with the NLV, 
SP1 or SP6 peptide from the CMV seropositive individuals, they were found to contain CD8+ 
T cells specific for the TPR peptide (Figure 5.15). The highest number of TPR specific T cells 
were contained within the cultures generated using the NLV peptide in donors 29 and 27, but 
in donor 25 the highest number of TPR specific T cells were contained within the culture 
expanded using the SP6 peptide. The number of TPR specific T cells generated from donor 
29 was lower than previously seen (Figure 5.11) this may have been because the cells used in 
this experiment had been cryopreserved resulting in a reduced proliferative capacity. From 
the results shown in figure 5.14 and figure 5.15 it can be shown that the SLL peptide did not 
expand any CMV specific T cells after two stimulations, this implies that the expansion of the 
TPR specific CD8+ T cells using the NLV or SP6 peptide is due to these peptides only and 
cannot be caused by another HLA-A*0201 restricted peptide.
Further experiments would need to be conducted to investigate the expansion of TPR specific 
CD8+ T cells using the NLV peptide. Further work would include the use of dendritic cells 
pulsed with the NLV peptide to rule out a possible effect that the T2 cells have on the 
generation of these cells. But such a cross reactivity of the TPR specific CD8+ T cells could 
explain why in HLA-B*0702 individuals a higher number of tetramer positive T cells can be 
detected compared with the NLV peptide. This would indicate that a peptide vaccine 
containing the NLV peptide would boost the number of TPR specific CD8+ T cells in HLA- 
A*0201/B*0702 individuals.
236
Chapter 5
5.5 Discussion
In this study we investigated the immune response to CMV in healthy individuals, HSCT and 
CVID patients using HLA/peptide tetramers. HLA/peptide tetramers were developed in the 
1990's (Altman et al. 1996) and have become an invaluable tool for the detection of antigen 
specific T cells. In this study four HLA/peptide tetramers were produced that were specific 
for the IE1 and pp65 antigens. The CMV tetramers were shown to be peptide and HLA 
specific. CMV peptide specific T cells were only detected in CMV seropositive individuals 
and were not detected in CMV seronegative individuals or those with an irrelevant HLA 
phenotype.
Three groups of individuals were recruited in this study, the first group were healthy 
individuals that were recruited from the laboratories based at ANRI, RFH and Southampton 
General Hospital. The second group consisted of CVID patients, whose B cells fail to 
differentiate into plasma cells resulting in hypo-immunoglobulinaemia. CVID patients are at 
increased risk of developing life threatening bacterial infections and in addition up to 50% of 
these patients are reported to have defects in their cellular immune responses (Kondratenko et 
al. 1997). The third group consisted of HSCT recipients who were either CMV seropositive 
before transplant or received a graft from a CMV seropositive donor.
The frequency of CMV specific T cells was determined for each group. The frequency of 
CMV specific T cells detected was highest in the HSCT patients compared with the healthy 
individuals and CVID patients. A higher frequency of NLV and TPR specific T cells were 
detected in the HSCT patients when compared with the healthy individuals, this was 
statistically significant (P=<0.05) when compared using the Mann-Whitney U test. The level 
of tetramer positive T cells detected in the HSCT patients was consistently higher than the 
other two groups. Interestingly, only three individuals had T cells specific for the IE1 peptide 
VLE. Among the healthy individuals only one individual had 0.11 % VLE specific tetramer 
positive CD8+ T cells. Only one CVID patient and one HSCT patient had T cells specific for 
the IE1 peptide VLE, in these individuals a high number of VLE specific T cells were 
detected (>4% CD3+CD8+ tetramer positive T cells). A study carried out by Khan et al. 
identified an IE1 epitope (VLEETSVML) presented in association with HLA-A*0201 (Khan 
et al. 2002a), in this study they compared the frequency of T cells specific for the pp65 
NLVPMVATV and the IE1 peptide VLEETSVML (VLE). They concluded that one third of 
HLA-A*0201 CMV positive individuals made responses to the EE 1 peptide and in some cases 
exceeded the responses detected against the pp65 NLVPMVATV peptide. From the data 
presented in this chapter we were unable to confirm these finding, only one HLA-A*0201
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healthy CMV seropositive individual had T cells specific for the IE1 VLE peptide, although 
our cohort consisted of mainly HLA-A2/B7 positive individuals and peptide presentation was 
biased towards HLA-B*0702. Among the HLA-A*0201 positive individuals T cells specific 
for the IE 1 VLE peptide were detected in the peripheral circulation of one HSCT patient and 
one CVID patient. The low frequency of VLE specific T cells detected could be because 
among this cohort of 15 HLA-A*0201 individuals half of diem are HLA-A*0201/B*0702. In 
individuals who are HLA-A*0201/B*0702 the dominant pp65 peptide is presented in the 
context of HLA-B*0702 and not HLA-A*0201, in chapter 4 an IE1 peptide (CRVLCCYVL) 
was identified that binds to HLA-B*0702. Among the HLA-A*0201/B*0702 individuals we 
found CD8+ T cells that produced IFNy in response to the CRVLCCYVL peptide these same 
individuals had very few NLV or VLE specific T cells.
The high level of VLE specific T cells detected in the CVID and HSCT patient could be as a 
result of these patients experiencing CMV reactivations. During the reactivation of CMV the 
ie l genes are expressed before pp65 which is not expressed until the late phase of viral 
replication. It is therefore plausible that in those who reactivate CMV a population of IE1 
specific CTLs would be generated. In healthy individuals the number of IE1 specific CTLs 
would be considerably lower than in HSCT recipients who experience CMV replication post 
transplant. Work performed in mice has shown that factors such as TNFa can induce the 
expression of iel (Cook et al. 1998; Cook et al. 2002; Hummel et al. 2001), if this finding 
could be confirmed in humans it could indicate that in HSCT where there is a release of 
inflammatory cytokines in the circulation that this might subsequently cause the reactivation 
of CMV. Although there is no published data reporting the incidence of CMV reactivations 
among CVID patients it is plausible that these patients are exposed to CMV and the 
intravenous immunoglobulin received prevents the development of CMV disease. There are a 
few reports in the literature of CVID patients developing CMV disease, these patients are at 
increased risk of developing autoimmune disease and are subsequently put on 
immunosuppressive therapy. A reduction in the immune responsiveness to CMV can result 
from steroid therapy leaving the patients at risk of developing CMV disease. Currently CVID 
patients on steroid therapy are not monitored for CMV reactivations and it is only when 
biopsies are taken that CMV inclusion bodies are found and a diagnosis can be made. The 
true incidence of CMV disease among CVID patients may be being underestimated and is 
only diagnosed when biopsies are taken.
Among the CVID patients, tetramer positive T cells could be detected although overall there 
was no statistically significant difference between the frequencies detected when compared 
with the healthy individuals (P=>0.05). Due to the limited availability of MHC class I
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tetramers it was only possible to determine the level of tetramer positive T cells in patients 
with HLA alleles that we had HLA matched tetramers for. In this study we only had CMV 
tetramers for HLA-A*0101, HLA-A*0201 and HLA-B*0702 and therefore patients of other 
phenotypes were excluded. To overcome this problem the functional responses of T cells to 
the IE1 and pp65 PepMixes (that were used in chapter 3) were determined. These PepMixes 
allow for the assessment of T cells responding to the different CMV antigens following an 
overnight incubation and the subsequent measurement of IFNy produced by intracellular 
staining. The results obtained indicate that the frequency of CMV specific T cells responding 
to the IE 1 antigen was higher when compared with the healthy individuals this difference was 
statistically significant (P=0.099) when compared using the Mann-Whitney U test, there was 
no difference seen in the T cell response to pp65 when comparing the CVID patients with the 
healthy individuals. Among HSCT and CVID patients CMV replication probably occurs more 
frequently than in healthy individuals leading to a greater expansion of the IE 1 specific T cell 
populations. We were unable to determine if these IE1 specific T cells are capable of killing, 
as we have no access to a suitable target cell that would express the IE1 antigen, this can be 
achieved by infecting cells with IE1 expressing canarypox virus recombinants. It was 
originally shown that IE 1 specific T cells were very poor at lysing CMV infected autologous 
fibroblasts (Gilbert et al. 1996), and that pp65 inhibited the presentation of IE1 and therefore 
in CMV infected pp65 expressing fibroblasts there would be no presentation of IE1 peptides 
(Gilbert et al. 1996). More recently it has been shown with the use of a viral vector containing 
the gene encoding IE1 that IE1 specific T cells are in fact cytotoxic (Gyulai et al. 2000). Our 
own data presented in chapter 3 shows that IE1 specific T cells enhance viral control in the 
HSCT setting, and in the solid organ transplant setting a recent publication by Bunde et al. 
(Bunde et al. 2005) has also shown that better protection from CMV is associated with IE1 
specific T cells.
In this study we have used tetramers to establish the frequency of CMV specific T cells in 
three cohorts. However, the drawback of using HLA tetramers is that the number of tetramer 
positive CD8 T cells does not always correlate with the number of functional CMV specific T 
cells, and it has been shown that not all tetramer positive cells are functional in terms of their 
ability to produce IFNy (Ozdemir et al. 2002). The highest frequency of CMV specific 
tetramer positive T cells we detected was in patient 11 (Chapter 3) where 39x106/L NLV 
specific CD3+CD8+ T cells were detected. The functional data from patient 11 described in 
chapter 3 shows that 14.7xl06/L CD3+CD8+ T cells produced IFNy in response to the pp65 
antigen demonstrating that only 36% of the tetramer positive T cells are functional in terms of 
IFNy production, however, these cells could be cytotoxic and therefore it cannot be concluded 
that they are dysfunctional. Longitudinal monitoring studies (Aubert et al. 2001; Cwynarski et
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al. 2001) assessing the levels of tetramer positive T cells post transplant are misleading as the 
majority of these tetramer positive T cells may not be functional and would therefore not 
provide any protection against CMV disease. Another limitation of tetramer use in this 
context is their single epitope specificity and HLA restriction and the results of tetramer 
analysis will not be representative of all peptide specific CTLs present in the circulation. 
Despite the identification of many CMV epitopes difficulties have been encountered with the 
synthesis of some HLA tetramers due to the difficulties with the refolding of HLA molecules 
with their cognate peptides. Despite these drawbacks tetramers have provided a means of 
studying the cellular response to viruses and tumours and have provided valuable information 
that has helped in the understanding of the immune response.
Tetramer studies have provided valuable information in relation to the immune response to 
CMV and have made it possible to examine the phenotype of CMV specific T cell 
populations. The phenotyping of CMV specific T cells from healthy individuals, CVID and 
HSCT patients was performed, within the T cell compartment three main sets of T cells exist. 
These are nai've T cells that have never encountered antigen, effector T cells which have 
encountered antigen and are cytotoxic and lastly memory T cells which have previously 
encountered antigen and are able to expand and kill upon re exposure. These three subsets 
were previously described according to their relative expression of the different isoforms of 
CD45 (Akbar et al. 1988; Michie et al. 1992). The naive T cells were thought to express 
CD45RA while primed T cells were thought to be CD45RO positive. However, recent studies 
have shown that some CD45RA positive T cells have characteristics of primed T cells and are 
thought to result from persistent antigen stimulation (Baars et al. 1995; De Jong et al. 1992). 
Phenotyping was performed on tetramer positive populations from three healthy individuals 
and three HSCT patients. From our data the healthy individuals have tetramer positive cells 
that highly express CD45RA with moderate to low expression of CD27 whilst lacking 
expression of the lymph node homing receptor CD62L. These CD45RA+CD27-CD62L have 
been reported in the literature as being functional in terms of cytoxicity and cytokine 
production (Hamann et al. 1997). In contrast to the healthy individuals the HSCT patients had 
tetramer positive T cells that highly express CD45RO with little or no expression of 
CD45RA. This CD45RO+ CD8+ population are reported to contain a high number of pCTLs 
that are cytotoxic upon antigen exposure (Merkenschlager and Beverley 1989).
Infection with CMV has a pronounced effect on the T cell repertoire, from the phenotyping 
performed on healthy CMV seropositive and CMV seronegative individuals, differences can 
be seen with the expression of CD57 and CD27. The CMV seropositive healthy individuals 
have more CD8+ T cells expressing CD57 and less expressing CD27 when compared with the
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healthy CMV seronegative individuals. The expression of CD57 increases as a result of 
chronic stimulation such as CMV, EBV, HTV and an increase is also seen with age (Khan et 
al. 2002b). In the elderly up to one quarter of their T cell repertoire is taken up by CD57+ T 
cells and it thought that this accumulation could impair their ability to respond to other 
infections (Khan et al. 2002b). To date the role of the CD57 molecule and the factors that lead 
to its expression are unknown, but it has been associated with repeated cell divisions, these 
CD57+ cells also have short telomeres which is a marker of replicative senescence 
(Brenchley et al. 2003). The second difference seen between the CMV seronegative and 
CMV seropositive individuals is the reduced expression of CD27 in the CMV seropositive 
individuals. CD27 is required for efficient interaction with other activated lymphocytes and 
studies examining CD45RA+CD27- T cells have shown that these cells proliferate poorly in 
response to antigen stimulation but are capable of responding to IL-2 (Hamann et al. 1997; 
Hamann et al. 1999). Overall a confusing picture emerges with regard to the phenotyping of T 
cells, many antigen experienced T cell populations show a high level of heterogeneity with 
regard to the expression of the different cell surface markers. This has been complicated even 
further with the description of an antigen-primed population of T cells expressing CD45RA. 
To date there is little information known on the factors that effect the transition of antigen 
primed CD45RO+ T cells into CD45RA+ T cells. Numerous studies have been conducted in 
an attempt to phenotype the different T cell populations but different groups have used 
different molecules to define various T cell populations and no consistency can be discerned.
The hierarchy of HLA alleles in the presentation of CMV peptides was briefly described in 
chapter 4 in relation to the relative dominance of the HLA-B*0702 molecule over HLA- 
A*0201 in the presentation of CMV peptides. Work was initially conducted to examine the 
frequency of CD8+ T cells detected with the NLV tetramer and to correlate this with 
functional IFNy responses to the NLV peptide. From the tetramer staining it was noticed that 
a number of CMV seropositive HLA-A*0201 individuals did not have any NLV specific 
tetramer positive T cells and no IFNy was produced in response to the NLV peptide. All the 
individuals who had no response to the NLV peptide were HLA-B*0702 and therefore it was 
plausible that they manifest their CMV response through another CMV peptide presented in 
the context of HLA-B*0702. Data presented in this chapter and chapter 4 demonstrates that 
HLA-A*0201/B*0702 individuals respond to the TPR pp65 peptide in terms of IFNy 
production, TPR specific T cells can also be detected by tetramer staining. The frequency of 
TPR specific T cells detected in HLA-A*0201/B *0702 individuals with the HLA-B*0702 
tetramer was compared with the frequency detected in HLA-A*0201 non-B*0702 individuals 
with the HLA-A*0201 NLV tetramer. There was a significantly higher frequency (P=0.0247, 
Figure 5.5) of TPR specific T cells detected in the HLA-A*0201/B*0702 individuals when
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compared with the HLA-A*0201 only donors, such a difference was also seen in response to 
the IE1 and pp65 PepMixes when measuring IFNy production (Chapter 4, Figure 4.7). The 
higher frequency of TPR specific T cells indicates that the TPR peptide specific response is 
more immunogenic than the HLA-A*0201 NLV peptide response, such an 
immunodominance of HLA-B*0702 over HLA-A*0201 has been previously described in the 
context of EBV (Hollsberg 2002). Early studies performed on the identification of CMV 
peptides described the NLV peptide as being immunodominant and NLV specific T cells 
could be detected in all HLA-A*0201 individuals (Diamond et al. 1997; Kern et al. 1999b), 
but this clearly no longer seems to be the case and a clear form of hierarchy exists. At the 
time of this finding at the end of 2002 there had been no published information about the 
hierarchy of HLA-A*0201 and HLA-B*0702 but subsequently this finding was also observed 
by Lacey et al (Lacey et al. 2003), in their study the relative dominance of the HLA-B*0702 
TPR over the HLA-A*0201 NLV peptide was described by using tetramer staining and by 
detecting IFNy production by ELISA, in addition a chromium release assay was also 
performed. Our own data provides a more accurate assessment of IFNy production through 
the use of intracellular staining for IFNy and gating on the CD8+ T cell population. The 
studies described by Lacey et al. only assesses the amount of IFNy produced by whole PBMC 
populations following peptide stimulation and can therefore not provide an accurate 
assessment of the specific CD8+IFNy T cell response.
In HLA-A*0201/B *0702 positive individuals very few if any NLV specific T cells could be 
detected by tetramer staining. To determine whether any NLV specific CD8+ T cells were 
present we generated NLV and TPR specific T cells from HLA-A*0201/B *0702 individuals 
to test whether it was possible to expand these CTLs ex vivo. In addition to the NLV and TPR 
peptides, SPHERE peptides from Genzyme (USA) were also used, which due to their 
sequence are reported to bind with a greater affinity to the T cell receptor on T cells specific 
for the NLV peptide. The SPHERE peptides have a different sequence from the NLV peptide 
and only have die leucine and valine anchor residues in common. An MHC stabilisation assay 
revealed that the SPHERE peptides (termed SP1 and SP6) could bind and stabilise HLA- 
A*0201 molecules on the surface of T2 cells. Similarly the TPR peptide was shown to bind 
only in the context of HLA-B*0702 on T2 cells transfected with the HLA-B*0702 (T2B7) 
allele and the NLV peptide was shown to bind only to HLA-A*0201 and not HLA-B*0702. 
Tetramer staining performed on PBMCs derived from donor 29 revealed that 1.67% CD8+ T 
cells were specific for the TPR peptide, following two stimulations with peptide pulsed T2B7 
cells these peptide specific T cells had expanded to 12.0%. Tetramer staining was also 
performed on day 14 using the HLA-A *0201/NLV tetramer revealing that only the TPR
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specific T cells were expanded following stimulation with the NLV peptide. In donor 29 only 
0.02% CD8+ T cells were specific for the NLV peptide, following two antigen stimulations 
with peptide pulsed T2 cells the level on day 14 had only increased to 0.16% 
(CD8+tetramer+). In contrast the SPHERE peptides were able to expand more NLV specific 
T cells than the NLV peptide, after the first stimulation with the SP1 peptide 0.27% CD8+ T 
cells were specific for the NLV peptide and with the SP6 peptide 0.74% CD8+ T cells were 
specific for the NLV peptide. After the second stimulation with the SP1 peptide 3.05% CD8+ 
T cells were specific for the NLV peptide while with the SP6 peptide the percentage 
decreased to 0.04%, these results demonstrated that in this individual NLV specific T cells 
could only be expanded using the SPHERE peptides. Unfortunately, we were not able to 
obtain enough SP1 or SP6 peptide from the company to make HLA-A*0201/peptide 
tetramers refolded with the SPHERE peptides, instead the HLA-A*0201/NLV tetramer was 
used to monitor the expansion of NLV specific cells in the culture generated using the 
SPHERE peptides. To check the peptide specificity of these T cells expanded using the HLA- 
A*0201 peptides (NLV, SP1, SP6), tetramer staining was performed using the HLA-B*0702 
tetramer. Interestingly, the number of TPR specific CD8+ T cells was quite high and 
exceeded the number of NLV specific T cells. The T cell culture expanded with the NLV 
peptide contained the highest number of TPR specific T cells with 8.43% CD8+ T cells 
specific for the TPR peptide. The same phenomenon was also seen with the SPHERE 
peptides but to a lesser extent. Interestingly it seems that in the cultures where very few NLV 
specific T cells were generated a large population of TPR specific CD8+ T cells were 
detected.
To demonstrate that these findings were reproducible these experiments were repeated in 
donor 29 and also in two additional CMV seropositive HLA-A*0201/B *0702 individuals 
(healthy individuals 25 and 27). To determine if this phenomenon was unique to CMV a 
CMV seronegative HLA-A*0201/B *0702 individual was also included (healthy individual 
34). Along with the no peptide control an additional self HLA-A*0201 peptide (SLL) was 
included to determine if any HLA-A*0201 restricted peptide would be capable of expanding 
these TPR specific T cells or if this was unique to the NLV peptide. The results demonstrated 
that the NLV, SP1 and SP6 peptides were capable of generating T cells specific for the TPR 
peptide, with two individuals (29 and 27) the NLV peptide produced the largest expansion of 
TPR specific T cells and for individual 25 the SP6 peptide produced the largest expansion of 
TPR specific T cells.
A second CMV peptide restricted by HLA-B*0702 has been described (RPHERNGFTVL) 
but this has not been examined as part of this study as the T cell response to the TPR peptide
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was the highest in the majority of HLA-A*0201/B*0702 positive individuals. Studies 
conducted by Lacey et al. (Lacey et al. 2003) also described the immunodominance of HLA- 
B*0702 over HLA-A*0201, they used both the TPR peptide and the RPHERNGFTVL 
peptide, although they saw the highest response to the TPR peptide, they could still confirm 
the immunodominance of the HLA-B*0702 RPHERNGFTVL peptide over the HLA-A*0201 
NLV peptide. Although this HLA combination is the only form of hierarchy described to date 
in the CMV field there has been a description of HLA hierarchy in the context of EBV and 
HLA-A*0201/B *0702, Hollsberg et al. used the ELISPOT method and described the relative 
dominance of HLA-B*0702 restricted peptides over the HLA-A*0201 restricted peptides 
(Hollsberg 2002). In addition work carried out by Khanna et al. (Khanna et al. 1997) 
demonstrated that different HLA-B44 subtypes are transported from the ER to the golgi at 
different rates, with the HLA-B*4405 subtype being transported faster and more efficiently 
than the other subtypes resulting in a rapid generation of peptide specific T cells. In the 
context of HLA-A*0201/HLA-B *0702 more work needs to be performed to establish why 
more TPR specific T cells are generated when compared with the NLV peptide, possibly 
HLA-B*0702 may also assemble faster than HLA-A*0201 and as with HLA-B*4405 is 
transported to the cell surface more efficiently.
This apparent cross reactivity of the NLV peptide with TPR specific T cells has not been 
described before in the context of CMV, except the immunodominance shown by Lacey et al. 
(Lacey et al. 2003) but they did not comment on the possibility of cross reactivity. From the 
experimental data shown in this chapter the following conclusions could be drawn. The TPR 
specific T cells that are expanded with the NLV peptide can only be accomplished with this 
peptide as the SLL peptide did not cause any expansion of the TPR specific T cells above the 
background level. In addition these TPR specific T cells were not exposed to any TPR peptide 
although it is plausible that APCs contained within the PBMCs might be presenting the TPR 
peptide and have survived long enough to prime a T cell response but if this was the case an 
expansion of TPR specific T cells would be seen in the no peptide controls. It is unlikely that 
APCs contained within the PBMC population primed the T cell response, a fellow colleague 
has recently selected CD8+ cells and generated dendritic cells from a CMV seropositive 
individual that were subsequently peptide pulsed and used to prime a T cell response. In this 
setting the same observation was seen in that dendritic cells pulsed with the NLV peptide can 
expand the TPR specific T cells and no contaminating TPR peptide was responsible for this 
expansion. In addition the MHC stabilisation assays revealed that the TPR peptide cannot 
bind to HLA-A*0201 and the NLV peptide does not bind to HLA-B*0702 and in addition 
algorithm programs did not show any evidence of the TPR peptide being able to bind to 
HLA-A*0201, the same is also true for the NLV peptide binding to HLA-B*0702. Another
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possibility could be that the addition of IL-2 and IL-7 caused the preferential expansion the 
TPR specific T cells in the cultures expanded with the NLV peptide, although a large 
expansion of the TPR specific T cells should also have occurred in the negative controls (T2 
cells with no peptide). Another explanation might be the existence of a CMV peptide that has 
a similar sequence to the TPR peptide that can bind in the context of HLA-A*0201 and 
therefore expand the TPR specific T cells, it was not possible to define such a peptide from 
our peptide mapping experiments described earlier. In experiments described in this chapter it 
is possible that the TCR is recognising a self-peptide similar to the TPR peptide but not 
demonstrating any HLA specificity.
From the literature the ability of T cells to cross react with more than one peptide has been 
described in the context of EBV. Studies by Burrows et al. (Burrows et al. 1997a; Burrows et 
al. 1997b) demonstrated that T cells specific for the Epstein Barr virus (EBV) peptide 
FLRGRAYGL which is presented in the context of HLA-B*0801 could cross react with 
alloantigens presented in the context of either HLA-B*14 or HLA-B35. There has for 
sometime been an association of Herpesvirus infections with the development of GVHD 
(Appleton and Sviland 1993; Jakel and Loning 1993; Pouteil-Noble et al. 1993) and if T cells 
can exhibit dual specificity this could be seen as a mechanism that leads to graft rejection. It 
was concluded from this data that degenerate peptide recognition by the TCR was responsible 
for the cross reactivity seen. Taking into account the data presented in this chapter it is 
unlikely that a self peptide or alloantigen has led to the expansion of TPR specific T cells 
with the NLV peptide because the CMV seronegative individual showed no expansion of the 
TPR or NLV specific T cells. Additional experiments would need to be conducted to 
determine if in CMV seropositive individuals who are only HLA-B*0702 and not HLA- 
A*0201 whether the NLV peptide can expand TPR specific T cells in an alloantigen setting. 
The T cell receptor used by the TPR specific T cells needs to be determined to establish 
whether this clone is able to tolerate the NLV peptide. The HLA-A*0201 molecule maybe 
more sensitive to the immune evasion strategies employed by the virus than the HLA-B*0702 
molecule, resulting in the faster presentation of HLA-B*0702 restricted peptides than 
peptides restricted by other HLA alleles. Recent studies by Barel et al. (Barel et al. 2003) 
have demonstrated that HLA-B7, -Cw3 and HLA-E were only marginally affected by the 
product of the US2 gene thus allowing more surface expression of these alleles. In contrast 
HLA-A2, B27 and HLA-G were more sensitive to the effects of US2 and a reduction in their 
cell surface expression was observed. The product of the US2 gene causes newly synthesised 
HI .A molecules in the ER to be translocated back into the cytosol where they are degraded. 
Therefore in the case of HLA-B*0702 more HLA/peptide complexes would reach the cell
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surface compared with the HLA-A*0201 complexes and would result in the priming of TPR 
specific T cells ahead of HLA-A*0201 thus eliminating the need for an HLA-A*0201 
response.
At this stage in view of the experimental data presented it is likely that the cross reactivity is 
due to the failure of the TCR to interact fully with the MHC-bound peptide. This theory is 
supported by the ability of the SP1 and SP6 peptides to expand the NLV specific T cells 
indicating that the TCR can cater for these different peptides. The SP1 and SP6 only have the 
anchor residues at position 2 and 9 in common with the NLV peptide and the central amino 
acids are different. It is the central amino acids of a peptide that comes into close proximity 
with the TCR, and as the central amino acids in the SP1 and SP6 are very different from the 
NLV peptide this would imply that the TCR in certain settings could tolerate a range of 
different amino acids. It is also possible that in HLA-A*0201/B*0702 positive individuals 
that NLV specific T cells could have been deleted due to the potential for self reactivity and 
induction of autoimmunity. Another possibility is that CD8+ T cells specific for dominant 
epitopes can suppress the T cell response to other minor epitopes this has been observed in 
the context of EBV (Burrows et al. 1994; Burrows et al. 1995). The potential effects of the 
immune evasion proteins of CMV on the presentation of the TPR and NLV peptides is 
another possibility that would also need to be investigated to determine if these cause the 
preferential expansion of TPR specific T cells. It would be of interest to determine whether in 
a CMV peptide vaccine that only included the NLV peptide in HLA-A*0201/B*0702 
individuals whether the same phenomenon could be observed in vivo. In agreement with the 
data published by Burrows et al. (Burrows et al. 1997a; Burrows et al. 1997b) it is likely that 
this cross reactivity occurs due to degenerate peptide recognition by the TCR and this could 
provide the link between CMV and GVHD.
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Chapter 6 
Summary of Conclusions
The data presented in this PhD thesis illustrates the functional T cell responses to 
cytomegalovirus in patients undergoing haematopoietic stem cell transplantation, and the 
subsequent identification of new epitopes for the development of a peptide vaccine.
Historically, CMV disease was a major cause of mortality in patients post HSCT, although 
due to recent advances in antiviral therapy and the adoptive transfer of specific T cells, the 
reactivation of CMV does not always develop into a life threatening disease. However, drug 
resistant strains of CMV are starting to be reported in the literature (Isada et al. 2002; Julin et 
al. 2002; Limaye et al. 2002; Smith et al. 1996) and with time all clinical isolates of the virus 
could be resistant to the antiviral drugs meaning that the mortality rate due to CMV disease 
could potentially increase. The generation of CMV specific T cells from the HSCT donor that 
can be transferred to the recipient has been used successfully to prevent the development of 
CMV disease in those patients who do not respond to antiviral therapy. However, the 
adoptive transfer of CMV specific T cells is restricted to a minority of HSCT recipients, 
notably those where the donor is available and is CMV seropositive and also due to the 
potential alloreactivity of the transferred T cells this therapy is only suitable for patients who 
have not developed GVHD. The vaccination of CMV seronegative donors would therefore 
suggest that it might be possible to perform adoptive transfer of CMV specific T cells in a 
greater number of HSCT recipients. A CMV peptide vaccine could also be given to solid 
organ transplant recipients to prevent CMV disease and subsequently reduce the risk of graft 
failure. Also a peptide vaccination could also be used in seronegative women of childbearing 
age to prevent the incidence of congenital CMV. The development of a CMV peptide vaccine 
requires the identification of the CMV antigens that induce a protective immune response, 
and then subsequently the identification of the minimal peptide epitopes. The first objective 
of this thesis was to monitor the functional immune responses to CMV in patients post HSCT.
In chapter 3, eighteen patients were monitored for functional T cell responses to CMV post 
HSCT. The main two antigens described in the literature as stimulating strong CD8+ T cell 
responses are the tegument protein pp65, and more recently the IE1 antigen. CD8+ T cell 
responses to the pp65 and IE1 antigens were determined by measuring the amount of IFNy 
produced by CD8+ T cells in response to individual stimulation with the IE1 and pp65 
PepMixes, these PepMixes contain 15mer peptides that overlap by 11 amino acids and cover
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the whole sequence of the protein. The antigens that stimulate a CD4+ helper T cell response 
are less well characterised and they are thought to be from the coat glycoprotein gB and the 
tegument protein pp65. The CD4+ T helper response was determined by measuring the 
amount of IFNy produced by CD4+ T cells in response to individual stimulation with the IE 1 
and pp65 PepMixes, 15mer peptides have been shown in the literature (Dunn et al. 2002; 
Kern et al. 2002) to stimulate both CD4+ and CD8+ T cell responses. The CD4+ helper T cell 
response to stimulation with CMV lysate was also determined, CMV lysate would 
incorporate the gB protein but would also allow peptides to be processed and presented in 
association with MHC class II molecules on the cell surface.
The data presented in chapter 3 demonstrates that the CD4+ helper T cell response to CMV 
lysate provides better viral control than the CD8+ T cell response to either pp65 or IE1. The 
reactivation of CMV occurred in 10 patients post HSCT and all of these patients had no 
detectable CD4+ T cell response to CMV lysate prior to the detection of viral replication. 
CD4+ T cells are necessary for the expansion of CTLs and for the modulation of the immune 
response to the virus; in the absence of CMV specific CD4+ T cells there would be little or no 
expansion of the CD8+ T cells in response to the virus. A CD8+ T cell response to both IE1 
and pp65 resulted in better viral control than having just a response to pp65. Interestingly the 
CD8+ T cell response to IE1 was detectable before a response to pp65 in those CMV 
seropositive recipients (R+) that received a graft from a CMV seropositive donor (D+), 
although this was not the case in all R+/D+ combinations and a larger study would be 
required to investigate this finding. During the reactivation of CMV the IE1 antigen would be 
present before pp65 and therefore IE1 specific CD8+ T cells would be generated before pp65 
specific T cells, although during a primary infection because pp65 is part of the tegument it is 
present on the cell surface prior to viral gene expression therefore pp65 peptides would be 
presented first.
Although both good CD4+ and CD8+ T cell response to CMV is essential in preventing CMV 
disease a number of factors post HSCT can effect CMV specific T cell reconstitution. The 
development and treatment of GVHD had the most detrimental effect on T cell responses, the 
data presented demonstrates that the initiation of steroid therapy had a rapid effect on CD4+ 
and CD8+ T cell numbers and function. Steroid therapy had a more dramatic effect on CD8+ 
T cells than the CD4+ T cells, with a quicker decline in function and number when compared 
with the CD4+ T cells. Another major factor effecting CMV specific T cell reconstitution is 
the use of T cell depleting reagents in the condition regimes, T cell depletion removes 
potentially alloreactive T cells from either the graft or recipient prior to the transplant thus 
reducing the incidence of GVHD. Unfortunately, while T cell depletion does reduce the
248
Chapter 6
incidence of GVHD it does increase the occurrence of CMV infections probably through the 
reduction of potential CMV specific T cells. The data presented in chapter 3 demonstrates 
that CMV infection occurred in 10 patients and all of these patients received Campath-IH as 
a form of T cell depletion.
In conclusion, CMV infection occurred in recipients post HSCT due to a drop in functional T 
cell responses to the CMV antigens prior to the onset of viral replication. In contrast to 
previous studies conducted using HLA tetramers (Aubert et al. 2001; Cwynarski et al. 2001) 
we have shown that the reconstitution of CMV specific CD4+ T cells is more important in 
preventing CMV reactivations than the CMV specific CD8+ T cells. This finding is supported 
by the adoptive transfer studies, where in the absence of sufficient CD4+ T cell reconstitution 
CMV specific CD8+ T cells were lost a few weeks after transfer (Walter et al. 1995). The 
reconstitution of CMV specific CD4+ and CD8+ T cells was affected by a number of factors, 
the most important ones being the development of GVHD and its treatment, and the use of T 
cell depletion in the conditioning regimens. The reactivation of CMV drives an immune 
response to the virus which if maintained can prevent further reactivation events. The IE1 and 
pp65 antigens are the main antigens targeted by CD8+ T cells, and those patients that had 
CD8+ T cell responses to both antigens exhibited better viral control post HSCT. To develop 
a CMV vaccine that can be given to CMV seronegative donors epitopes from both the IE1 
and pp65 antigen would need to be included to generate a CD8+ T cell response, while 
epitopes from gB might be required to generate a CD4+ T helper response. A recent study 
conducted by Sylwester et al. (Sylwester et al. 20Q5) suggested that even more antigens 
should be included. They looked at the CD4+ and CD8+ T cell IFNy response to 213 open 
reading frames (ORFs) by generating 13,687 overlapping 15mer peptides. Their results 
showed that 151 ORFs are immunogenic for CD4+ or CD8+ T cells. They demonstrated that 
for the CD4+ T cell response six of the most immunogenic ORFs (UL55, UL83, UL86, 
UL99, UL153 and UL32) could be combined to equal the total CD4+ T cell response to 
CMV. The CD8+ T cell response was more variable and the total CD8+ T cell response to 
CMV could be generated from fifteen ORFs (UL123, UL83, UL122, UL28, UL48, US3, 
UL151, UL82, UL94, US29, UL99, UL103, US32 and UL36).
In chapter 4, the identification of CMV epitopes derived from pp65 and IE1 was conducted 
using peptide mapping pools that contained 15mer peptides each overlapping by 11 amino 
acids. This method was chosen as it provided a rapid method for identifying new epitopes 
restricted by a variety of HLA alleles. The importance of both a CD8+ T cell response to 
pp65 and IE1 in preventing the reactivation of CMV was demonstrated in chapter 3, therefore 
the identification of new CD8+ T cell epitopes focused on these two antigens. For the IE1
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antigen 8 mapping pools were constructed, each pool contained 15 peptides that overlapped 
by 11 amino acids, for the pp65 antigen 9 mapping pools were created.
To determine if we would be able to identify new CD8+ T cell restricted CMV epitopes from 
healthy individuals we measured the amount of IFNy produced in response to stimulation 
with the IE1 and pp65 PepMixes. In agreement with already published data (Gyulai et al. 
2000; Kern et al. 2000) we could detect CD8+ T cell responses to both pp65 and IE1, 
however, there was no significant difference (P=0.391) in the response to the two antigens. 
Because we could detect a CD8+ T cell IFNy response in healthy individuals we could be 
confident that we would be able to identify new CMV epitopes.
In the literature 15mer peptides have been used to stimulate both CD4+ and CD8+ T cell 
responses simultaneously (Dunn et al. 2002; Kern et al. 2002), in chapter 3 we also used 
15mer peptides to stimulate both CD4+ and CD8+ T cell responses. To establish how 15mer 
peptides bind to the MHC binding cleft we used a fluorescently labelled HLA-A*0201 
restricted 15mer peptide (AGILARNLVPMVATV) and as a positive control the HLA- 
A*0201 restricted 9mer peptide (NLVPMVATV) was included. The results demonstrated that 
the 15mer peptide was able to bind to the MHC binding although the 9mer peptide was better 
at stabilising the MHC molecules when compared with the 15mer peptide. To determine if the 
position of the 9mer peptide within the 15mer sequence contributes to binding of the 15mer 
peptide two 15mer peptides from the pp65 mapping pool 9 (AGILARNLVPMVATV and 
ARNLVPMVATVQGQN) and the 9mer peptide (NLVPMVATV) were used in an MHC 
stabilisation assay. The AGILARNLVPMVATV peptide contains the 9mer peptide sequence 
towards the C terminal end, whereas the ARNLVPMVATVQGQN contains the 9mer peptide 
sequence towards the N terminal end. The results obtained showed that the 
AGILARNLVPMVATV peptide could stabilise the MHC molecules on the cell surface 
whereas the ARNLVPMVATVQGQN could not stabilise the MHC molecules. These results 
demonstrate that 15mer peptides molecules can bind to MHC molecules but this binding is 
dependent on the location of the epitope within the 15mer, if the epitope in located towards 
the C terminal end the peptide can bind to the MHC binding groove but if the epitope is 
located towards the N terminal domain the peptide cannot bind. The binding groove of MHC 
class I molecules are closed and therefore peptides can either bulge centrally from the binding 
cleft (Guo et al. 1992; Horig et al. 1999) or occasionally can extend beyond the C terminal 
anchor site (Collins et al. 1995). Because the AGILARNLVPMVATV peptide could stabilise 
MHC molecules this would suggest that the peptide does not extend over the C terminal 
anchor site but it is most likely that the 15mer peptide bulges away from the binding groove
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and that some trimming of this 15mer peptide could occur due to the presence of 
aminopeptidase's at the cell surface.
The mapping pools for both the pp65 and IE 1 antigens were used to identify the immunogenic 
portion of these antigens by stimulating PBMCs from 31 healthy CMV seropositive 
individuals and measuring the amount of IFNy produced using the intracellular staining 
method. The stimulation of PBMCs with the IE1 and pp65 mapping pools demonstrated that 
the CD8+ T cell responses to IE1 were mainly focused on mapping pools 4 and 6, in contrast 
the CD8+ T cell responses to the pp65 mapping pools was very heterogeneous with the 
majority of the cohort responding to mapping pools 5-9. From this data it was noticed that the 
CD8+ T cell response to the IE 1 antigen was greater in donors expressing HLA-B*0702 when 
compared with non-B*0702 donors this was statistically significant (P=0.0001, Mann- 
Whitney U test), however, there was no significant difference seen (P=0.6936, Mann- 
Whitney U test) when comparing the responses of the same groups to the pp65 antigen. Thus 
it is likely that an epitope restricted by HLA-B*0702 is contained within IE1 mapping pool 6.
Each mapping pool covers approximately 50 amino acids of the antigen sequence, to identify 
the immunogenic 15mer peptide the individual 15mer peptides that make up each mapping 
pool were synthesised individually. Due to financial constraints only individual 15mer 
peptides were synthesised for IE1 mapping pools 4 and 6 and for pp65 mapping pools 4-6. 
These individual 15mer peptides were used to stimulate PBMCs from those individuals that 
showed a high level of IFNy production in response to the mapping pool under investigation. 
Using these individual peptides immunogenic 15mer peptides were identified that stimulated 
a CD8+ T cell response in 11 individuals. For some individuals the amount of IFNy produced 
was very low in comparison to the initial CD8+ T cell response to the mapping pool, for one 
individual real time PCR for the relative quantification of gene expression was used to 
improve the detection of IFNy production. In order to finally confirm the peptide epitope, 
algorithm databases were utilised to predict the HLA restriction and the most likely 9mer 
peptides possible from these, from the 15mer peptides there is only potentially seven possible 
9mer peptides that can be derived but there is always the possibility that the peptide can be 
truncated across two 15mer peptides.
Algorithm programs have been used to identify the peptide with the highest affinity for a 
particular HLA molecule from all the possible peptides in a given antigen (Elkington et al. 
2003; Frankenberg et al. 2002; Gallez-Hawkins et al. 2003). The two publicly available 
databases SYFPEITHI and BIMAS were used to predict the most likely epitope from the 
sequences of the immunogenic 15mer peptides, in addition two proteasomal cleavage
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databases (PAPROCC and NetChop) were used to determine what peptides would be 
generated from the proteasomal cleavage of the immunogenic 15mer peptides.
The algorithm databases produced mixed results, they predicted the same peptide for the 
majority of the donors, but some discrepancies were seen with some peptides, which may 
reflect the different ways these databases predict peptides. The BIMAS and PAPROCC 
databases are trained using experimental affinities, and the SYFPEITHI and NetChop 
databases are trained using theoretically based affinities. To overcome these discrepancies we 
used these databases in combination with our own experimental evidence and information 
available on the peptide binding motifs for each HLA allele to predict new CMV epitopes. It 
is generally recommended that these databases should not be used to identify new epitopes 
(Pelteetal. 2004).
With the use of mapping pools we were able to identify two new 9mer peptides derived from 
the IE 1 antigen and one new 9mer peptide derived from pp65. Numerous 15mer peptides 
were also identified but due to financial constraints the 9mer peptides could not be identified 
but clearly this work could be pursued in the near future. From the two new IE1 peptides that 
were identified, the first peptide (CRVLCCYVL) was shown by MHC stabilisation assays to 
be restricted by HLA-B*0702 and was able to stimulate cell proliferation. However, the 
CRVLCCYVL peptide was only able to stabilise MHC molecules on T2B7 cells when lOOpg 
peptide was used and attempts to generate HLA:peptide tetramers failed but CD8+ T cells did 
produce IFNy in response to peptide stimulation. The cell proliferation assay did indicate that 
the CRVLCCYVL peptide could stimulate cells to proliferate although the level of 
proliferation was low with two donors (6 and 49), possibly indicating that peptide pulsing 
alone was not able to provide all the relevant signals for maximal stimulation and using 
peptide pulsed APCs would have been a better choice. Another possibility is that the 
CRVLCCYVL peptide was not the optimal peptide and for future experiments one could 
evaluate the response to additions or truncations of the peptide at its two ends and the effects 
these would have on its stimulating capacity.
The second IE1 peptide to be identified was RRKMMYMCY and was shown to be restricted 
by HLA-B*2705. The HLA restriction of this peptide could not be tested using the MHC 
stabilisation assay as T2 cells expressing HLA-B*2705 were not available, the HLA 
restriction was confirmed using an EBV transformed B cell line that was matched for HLA- 
B*2705. This method has never been used previously to identify the HLA restriction of new 
CMV peptide epitopes but due to the availability of a large bank of EBV transformed B cell
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lines we were able to find a match for the HLA allele under investigation. The same method 
was also used for the identification of the HLA-B*5801 pp65 peptide (VAFTSHEHF), 
subsequent functional assays confirmed that CD8+ T cells responded to these peptides when 
presented by their respective HLA alleles. We have only identified new CMV epitopes on the 
basis of some functional assays, clearly cytotoxicity assays would need to be conducted to 
provide definitive confirmation of in vivo functional relevance, although new epitopes have 
been published based on functional assessments alone (Kern et al. 1999).
The identification of new CMV epitopes was successful using overlapping peptide libraries, 
although this is a rapid method a reasonable period of time is required to fully interpret the 
results. The possibly impact of certain HLA combinations means that a peptide that induces 
IFNy production in one individual for example who is HLA-B*5801 may not induce any 
IFNy production in another HLA-B*5801 individual, this could be due to the effects other 
HLA alleles are exerting through the presentation of more immunodominant peptides. This 
concept was expanded in chapter 5 with respect to the presentation of the HLA-A*0201 
peptide NLVPMVATV which is presented in HLA-A*0201 positive individuals but not in 
HLA-A*0201/B*0702 individuals where the HLA*0702 restricted peptide 
(TPRVTGGGAM) is presented, although traditionally one would still expect to have 
presentation of the HLA-A*0201 peptide. This hierarchy in the presentation of CMV peptides 
complicates the identification of new epitopes and the combination of HLA alleles should 
also be studied instead of looking solely at single HLA alleles. The use of overlapping 
peptides provides a faster method for identifying new CMV epitopes, however, the mapping 
of new peptides does require extensive analysis and although the method is relatively faster 
than the available alternatives the interpretation of results can be complex and needs to be 
performed thoroughly to obtain the correct information. The cost of the peptide libraries can 
seem high initially but the saving in time from not following false leads offsets this in the 
long-term.
The mapping pools for pp65 and IE1 enabled us to examine previously identified epitopes 
and to establish whether one could observe CD8+ T cell responses to the mapping pools that 
contained the known epitopes and this then allowed us to ascertain whether the previously 
described epitopes were functional. Due to the high level of responses to the pp65 mapping 
pools 5-9 and the inclusion of many epitopes in these pools it was difficult to test all of the 
identified epitopes. However, three epitopes have been described in the literature and are 
located in pp65 mapping pools 1 and 2, among our cohort we only found one individual that 
showed a CD8+ T cell response to one of the mapping pools. For the IE1 antigen one HLA- 
A*0201 peptide TMYGGISLL has been described in the literature and is contained within
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peptide pool 5, however, out of 16 HLA-A*0201 positive individuals no one responded to 
this peptide. This analysis reveals that due to the different methods used to identify CMV 
epitopes in the past many discrepancies have occurred indicating that the decision about 
which are the best peptides to include in a CMV peptide vaccine are somewhat misleading.
In chapter 5, the frequency of CMV specific T cells was determined among three cohorts 
comprised of healthy individuals, HSCT recipients and those with common variable 
immunodeficiency (CVID). We were particularly interested in determining the number of 
CMV specific T cells that were detectable in patients with CVID, these individuals have low 
serum immunoglobulin levels and other abnormalities associated with their lack of T cell 
immunity have also been reported. At the Royal Free hospital (London) three cases of CMV 
disease were suspected or confirmed in CVID patients, we therefore determined the 
frequency of CMV specific T cells in these patients and attempted to assess how these levels 
compared with healthy individuals and HSCT recipients. To determine the frequency of CMV 
specific T cells HLA tetramers were generated using peptides derived from the IE1 and pp65 
antigens, these tetramers were shown to be specific when tetramer staining was performed on 
PBMCs from CMV seronegative or HLA mismatched CMV seropositive individuals.
The frequency of CMV specific T cells in the peripheral circulation was determined in 
healthy individuals and compared with the level detected in CVID patients and HSCT 
recipients. The highest frequency of tetramer positive T cells was detected in the HSCT 
recipients possibly due to the frequent reactivation of the virus post transplant, however, the 
only significant difference was seen when comparing the number of NLV specific T cells 
detected in the HSCT patients when compared with the healthy individuals (P=0.05). 
Interestingly, the number of T cells specific for the IE1 peptide VLE was highest among the 
CVID patients and the HSCT recipients, however, only a few individuals could be analysed 
with the VLE tetramer due to low cell numbers and therefore overall no significant 
differences could be discerned between the three groups. During the reactivation of CMV the 
iel gene is expressed in the immediate early phase of viral gene expression therefore peptides 
could be presented, the pp65 gene is expressed in the late phase and inhibits the presentation 
of IE1 peptides on the cell surface. In the HSCT recipients CMV reactivation does occur post 
transplant and this could result in the high level of IE1 specific T cells seen, no data is 
currently available on the reactivation of CMV in CVID patients but it is likely that the virus 
does reactivate resulting in die generation of BE1 specific CTLs in these patients also.
The highest number of CMV specific T cells detected was in a HSCT recipient (patient 32), 
where 67% of CD8+ T cells were shown to be specific for the NLV peptide. From the data
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obtained in chapter 3 we calculated that only 36% of tetramer positive T cells responded to 
the pp65 antigen demonstrating that the longitudinal monitoring of patients post HSCT with 
HLA tetramers does not accurately reflect CMV specific immune reconstitution.
HLA tetramers have provided valuable information about the immune response to viruses and 
tumours and have provided additional information regarding the phenotype of antigen 
specific CD8+ T cells. The limitation of tetramer studies is that it is difficult to gain 
information regarding the function of the T cells and one is limited to one specific peptide and 
HLA allele combination per analyses. To obtain more information about the functional 
responsiveness of T cells in CVID patients, PepMixes for the pp65 and IE1 antigens were 
utilised. These PepMixes were able to provide more information about the CD8+ T cell 
response to the two antigens with respect to the amount of IFNy produced following 
overnight stimulation. The amount of IFNy produced was determined in seven CVID patients 
and compared with the T cell response in healthy individuals. The data obtained demonstrates 
that CD8+ T cells from the CVID patients produced more IFNy in response to the IE1 antigen 
when compared with healthy individuals (P=0.0099) but the data obtained from the tetramer 
staining showed no significant difference between the two groups, this again demonstrates 
that either tetramer positive T cells are dysfunctional or because the HLA tetramer is peptide 
specific the results from the PepMixes provide a more accurate assessment of CMV specific 
T cells. When the functional response to the pp65 antigen was compared between the CVID 
patients and the healthy individuals no significant difference was observed (P=0.0714), 
indicating that the reactivation of CMV probably occurs more in the CVID patients leading to 
a greater expansion of IE1 specific T cells. Because CVID patients can become 
immunosuppressed due to steroid therapy the reactivation of CMV could easily occur, the 
greater expansion of T cells specific for the IE1 antigen might be as a result of ie l gene 
expression prior to pp65 resulting in a greater expansion of IE1 specific T cells.
HLA tetramers can help provide valuable information in relation to the phenotype of antigen 
specific T cells in the peripheral circulation, such information cannot be gained using the 
PepMixes which stimulate T cells overnight and lead to a greater down regulation or up 
regulation of various cell surface markers when compared to T cells stained with HLA 
tetramers, therefore the phenotype of the stimulated T cells would not represent the true 
phenotype of these cells in vivo. Due to the limited availability of PBMCs from CVID 
patients, the phenotyping of tetramer positive T cells was conducted in healthy individuals 
and HSCT recipients. From the phenotyping of tetramer positive T cells the following 
conclusions could be derived, in the HSCT recipient the tetramer positive T cells were of the 
effector memory subtype mainly denoted by the high level of CD45RO expression on the cell
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surface. In healthy individuals tetramer positive T cells expressed high levels of CD45RA 
indicating that these are terminal effector memory cells that have reverted from being 
CD45RO positive to CD45RA positive. Both the healthy individuals and HSCT recipients 
expressed high levels of the cell surface marker CD57, although the function of this molecule 
is unknown it is thought to result from persistent antigen stimulation, the expression of CD57 
is known to increase with age.
The expression of the different cell surface markers (CD27, CD28, CD45RO, CD45RA, 
CD57 and CD62L) on unstimulated CD8+ T cells was determined in CMV seropositive and 
CMV seronegative individuals, CVID patients and HSCT recipients. The difference in the 
cell surface expression of CD57 according to the individuals CMV serostatus was also 
determined, the CMV seronegative individuals had less than 20% CD8+ T cells that 
expressed the CD57 molecule, in contrast in CMV seropositive individuals 40-100% CD8+ T 
cells expressed CD57 with the higher levels observed in the patient groups. These results 
indicate that CMV can induce the expression of CD57 leading to a greater accumulation of 
these cells with age. The CD8+ T cell repertoire in the CVID and HSCT patients contained 
more than 20% CD8+CD45RO+ T cells, which were absent in the healthy individuals; these 
are most probably effector memory T cells that result from recent infections. The CD8+ T cell 
repertoire of healthy individuals contained a high percentage of CD8+CD45RA+ T cells, 
these are either antigen experienced memory T cells that have reverted back to CD45RA or 
represent naive T cells. Overall, the phenotyping results do show differences in the expression 
of different cell surface markers between CMV seronegative and CMV seropositive 
individuals as well as the two patient groups. However, the results demonstrate that there is a 
large degree of heterogeneity with expression of the different cell surface markers between 
different individuals and as the phenotyping of T cells becomes more complicated with the 
discovery of CD45RA antigen experienced T cells more markers are required to assign a 
particular phenotype.
From the data in chapter 4 a HLA hierarchy seems to exist in relation to the presentation of 
CMV peptides. In CMV seropositive HLA-A*0201/B*0702 individuals it was shown that a 
higher number of CD8+ T cells were specific for HLA*0702 restricted pp65 peptide (TPR) 
and few if any CD8+ T cells specific for the dominant HLA-A*0201 restricted pp65 (NLV) 
peptide were detected. We were therefore interested in determining whether there were any T 
cells present in the circulation specific for the NLV peptide and if these could be expanded ex 
vivo. To generate CMV specific T cells the traditional NLV and TPR peptides were used, in 
addition two SPHERE peptides (SP1 and SP6) were obtained commercially, these peptides 
are reported to have a greater affinity for the TCR than the NLV peptide. CMV specific T
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cells were expanded using peptide pulsed T2 cells or T2 cells transfected with HLA-B*0702 
as antigen presenting cells. Before each stimulation tetramer staining assessed the percentage 
of peptide specific T cells that had been expanded. Following two stimulations the number of 
tetramer positive T cells specifically generated with the NLV peptide had increased from 
0.04% (day 0) to 0.16% (day 14), but the greatest expansion of NLV specific T cells were 
generated using the SP1 SPHERE peptide where 3.05% tetramer positive T cells were 
detected at day 14. The greatest number of T cells were expanded using the HLA-B*0702 
peptide where 1.68% tetramer positive CD8+ T cells were detected, following two 
stimulations with the TPR peptide, the number of tetramer positive T cells had increased to 
12%. These results demonstrate that NLV specific T cells do exist, however, the percentage is 
low and even following ex vivo stimulation they cannot be easily expanded, these T cells 
could be possibly anergic or are of low affinity. In contrast the TPR peptide can expand TPR 
specific T cells and therefore this would appear to be the dominant peptide that is presented in 
all HLA-A*0201/B*0702 individuals, however, the impact of the other HLA alleles within 
the phenotype on this is unknown at present.
As a control the specificity for each T cell line generated was assessed using tetramer 
staining. The three T cell lines generated with the NLV, SP1 and SP6 peptide were each 
stained with the HLA-B*0702/TPR tetramer, the T cell line generated with the TPR peptide 
was stained with the HLA-A*0201/NLV tetramer. Tetramer staining performed with the 
HLA-A*0201/NLV tetramer on the T cell line generated using the TPR peptide revealed that 
only a background level of NLV specific T cells were present in the culture 
(0.27%CD8+tetramer+). Interestingly, when tetramer staining using the HLA-B*0702/TPR 
tetramer was performed on the cell line generated using the HLA-A*0201 restricted peptides 
a significant expansion of the TPR specific T cells was detected. In the culture generated with 
the NLV peptide 8.43% CD8+ T cells were shown to be specific for die TPR peptide, in the 
culture generated with the SP6 peptide 4.07% (CD8+tetramer+) CD8+ T cells were specific 
for the TPR peptide. To confirm these results, CMV specific T cell lines were generated in 
three additional HLA-A*0201/B*0702 individuals, the results were the same with the HLA- 
A*0201 peptides expanding TPR specific T cells. These results demonstrate that either the 
NLV peptide can cross react with the TPR specific T cells or the TCR lacks the ability to 
discriminate between the two peptides as demonstrated with the NLV specific T cells which 
can also respond to the SP1 and SP6 peptides, these peptides have a different sequence from 
the NLV peptide demonstrating that the TCR can accommodate these different peptides.
The cross reactivity of T cells in the context of CMV has never been described, but a similar 
phenomenon has been seen in the context of EBV. Worked carried out by Burrows et al.
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(Burrows et al. 1997a; Burrows et al. 1997b) has demonstrated that T cells specific for the 
EBV peptide FLRGRAYGL is presented in the context of HLA-B*0801 cross reacts with 
alloantigens presented in the context of either HLA-B*14 or HLA-B35. CMV has been 
implicated as playing a role in the development of GVHD, but to date the published data is 
inconclusive, if CMV specific T cells are cross reactive then it is plausible that they could 
also cross react with alloantigens. Further work would need to be conducted to confirm this in 
an autologous system that CMV specific T cells are cross-reactive this could be established 
by utilising autologous and allogeneic dendritic cells. It might also prove informative to 
generate an allogeneic HLA-A*0201 T cell line in a non HLA-A*0201 but HLA-B*0702 
positive individual and determine whether the TPR specific T cell population is expandable. 
If it were possible to expand TPR specific T cells in the allogeneic setting this could provide 
the link between the development of GVHD and CMV which to date has only been a clinical 
observation. Overall, these finding have important implications for the development of a 
CMV vaccine whereby the NLV peptide alone could expand the TPR specific T cells in 
HLA-A*0201/B*0702 individuals. The cross reactivity of CMV specific T cells has 
important implications in the clinical setting where such cells could mediate the development 
of GVHD.
Due to medical advances in the transplantation field both in solid organ and HSCT the 
number of severely immunocompromised patients is increasing, this has resulted in an 
increase in opportunistic infections caused by CMV. The emergence of the HIV virus in the 
1980's has also created another set of immunocompromised patients that can develop 
significant clinical consequences such as blindness due to the development of CMV retinitis. 
The current CMV antiviral therapy is effective in preventing CMV disease, however, a 
worryingly growing number of drug resistant strains of CMV are being reported. Hopefully, 
with more studies looking at the role of CMV in the clinical setting and the prospect of a 
CMV vaccine emerging from clinical trials, morbidity and mortality due to CMV disease will 
become a thing of the past.
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Appendix 1.1
GP/(Consultant) INFORMATION SHEET 
Title of Project
Monitoring of CMV antigen specific T cells in Bone marrow transplant patients before 
and after transplant.
We at the Anthony Nolan Research Institute and Haematology Dept of the RFH are currently 
embarking on a project to investigate the reconstitution of the immune system after bone 
marrow transplantation. As you will be aware, the immune system is severely depleted after 
pre-transplant conditioning. Research has shown that specific cells in the normal immune 
system are responsible for combating many virus infections but of specific importance to 
transplant patients is CMV. The precise details of how fast these cells regenerate and how 
effective they are in fighting CMV virus in Bone marrow transplant patients still remains 
unclear. This project uses newly developed techniques which will provide valuable 
information about the levels and activity of these cells in patients after bone-marrow 
transplantation.
To help us carry out this work we require 20mls of blood. These samples would be taken at 
the same time as the regular checks occurring at the hospital and will not require additional 
venepuncture.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and then subsequently at 
the same times when blood is being taken for routine monitoring of CMV status, this is 
usually twice weekly during the early phase post transplant. Monitoring will continue at 
outpatient appointments for up to 9 months following transplant.
DONORS- blood is required once at the pre-donation health check.
The cells extracted from these samples will only be used for the research project that the 
patient has agreed to take part in.
The proposed study will use class I soluble HLA molecules in the form of tetramers. These 
will be used to specifically detect the presence of circulating antigen specific T cells in the 
peripheral blood of patient who reactivate CMV following BMT.
CMV viraemia is a significant problem in immunosuppressed patients following BMT, and 
before their new haemopoetic system has been able to fully develop to provide the 
appropriate level of immune response to counteract the occurrence of CMV infection de novo 
or through the reactivation of pre-existing CMV. Monitoring the immune potential of a 
patient to mount a specific immune response to a virus such as CMV, will allow us to obtain a 
better understanding of what is happening to the CMV specific T cells in patients who 
reactivate CMV post BMT or who develop de-novo CMV viraemia following BMT. The 
acquisition of such data will allow us to correlate the ability of patients to resolve CMV with 
the concurrent expansion or development of CMV specific CD8 T cells in their peripheral 
circulation. The analysis of such information has implications for improved therapy or 
clinical intervention at specific time points resulting in improved treatment of patients 
developing CMV disease post BMT.
The role of CMV specific CD8+ T cells in the resolution of CMV viraemia is well 
documented. However specific details about the dynamics of expanded CMV +ve 
populations the relative relevance of CD4+ T cells to the action of CD8 antigen specific cells 
and whether CD8 population expansions are productive or unable to act specifically to
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remove CMV positive cells in BMT patients are all questions which need answering. In 
addition the contribution of chimerism to the cellular dynamics of antigen specific T cells in 
BMT patients is also an important question that needs to be investigated.
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Appendix 1.2
PARTICIPANT INFORMATION SHEET
Title o f Project
Monitoring of CMV antigen specific T cells in Bone marrow transplant patients before 
and after transplant.
We at the Anthony Nolan Research Institute are currently embarking on a 
project to investigate the reconstitution of the immune system after bone 
marrow transplantation. As you will be aware, the immune system is severely 
depleted after pre-transplant conditioning. Research has shown that specific 
cells in the normal immune system are responsible for combating many virus 
infections but of specific importance to transplant patients is CMV. The 
precise details of how fast these cells regenerate and how effective they are 
in fighting CMV virus in Bone marrow transplant patients still remains unclear. 
This project uses newly developed techniques which will provide valuable 
information about the levels and activity of these cells in patients after bone- 
marrow transplantation.
To help us carry out this work we require 20mls of blood (which is 
approximately an egg cup full). These samples would be taken at the same 
time as the regular checks you will have at the hospital and will not require 
you to have any extra venepunctures.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and at the 
same times when blood is being taken for routine monitoring of CMV status, 
this is usually twice weekly during the early phase post transplant, you will 
then be monitored at your outpatient appointments for up to 1 year 
following transplant.
DONORS- blood is required once at your pre-donation health check.
The cells extracted from these samples will only be used for the research 
project you have agreed to take part in.
If you are willing to take part in this study and agree to provide the samples 
requested, your medical records will also be examined by researchers from 
The Anthony Nolan Bone Marrow Trust's Research Institute, who are outside 
the employment of the NHS. All information will remain confidential.
261
Appendix
Appendix 1.3
1 PARTICIPANT CONSENT FORM
TITLE OF PROJECT
Monitoring of CMV antigen specific T cells in post Bone marrow transplant patients
The patient should complete the whole of this sheet themselves.
Have you read the Patient Information Sheets? YES / NO
Have you had an opportunity to ask questions and discuss YES / NO
this study?
Have you received satisfactory answers to all your questions? Y ES/ NO
Have you received enough information about the study? YES / NO
Who have you spoken to? Dr / Mr / Mrs
Do you understand that you are free to withdraw from the
study at any time, without having to give a reason for
withdrawing and without affecting your future medical care? YES / NO
Do you agree to enter your this study and in doing so give
permission for the researchers to have access to your
medical notes? YES / NO
Do you give permission for us to notify your GP that you have
entered this study? YES / NO
• Do you agree to enter in this study? YES / NO
Patient’s name
(in block letters)
Sianature Date 1 1 1 1
Dr’s sianature Date 1 1 1 1
Dr’s name
(in block letters)
File one copy in patients notes, one copy in CRF and one copy to patient.
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Appendix 1.4
Inform ation s h e e t  
In troduction
We at the Anthony Nolan Research Institute are establishing a project to 
investigate the  functioning o f the immune system a fte r bone marrow 
transplantation. As you may know, the immune system is severely depleted 
as a consequence o f having a Bone marrow transplant and it takes some 
time, up to  1 year for the new marrow and the cells tha t it generates to fully 
re-establish an effective and fully functional immune system in the patient. 
Research has shown tha t specific types of cells in the normal immune system 
are responsible for combating many virus infections, one virus that is of some 
importance to  transplant patients is CMV. The precise details of how fast 
these specific cells regenerate and how effective they are in fighting the CMV 
virus in Bone marrow transplant patients still remains unclear. As mentioned 
previously a significant number o f the population has this virus and in healthy 
people it is relatively benign and causes no harm.
This project will use newly developed techniques which will provide valuable 
information about the levels and the activ ity o f these cells in normal healthy 
individuals and we will then be able to  contrast th is w ith our findings in 
patients.
W hat is th e  main p u rp o se  o f th e  re sea rch ?
The aims o f th is research project are to  determine which cells in normal 
individuals are responsible fo r the control o f CMV virus and to  define the 
conditions needed to  boost these cells in bone marrow transplant patients. In 
addition we will establish methods for screening for these cells in transplant 
patients so tha t their levels can be monitored after transplant.
How you can  help w ith th is  s tu d y
When you joined the register a blood sample was taken to  establish your 
tissue type, at the same time you were tested for CMV. From the results 
obtained we know your tissue type and that you are positive for CMV.
As part of our project we aim to  investigate the immune response to CMV in 
normal healthy individuals, we are focusing on your particular tissue type. We 
will use this information to  help in the development o f sensitive screening 
tests fo r the virus and to  hopefully develop a CMV vaccine tha t could 
eventually be used to  prevent CMV problems in Bone Marrow transplant 
patients.
W hat would b e  involved if you ag ree  to  tak e  p a rt?
To help us carry ou t this work we would require 20mls of blood (which is 
approximately two egg cups full).
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The cells extracted from your blood sample will only be used for this research 
project.
W here can  th e  blood sam ple be tak en ?
You can make arrangements to  have the blood sample taken at your local 
hospital or general practitioner. If you wish and find it more convenient you 
can arrange to  come to  the Anthony Nolan Trust. If you would like to take 
part in this study please sign and return the enclosed consent form and we 
will send you a kit to  take to  your GP's with you.
W here can  I g e t  fu r th e r  inform ation?
If you have any other questions, please contact the following people:
Dr. Anthony I. Dodi, MSc, PhD,
Senior Research Scientist
The Anthony Nolan Research Institute &
The Royal Free Hospital and University College 
Medical School 
Hampstead 
London 
NW3 2QG
Tel:  
Miss E Harkin
Pre-Harvest Section Manager 
The Anthony Nolan Trust 
Unit 2-3 Heathgate Place 
Agincourt Road 
London 
NW3 2NU
Tel: 
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Appendix 1.5
1 PARTICIPANT CONSENT FORM |
TITLE OF PROJECT
Monitoring of CMV antigen specific T cells in patients following Bone marrow 
transplant and in control healthy individuals
You should complete the whole of this sheet yourself.
Have you read the Information Sheet? YES I NO
Have you received satisfactory answers to all your questions? YES I NO
Have you received enough information about the study? YES I NO
Do you agree to enter in this study? YES I NO
Name_________________________________________________
(in block letters)
Signature Date I I I I
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Appendix 1.6
IMPORTANT NOTE: Please dispose of sharps on site. 
Health & safety regulations require that used needles 
are NOT returned in this package. Thank you for your 
attention to  this matter.
The General Practitioner or Practice Nurse 
Pathologist
Phlebotomist
Dear Colleague
COLLECTION OF BLOOD SAMPLE FOR RESEARCH PROJECT:
Monitoring of CMV antigen specific T cells in patients following Bone marrow 
transplant and in control healthy individuals
We at the Anthony Nolan Research Institute are currently embarking on a project to 
investigate the reconstitution of the immune system after bone marrow 
transplantation. As you will be aware, the immune system is severely depleted after 
pre-transplant conditioning. Research has shown that specific cells in the normal 
immune system are responsible for combating many virus infections but of specific 
importance to transplant patients is CMV. The precise details of how fast these cells 
regenerate and how effective they are in fighting CMV virus in Bone marrow 
transplant patients still remains unclear. This projects aims to establish how the 
immune system controls CMV in healthy individuals and then compare this with the 
finding that we have made in transplant patients. We have selected a few individuals 
of a specific tissue type from the Anthony Nolan Register so that we can examine the 
immune response in these healthy individuals.
To help us carry out this work we require a single one off 20ml sample of blood. We 
appreciate the already heavy demands on your time but would be most grateful if you 
could assist us in the above matter.
0 Please take the blood into the Vacutainer™ supplied to the donor and gently
shake the tube to ensure that the blood is thoroughly mixed with the anti­
coagulant already supplied in the tube.
□ The BD Vacutainer™ should then be placed in the red mailing containers
provided. Please ensure that the caps are pressed down firmly onto each end 
of the container to avoid possible leakage. It is not necessary to seal down 
the top. A special liner is already in place inside the containers to absorb 
leakage. The mailing container should then be placed in the polythene bag 
provided and inserted into the padded envelope.
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□ Peel back the large prepaid self-adhesive label (white with red/pink print), 
place it on the front of the envelope, ensuring that part of the label overlaps 
sufficiently to cover and seal down the flap of the padded envelope. **
As it is of utmost importance that we obtain the blood on the day following 
phlebotomy, would you please be so kind as to ensure that the samples are posted 
to us without delay once taken.
Please do not hesitate to contact us if you have any queries or problems concerning 
this. The continuing support of colleagues throughout the United Kingdom has 
helped us to provide well over 3,500 donors for transplants worldwide and save the 
lives of many patients who would otherwise have died, with an increasing 
understanding of the immune reconstitution it is hoped that many other lives will be 
saved in the future.
If you have any enquires regarding the project please do not hesitate to contact Dr I 
A Dodi , or Miss Harkin regarding the taking of blood samples.
Thank you for you're kind assistance - it is much appreciated.
Yours sincerely 
Miss E Harkin
Pre-Harvest Section Manager 
** Post Office Regulations
These require that pathological specimens be packaged by a recognised 
laboratory or institution, a qualified medical or dental practitioner or a 
veterinary surgeon, who then posts the package. The package should show 
the name and address of the sender.
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pBJINeo vector
Appendix
Poly-linker
5’
Bgl
Pvu I
SRa promote]
Poly-linker
Neo1
SV40 poly A
pBR322 ori
Bgl I
Pvu ISsp I
Xho I X ba I Spi I Not I EcoR I EcoRV Hind III Cla I
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pET3a Vector Map
Appendix
Aat 11(4567), 
Ssp 1(4449) , I
EcoR 1(4638) 
,Apo 1(4638)
>Cla 1(24) 
Hind 111(29)
Sea 1(4125) 
Pvu 1(4015)
Pst 1(3890)
Earn 1105 1(3645
HgiE 11(3338)
AlwN 1(3168)
Bpu1102 I(458) 
BamH 1(510)
Nde 1(550) 
Xba 1(588) 
Bgl 11(646) 
SgrA 1(687)
pET-3a
( 4 6 4 O b p )
Sph 1(843) 
EooN 1(903) 
Sal 1(928) 
PshA 1(993)
,E ag  1(1216)
-*Nru 1(1251) 
ApaB 1(1329) 
BspM 1(1331)
BspLUl 1 1(2752)
Afl 111(2752)
Sap 1(2636)
Bst1107 1(2523)
BsaA 1(2504)
Tth111 1(2497)
BsmB 1(2393) 
Pvu 11(2343)
Bsm 1(1636) 
Ava 1(1702) 
MSC 1(1723) 
Bpu10 1(1858)
BscG 1(1912)
pET3a cloning/expression region
T7 promoter prinwr *69346-3
g ^ l l  T7 promoter—  Xba I
*a*teTtC*TCreCC6M «TTm*CtACTC*CT*TAa6CWCC*WCBCTnCCCTCT*a*AAT*ATTTTtTTT*ACTTr iU6**68*6*
J t £  l_ T7»T»g BwtM I Bpu11021
T*TAC*T*T»<CT^^ Tm^ *e*« ^ ^ T a ^ *TCtMCTaCTIUCUACCCC6***4<*A«CIC*aTT6»tT|CT|Ct*CaCTMteAi>TAi<T*8{*TM
^ r m i n a o r  arimor *68337-3
p T T -»
fffcol 
TKCATttCTMC.
pST-Jh
. QlyJLrtAtpProAlaA loAonLy *A li|Ala(l v L te tM la M iT k r t ia i  4 1 iCte
_______________T7 tormin«tor
CttCTTKCCCCTCTM A eeeeTCTTCA W eG TTnTTC
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Appendix 2.3
pp65 peptide mapping pools
Pool 1 Peptide sequence
1 MESRGRRCPEMISVL
2 GRRCPEMISVLGPIS
3 PEMISVLGPISGHVL
4 SVLGPISGHVLKAVF
5 PISGHVLKAVFSRGD
6 HVLKAVFSRGDTPVL
7 AVFSRGDTPVLPHET
8 RGDTPVLPHETRLLQ
9 PVLPHETRLLQTGIH
10 HETRLLQTGIHVRVS
11 LLQTGIHVRVSQPSL
12 GIH VRV SQPSLILV S
13 RV SQPSLILV SQ YTP
14 PSLILVSQ YTPDSTP
15 L VSQYTPDSTPCHRG
Pool 2 Peptide sequence
16 YTPDSTPCHRGDNQL
17 STPCHRGDNQLQVQH
18 HRGDNQLQV QHTYFT
19 NQLQVQHTYFTGSEV
20 VQHTYFTGSEVENVS
21 YFTGSE VENV S VNVH
22 SEVEN VS VNVHNPTG
23 NV S VNVHNPTGRSIC
24 NVHNPTGRSICPSQE
25 PTGRSICPSQEPMSI
26 SICPSQEPMSIYV Y A
27 SQEPMSIYVYALPLK
28 MSIYVY ALPLKMLNI
29 VYALPLKMLNIPSIN
30 PLKMLNIPSINVHHY
Pool 3 Peptide sequence
31 LNIPSINVHHYPSAA
32 SINVHHYPSAAERKH
33 HHYPSAAERKHRHLP
34 SAAERKHRHLPVADA
35 RKHRHLPVADAVIHA
36 HLPV AD A VIH ASGKQ
37 ADAVIHASGKQMWQA
38 IHASGKQMWQARLTV
39 GKQMWQARLTVSGLA
40 v WQARLTVSGLAWTRQ
41 LTV SGLAWTRQQNQW
42 GLAWTRQQNQWKEPD
43 TRQQNQWKEPDVYYT
44 NQWKEPDVYYTSAFV
45 EPDVYYTSAFVFPTK
Pool 4 Peptide sequence
46 Y YTS AFVFPTKD V AL
47 AFVFPTKDVALRHVV
48 PTKD V ALRH V V C AHE
49 VALRHWCAHELVCS
50 H V V C AHEL V C S MENT
51 AHELVCSMENTRATK
52 VCSMENTRATKMQ VI
53 ENTRATKMQVIGDQY
54 ATKMQVIGDQYVKVY
55 QVIGDQYVKVYLESF
56 DQYVKVYLESFCEDV
57 KVYLESFCEDVPSGK
58 ESFCEDVPSGKLFMH
59 EDVPSGKLFMHVTLG
60 SGKLFMHVTLGSDVE
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Pool 5 Peptide sequence
61 FMHVTLGSDVEEDLT
62 TLGSDVEEDLTMTRN
63 DVEEDLTMTRNPQPF
64 DLTMTRNPQPFMRPH
65 TRNPQPFMRPHERNG
66 QPFMRPHERNGFTVL
67 RPHERNGFTVLCPKN
68 RNGFTVLCPKNMIIK
69 TVLCPKNMIIKPGKI
70 PKNMIIKPGKISHIM
71 IIKPGKISHIMLDVA
72 GKISHIMLDVAFTSH
73 HIMLDVAFTSHEHFG
74 DVAFTSHEHFGLLCP
75 TSHEHFGLLCPKSIP
Pool 6 Peptide sequence
76 HFGLLCPKSIPGLSI
77 LCPKSIPGLSISGNL
78 SIPGLSISGNLLMNG
79 LSISGNLLMNGQQIF
80 GNLLMNGQQIFLEVQ
81 MNGQQIFLEVQAIRE
82 QIFLEVQAIRETVEL
83 EVQAIRETVELRQYD
84 IRETVELRQYDPVAA
85 VELRQ YDPV A ALFFF
86 QYDPVAALFFFDIDL
87 VAALFFFDIDLLLQR
88 FFFDIDLLLQRGPQY
89 IDLLLQRGPQ Y SEHP
90 LQRGPQ Y SEHPTFTS
Pool 7 Peptide sequence
91 PQ Y SEHPTFTSQYRI
92 EHPTFTSQYRIQGKL
93 FTSQYRIQGKLEYRH
94 YRIQGKLEYRHTWDR
95 GKLEYRHTWDRHDEG
96 YRHTWDRHDEGAAQG
97 WDRHDEGAAQGDDDV
98 DEGAAQGDDDVWTSG
99 AQGDDDVWTSGSDSD
100 DDVWTSGSDSDEELV
101 TSGSDSDEELVTTER
102 DSDEELVTTERKTPR
103 ELVTTERKTPRVTGG
104 TERKTPRVTGGGAMA
105 TPRVTGGGAMAGAST
Pool 8 Peptide sequence
106 TGGGAMAGASTSAGR
107 AMAGASTSAGRKRKS
108 ASTSAGRKRKSASSA
109 AGRKRKSASSATACT
110 RKSASSATACTSGVM
111 SSATACTSGVMTRGR
112 ACTSGVMTRGRLKAE
113 GVMTRGRLKAESTVA
114 RGRLKAESTVAPEED
115 KAESTVAPEEDTDED
116 TV APEEDTDEDSDNE
117 EEDTDEDSDNEIHNP
118 DEDSDNEIHNPAVFT
119 DNEIHNPAVFTWPPW
120 HNPA VFTWPPW Q AGI
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Pool 9 Peptide sequence
121 VFTWPPW Q AGIL ARN
122 PPWQAGILARNLVPM
123 AGILARNLVPMVATV
124 ARNLVPMVATV QGQN
125 VPMV ATV QGQNLK Y Q
126 ATVQGQNLKYQEFFW
127 GQNLK Y QEFFWDAND
128 K Y QEFFWD ANDIYRI
129 FFWDANDIYRIFAEL
130 ANDIYRIFAELEGVW
131 YRIFAELEGVWQPAA
132 AELEGVWQPAAQPKR
133 GVWQPAAQPKRRRHR
134 PAAQPKRRRHRQDAL
135 PKRRRHRQDALPGPC
136 RHRQDALPGPCIAST
137 DALPGPCIASTPKKH
138 LPGPCIASTPKKHRG
Appendix
Appendix 2.4
IE1 peptide mapping pools
Pool 1 Peptide sequence
1 MESSAKRKMDPDNPD
2 AKRKMDPDNPDEGPS
3 MDPDNPDEGPSSKVP
4 NPDEGPS SKVPRPET
5 GPSSKVPRPETPVTK
6 KVPRPETPVTKATTF
7 PETPVTKATTFLQTM
8 VTKATTFLQTMLRKE
9 TTFLQTMLRKEVNSQ
10 QTMLRKEVNSQLSLG
11 RKEVNSQLSLGDPLF
12 NSQLSLGDPLFPELA
13 SLGDPLFPELAEESL
14 PLFPELAEESLKTFE
15 ELAEESLKTFEQVTE
Pool 2 Peptide sequence
16 ESLKTFEQVTEDCNE
17 TFEQVTEDCNENPEK
18 VTEDCNENPEKDVLA
19 CNENPEKDVLAELVK
20 PEKDVLAELVKQIKV
21 VLAELVKQIKVRVDM
22 LVKQIKVRVDMVRHR
23 IKVRVDMVRHRIKEH
24 VDMVRHRIKEHMLKK
25 RHRIKEHMLKKYTQT
26 KEHMLKKYTQTEEKF
27 LKKYTQTEEKFTGAF
28 TQTEEKFTGAFNMMG
29 EKFTGAFNMMGGCLQ
30 GAFNMMGGCLQNALD
Pool 3 Peptide sequence
31 MMGGCLQNALDILDK
32 CLQNALDILDKVHEP
33 ALDILDKVHEPFEEM
34 LDKVHEPFEEMKCIG
35 HEPFEEMKCIGLTMQ
36 EEMKCIGLTMQSMYE
37 c ig l ™ q s m y e n y iv
38 TMQSMYENYTVPEDK
39 MYENYIVPEDKREMW
40 YIVPEDKREMWMACI
41 EDKREMWMACIKELH
42 EMWM ACIKELHD V SK
43 ACIKELHD VSKGAAN
44 ELHDV SKG AANKLGG
45 V SKG AANKLGG ALQ A
Pool 4 Peptide sequence
46 AANKLGG ALQ AKARA
47 LGGALQAKARAKKDE
48 LQAKARAKKDELRRK
49 ARAKKDELRRKMMYM
50 KDELRRKMMYMCYRN
51 RRKMMYMCYRNIEFF
52 MYMCYRNIEFFTKNS
53 YRNIEFFTKNS AFPK
54 EFFTKNSAFPKTTNG
55 KNSAFPKTTNGCSQA
56 FPKTTNGCSQAMAAL
57 TNGCSQAMAALQNLP
58 SQAMAALQNLPQCSP
59 AALQNLPQCSPDEIM
60 NLPQCSPDEIMAYAQ
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Pool 5 Peptide sequence
61 CSPDEIM A Y AQKIFK
62 EIM A Y AQKIFKILDE
63 Y AQKIFKILDEERDK
64 IFKILDEERDKVLTH
65 LDEERDKVLTHIDHI
66 RDKVLTHIDHIFMDI
67 LTHIDHIFMDILTTC
68 DHIFMDILTTCVETM
69 MDILTTCVETMCNEY
70 TTCVETMCNEYKVTS
71 ETMCNEYKVTSDACM
72 NEYKVTSDACMMTMY
73 VTSD ACMMTM Y GGIS
74 ACMMTMY GGISLLSE
75 TM Y GGISLLSEFCRV
Pool 7 Peptide sequence
91 LRV CSPS VDDLRAIA
92 SPSVDDLRAIAEESD
93 DDLRAIAEESDEEEA
94 AIAEESDEEE AIV AY
95 ESDEEEATVAYTLAT
96 EE AI V A YTL AT AG V S
97 VAYTLATAGVSSSDS
98 LATAGVSSSDSLVSP
99 GVSSSDSLVSPPESP
100 SDSLV SPPESPVPAT
101 V SPPESPVPATIPLS
102 ESPVPATIPLSSVIV
103 PATIPLSSVIVAENS
104 PLS S VIV AEN SDQEE
105 VIVAENSDQEESEQS
Pool 6 Peptide sequence
76 GISLLSEFCRVLCCY
77 LSEFCRVLCCYVLEE
78 CRVLCCYVLEETSVM
79 CCYVLEETSVMLAKR
80 LEETSVMLAKRPLIT
81 SVMLAKRPLITKPEV
82 AKRPLITKPEVISVM
83 LITKPEVISVMKRRI
84 PEVISVMKRRIEEIC
85 SVMKRRIEEICMKVF
86 RRIEEICMKVFAQYI
87 EICMKVFAQYILGAD
88 KVFAQYILGADPLRV
89 QYILGADPLRVCSPS
90 GADPLRVCSPSVDDL
Pool 8 Peptide sequence
106 ENSDQEESEQSDEEE
107 QEESEQSDEEEEEGA
108 EQSDEEEEEGAQEER
109 EEEEEGAQEEREDTV
110 EGAQEEREDTVSVKS
111 EEREDTV S VKSEPV S
112 DTV S VKSEPV SEIEE
113 VKSEPV SEIEE V APE
114 PV SEIEEV APEEEED
115 IEE V APEEEEDG AEE
116 APEEEEDGAEEPTAS
117 EEDG AEEPTASGGKS
118 AEEPTASGGKSTHPM
119 TASGGKSTHPMVTRS
120 GKSTHPMVTRSKADQ
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